Human signal peptide-containing proteins

ABSTRACT

The invention provides a human signal peptide-containing proteins, the polynucleotides which encode them and methods for their use. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention further provides methods for diagnosing or treating disorders associated with expression of the proteins

[0001] This application is a divisional of U.S. Ser. No. 09/002,485 filed on Dec. 31, 1997.

FIELD OF THE INVENTION

[0002] This invention relates to nucleic acid and amino acid sequences of human signal peptide-containing proteins and to the use of these sequences in the diagnosis and treatment of cancer and immunological disorders.

BACKGROUND OF THE INVENTION

[0003] Protein transport is an essential process for all living cells. Transport of an individual protein usually occurs via an amino-terminal signal sequence which directs, or targets, the protein from its ribosomal assembly site to a particular cellular or extracellular location. Transport may involve any combination of several of the following steps: contact with a chaperone, unfolding, interaction with a receptor and/or a pore complex, addition of energy, and refolding. Moreover, an extracellular protein may be produced as an inactive precursor. Once the precursor has been exported, removal of the signal sequence by a signal peptidase and post-translational processing (for example, glycosylation or phosphorylation) activates the protein. Signal sequences are common to receptors; matrix molecules such as adhesion, cadherin, extracellular matrix, integrin, and selectin; cytokines, hormones, growth and differentiation factors; neuropeptides and vasomediators; phosphokinases, phosphatases, phospholipases, and phosphodiesterases; G and Ras-related proteins; ion channels and transporters/pumps; proteases; and transcription factors.

[0004] G-protein coupled receptors (GPCRs) are a superfamily of integral membrane proteins which transduce extracellular signals. GPCRs include receptors for biogenic amines such as dopamine, epinephrine, histamine, glutamate (metabotropic effect), acetylcholine (muscarinic effect), and serotonin; for lipid mediators of inflammation such as prostaglandins, platelet activating factor, and leukotrienes; for peptide hormones such as calcitonin, C5a anaphylatoxin, follicle stimulating hormone, gonadotropin releasing hormone, neurokinin, oxytocin, and thrombin; and for sensory signal mediators, such as retinal photopigments and olfactory stimulatory molecules.

[0005] The structure of these highly-conserved receptors consists of seven hydrophobic transmembrane regions, cysteine disulfide bridges between the second and third extracellular loops, an extracellular N-terminus, and a cytoplasmic C-terminus. Three extracellular loops alternate with three intracellular loops to link the seven transmembrane regions. The N-terminus interacts with ligands, the disulfide bridge interacts with agonists and antagonists, and the large third intracellular loop interacts with G proteins to activate second messengers such as cyclic AMP (cAMP), phospholipase C, inositol triphosphate, or ion channel proteins. The most conserved parts of these proteins are the transmembrane regions and the first two cytoplasmic loops. A conserved, acidic-Arg-aromatic triplet present in the second cytoplasmic loop may interact with the G proteins. The consensus pattern, [GSTALIVMYWC]-[GSTANCPDE]-{EDPKRH}-x(2)-[LIVMNQGA]-x(2)-[LIVMFT]-[GSTANC]-[LIVMFYWSTAC]-[DENH]-R-[FYWCSH]-x(2)-[LIVM] is characteristic of most proteins belonging to this superfamily (Watson and Arkinstall (1994) The G-protein Linked Receptor Facts Book, Academic Press, San Diego Calif., pp. 2-6; Bolander (1994) Molecular Endocrinology, Academic Press, San Diego Calif., pp. 8-19).

[0006] Tetraspanins are a superfamily of membrane proteins which facilitate the formation and stability of cell-surface signaling complexes containing lineage-specific proteins, integrins, and other tetraspanins. They are involved in cell activation, proliferation (including cancer), differentiation, adhesion, and motility. These proteins cross the membrane four times, have conserved intracellular—and C-termini and an extracellular, non-conserved hydrophilic domain. Three highly conserved polar amino acids are located in the transmembrane domains (TM), an asparagine in TM1 and a glutamate or glutamine in TM3 and TM4. Two to three conserved charged residues, including a glutamic acid residue, are present in the cytoplasmic loop between TM2 and TM3. The extracellular loop between TM3 and TM4 contains four conserved cysteine residues: two in a conserved CCG motif located about 50 residues C-terminal to TM3; one, often preceded by glycine, 11 residues N-terminal to TM4; and one in the extracellular loop may be found in a PXSC motif. Tetraspanins include platelet and endothelial cell membrane proteins, leukocyte surface proteins, tissue specific and tumorous antigens, and the retinitis pigmentosa-associated gene peripherin (Maecker et al. (1997) FASEB J 11:428-442).

[0007] Matrix proteins (Mps) function in formation, growth, remodeling and maintenance of tissues and as important mediators and regulators of the inflammatory response. The expression and balance of MPs may be perturbed by biochemical changes that result from congenital, epigenetic, or infectious diseases. In addition, MPs affect leukocyte migration, proliferation, differentiation, and activation in immune response.

[0008] MPs encompass a variety of proteins and their functions. Extracellular matrix (ECM) proteins are multidomain proteins that play an important role in the diverse functions of the ECM. ECM proteins are frequently characterized by the presence of one or more domains which may include collagen-like domains, EGF-like domains, immunoglobulin-like domains, fibronectin-like domains, vWFA-like modules (Ayad et al. (1994) The Extracellular Matrix Facts Book, Academic Press, San Diego Calif., pp. 2-16). Cell adhesion molecules (CAMs) have been shown to stimulate axonal growth through homophilic and/or heterophilic interactions with other molecules. In addition, interactions between adhesion molecules and their receptors can potentiate the effects of growth factors upon cell biochemistry via shared signaling pathways (Ruoslahti (1997) Kidney Int 51:1413-1417). Cadherins comprise a family of calcium-dependant glycoproteins that function in mediating cell-cell adhesion in solid tissues of multicellular organisms. Integrins are ubiquitous transmembrane adhesion molecules that link cells to the ECM by interacting with the cytoskeleton. Integrins also function as signal transduction receptors and stimulate changes in intracellular calcium levels and protein kinase activity (Sjaastad and Nelson (1997) BioEssays 19:47-55).

[0009] Lectins are proteins characterized by their ability to bind carbohydrates on cell membranes by means of discrete, modular carbohydrate recognition domains, CRDs (Kishore et al. (1997) Matrix Biol 15:583-592). Certain cytokines and membrane-spanning proteins have CRDs which may enhance interactions with extracellular or intracellular ligands, proteins in secretory pathways, or molecules in signal transduction pathways. The lipocalin superfamily constitutes a phylogenetically conserved group of more than forty proteins that function by binding to and transporting a variety of physiologically important ligands. Members of this family function as carriers of retinoids, odorants, chromophores, pheromones, and sterols, and a subset of these proteins may be multifunctional, serving as either a biosynthetic enzyme or as a specific enzyme inhibitor (Tanaka et al. (1997) J Biol Chem 272:15789-15795; van't Hof et al. (1997) J Biol Chem 272:1837-1841). Selectins are a family of calcium ion-dependent lectins expressed on inflamed vascular endothelium and the surface of some leukocytes. They mediate rolling movement and adhesive contacts between blood cells and blood vessel walls. The structure of the selectins and their ligands supports the type of bond formation and dissociation that allows a cell to roll under conditions of flow (Rossiter et al. (1997) Mol Med Today 3:214-222).

[0010] Protein kinases regulate many different cell proliferation, differentiation, and signaling processes by adding phosphate groups to proteins. Reversible protein phosphorylation is a key strategy for controling protein functional activity in eukaryotic cells. The high energy phosphate which drives this activation is generally transferred from adenosine triphosphate molecules (ATP) to a particular protein by protein kinases and removed from that protein by protein phosphatases. Phosphorylation occurs in response to extracellular signals, cell cycle checkpoints, and environmental or nutritional stresses. Protein kinases may be roughly divided into two groups; protein tyrosine kinases (PTKs) which phosphorylate tyrosine residues, and serine/threonine kinases (STKs) which phosphorylate serine or threonine residues. A few protein kinases have dual specificity. A majority of kinases contain a similar 250-300 amino acid catalytic domain which can be further divided into eleven subdomains. The N-terminal domain, which contains subdomains I to IV, generally folds into a two-lobed structure which binds and orients the ATP (or GTP) donor molecule. The larger C terminal domain, which contains subdomains VIA to XI, binds the protein substrate and carries out the transfer of the gamma phosphate from ATP to the hydroxyl group of the target amino acid residue. Subdomain V links the two domains. Each of the 11 subdomains contain specific residues and motifs that are characteristic and are highly conserved (Hardie and Hanks (1995) The Protein Kinase Facts Book, Vol I, Academic Press, San Diego Calif., pp. 7-47).

[0011] Protein phosphatases remove phosphate groups from molecules previously modified by protein kinases thus participating in cell signaling, proliferation, differentiation, contacts, and oncogenesis. Protein phosphorylation is a key strategy used to control protein functional activity in eukaryotic cells. The high energy phosphate is transferred from ATP to a protein by protein kinases and removed by protein phosphatases. There appear to be three, evolutionarily-distinct protein phosphatase gene families: protein phosphatases (PPs); protein tyrosine phosphatases (PTPs); and acid/alkaline phosphatases (APs). PPs dephosphorylate phosphoserine/threonine residues and are an important regulator of many cAMP mediated, hormone responses in cells. PTPs reverse the effects of protein tyrosine kinases and therefore play a significant role in cell cycle and cell signaling processes. Although APs dephosphorylate substrates in vitro, their role in vivo is not well known (Carbonneau and Tonks (1992) Annu Rev Cell Biol 8:463-493).

[0012] Protein phosphatase inhibitors control the activities of specific phosphatases. A specific inhibitor of PP-I, I-1, has been identified that when phosphorylated by cAMP-dependent protein kinase (PKA) specifically binds to PP-I and inhibits its activity. Since PP-I dephosphorylates many of the proteins phosphorylated by PKA, activation of I-1 by PKA serves to amplify the effects of PKA and the many cAMP-dependent responses mediated by PKA. In addition, since PP-I also dephosphorylates many phosphoproteins that are not phosphorylated by PKA, I-1 activation serves to exert cAMP control over other protein phosphorylations. I₁PP2A is a specific and potent inhibitor of PP-IIA (Li et al. (1996) Biochemistry 35:6998-7002). Since PP-IIA is the main phosphatase responsible for reversing the phosphorylations of serine/threonine kinases, I₁PP2A has broad effects in controlling protein phosphorylations.

[0013] Cyclic nucleotides (cAMP and cGMP) function as intracellular second messengers to transduce a variety of extracellular signals, including hormones, and light and neurotransmitters. Cyclic nucleotide phosphodiesterases (PDEs) degrade cyclic nucleotides to their corresponding monophosphates, thereby regulating the intracellular concentrations of cyclic nucleotides and their effects on signal transduction. At least seven families of mammalian PDEs have been identified based on substrate specificity and affinity, sensitivity to cofactors and sensitivity to inhibitory drugs (Beavo (1995) Physiological Reviews 75: 725-748). PDEs are composed of a catalytic domain of ˜270 amino acids, an N-terminal regulatory domain responsible for binding cofactors and, in some cases, a C-terminal domain with unknown function. Within the catalytic domain, there is approximately 30% amino acid identity between PDE families and ˜85-95% identity between isozymes of the same family. Furthermore, within a family there is extensive similarity (>60%) outside the catalytic domain, while across families there is little or no sequence similarity. A variety of diseases have been attributed to increased PDE activity and inhibitors of PDEs have been used effectively as anti-inflammatory, antihypertensive, and antithrombotic agents (Verghese et al. (1995) Mol Pharmacol 47:1164-1171; Banner and Page (1995) Eur Respir J 8:996-1000).

[0014] Phospholipases (PLs) are enzymes that catalyze the removal of fatty acid residues from phosphoglycerides. PLs play an important role in transmembrane signal transduction and are named according to the specific ester bond in phosphoglycerides that is hydrolyzed, i.e., A₁, A₂, C or D. PLA₂ cleaves the ester bond at position 2 of the glycerol moiety of membrane phospholipids giving rise to arachidonic acid. Arachidonic acid is the common precursor to four major classes of eicosanoids; prostaglandins, prostacyclins, thromboxanes and leukotrienes. Eicosanoids are signaling molecules involved in the contraction of smooth muscle, platelet aggregation, and pain and inflammatory responses. PLC is an important link in certain receptor-mediated, signaling transduction pathways. Extracellular signaling molecules including hormones, growth factors, neurotransmitters, and immunoglobulins bind to their respective cell surface receptors and activate PLC. Activated PLC generates second messenger molecules from the hydrolysis of inositol phospholipids that regulate cellular processes, such as secretion, neural activity, metabolism and proliferation (Alberts et al. (1994) Molecular Biology of The Cell, Garland Publishing,, New York N.Y., pp. 85, 211, 239-240, 642-645).

[0015] The nucleotide cyclases, i.e., adenylate and guanylate cyclase, catalyze the synthesis of the cyclic nucleotides, cAMP and cGMP, from ATP and GTP, respectively. They act in concert with phosphodiesterases, which degrade cAMP and cGMP, to regulate the cellular levels of these molecules and their functions. cAMP and cGMP function as intracellular second messengers to transduce a variety of extracellular signals from hormones, light, and neurotransmitters. Adenylate cyclase is a plasma membrane protein that is coupled with various hormone receptors also located on the plasma membrane. Binding of a hormone to its receptor activates adenylate cyclase which, in turn, increases the levels of cAMP in the cytosol. The activation of other molecules by cAMP leads to the cellular effect of the hormone. In a similar manner, guanylate cyclase participates in the process of visual excitation and phototransduction in the eye (Stryer (1988) Biochemistry W H Freeman, New York N.Y. pp. 975-980, 1029-1035).

[0016] Cytokines are produced in response to cell perturbation. Some cytokines are produced as precursor forms, and some form multimers in order to become active. They are produced in groups and in patterns characteristic of the particular stimulus or disease, and the members of the group interact with one another and other molecules to produce an overall biological response. Interleukins, neurotrophins, growth factors, interferons, and chemokines are all families of cytokines which work in conjunction with cellular receptors to regulate cell proliferation and differentiation and to affect such activities as leukocyte migration and function, hematopoietic cell proliferation, temperature regulation, acute response to infections, tissue remodeling, and cell survival. Studies using antibodies or other drugs that modify the activity of a particular cytokine are used to elucidate the roles of individual cytokines in pathology and physiology.

[0017] Chemokines are a small chemoattractant cytokines which are active in leukocyte trafficking. Initially, chemokines were isolated and purified from inflamed tissues, but recently several chemokines have been discovered through molecular cloning techniques. Chemokines have been shown to be active in cell activation and migration, angiogenic and angiostatic activities, suppression of hematopoiesis, HIV infectivity, and promoting Th-1 (IL-2-, interferon γ-stimulated) cytokine release.

[0018] Chemokines generally contain 70-100 amino acids and are subdivided into four subfamilies based on the presence and arrangement of conserved CXC, CC, CX3C and C motifs. The CXC (alpha), CC (beta), and CX3C chemokines contain four conserved cysteines. The CC subfamily is active on monocytes, lymphocytes, eosinophils, and mast cells; the CXC subfamily, on neutrophils; CX3C and C subfamilies, on T-cells. Many of the CC chemokines have been characterized functionally as well as structurally (Callard and Gearing (1994) The Cytokine Facts Book, Academic Press, New York N.Y., pp. 181-190, 210-213, and 223-227).

[0019] Growth and differentiation factors function in intercellular communication. Once secreted from the cell, some factors require oligomerization or association with ECM in order to function. Complex interactions among these factors and their receptors result in the stimulation or inhibition of cell division, cell differentiation, cell signaling, and cell motility. Some factors act on their cell of origin (autocrine signaling); on neighboring cells (paracrine signaling); or on distant cells (endocrine signaling).

[0020] There are three broad classes of growth and differentiation factors. The first class includes the large polypeptide growth factors such as epidermal growth factor, fibroblast growth factor, transforming growth factor, insulin-like growth factor, and platelet-derived growth factor. Each of these defines a family of related molecules which stimulate cell proliferation for wound healing, bone synthesis and remodeling, and regeneration of epithelial, epidermal, and connective tissues, and induce differentiation of embryonic tissues. Nerve growth factor functions specifically as a neurotrophic factor, and all induce differentiation of embryonic tissues. The second class includes the hematopoietic growth factors which stimulate the proliferation and differentiation of blood cells such as B-lymphocytes, T-lymphocytes, erythrocytes, platelets, eosinophils, basophils, neutrophils, macrophages, and their stem cell precursors. These factors include colony-stimulating factors, erythropoietin, and the cytokines—interleukins, interferons (IFNs), and tumor necrosis factor (TNF). Cytokines are secreted by cells of the immune system and function in immunomodulation. The third class includes small peptide factors such as bombesin, vasopressin, oxytocin, endothelin, transferrin, angiotensin II, vasoactive intestinal peptide, and bradykinin, which function as hormones to regulate cellular functions other than proliferation.

[0021] Growth and differentiation factors have been shown to play critical roles in neoplastic transformation of cells in vitro and in tumor progression in vivo. Inappropriate expression of growth factors by tumor cells may contribute to vascularization and metastasis of melanotic tumors. In hematopoiesis, growth factor misregulation can result in anemias, leukemias and lymphomas. Certain growth factors such as IFN, are cytotoxic to tumor cells both in vivo and in vitro. Moreover, growth factors and/or their receptors are related both structurally and functionally related to oncoproteins. In addition, growth factors affect transcriptional regulation of both proto-oncogenes and oncosuppressor genes (Pimentel (1994) Handbook of Growth Factors, CRC Press, Ann Arbor Mich., pp. 6-25).

[0022] Proteolytic enzymes or proteases degrade proteins by reducing the activation energy needed for the hydrolysis of peptide bonds. The major families are the zinc, serine, cysteine, thiol, and carboxyl proteases.

[0023] Zinc proteases, such as carboxypeptidase A, have a zinc ion bound to the active site, recognize C-terminal residues that contain an aromatic or bulky aliphatic side chain, and hydrolyze the peptide bond adjacent to the C-terminal residues. Serine proteases have an active site serine residue and include digestive enzymes (trypsin and chymotrypsin), components of the complement and blood-clotting cascades, and enzymes that control the degradation and turnover of extracellular matrix (ECM) molecules. Subfamilies of serine proteases include tryptases (cleavage after arginine or lysine), aspases (cleavage after aspartate), chymases (cleavage after phenylalanine or leucine), metases (cleavage after methionine), and serases (cleavage after serine). Cysteine proteases such as cathepsin are produced by monocytes, macrophages and other immune cells and are involved in diverse cellular processes ranging from the processing of precursor proteins to intracellular degradation. Overproduction of these enzymes can cause the tissue destruction associated with rheumatoid arthritis and asthma. Thiol proteases, such as papain, contain an active site cysteine and are widely distributed within tissues. Thiol proteases effect catalysis through a thiol ester intermediate facilitated by a proximal histidine side chain. Carboxyl proteases such as pepsin are active only under acidic conditions (pH 2-3). The active site of pepsin contains two aspartate residues; when one aspartate is ionized and the other is not, the enzyme is active. A common feature of the carboxyl proteases is that they are inhibited by very low concentrations (10⁻¹⁰ M) of the inhibitor pepstatin. A substrate analog which induces structural changes at the active site of a protease functions as an antagonist or inhibitor.

[0024] Guanosine triphosphate-binding proteins (G proteins) participate in intracellular signal transduction and control regulatory pathways through cell surface receptors. These receptors respond to hormones, growth factors, neuromodulators, or other signaling molecules, by binding GTP. Binding of GTP leads to the production of cAMP which controls phosphorylation and activation of other proteins. During this process, the hydrolysis of GTP acts as an energy source as well as an on-off switch for the GTPase activity.

[0025] The G proteins are small proteins which consist of single 21-30 kDa polypeptides. They can be classified into five subfamilies: Ras, Rho, Ran, Rab, and ADP-ribosylation factor. These proteins regulate cell growth, cell cycle control, protein secretion, and intracellular vesicle interaction. In particular, the Ras proteins are essential in transducing signals from receptor tyrosine kinases to serine/threonine kinases which control cell growth and differentiation. Mutant Ras proteins, which bind but can not hydrolyze GTP, are permanently activated and cause continuous cell proliferation or cancer.

[0026] All five subfamilies share common structural features and four conserved motifs, I to IV. Motif I is the most variable and has the signature of GXXXXGK, in which lysine interacts with the β- and γ-phosphate groups of GTP. Motif II, III, and IV have DTAGQE, NKXD, and EXSAX as their respective signatures and regulate the binding of g-phosphate, GTP, and the guanine base of GTP, respectively. Most of the membrane-bound G proteins require a carboxy terminal isoprenyl group (CAAX), added post-translationally, for membrane association and biological activity. The G proteins also have a variable effector region, located between motifs I and II, which is characterized as the interaction site for guanine nucleotide exchange factors or GTPase-activating proteins.

[0027] Eukaryotic cells are bound by a membrane and subdivided into membrane bound compartments. As membranes are impermeable to many ions and polar molecules, transport of these molecules is mediated by ion channels, ion pumps, transport proteins, or pumps. Symporters and antiporters regulate cytosolic pH by transporting ions and small molecules such as amino acids, glucose, and drugs, across membranes; symporters transport small molecules and ions in the same direction, and antiporters, in the opposite direction. Transporter superfamilies include facilitative transporters and active ATP binding cassette transporters involved in multiple-drug resistance and the targeting of antigenic peptides to MHC Class I molecules. These transporters bind to a specific ion or other molecule and undergo conformational changes in order to transfer the ion or molecule across a membrane. Transport can occur by a passive, concentration-dependent mechanism or can be linked to an energy source such as ATP hydrolysis or an ion gradient.

[0028] Ion channels are formed by transmembrane proteins which form a lined passageway across the membrane through which water and ions such as Na⁺, K⁺, Ca²⁺, and Cl⁻ enter and exit the cell. For example, chloride channels are involved in the regulation of the membrane electric potential as well as absorption and secretion of ions across the membrane. In intracellular membranes of the Golgi apparatus and endocytic vesicles, chloride channels also regulate organelle pH. Electrophysiological and pharmacological studies suggest that a variety of chloride channels exist in different cell types and that many of these channels have one or more protein kinase phosphorylation sites.

[0029] Ion pumps are ATPases which actively maintain membrane gradients. Ion pumps can be grouped into three classes—P, V, and F according to their structure and function. All have one or more binding sites for ATP on the cytosolic face of the membrane. The P-class ion pumps consist of two α and two β transmembrane subunits, include Ca²⁺ ATPase and Na⁺/K⁺ ATPase, and function in transporting H⁺, Na⁺, K⁺, and Ca²⁺ ions. The V- and F-class ion pumps have similar structures, a cytosolic domain formed by at least five extrinsic polypeptides and at least 2 transmembrane proteins, and only transport H⁺. F class H⁺ pumps have been identified from the membranes of mitochondria and chloroplast, and V-class H⁺ pumps regulate acidity inside lysosomes, endosomes, and plant vacuoles.

[0030] A family of structurally related intrinsic membrane proteins known as facilitative glucose transporters catalyze the movement of glucose and other selected sugars across the plasma membrane. The proteins in this family contain a highly conserved, large transmembrane domain made of 12 transmembrane α-helices, and several less conserved, asymmetric, cytoplasmic and exoplasmic domains (Pessin and Bell (1992) Annu Rev Physiol 54:911-930).

[0031] Amino acid transport is mediated by Na⁺ dependent amino acid transporters. These transporters are involved in gastrointestinal and renal uptake of dietary and cellular amino acids and the re-uptake of neurotransmitters. Transport of cationic amino acids is mediated by the system y+ family members and the cationic amino acid transporter (CAT) family. Members of the CAT family share a high degree of sequence homology, and each contains 12-14 putative transmembrane domains (Ito and Groudine (1997) J Biol Chem 272:26780-26786).

[0032] Proton-coupled, 12 membrane-spanning domain transporters such as PEPT 1 and PEPT 2 are responsible for gastrointestinal absorption and for renal reabsorbtion of peptides using an electrochemical H⁺ gradient as the driving force. A heterodimeric peptide transporter, consisting of TAP 1 and TAP 2, is associated with antigen processing. Peptide antigens are transported across the membrane of the endoplasmic reticulum so they can be presented to the major histocompatibility complex class I molecules. Each TAP protein consists of multiple hydrophobic membrane spanning segments and a highly conserved ATP-binding cassette (Boll et al. (1996) Proc Natl Acad Sci 93:284-289).

[0033] Hormones are secreted molecules that circulate in the body fluids and bind to specific receptors on the surface of, or within, target tissue cells. Although they have diverse biochemical compositions and mechanisms of action, hormones can be grouped into two categories. One category consists of small lipophilic molecules that diffuse through the plasma membrane of target cells, bind to cytosolic or nuclear receptors, and form a complex alters gene expression. Examples of this category include retinoic acid, thyroxine, and the cholesterol derived steroid hormones, progesterone, estrogen, testosterone, cortisol, and aldosterone. These hormones have a long half-life (several hours to days) and long-term effects on their target cells. Their solubility in the blood may be increased by their association with carrier molecules. Within the target cell nucleus, hormone/receptor complexes bind to specific response elements in target gene regulatory regions.

[0034] A second category consists of hydrophilic hormones that function by binding to cell surface receptors and transducing the signal across the plasma membrane. Examples of this category include amino acid derivatives, such as catecholamines such as epinephrine, norepinephrine, and histamine; peptide hormones, such as glucagon, insulin, gastrin, secretin, cholecystokinin, adrenocorticotropic hormone, follicle stimulating hormone, luteinizing hormone, thyroid stimulating hormone, parathormone, and vasopressin. Peptide hormones are synthesized as inactive forms and stored in secretory vesicles. These hormones are activated by protease cleavage before being released from the cell. Many hydrophilic hormones have a very short half-life and effect (seconds to hours) and are inactivated by proteases in the blood (Lodish et al. (1995) Molecular Cell Biology, Scientific American Books, New York N.Y., pp. 856-864).

[0035] Neuropeptides and vasomediators (NP/VM) comprise a large family of endogenous signaling molecules. Included in the family are neurotransmitters such as bombesin, neuropeptide Y, neurotensin, neuromedin N, melanocortins, opioids (enkephalins, endorphins and dynorphins), galanin, somatostatin, tachykinins, vasopressin, and vasoactive intestinal peptide, and circulatory system-borne signaling molecules such as angiotensin, complement, calcitonin, endothelins, formyl-methionyl peptides, glucagon, cholecystokinin and gastrin. These proteins are synthesized as “pre-pro” molecules, and are activated and inactivated by proteolytic cleavage. NP/VMs can transduce signals directly, modulate the activity or release of other neurotransmitters and hormones, and act as catalytic enzymes in cascades. The effects of NP/VMs range from extremely brief to as long-lasting as the melanocortin-mediated changes in skin melanin.

[0036] Regulatory molecules turn individual genes or groups of genes on and off in response to various inductive mechanisms of the cell or organism; act as transcription factors by determining whether or not transcription is initiated, enhanced, or repressed; and splice transcripts as dictated in a particular cell or tissue. Although they interact with short stretches of DNA scattered throughout the entire genome, most gene expression is regulated near the site at which transcription starts or within the open reading frame of the gene being expressed. The regulated stretches of the DNA can be simple and interact with only a single protein, or they can require several proteins acting as part of a complex to regulate gene expression. The external features of the double helix which provide recognition sites are hydrogen bond donor and acceptor groups, hydrophobic patches, major and minor grooves, and regular, repeated stretches of sequences which cause distinct bends in the helix. The surface features of the regulatory molecule are complementary to those of the DNA.

[0037] Many of the transcription factors incorporate one of a set of DNA-binding structural motifs, each of which contains either α helices or β sheets and binds to the major groove of DNA. Seven of the structural motifs common to transcription factors are helix-turn-helix, homeodomains, zinc finger, steroid receptor, β sheets, leucine zipper, and helix-loop-helix (Pabo and Sauer (1992) Ann Rev Biochem 61:1053-95). Other domains of transcription factors may form crucial contacts with the DNA. In addition, accessory proteins provide important interactions which may convert a particular protein complex to an activator or a repressor or may prevent binding (Alberts, supra, pp. 401-474).

[0038] The discovery of new human signal peptide-containing proteins and the polynucleotides encoding these molecules satisfies a need in the art by providing new compositions which are useful in the diagnosis and treatment of cancer and immunological disorders.

SUMMARY OF THE INVENTION

[0039] The invention features purified polypeptides, human signal peptide-containing proteins, referred to collectively as “SIGP” and individually as “SIGP-1 through SIGP-77”. In one embodiment, the purified polypeptide, SIGP, comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-77. The invention includes a purified variant having at least 90% amino acid identity to the amino acid sequences of SEQ ID NOs: 1-77 or fragments thereof.

[0040] The invention provides an isolated and purified polynucleotide encoding the SIGP comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-77 and fragments thereof. The invention also includes an isolated variant having at least 90% sequence identity to the polynucleotide encoding the SIGP comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-77 and fragments thereof.

[0041] The invention also provides an isolated polynucleotide comprising a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 78-154 and fragments and complements of SEQ ID NOs: 78-154. The invention includes a variant having at least 90% sequence identity to the polynucleotide selected from the group consisting of SEQ ID NOs: 78-154 and complements and fragments thereof.

[0042] The invention further provides an expression vector containing at least a fragment of the polynucleotide encoding the SIGP comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-77 and fragments thereof. In another aspect, the expression vector is contained within a host cell. The invention still further provides a the method for using a polynulceotide to produce a polypeptide comprising culturing the host cell containing an expression vector containing at least a fragment of a polynucleotide encoding the SIGP under conditions for the expression of the polypeptide and recovering the polypeptide from the host cell culture.

[0043] The invention yet still further provides a method for using a polynucleotide to detect a nucleic acid encoding a SIGP having the amino acid sequence of SEQ ID NOs: 1-77 in a sample comprising hybridizing the polynucleotide or the complement thereof to at least one nucleic acid in the sample, thereby forming a hybridization complex and detecting the hybridization complex, wherein the presence of the hybridization complex indicates the expression of the nucleic acid in the sample. In one aspect, the nucleic acids of the sample are amplified prior to hybridization. In another aspect, the polynucleotides are operably-linked to a substrate.

[0044] The invention additionally provides a method of using a polynucleotide to screen a plurality of molecules to identify a molecule which specifically binds the polynucleotide comprising combining the polynucleotide with the plurality of molecules under conditions to allow specific binding and detecting specific binding, thereby identifying a molecule which specifically binds the polynucleotide. In one aspect, the molecule is selected from DNA molecules, RNA molecules, peptide nucleic acids, artificial chromosome constructions, peptides, and proteins.

[0045] The method provides purified polypeptides comprising an amino acid sequence selected from SEQ ID NOs: 1-77, and fragments thereof.

[0046] The invention also provides a method for using a polypeptide to screen a plurality of molecules to identify a molecule which specifically binds the polypeptide comprising combining the SIGP with the plurality of molecules under conditions to allow specific binding and detecting specific binding, thereby identifying a molecule which specifically binds the SIGP. In one aspect, the molecules are selected from agonists, antagonists, antibodies, DNA molecules, RNA molecules, peptide nucleic acids, immunoglobulins, inhibitors, drug compounds, peptides, and pharmaceutical agents.

[0047] The invention further provides a method of using a polypeptide to purify a molecule which specifically binds the polypeptide from a sample comprising combining a polypeptide with a sample under conditions to allow specific binding, recovering the bound polypeptide, and separating the molecule from the polypeptide, thereby obtaining the purified molecule.

[0048] The invention still further provides a method for using a polypeptide to produce an antibody, comprising immunizing an animal with the polypeptide under conditions to elicit an antibody response and isolating antibodies which bind specifically to the polypeptide.

[0049] The invention yet further provides a method for using a polypeptide to identify an antibody which specifically binds the polypeptide comprising combining the polypeptide with a plurality of antibodies under conditions allow specific binding, recovering the bound polypeptide, and separating the antibody from the polypeptide, thereby obtaining antibody which specifically binds the polypeptide. In one aspect, the antibodies are selected from polyclonal antibodies, monoclonal antibodies, chimeric antibodies, single chain antibodies; Fab fragments, Fv fragments, and F(ab′)₂ fragments.

[0050] The invention additionally provides a purified antibody which specifically binds the SIGP having the amino acid sequence selected from the group consisting of SEQ ID NOs: 1-77 and fragments thereof.

[0051] The invention provides compositions comprising an isolated polynucleotide encoding a SIGP having an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-77 and fragments thereof and a reporter molecule or a purified polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-77 and fragments thereof and a pharmaceutical carrier.

[0052] The invention also provides a method for treating a cancer associated with the decreased expression or activity of a SIGP, the method comprising the step of administering to a subject in need of such treatment an effective amount of a pharmaceutical composition containing SIGP.

[0053] The invention also provides a method for treating a cancer associated with the increased expression or activity of SIGP, the method comprising the step of administering to a subject in need of such treatment an effective amount of an antagonist of SIGP.

[0054] The invention also provides a method for treating an immune response associated with the increased expression or activity of SIGP, the method comprising the step of administering to a subject in need of such treatment an effective amount of an antagonist of SIGP.

[0055] The invention also provides a microarray containing at least a fragment of at least one of the polynucleotides encoding a SIGP having an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-77.

DESCRIPTION OF THE INVENTION

[0056] Before the present proteins, nucleotide sequences, and methods are described, it is understood that this invention is not limited to the particular methodology, protocols, cell lines, vectors, and reagents described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

[0057] It must be noted that as used herein and in the appended claims, the singular forms “a,” “an,” and “the” include plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to “a host cell” includes a plurality of such host cells, and a reference to “an antibody” is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

[0058] Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods, devices, and materials are now described. All publications mentioned herein are cited for the purpose of describing and disclosing the cell lines, vectors, and methodologies which are reported in the publications and which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

[0059] DEFINITIONS

[0060] “SIGP” refers to the amino acid sequences of a purified SIGP obtained from any species, particularly a mammalian species, including bovine, ovine, porcine, murine, equine, and preferably the human species, from any source, whether natural, synthetic, semi-synthetic, or recombinant.

[0061] “Agonist” refers to a molecule which, when bound to SIGP, increases or prolongs the duration of the effect of SIGP. Agonists may include proteins, nucleic acids, carbohydrates, or any other molecules which bind to and modulate the effect of SIGP.

[0062] “Altered” nucleic acids encoding SIGP include those sequences with deletions, insertions, or substitutions of different nucleotides, resulting in a polynucleotide encoding the same SIGP or a polypeptide with at least one functional characteristic of SIGP. Included within this definition are polymorphisms which may or may not be readily detectable using a particular probe of the polynucleotide encoding SIGP, and unexpected hybridization to alleles, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding SIGP. The encoded protein may also be “altered” and may contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent SIGP. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological or immunological activity of SIGP is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid, positively charged amino acids may include lysine and arginine, and amino acids with uncharged polar head groups having similar hydrophilicity values may include leucine, isoleucine, and valine; glycine and alanine; asparagine and glutamine; serine and threonine; and phenylalanine and tyrosine.

[0063] “Amino acid” refers to an oligopeptide, peptide, polypeptide, or protein, or a fragment thereof whether naturally occurring or synthetic. “Fragments”, “immunogenic fragments ”, or “antigenic fragments” refer to portions of SIGP which are preferably about 5 to about 15 amino acids in length and which retain some biological or immunological activity of SIGP. “Amino acid sequence” refers to the sequence of a naturally occurring molecule and is not meant to be limited to the complete native amino acid sequence of the polypeptide.

[0064] “Amplification” relates to the production of additional copies of a nucleic acid sequence. Amplification is carried out using polymerase chain reaction (PCR) technologies well known in the art (Dieffenbach and Dveksler (1995) PCR Primer, a Laboratory Manual, Cold Spring Harbor Press, Plainview N.Y., pp.1-5).

[0065] “Antagonist” refers to a molecule which, when bound to SIGP, decreases the amount or the duration of the biological or immunological activity of SIGP. Antagonists may include proteins, nucleic acids, carbohydrates, antibodies, or any other molecules which decrease the effect of SIGP.

[0066] “Antibody” refers to intact molecules as well as to fragments thereof, such as Fa, F(ab′)₂, and Fv fragments, which are capable of binding a particular epitopic determinant. Antibodies that bind SIGP can be prepared using intact polypeptides or using fragments thereof as the immunizing antigen. The polypeptide, fragment or oligopeptide used to immunize an animal (mouse, rat, rabbit, or goat) can be derived from the translation of RNA, or synthesized chemically, and can be conjugated to a carrier protein. Commonly used, chemically coupled carriers include bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin (KLH). The coupled peptide is then used to immunize the animal.

[0067] “Antigenic determinant” refers to that fragment of a molecule, an epitope, that makes contact with a particular antibody. When a protein or a fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to antigenic determinants, given regions or three-dimensional structures on the protein. An antigenic determinant may compete with the intact antigen, the immunogen used to elicit the immune response, for binding to an antibody.

[0068] “Biologically active” refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, “immunologically active” refers to the capability of the natural, recombinant, or synthetic SIGP to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

[0069] “Complementary” refers to the natural bonding of polynucleotides under permissive salt and temperature conditions by base pairing. For example, the sequence “A-G-T” binds to the complementary sequence “T-C-A ”. The degree of complementarity between nucleic acid strands has significant effects on the efficiency and strength of the hybridization. This is of particular importance in amplification reactions and in the design and use of peptide nucleic acid (PNA) molecules.

[0070] A “composition comprising a polynucleotide” or a “composition comprising a polypeptide” refer broadly to any composition containing the polynucleotide or polypeptide and at least one other molecule. The other molecule may be a labeling moiety, a reporter molecule, a pharmaceutical excipient, or the like. For example, SEQ ID NOs: 78-154, or fragments thereof, may be employed as hybridization “probes ”. The probes may be stored as compositions in freeze-dried form or may be associated with a stabilizing agent such as a carbohydrate. In hybridizations, the probe may be deployed in an aqueous solution containing salts, detergents, and other components such as Denhardt's solution, dry milk, salmon sperm DNA, and the like.

[0071] “Consensus sequence” refers to a nucleic acid sequence which has been resequenced to resolve uncalled bases, extended using XL-PCR kit (Applied Biosystems, Foster City Calif.) in the 5′ and/or the 3′ direction, resequenced or assembled from overlapping sequence found in additional Incyte Clones using a computer program such as the GELVIEW Fragment Assembly system (Genetics Computer Group, Madison Wis.). Most consensus sequences result from both extension and assembly.

[0072] “SIGP” refers to any or all of the human polypeptides, SIGP-1 through SIGP-77.

[0073] A “deletion” refers to a change in an amino acid or nucleotide sequence that results in the absence of one or more amino acid residues or nucleotides.

[0074] “Derivative” refers to the chemical modification of SIGP, of a polynucleotide sequence encoding SIGP, or of the complement of a polynucleotide encoding SIGP. Chemical modifications of a polynucleotide sequence can include, for example, replacement of hydrogen by an alkyl, acyl, or amino group. A derivative polynucleotide encodes a polypeptide which retains at least one biological or immunological function of the natural molecule. A derivative polypeptide is one modified by glycosylation, pegylation, or any similar process that retains at least one biological or immunological function of the polypeptide from which it was derived.

[0075] “Homology” refers to degree of identity. “Percent identity” is determined by comparison of two or more amino acid or nucleic acid sequences. It can be determined electronically using the MegAlign program of LASERGENE software (DNASTAR, Madison Wis.). This program can create alignments between two or more sequences according to a selected method such as the clustal method (Higgins and Sharp (1988) Gene 73:237-244). The clustal algorithm groups sequences into clusters by examining the distances between all pairs. The clusters are first aligned pairwise and then in groups. The percentage identity between two amino acid sequences, for example sequence A and sequence B, is calculated by dividing the length of sequence A, minus the number of gap residues in sequence A, minus the number of gap residues in sequence B, into the sum of the residue matches between sequence A and sequence B, times one hundred. Gaps of low or of no homology between the two amino acid sequences are not included in determining percentage identity. Percent identity between nucleic acid sequences can also be calculated by the Jotun Hein method (Hein (1990) Methods Enzymol 183:626-645). Identity between sequences can also be determined by other methods known in the art, such as by varying hybridization conditions.

[0076] “Hybridization” refers to any process by which a strand of nucleic acid binds with a complementary strand through base pairing. Hybridization efficiency or stringency is determined by salt, temperature, and nucleotide composition.

[0077] “Hybridization complex” refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary bases. A hybridization complex may be formed in solution or formed between one nucleic acid sequence present in solution and another immobilized on a substrate.

[0078] “Immune response” can refer to conditions associated with inflammation, trauma, immune disorders, or infectious or genetic diseases, and the like. These conditions can be characterized by expression of various factors such as cytokines, chemokines, and other signaling molecules, which may affect cellular and systemic defense.

[0079] “Microarray” refers to a distinct arrangement of polynucleotides or oligonucleotides on a substrate.

[0080] “Nucleic acid” refers to an oligonucleotide, polynucleotide, or any fragment thereof, to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent the sense or the antisense strand, to a PNA, or to any DNA-like or RNA-like material. “Fragments” refers to those nucleic acids which are greater than about 60 nucleotides in length, and most preferably are at least about 100 nucleotides, at least about 1000 nucleotides, or at least about 10,000 nucleotides in length.

[0081] “Operably-associated” refer to functionally related nucleic acids. A promoter is operably—associated with a coding sequence if the promoter controls the transcription of the coding sequence.

[0082] “Operably-linked” refers to an attachment by any means which permits functionality of the molecules, compounds, compositions, substrate or apparatus. Nucleic acids may be operably-linked to a substrate for hybridization reactions.

[0083] “Oligonucleotide refers to a nucleic acid of at least about 6 nucleotides to about 60 nucleotides, preferably about 15 to 30 nucleotides, and most preferably about 20 to 25 nucleotides, which can be used in amplification or hybridization. The term is equivalent to “amplimers ”, “primers ”, and “oligomers ”.

[0084] “Peptide nucleic acid” refers to an antisense molecule or anti-gene agent which comprises an oligonucleotide of at least about 5 nucleotides in length linked to a peptide backbone of amino acid residues ending in lysine. The terminal lysine confers solubility to the composition. PNAs preferentially bind complementary single stranded DNA and RNA, act as inhibitors, and may be pegylated to extend their lifespan in the cell (Nielsen et al. (1993) Anticancer Drug Des 8:53-63).

[0085] “Sample” is used in its broadest sense. A sample containing nucleic acid molecules may comprise a bodily fluid; an extract from cell media, a cell, chromosome, organelle, or membrane isolated from a cell; genomic DNA, RNA, or cDNA in solution or bound to a substrate; a cell; a tissue; a tissue print; and the like.

[0086] “Specific binding” refers to a specific interaction between a nucleotide or protein and molecules with which it interacts. These molecules include, but are not limited to, DNA molecules, RNA molecules, peptide nucleic acids, artificial chromosome constructions, peptides, proteins, agonists, antibodies, antagonists, immunoglobulins, inhibitors, drug compounds, peptides, and pharmaceutical agents. The interaction between the polynucleotide or polypeptide and the bound molecule is dependent upon the presence of a particular structure of the polynucleotide or protein recognized by the binding molecule. For example, if an antibody is specific for epitope “A,” the presence of a polypeptide containing the epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A and the antibody will reduce the amount of labeled A that binds to the antibody.

[0087] “Purified” refers to nucleic acid or amino acid sequences that are removed from their natural environment or from cell culture and are isolated or separated from other components with which they are associated.

[0088] A “substitution” refers to the replacement of one or more amino acids or nucleotides by different amino acids or nucleotides, respectively.

[0089] “Substrate” refers to any solid support including, but not limited to, membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, capillaries or other tubing, plates, polymers, and microparticles with a variety of surface forms including wells, trenches, pins, channels and pores to which cells or their nucleic acids have been attached.

[0090] A “variant” of refers to an nucleic or amino acid sequence that is altered by one or more nucleotides or amino acids. The variant may have “conservative” changes, wherein the substituted molecule has similar structural or chemical properties (a purine is substituted for a purine, or a leucine is replaced by an isoleucine). More rarely, a variant may have “nonconservative” changes (a purine is substituted for a pyrimidine or a glycine replaced by a tryptophan). Guidance in determining which nucleotide or amino acid residues may be substituted, added or deleted without abolishing biological or immunological activity may be found using computer programs well known in the art, for example, LASERGENE software (DNASTAR).

[0091] THE INVENTION

[0092] The invention is based on the discovery of new human signal peptide-containing proteins, collectively referred to as SIGP and individually as SIGP-1 through SIGP-77; polynucleotides encoding SIGP, SEQ ID NOs: 78-154; and the use of compositions for the diagnosis or treatment of cancer and immunological disorders. Table 1 shows the SEQ ID NO, Incyte Clone number, cDNA library, and in some cases, the TABLE 1 Protein Nucleotide Clone ID Library NCBI I.D. Homolog species SEQ ID NO:1 SEQ ID NO:78  305841 HEARNOT01 GI 505652 Homo sapiens SEQ ID NO:2 SEQ ID NO:79  322866 EOSIHET02 GI 180141 Homo sapiens SEQ ID NO:3 SEQ ID NO:80  546656 BEPINOT01 GI 2290530 Homo sapiens SEQ ID NO:4 SEQ ID NO:81  693453 SYNORAT03 GI 1419461 Caenorhabditis elegans SEQ ID NO:5 SEQ ID NO:82  866885 BRAITUT03 GI 1488683 Rattus norvegicus SEQ ID NO:6 SEQ ID NO:83 1242271 LUNGNOT03 GI 1523073 Homo sapiens SEQ ID NO:7 SEQ ID NO:84 1255027 LUNGFET03 GI 1684845 Canis familiaris SEQ ID NO:8 SEQ ID NO:85 1273453 TESTTUT02 SEQ ID NO:9 SEQ ID NO:86 1275261 TESTTUT02 GI 56805 Rattus norvegicus SEQ ID NO:10 SEQ ID NO:87 1281682 COLNNOT16 SEQ ID NO:11 SEQ ID NO:88 1298305 BRSTNOT07 SEQ ID NO:12 SEQ ID NO:89 1360501 LUNGNOT12 GI 1019433 Trypanosoma cruzi SEQ ID NO:13 SEQ ID NO:90 1362406 LUNGNOT12 GI 2072705 Mycobacterium tuberculosis SEQ ID NO:14 SEQ ID NO:91 1405329 LATRTUT02 SEQ ID NO:15 SEQ ID NO:92 1415223 BRAINOT12 GI 205250 Rattus norvegicus SEQ ID NO:16 SEQ ID NO:93 1416553 BRAINOT12 SEQ ID NO:17 SEQ ID NO:94 1418517 KIDNN0T09 SEQ ID NO:18 SEQ ID NO:95 1438165 PANCNOT08 GI 1515161 Caenorhabditis elegans SEQ ID NO:19 SEQ ID NO:96 1440381 THYRNOT03 GI 1065459 Caenorhabditis elegans SEQ ID NO:20 SEQ ID NO:97 1510839 LUNGNOT14 GI 2145052 Plasmodium berghei SEQ ID NO:21 SEQ ID NO:98 1534876 SPLNNOT04 SEQ ID NO:22 SEQ ID NO:99 1559131 SPLNNOT04 GI 496667 Saccharomyces cerevisiae SEQ ID NO:23 SEQ ID NO:100 1601473 BLADNOT03 SEQ ID NO:24 SEQ ID NO:101 1615809 BRAITUT12 SEQ ID NO:25 SEQ ID NO:102 1634813 COLNNOT19 GI 2196924 Mus musculus SEQ ID NO:26 SEQ ID NO:103 1638407 UTRSNOT06 GI 200547 Mus musculus SEQ ID NO:27 SEQ ID NO:104 1653112 PROSTUT08 GI 49794 Mus musculus SEQ ID NO:28 SEQ ID NO:105 1664634 BRSTNOT09 GI 1890375 Caenorhabditis elegans SEQ ID NO:29 SEQ ID NO:106 1690990 PROSTUT10 SEQ ID NO:30 SEQ ID NO:107 1704050 DUODNOT02 GI 1814277 Homo sapiens SEQ ID NO:31 SEQ ID NO:108 1711840 PROSNOT16 GI 182651 Homo sapiens SEQ ID NO:32 SEQ ID NO:109 1747327 STOMTUT02 GI 2062391 Homo sapiens SEQ ID NO:33 SEQ ID NO:110 1750632 STOMTUT02 GI 459002 Caenorhabditis elegans SEQ ID NO:34 SEQ ID NO:111 1812375 PROSTUT12 SEQ ID NO:35 SEQ ID NO:112 1818761 PROSNOT20 GI 2493789 Homo sapiens SEQ ID NO:36 SEQ ID NO:113 1824469 GBLATUT01 GI 2052134 Mycobacterium tuberculosis SEQ ID NO:37 SEQ ID NO:114 1864292 PROSNOT19 GI 295671 Saccharomyces cerevisiae SEQ ID NO:38 SEQ ID NO:115 1866437 THP1NOT01 SEQ ID NO:39 SEQ ID NO:116 1871375 SKINBIT01 SEQ ID NO:40 SEQ ID NO:117 1880830 LEUKNOT03 GI 1872521 Arabidopsis thaliana SEQ ID NO:41 SEQ ID NO:118 1905325 OVARNOT07 GI 1754971 Homo sapiens SEQ ID NO:42 SEQ ID NO:119 1919931 BRSTTUT01 GI 2104517 Homo sapiens SEQ ID NO:43 SEQ ID NO:120 1969426 BRSTNOT04 SEQ ID NO:44 SEQ ID NO:121 1969948 UCMCL5T01 SEQ ID NO:45 SEQ ID NO:122 1988911 LUNGAST01 GI 56649 Rattus norvegicus SEQ ID NO:46 SEQ ID NO:123 2061561 OVARNOT03 SEQ ID NO:47 SEQ ID NO:124 2084489 PANCNOT04 GI 2262136 Arabidopsis thaliana SEQ ID NO:48 SEQ ID NO:125 2203226 SPLNFET02 GI 1911776 Homo sapiens SEQ ID NO:49 SEQ ID NO:126 2232884 PROSNOT16 SEQ ID NO:50 SEQ ID NO:127 2328134 COLNNOT11 GI 1911776 Homo sapiens SEQ ID NO:51 SEQ ID NO:128 2382718 ISLTNOT01 GI 1814277 Homo sapiens SEQ ID NO:52 SEQ ID NO:129 2452208 ENDANOT01 SEQ ID NO:53 SEQ ID NO:130 2457825 ENDANOT01 GI 1418625 Caenorhabditis elegans SEQ ID NO:54 SEQ ID NO:131 2470740 THP1NOT03 SEQ ID NO:55 SEQ ID NO:132 2479092 SMCANOT01 SEQ ID NO:56 SEQ ID NO:133 2480544 SMCANOT01 GI 169345 Phaseolus vulgaris SEQ ID NO:57 SEQ ID NO:134 2518547 BRAITUT21 GI 33969 Homo sapiens SEQ ID NO:58 SEQ ID NO:135 2530650 GBLANOT02 GI 2204111 Bos taurus SEQ ID NO:59 SEQ ID NO:136 2652271 THYMNOT04 GI 895855 Solanum lycopersicum SEQ ID NO:60 SEQ ID NO:137 2746976 LUNGTUT11 GI 191983 Mus musculus SEQ ID NO:61 SEQ ID NO:138 2753496 THP1AZS08 GI 987286 Schizosaceharomyces pombe SEQ ID NO:62 SEQ ID NO:139 2781553 OVARTUT03 SEQ ID NO:63 SEQ ID NO:140 2821925 ADRETUT06 SEQ ID NO:64 SEQ ID NO:141 2879068 UTRSTUT05 GI 870749 Homo sapiens SEQ ID NO:65 SEQ ID NO:142 2886757 SINJNOT02 GI 1420026 Saceharomyces cerevisiae SEQ ID NO:66 SEQ ID NO:143 2964329 SCORNOT04 GI 311667 Saceharomyces cerevisiae SEQ ID NO:67 SEQ ID NO:144 2965248 SCORNOT04 GI 1478503 Homo sapiens SEQ ID NO:68 SEQ ID NO:145 3000534 TLYMNOT06 GI 1741868 Homo sapiens SEQ ID NO:69 SEQ ID NO:146 3046870 HEAANOT01 GI 1067079 Caenorhabditis elegans SEQ ID NO:70 SEQ ID NO:147 3057669 PONSAZT01 GI 260241 SEQ ID NO:71 SEQ ID NO:148 3088178 HEAONOT03 GI 498997 Saceharomyces cerevisiae SEQ ID NO:72 SEQ ID NO:149 3094321 BRSTNOT19 GI 793879 Saccharomyces cerevisiae SEQ ID NO:73 SEQ ID NO:150 3115936 LUNGTUT13 GI 517174 Saccharomyces cerevisiae SEQ ID NO:74 SEQ ID NO:151 3116522 LUNGTUT13 GI 1669560 Homo sapiens SEQ ID NO:75 SEQ ID NO:152 3117184 LUNGTUT13 GI 1418628 Caenorhabditis elegans SEQ ID NO:76 SEQ ID NO:153 3125156 LNODNOT05 GI 804750 Homo sapiens SEQ ID NO:77 SEQ ID NO:154 3129120 LUNGTUT12 GI 1256890 Saccharomyces cerevisiae

[0093] NCBI sequence identifier and GenBank description for each of the human signal peptide-containing proteins disclosed herein.

[0094] Nucleic acids encoding SIGP-1 of the present invention were first identified in Incyte Clone 305841 from the heart tissue cDNA library (HEARNOT01) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 78, was derived from Incyte Clones 305841 (HEARNOT01), 22049 (ADENINBO01),168880 (LIVRNOT01), 1321915 (BLADNOT04), and the shotgun sequences SAWA02804, SAWA02781, SAWA01969, and SAWA01937.

[0095] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 1. SIGP-1 is 348 amino acids in length and has a potential amidation site at Q120; a potential N-glycosylation site at N181; two potential casein kinase II phosphorylation sites at S19 and T279; a potential glycosaminoglycan attachment site at S35; and three potential protein kinase C phosphorylation sites at S19, S268, and S343. SIGP-1 shares 56% identity with human GP36b glycoprotein (GI 505652). A fragment of SEQ ID NO: 78 from about nucleotide 117 to about nucleotide 161 is useful for hybridization. Northern analysis shows the expression of this sequence in reproductive, neural, cardiovascular, hematopoietic and immune, and developmental cDNA libraries. Approximately 42% of these libraries are associated with neoplastic disorders, 28% with inflammation, and 21% with cell proliferation.

[0096] Nucleic acids encoding SIGP-2 of the present invention were first identified in Incyte Clone 322866 from the eosinophil cDNA library (EOSIHET02) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 79, was derived from Incyte Clones 322866 (EOSIHET02), 470107 (MMLR1DT01), 873933 (LUNGAST01), and 2268817 (UTRSNOT02).

[0097] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 2. SIGP-2 is 194 amino acids in length and has two potential N-glycosylation sites at N129 and N148; two potential casein kinase II phosphorylation sites at S74 and S151; four potential protein kinase C phosphorylation sites at S5, S74, S130, and S163; a potential tyrosine kinase phosphorylation site at Y171; two potential prokaryotic membrane lipoprotein lipid attachment sites at F15 and S61; and a transmembrane 4 protein family signature from G60 to L82. SIGP-2 shares 90% identity with CD53, a human cell surface antigen (GI 180141). The fragment of SEQ ID NO: 79 from about nucleotide 624 to about nucleotide 686 is useful for hybridization. Northern analysis shows the expression of this sequence in hematopoietic and immune, gastrointestinal, cardiovascular, reproductive, musculoskeletal, and neural cDNA libraries. Approximately 54% of these libraries are associated with inflammation, 39% with neoplastic disorders, and 11% with cell proliferation.

[0098] Nucleic acids encoding SIGP-3 of the present invention were first identified in Incyte Clone 546656 from the bronchial epithelium primary cell line cDNA library (BEPINOT01) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 80, was derived from Incyte Clones 546656 (BEPINOT01), 1316266 (BLADTUT02), 2095988 (BRAITUT02), 1318172 (BLADNOT04), 2809506 (TLYMNOT04), 1293412 and 1293630 (PGANNOT03), 2585048 (BRAITUT22), 2941370 (HEAONOT03), 2297230 (BRSTNOT05), 1233586 (LUNGFET03), and the shotgun sequence SAEA02986.

[0099] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 3. SIGP-3 is 342 amino acids in length and has a potential amidation site at H4; a potential N-glycosylation site at N23; seven potential casein kinase II phosphorylation sites at S38, T90, T105, T124, S139, T284, and T324; three potential protein kinase C phosphorylation sites at S25, T71, and S200; two potential tyrosine kinase phosphorylation sites at Y13 and Y69; and a beta-transducin family Trp-Asp repeats signature sequence from I282 to I296. SIGP-3 shares 100% identity with human HAN11 (GI 2290530). The fragment of SEQ ID NO: 80 from about nucleotide 107 to about nucleotide 139 is useful for hybridization. Northern analysis shows the expression of this sequence in reproductive, cardiovascular, hematopoietic and immune, neural, urologic, and developmental cDNA libraries. Approximately 43% of these libraries are associated with neoplastic disorders, 25% with inflammation, and 20% with cell proliferation.

[0100] Nucleic acids encoding SIGP-4 of the present invention were first identified in Incyte Clone 693453 from the synovial membrane cDNA library (SYNORAT03) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 81, was derived from Incyte Clones 693453 (SYNORAT03), 2505458 (CONUTUT01), 1527363 (UCMCL5T01), 1275308 (TESTTUT02), 1377126 (LUNGNOT10), 538256 (LNODNOT02), 3125441 (LNODNOT05), 1955296 (CONNNOT01), 1821536 (GBLATUT01), 2055631 (BEPINOT01), and 2028161 (KERANOT02).

[0101] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 4. SIGP-4 is 656 amino acids in length and has a potential N-glycosylation site at N73, nine potential casein kinase II phosphorylation sites at S140, S191, T250, T252, S330, S340, S517, S617, and T630; a potential leucine zipper pattern from L430 to L451; four potential N-myristoylation sites at G77, G246, G484, and A651; eleven potential protein kinase C phosphorylation sites at S18, T90, S93, T318, S490, S503, S532, T565, T608, S609, and T629; and a potential tyrosine kinase phosphorylation site at Y326. SIGP-4 shares 20% identity with Caenorhabditis elegans protein encoded by T01G9.4 (GI 1419461). The fragment of SEQ ID NO: 81 from about nucleotide 202 to about nucleotide 255 is useful for hybridization. Northern analysis shows the expression of this sequence in reproductive, hematopoietic and immune, neural, and developmental cDNA libraries. Approximately 40% of these libraries are associated with neoplastic disorders, 30% with inflammation, and 30% with cell proliferation.

[0102] Nucleic acids encoding SIGP-5 of the present invention were first identified in Incyte Clone 866885 from the brain tumor cDNA library (BRAITUT03) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 82, was derived from Incyte Clones 866885 (BRAITUT03), 2991983 (KIDNFET02), 067954 (HUVESTB01), and 1499109 (SINTBST01).

[0103] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 5. SIGP-5 is 236 amino acids in length and has a potential N-glycosylation site at N199; two potential casein kinase II phosphorylation sites at S8 and T72; a potential N-myristoylation site at G169; and three potential protein kinase C phosphorylation sites at T43, S96, and T201. SIGP-5 shares 24% identity with rat syntaxin (GI 1488683). The fragment of SEQ ID NO: 82 from about nucleotide 43 to about nucleotide 93 is useful for hybridization. Northern analysis shows the expression of this sequence in hematopoietic and immune, reproductive, gastrointestinal, neural, cardiovascular, and developmental cDNA libraries. Approximately 43% of these libraries are associated with neoplastic disorders, 26% with inflammation, and 19% with cell proliferation.

[0104] Nucleic acids encoding SIGP-6 of the present invention were first identified in Incyte Clone 1242271 from the lung tissue cDNA library (LUNGNOT03) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 83, was derived from Incyte Clones 1242271 (LUNGNOT03), 968114 (BRSTNOT05), 1251728 (LUNGFET03), and the shotgun sequence SAZA00142.

[0105] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 6. SIGP-6 is 195 amino acids in length and has a potential cAMP- and cGMP-dependent protein kinase phosphorylation site at S79; six potential casein kinase II phosphorylation sites at S79, T85, S113, T166, T171, and T188; three potential protein kinase C phosphorylation sites at S20, S150, and S185; and a potential mitochondrial energy transfer proteins signature from P25 to Y33. The fragment of SEQ ID NO: 83 from about nucleotide 98 to about nucleotide 133 is useful for hybridization. Northern analysis shows the expression of this sequence in urologic, neural, reproductive, and cardiovascular cDNA libraries. Approximately 50% of these libraries are associated with neoplastic disorders, 14% with inflammation, and 21% with cell proliferation.

[0106] Nucleic acids encoding SIGP-7 of the present invention were first identified in Incyte Clone 1255027 from the fetal lung cDNA library ( LUNGFET03) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 84, was derived from Incyte Clones 1255027 (LUNGFET03), 2055704 (BEPINOT01), 1351096 (LATRTUT02), 835188 (PROSNOT07), and 1695810 (COLNNOT23).

[0107] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 7. SIGP-7 is 608 amino acids in length and has a potential amidation site at T112; five potential N-glycosylation sites at N73, N110, N410, N436, and N478; two potential cAMP- and cGMP-dependent protein kinase phosphorylation sites at S123 and S185; ten potential casein kinase II phosphorylation sites at T2, S75, S166, S170, S185, S274, S463, S505, S517, and T588; and thirteen potential protein kinase C phosphorylation sites at T19, S32, S46, T112, T221, S274, S299, T337, S373, S412, S431, S438, and S555. SIGP-7 shares 16% identity with canine pinin (GI 1684845). The fragment of SEQ ID NO: 84 from about nucleotide 181 to about nucleotide 219 is useful for hybridization. Northern analysis shows the expression of this sequence in reproductive, gastrointestinal, neural, cardiovascular, and developmental cDNA libraries. Approximately 43% of these libraries are associated with neoplastic disorders, 21 % with inflammation, and 20% with cell proliferation.

[0108] Nucleic acids encoding SIGP-8 of the present invention were first identified in Incyte Clone 1273453 from the testicle cDNA library (TESTTUT02) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 85, was derived from Incyte Clones 1273453 (TESTTUT02), 1970337 (UCMCL5T01), 1218926 (NEUTGMT01), 1881349 (LEUKNOT03), and 1722377 (BLADNT06).

[0109] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 8. SIGP-8 is 267 amino acids in length and has a potential N glycosylation site at N230, five potential casein kinase II phosphorylation sites at S9, T45, T77, S190, and T263, and two potential protein kinase C phosphorylation sites at S232 and S236. The fragment of SEQ ID NO: 85 from about nucleotide 140 to about nucleotide 175 is useful for hybridization. Northern analysis shows the expression of this sequence in reproductive, cardiovascular, and hematopoietic and immune cDNA libraries. Approximately 42% of these libraries are associated with neoplastic disorders and 40% with immune response.

[0110] Nucleic acids encoding SIGP-9 of the present invention were first identified in Incyte Clone 1275261 from the testicle cDNA library (TESTTUT02) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 86, was derived from Incyte Clones 1275261 (TESTTUT02), 775078 (COLNNOT05), 514772 (MMLR1DT01), and 3224071 (COLNNON03).

[0111] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 9. SIGP-9 is 285 amino acids in length and has a potential amidation site at S260, three potential N glycosylation sites at N85, N100 and N156, a potential cAMP- and cGMP-dependent protein kinase phosphorylation site at T168, three potential casein kinase II phosphorylation sites at T168, T215, and S230, three potential protein kinase C phosphorylation sites at S163, S230, and S260, and a potential tyrosine kinase phosphorylation site at Y72. SIGP-9 shares 24% identity with rat OX-45 antigen preprotein (GI 56805). The fragment of SEQ ID NO: 86 from about nucleotide 243 to about nucleotide 293 is useful for hybridization. Northern analysis shows the expression of this sequence in reproductive, gastrointestinal, and hematopoietic and immune cDNA libraries. Approximately 50% of these libraries are associated with neoplastic disorders and 50% with immune response.

[0112] Nucleic acids encoding SIGP-10 of the present invention were first identified in Incyte Clone 1281682 from the colon cDNA library (COLNNOT16) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 87, was derived from Incyte Clones 2681940 (SINIUCT01), 1335652 (COLNNOT13), 2079572 (UTRSNOT08), 627405 (PGANNOT01) and 1281682 and 1282887 (COLNNOT16).

[0113] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 10. SIGP-10 comprises a peptide of 76 amino acids in length, and has a potential signal peptide sequence from M1 to S18. The fragment of SEQ ID NO: 87 encoding the potential signal peptide sequence from about nucleotide 908 through 970 is useful for hybridization. Northern analysis shows the expression of this sequence in gastrointestinal, neural, reproductive, and hematopoietic and immune cDNA libraries. Approximately 32% of these libraries are associated with neoplastic disorders and 53% with immune response.

[0114] Nucleic acids encoding SIGP-11 of the present invention were first identified in Incyte Clone 1298305 from the breast cDNA library (BRSTNOT09) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 88, was derived from Incyte Clones 1298305 (BRSTNOT09), 3451203 (UTRSNON03), 2529672 (GBLAN0502), 2780863 (OVARTUT03), 927988 (BRAINOT04), 1684424 (PROSNOT15), 2243053 (PANCTUT02), and shotgun sequences SANA03310 and SANA00700.

[0115] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 11. SIGP-11 is 147 amino acids in length and has a prokaryotic membrane lipoprotein lipid attachment site from L34 through C44. SIGP-11 also has a potential cAMP- and cGMP-dependent protein kinase phosphorylation site at S91, and a potential protein kinase C phosphorylation site at S13. The fragment of SEQ ID NO: 88 from about nucleotide 1561 to about nucleotide 1611 is useful for hybridization. Northern analysis shows the expression of this sequence in reproductive, gastrointestinal, and neural cDNA libraries. Approximately 50% of these libraries are associated with neoplastic disorders and 22% with immune response.

[0116] Nucleic acids encoding SIGP-12 of the present invention were first identified in Incyte Clone 1360501 from the lung cDNA library (LUNGNOT12) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 89, was derived from Incyte Clones 1360501 (LUNGNOT12), 2121661 (BRSTNOT07), 1706518 (DUODNOT02) and shotgun sequences SAJA02519, SAJA00749, SAJA01160, and SANA00513.

[0117] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 12. SIGP-12 is 261 amino acids in length and has six potential N glycosylation sites at N19, N28, N98, N104, N164 and N178. SIGP-12 also has five potential casein kinase II phosphorylation sites at T82, S83, T91, T160, and S233, and nine potential protein kinase C phosphorylation sites at T35, T60, T82, S121, S131, T184, S233, S237, and T242. SIGP-12 shares 22% identity with Trypanosoma cruzi mucin-like protein (GI 1019433). In addition, SIGP-12 shares two potential phosphorylation sites and a potential N-glycosylation site with the mucin-like protein. The fragment of SEQ ID NO: 89 from about nucleotide 183 to about nucleotide 236 is useful for hybridization. Northern analysis shows the expression of this sequence in reproductive, cardiovascular, and gastrointestinal cDNA libraries. Approximately 39% of these libraries are associated with neoplastic disorders and 26% with immune response.

[0118] Nucleic acids encoding SIGP-13 of the present invention were first identified in Incyte Clone 1362406 from the lung cDNA library (LUNGNOT12) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 90, was derived from Incyte Clones 1362406 (LUNGNOT12), 1854401 (HNT3AZT01), 1570003 (UTRSNOT05) and shotgun sequences SANA03704, SANA00366, and SANA02152.

[0119] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 13. SIGP-13 is 213 amino acids in length and has three potential protein kinase C phosphorylation sites at T40, S136, and T166. In addition, SIGP-13 has a highly hydrophobic signal peptide sequence from residue M1 to E34. SIGP-13 shares 20% identity with a Mycobacterium tuberculosis membrane protein (GI 2072705). The fragment of SEQ ID NO: 90 encoding the potential signal peptide sequence domain from about nucleotide 157 to about nucleotide 219 is useful for hybridization. Northern analysis shows the expression of this sequence in reproductive, developmental, neural, and cardiovascular cDNA libraries. Approximately 50% of these libraries are associated with neoplastic disorders and 18% with immune response.

[0120] Nucleic acids encoding SIGP-14 of the present invention were first identified in Incyte Clone 1405329 from the heart cDNA library (LATRTUT02) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 91, was derived from Incyte Clones 1405329 (LATRTUT02), and 2830813 (TLYMNOT03).

[0121] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 14. SIGP-14 is 67 amino acids in length and has a cell attachment sequence comprising R13 through D15. In addition, SIGP-14 has a potential casein kinase II phosphorylation site at T12, and a potential protein kinase C phosphorylation site at T42. The fragment of SEQ ID NO: 91 from about nucleotide 36 to about nucleotide 95 is useful for hybridization. Northern analysis shows the expression of this sequence in cardiovascular, developmental, reproductive, and hematopoietic and immune cDNA libraries. Approximately 43% of these libraries are associated with neoplastic disorders and 21% with immune response.

[0122] Nucleic acids encoding SIGP-15 of the present invention were first identified in Incyte Clone 1415223 from the brain cDNA library (BRAINOT12) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 92, was derived from Incyte Clones 1415223 (BRAINOT12) and 529786 (BRAINOT03).

[0123] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 15. SIGP-15 is 161 amino acids in length and has a potential N-glycosylation site at N57, two potential casein kinase II phosphorylation sites at S84 and S96, and five potential protein kinase C phosphorylation sites at S11, T62, S75, S83, and S84. SIGP-15 shares 30% identity with rat Ly6C antigen (GI 205250). The fragment of SEQ ID NO: 92 from about nucleotide 28 to about nucleotide 81 is useful for hybridization. Northern analysis shows the expression of this sequence in developmental, reproductive, and neural cDNA libraries. Approximately 33% of these libraries are associated with neoplastic disorders, 33% with cell proliferation, and 17% with immune response.

[0124] Nucleic acids encoding SIGP-16 of the present invention were first identified in Incyte Clone 1416553 from the brain cDNA library (BRAINOT12) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 93, was derived from Incyte Clones 1416553 (BRAINOT12), 663124 (BRAINOT03) and shotgun sequences SANA01409, SANA03513, and SANA02713.

[0125] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 16. SIGP-16 is 141 amino acids in length and has a glycosaminoglycan attachment site at S20. In addition, SIGP-16 has a potential casein kinase II phosphorylation site at S61, and a potential protein kinase C phosphorylation site at S53. The fragment of SEQ ID NO: 93 from about nucleotide 784 to about nucleotide 831 is useful for hybridization. Northern analysis shows the expression of this sequence in neural cDNA libraries. Approximately 27% of these libraries are associated with neoplastic disorders, and 27% with neurological disorders.

[0126] Nucleic acids encoding SIGP-17 of the present invention were first identified in Incyte Clone 1418517 from the kidney cDNA library (KIDNNOT09) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 94, was derived from Incyte Clones 1418517 (KIDNNOT09), 2456866 (ENDANOT01), 136927 (SYNORAB01), 1620442 (BRAITUT13), 1492394 (PROSNON01), 1534435 (SPLNNOT04), and 2505923 (CONUTUT01).

[0127] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 17. SIGP-17 is 152 amino acids in length and has a potential N glycosylation site at N76; a potential cAMP- and cGMP-dependent protein kinase phosphorylation site at T67; four potential casein kinase II phosphorylation sites at S9, T30, S107, and S 124; and three potential protein kinase C phosphorylation sites at T30, S34, and T78. The fragment of SEQ ID NO: 94 from about nucleotide 49 to about nucleotide 99 is useful for hybridization. Northern analysis shows the expression of this sequence in reproductive, cardiovascular, musculoskeletal, and gastrointestinal cDNA libraries. Approximately 44% of these libraries are associated with neoplastic disorders, 23% with immune response, and 20% with cell proliferation.

[0128] Nucleic acids encoding SIGP-18 of the present invention were first identified in Incyte Clone 1438165 from the pancreas cDNA library (PANCNOT08) using a computer search for amino acid alignments. A consensus sequence, SEQ ID NO: 95, was derived from Incyte Clones 360389 (SYNORAB01), 485693 (HNT2RAT01), 1233177 (LUNGFET03), 1255551 (MENITUT03),1438165 (PANCNOT08),1554990 (BLADTUT04), and shotgun sequences SAOA00854 and SAOA00855.

[0129] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 18. SIGP-18 is 742 amino acids in length and has a potential N-glycosylation site at N448; a microbodies C-terminal targeting signal in the triplet N740HL; twelve potential casein kinase II phosphorylation sites at S3, S53, S120, T122, T169, T178, S179, S195, T284, S290, S400, and S573; five potential protein kinase C phosphorylation sites at T178, S195, S208, S299, and S364; and two potential tyrosine kinase phosphorylation sites at Y296 and Y512. Cysteine residues, representing potential intramolecular disulfide bridging sites, are found at residues C87, C204, C312, C339, C343, C469, C497, C558, C657, C693, and C720. SIGP-18 shares 19% homology with C. elegans protein encoded by M163.4 (GI 1515161), including eight of the eleven cysteine residues found in SIGP-18. The fragment of SEQ ID NO: 95 from about nucleotide 322 to about nucleotide 387 is useful for hybridization. Northern analysis shows the expression of this sequence in cardiovascular, male and female reproductive, and gastrointestinal cDNA libraries. Approximately 44% of these libraries are associated with neoplastic disorders, 23% with inflammation and the immune response, and 19% with fetal development.

[0130] Nucleic acids encoding SIGP-19 of the present invention were first identified in Incyte Clone 1440381 from the thyroid cDNA library (THYRNOT03) using a computer search for amino acid alignments. A consensus sequence, SEQ ID NO: 96, was derived from Incyte Clones 989671 (COLNNOT11),1440381 (THYRNOT03), 3507668 (CONCNOT01), and shotgun sequences SAOA03364, SAOA02692, SAOA00489, SAOA02355, SAOA02405, SAOA01209, SAOA00809, and SAOA00274.

[0131] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 19. SIGP-19 is 805 amino acids in length and has three potential N-glycosylation sites at N211, N215, and N327; one cAMP- and cGMP-dependent protein kinase potential phosphorylation sites at T749; sixteen potential casein kinase II phosphorylation sites at S8, T54, T175, T228, S229, S250, S292, S329, T390, S401, S415, S471, S492, S671, T780, and S795; ten potential protein kinase C phosphorylation sites at S206, T396, S401, S442, T455, S600, S671, T683, S730, and S795; and two potential tyrosine kinase phosphorylation sites at Y437 and Y476. SIGP-19 shares 33% homology with a ubiquitin-conjugating, E2-like enzyme from C. elegans (GI 1065459). Both molecules share a “UBC domain” characteristic of ubiquitin-conjugating enzymes extending from approximately residue V559 to I647 of SIGP-19, and containing an active site cysteine residue, C614, required for thiolester formation. A characteristic proline-rich region, found at the N-terminal end of the UBC domain and extending from approximately P564 to P589 in SIGP-19, is also shared by both proteins. The fragment of SEQ ID NO: 96 from about nucleotide 1678 to about nucleotide 1800 is useful for hybridization. Northern analysis shows the expression of this sequence in cardiovascular and male and female reproductive cDNA libraries. Approximately 50% of these libraries are associated with neoplastic disorders, 14% with inflammation and the immune response, and 19% with fetal development.

[0132] Nucleic acids encoding SIGP-20 of the present invention were first identified in Incyte Clone 1510839 from the lung cDNA library (LUNGNOT14) using a computer search for amino acid alignments. A consensus sequence, SEQ ID NO: 97, was derived from Incyte Clones 962326 (BRSTTUT03), 1383254 (BRAITUT08), 1510839 (LUNGNOT14), 1970949 (UCMCL5T01), 2214224 (SINTFET03), and shotgun sequences SAOA01059 and SAOA02595.

[0133] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 20. SIGP-20 is 195 amino acids in length and has a potential signal peptide sequence between M1 and A39. SIGP-20 also has a potential N-glycosylation site at N83; and three potential casein kinase II phosphorylation sites at T161, T169, and T181; and three potential protein kinase C phosphorylation sites at T121, T143, and T153. SIGP-20 shares 21% homology with Plasmodium berghei merozoite surface protein-1 (GI 2145052). The fragment of SEQ ID NO: 97 from about nucleotide 439 to about nucleotide 502 is useful for hybridization. Northern analysis shows the expression of this sequence in cardiovascular, male and female reproductive, and developmental cDNA libraries. Approximately 48% of these libraries are associated with neoplastic disorders, 13% with inflammation and the immune response, and 19% with fetal development.

[0134] Nucleic acids encoding SIGP-21 of the present invention were first identified in Incyte Clone 1534876 from the spleen cDNA library (SPLNNOT04) using a computer search for amino acid alignments. A consensus sequence, SEQ ID NO: 98, was derived from Incyte Clones 1253004 (LUNGFET03), 1382838 (BRAITUT08), 1532501 (SPLNNOT04), 1534876 (SPLNNOT04), 1705806 (DUODNOT02), 1738301 (COLNNOT22), 1926209 (BRSTNOT02), and shotgun sequences SAOA00587, SAOA02048, and SAOA03535.

[0135] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 21. SIGP-21 is 161 amino acids in length and has a potential signal peptide sequence between M1 and C13. SIGP-21 also has 17 cysteine residues with the potential for forming intramolecular disulfide bridges. Six of these cysteine residues, between residues C129 and C152, are found in a signature sequence for trypsin/alpha-amylase inhibitors that form a structure with intramolecular disulfide bridges. SIGP-21 has two potential casein kinase II phosphorylation sites at T25 and S35; and two potential protein kinase C phosphorylation sites at S35 and T87. The fragment of SEQ ID NO: 98 from about nucleotide 406 to about nucleotide 477, which encompasses the trypsin/alpha-amylase inhibitor signature sequence, is useful for hybridization. Northern analysis shows the expression of this sequence in gastrointestinal and male and female reproductive cDNA libraries. Approximately 45% of these libraries are associated with neoplastic disorders and 28% with inflammation and the immune response.

[0136] Nucleic acids encoding SIGP-22 of the present invention were first identified in Incyte Clone 1559131 from the spleen cDNA library (SPLNNOT04) using a computer search for amino acid alignments. A consensus sequence, SEQ ID NO: 99, was derived from Incyte Clones 1559131 (SPLNNOT04), 1671080 (BMARNOT03), 1924001 (BRSTTUT01), and shotgun sequences SAPA01073 and SAOA02895.

[0137] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 22. SIGP-22 is 160 amino acids in length and has cysteine residues capable of forming intramolecular disulfide bridges at C40, C47, C108, C114, C129, C154, and C158. SIGP-22 has one potential casein kinase II phosphorylation site at S9 and one potential protein kinase C phosphorylation site at S31. SIGP-22 shares 26% homology with C-215 protein from Saccharomyces cerevisiae (GI 496667), including four of the cysteine residues found in SIGP-22. The fragment of SEQ ID NO: 99 from about nucleotide 154 to about nucleotide 193 is useful for hybridization. Northern analysis shows the expression of this sequence in hematopoietic and male and female reproductive cDNA libraries. Approximately 33% of these libraries are associated with neoplastic disorders and 67% with the immune response.

[0138] Nucleic acids encoding SIGP-23 of the present invention were first identified in Incyte Clone 1601473 from the bladder cDNA library (BLADNOT03) using a computer search for amino acid alignments. A consensus sequence, SEQ ID NO: 100, was derived from Incyte Clones 1601473 (BLADNOT03), and shotgun sequences SAOA00407, SAOA02497, SAOA02747, and SAOA02958.

[0139] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 23. SIGP-23 is 76 amino acids in length and has two cysteine residues with the potential of forming an intramolecular disulfide bridge at C58 and C72. SIGP-23 has one potential casein kinase II phosphorylation site at S7 and three potential protein kinase C phosphorylation sites at S7, T29, and T46. The fragment of SEQ ID NO: 100 from about nucleotide 139 to about nucleotide 180 is useful for hybridization. Northern analysis shows the expression of this sequence in breast, brain, spleen, thyroid, and bladder cDNA libraries. Approximately 33% of these libraries are associated with neoplastic disorders, 17% with neural disorders, and 17% with immune disorders.

[0140] Nucleic acids encoding SIGP-24 of the present invention were first identified in Incyte Clone 1615809 from the brain tumor cDNA library (BRAITUT12) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 101, was derived from Incyte Clones 1615809 (BRAITUT12), 924499 (BRAINOT04), 1273065 (TESTTUT02), 1517058 (PANCTUT01), 1596867 (BRAINOT14), and 1361446 (LUNGNOT12), and shotgun sequence SAOA02975.

[0141] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 24. SIGP-24 is 336 amino acids in length and has 13 potential phosphorylation sites at T27, T72, S74, S76, T99, S104, S109, S140, S178, S210, T281, S326, S39. SIGP-24 also has a potential signal peptide sequence between M1 and Y18. The fragment of SEQ ID NO: 101 from about nucleotide 187 to about nucleotide 247 is useful for hybridization. Northern analysis shows the expression of this sequence in cardiovascular, gastrointestinal, neural, and reproductive cDNA libraries. Approximately 48% of these libraries are associated with neoplastic disorders and 21 % with immune response.

[0142] Nucleic acids encoding SIGP-25 of the present invention were first identified in Incyte Clone 1634813 from the cecal tissue cDNA library (COLNNOT19) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 102, was derived from Incyte Clones 1634813 (COLNNOT19), 2904583 (THYMNOT05), 1634813 (COLNNOT19), and 1310492 (COLNFET02), and shotgun sequence SAPA04436.

[0143] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 25. SIGP-25 is 150 amino acids in length and has one potential N-glycosylation site at N139; and five potential phosphorylation sites at T48, S118, S126, S135, and S136. SIGP-25 also has a potential signal peptide sequence encompassing residues M1-A23. SIGP-25 shares 28% identity with mouse beta chemokine, Exodus-2 (GI 2196924). The fragment of SEQ ID NO: 102 from about nucleotide 175 to about nucleotide 235 is useful for hybridization. Northern analysis shows the expression of this sequence in gastrointestinal, developmental, hematopoietic, and immunological cDNA libraries. Approximately 50% of these libraries are associated with fetal development/cell proliferation and 25% with immune response.

[0144] Nucleic acids encoding SIGP-26 of the present invention were first identified in Incyte Clone 1638407 from the myometrial tissue cDNA library (UTRSNOT06) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 103, was derived from Incyte Clones 1638407 (UTRSNOT06), 3541410 (SEMVNOT04), 1290413 (BRAINOT11), 1467841 (PANCTUT02), 1306495 (PLACNOT02), and 1907983 (CONNTUT01).

[0145] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 26. SIGP-26 is 217 amino acids in length and has seven potential phosphorylation sites at T214, S68, S148, S189, S30, S110, and Y149. SIGP-26 also has a potential signal peptide sequence between M1 and G31. SIGP-26 shares 18% identity with a mouse proline-rich protein (GI 200547). The fragment of SEQ ID NO: 103 from about nucleotide 146 to about nucleotide 206 is useful for hybridization. Northern analysis shows the expression of this sequence in gastrointestinal, hematopoietic, immunological, and reproductive cDNA libraries. Approximately 42% of these libraries are associated with neoplastic disorders and 39% with immune response.

[0146] Nucleic acids encoding SIGP-27 of the present invention were first identified in Incyte Clone 1653112 from the prostate tumor tissue cDNA library (PROSTUT08) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 104, was derived from Incyte Clones 1653112 (PROSTUT08), 3450102 (UTRSNON03), 1969850 (UCMCL5T01), 1880259 (LEUKNOT03), 1504393 (BRAITUT07), and 394029 (TMLR2DT01).

[0147] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 27. SIGP-27 is 504 amino acids in length and has eight potential phosphorylation sites at T338, T13, S38, T56, T132, T490, S33, and T472. SIGP-27 also has one potential leucine zipper pattern between L418 and L439. SIGP-27 shares 16% identity with mouse alpha-1 type-X collagen (GI 49794). The fragment of SEQ ID NO: 104 from about nucleotide 130 to about nucleotide 190 is useful for hybridization. Northern analysis shows the expression of this sequence in cardiovascular, endocrine, hematopoietic, immunological, neural, and reproductive cDNA libraries. Approximately 55% of these libraries are associated with neoplastic disorders and 22% with immune response.

[0148] Nucleic acids encoding SIGP-28 of the present invention were first identified in Incyte Clone 1664634 from the breast tissue cDNA library (BRSTNOT09) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 105, was derived from Incyte Clones 1664634 (BRSTNOT09) and 571656 (OVARNON01), and shotgun sequences SAPA04612, SAPA00377, and SAPA03034.

[0149] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 28. SIGP-28 is 320 amino acids in length and has two potential N-glycosylation sites at N122 and N139; and eight potential phosphorylation sites at T30, S52, S109, S162, S220, S96, T258, and S280. SIGP-28 also has a potential signal peptide sequence between M1 and A21. SIGP-28 shares 28% identity with a C. elegans protein encoded by F32A7.4 (GI 1890375). The fragment of SEQ ID NO: 105 from about nucleotide 280 to about nucleotide 340 is useful for hybridization. Northern analysis shows the expression of this sequence in cardiovascular, gastrointestinal, hematopoietic, immunological, neural, and reproductive cDNA libraries. Approximately 38% of these libraries are associated with neoplastic disorders and 32% with immune response.

[0150] Nucleic acids encoding SIGP-29 of the present invention were first identified in Incyte Clone 1690990 from the prostatic tumor tissue cDNA library (PROSTUT10) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 106, was derived from Incyte Clone 1690990 (PROSTUT10), and shotgun sequences SAPA01051, SAPA04063, SAPA01670, SAPA02170, SAPA01946, and SAPA00282.

[0151] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 29. SIGP-29 is 117 amino acids in length and has one potential N-glycosylation site at N96; four potential phosphorylation sites at S16, S34, T78, and S62; and one potential N-myristoylation site at G5. SIGP-29 also has one potential microbodies C-terminal targeting signal at S115. The fragment of SEQ ID NO: 106 from about nucleotide 1000 to about nucleotide 1062 is useful for hybridization. Northern analysis shows the expression of this sequence in gastrointestinal, reproductive, dermal, musculoskeletal, neural, and urogenital cDNA libraries. Approximately 77% of these libraries are associated with neoplastic disorders and 8% with immune response.

[0152] Nucleic acids encoding SIGP-30 of the present invention were first identified in Incyte Clone 1704050 from the duodenal cDNA library (DUODNOT02) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 107, was derived from Incyte Clones 865233 (BRAITUT03), 1359660 (LUNGNOT12), and 1704050 (DUODNOT02) and shotgun sequence SAPA02672.

[0153] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 30. SIGP-30 is 298 amino acids in length and has one potential amidation site at P226; four potential N-glycosylation sites at N98, N187, N236, and N277; seven potential casein kinase II phosphorylation sites at T39, S59, T100, T149, S205, T284, and S286; three potential protein kinase C phosphorylation sites at T52, S58, and S279; a potential signal sequence from M1 to G22; and a potential transmembrane spanning region from M230 to A261. SIGP-30 contains two potential immunoglobulin superfamily domains, from about F29 to about L131 and from about S138 to about R224. SIGP-30 shares 25% identity with the human A33 antigen precursor expressed in normal human colonic and small bowel epithelium and in human colon cancers (GI 1814277). In addition, the position of the hydrophobic transmembrane domain is conserved between these molecules. The cysteine residues at C50, C109, C139, C155, C214, and C254 are conserved between these molecules. The fragment of SEQ ID NO: 107 from about nucleotide 1150 to about nucleotide 1209 is useful for hybridization. Northern analysis shows the expression of this sequence in neural, reproductive, cardiovascular, and endocrine cDNA libraries. Approximately 68% of these libraries are associated with cancer and 9% with immune response.

[0154] Nucleic acids encoding SIGP-31 of the present invention were first identified in Incyte Clone 1711840 from the prostate cDNA library (PROSNOT16) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 108, was derived from Incyte Clones 1711840 (PROSNOT16) and 2550483 (LUNGTUT06) and shotgun sequence SAQA03185.

[0155] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 31. SIGP-31 is 118 amino acids in length and has three potential protein kinase C phosphorylation sites at S48, T103, and S109; and a potential signal peptide sequence from M1 to A20. SIGP-31 shares 61% identity with human midkine, a retinoic acid-responsive heparin binding factor involved in regulation of growth and differentiation (GI 182651). The fragment of SEQ ID NO: 108 from about nucleotide 511 to about nucleotide 555 is useful for hybridization. Northern analysis shows the expression of this sequence in reproductive, gastrointestinal, developmental, neural, and cardiovascular cDNA libraries. Approximately 58% of these libraries are associated with cancer, 16% with immune response, and 23% with fetal/proliferating cells.

[0156] Nucleic acids encoding SIGP-32 of the present invention were first identified in Incyte Clone 1747327 from the stomach tumor cDNA library (STOMTUT02) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 109, was derived from Incyte Clones 475228 (MMLR2DT01), 1500771 (SINTBST01), 1880656 (LEUKNOT03), 1747327 (STOMTUT02), and 2720285 (LUNGTUT10).

[0157] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 32. SIGP-32 is 248 amino acids in length and has one potential N-glycosylation site at N56; three potential casein kinase II phosphorylation sites at S46, S134, and S140; and one potential protein kinase C phosphorylation site at T217. SIGP-32 shares 100% identity with human K12 protein precursor which is expressed in breast cancer cells and peripheral blood leukocytes (GI 2062391). Northern analysis shows the expression of this sequence in gastrointestinal, reproductive, hematopoietic/immune, and cardiovascular cDNA libraries. Approximately 59% of these libraries are associated with cancer and 35% with immune response.

[0158] Nucleic acids encoding SIGP-33 of the present invention were first identified in Incyte Clone 1750632 from the stomach tumor cDNA library (STOMTUT02) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 110, was derived from Incyte Clones 1521122 (BLADTUT04) and 1750632 (STOMTUT02) and shotgun sequences SAEA02182 and SAEA10021.

[0159] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 33. SIGP-33 is 150 amino acids in length and has one potential protein kinase C phosphorylation site at S6. SIGP-33 shares 49% identity with the C. elegans protein encoded by R151.6 (GI 459002). The fragment of SEQ ID NO: 110 from about nucleotide 514 to about nucleotide 573 is useful for hybridization. Northern analysis shows the expression of this sequence in cardiovascular and gastrointestinal cDNA libraries. Approximately 88% of these libraries are associated with cancer and 13% with immune response.

[0160] Nucleic acids encoding SIGP-34 of the present invention were first identified in Incyte Clone 1812375 from the prostate tumor cDNA library (PROSTUT12) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 111, was derived from Incyte Clones 775001 (COLNNOT05), 834305 (PROSNOT07), 1504623 (BRAlTUT07), and 1812375 (PROSTUT12) and shotgun sequences SAQA02414, SATA00657, and SATA01478.

[0161] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 34. SIGP-34 is 431 amino acids in length and has four potential N-glycosylation sites at N11, N49, N73, and N312; one potential cAMP- and cGMP-dependent protein kinase phosphorylation site at S197; six potential casein kinase II phosphorylation sites at T38, S79, S130, S165, S177, and T188; three potential protein kinase C phosphorylation sites at S184, T254, and S337; and a potential high affinity calcium ion-binding, vitamin K-dependent carboxylation domain between W371 and W408. The fragments of SEQ ID NO: 111 from about nucleotide 222 to about nucleotide 282 and the potential carboxylation domain encoded from about nucleotide 1267 to about nucleotide 1380 are useful for hybridization. Northern analysis shows the expression of this sequence in reproductive, neural, gastrointestinal, cardiovascular, and hematopoietic/immune DNA libraries. Approximately 52% of these libraries are associated with cancer, 24% with immune response, and 20% with fetal/proliferating cells.

[0162] Nucleic acids encoding SIGP-35 of the present invention were first identified in Incyte Clone 1818761 from the prostate cDNA library (PROSNOT20) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 112, was derived from Incyte Clone 1818761 (PROSNOT20) and shotgun sequences SAJA00040, SAJA00601, SAJA01791, and SAJA02873.

[0163] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 35. SIGP-35 is 278 amino acids in length and has one potential N-glycosylation site at N91; three potential casein kinase II phosphorylation sites at S9, S125, and S156; two potential protein kinase C phosphorylation sites at S77 and S224; one potential tyrosine kinase phosphorylation site at Y258; and a potential signal sequence from M1to A30. SIGP-35 has fourteen consecutive collagen repeats (G-X-P or G-X-X) from G97 to P138 which could form a triple helical structure. SIGP-35 shares 28% identity with the human adipocyte complement-related protein precursor (Acrp30) (GI 2493789). The fragment of SEQ ID NO: 112 from about nucleotide 157 to about nucleotide 210 is useful for hybridization. Northern analysis shows the expression of this sequence in developmental, dermal, gastrointestinal, hematopoietic/immune, neural, and reproductive cDNA libraries. Approximately 29% of these libraries are associated with cancer, 43% with immune response, and 29% with fetal development.

[0164] Nucleic acids encoding SIGP-36 of the present invention were first identified in Incyte Clone 1824469 from the gallbladder tumor cDNA library (GBLADTUT01) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 113, was derived from Incyte Clones 1664262 (BRSTNOT09), 1733422 (BRSTTUT08), 1824469 (GBLADTUT01), 2057044 (BEPINOT01), and 2449822 (ENDANOT01).

[0165] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 36. SIGP-36 is 286 amino acids in length and has one potential N-glycosylation site at N271; four potential casein kinase II phosphorylation sites at S50, S192, T230, and T251; and five potential protein kinase C phosphorylation sites at T29, T41, S50, T160, and T273. SIGP-36 shares 24% identity with the Mycobacterium tuberculosis protein encoded by MTC1237.14c (GI 2052134). The fragment of SEQ ID NO: 113 from about nucleotide 415 to about nucleotide 468 is useful for hybridization. Northern analysis shows the expression of this sequence in reproductive, gastrointestinal, hematopoietic/immune, and neural cDNA libraries. Approximately 49% of these libraries are associated with cancer, 21% with immune response, and 21% with fetal/proliferating cells.

[0166] Nucleic acids encoding SIGP-37 of the present invention were first identified in Incyte Clone 1864292 from the diseased prostate cDNA library (PROSNOT19) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 114, was derived from Incyte Clone 1864292 (PROSNOT19) and shotgun sequences SARA02195, SARA03070, SARA03675, and SATA02454.

[0167] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 37. SIGP-37 is 404 amino acids in length and has one potential amidation site at V136; one potential cAMP- and cGMP-dependent protein kinase phosphorylation site at S66; twenty potential casein kinase II phosphorylation sites at S23, T27, T74, S110, S111, S118, T122, S143, S145, S205, S207, S218, S219, S220, T252, S254, S328, S330, S385, and T393; and twelve potential protein kinase C phosphorylation sites at T27, S76, T81, S140, S161, S176, S229, T285, S309, S356, S367, and S398. SIGP-37 shares 18% identity with the S. cerevisiae protein encoded by SRP40, a weak suppressor of a mutant of the subunit AC40 of DNA-dependent RNA polymerases I and II (GI 295671). The fragment of SEQ ID NO: 114 f rom about nucleotide 193 to about nucleotide 222 is useful for hybridization. Northern analysis shows the expression of this sequence in reproductive, cardiovascular, and hematopoietic/immune cDNA libraries. Approximately 75% of these libraries are associated with cancer and 25% with immune response.

[0168] Nucleic acids encoding SIGP-38 of the present invention were first identified in Incyte Clone 1866437 from the human promonocyte cell line cDNA library (THP1NOT01) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 115, was derived from Incyte Clones 817970 (OVARTUT01), 825684 (PROSNOT06), 1866437 (THP1NOT01), 2190170 (PROSNOT26), and 3137972 (SMCCNOT02).

[0169] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 38. SIGP-38 is 405 amino acids in length and has one potential N-glycosylation site at N378; one potential cAMP- and cGMP-phosphorylation site at S332; nine potential casein kinase II phosphorylation sites at T34, S51, T77, S107, S158, S264, T266, S296, and S332; and one potential protein kinase C phosphorylation site at S68. The fragment of SEQ ID NO: 115 from about nucleotide 85 to about nucleotide 144 is useful for hybridization. Northern analysis shows the expression of this sequence in reproductive, hematopoietic/immune, neural, and developmental cDNA libraries. Approximately 37% of these libraries are associated with cancer, 33% with immune response, and 22% with fetal/proliferating cells.

[0170] Nucleic acids encoding SIGP-39 of the present invention were first identified in Incyte Clone 1871375 from the leg skin erythema nodosum cDNA library (SKINBIT01) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 116, was derived from Incyte Clones 1428052 (SINTBST01), 1871375 (SKINBIT01), and 3210563 (BLADNOT08).

[0171] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 39. SIGP-39 is 177 amino acids in length and has one potential casein kinase II phosphorylation site at S133; one potential glycosaminoglycan attachment site at S28GGG; and four potential protein kinase C phosphorylation sites at S44, S82, S115, and T148. SIGP-39 contains a signature sequence shared by the binding domains of receptors for lymphokines, hematopoietic growth factors and growth hormone-related molecules at S52RWSLWS. The fragment of SEQ ID NO: 116 encoding the sequence surrounding the receptor binding domain signature from about nucleotide 190 to about nucleotide 249 is useful for hybridization. Northern analysis shows the expression of this sequence in reproductive, cardiovascular, gastrointestinal, and developmental cDNA libraries. Approximately 44% of these libraries are associated with cancer and 19% with immune response.

[0172] Nucleic acids encoding SIGP-40 of the present invention were first identified in Incyte Clone 1880830 from the leukocyte cDNA library (LEUKNOT03) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 117, was derived from Incyte Clones 361577 (PROSNOT01); 2113591 (BRAITUT03); 1880830 (LEUKNOT03) and shotgun sequences SATA03292 and SATA00377.

[0173] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 40. SIGP-40 is 197 amino acids in length and has a potential cAMP- and cGMP-dependent protein kinase phosphorylation site at S121; and four potential protein kinase C phosphorylation sites at T3, S57, T107, and T153. SIGP-40 shares 15% identity with the Arabidopsis thaliana zinc-finger protein Lsd1 (GI 1872521). The fragment of SEQ ID NO: 117 from about nucleotide 567 to about nucleotide 621 is useful for hybridization. Northern analysis shows the expression of this sequence in neural and reproductive cDNA libraries. Approximately 49% of these libraries are associated with neoplastic disorders, 24% with immune response, and 16% with fetal development.

[0174] Nucleic acids encoding SIGP-41 of the present invention were first identified in Incyte Clone 1905325 from the ovary cDNA library (OVARNOT07) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 1 18, was derived from Incyte Clones 1905325 (OVARNOT07); 621454 (PGANNOT01); 621326 (PGANNOT01); 1264490 (SYNORAT05); 487357 (HNT2AGT01); 773311 (COLNCRT01); and shotgun sequence SATA03582.

[0175] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 41. SIGP-41 is 302 amino acids in length and has two potential N-glycosylation sites at N80 and N252; three potential casein kinase II phosphorylation sites at S46, T58, and S143; and four potential protein kinase C phosphorylation sites at T58, S62, T147, and S300. SIGP-41 shares 27% identity with human necdin-related protein (GI 1754971). The fragment of SEQ ID NO: 118 from about nucleotide 1701 to about nucleotide 1800 is useful for hybridization. Northern analysis shows the expression of this sequence in reproductive, neural, and gastrointestinal cDNA libraries. Approximately 51% of these libraries are associated with neoplastic disorders and 20% with immune response, and 18% with fetal development.

[0176] Nucleic acids encoding SIGP-42 of the present invention were first identified in Incyte Clone 1919931 from the breast tumor cDNA library (BRSTTUT01) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 119, was derived from Incyte Clones 1919931 (BRSTTUT01) and shotgun sequences SATA02529, SATA01526 and SATA00892.

[0177] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 42. SIGP-42 is 164 amino acids in length and has one potential casein kinase II phosphorylation site at T68; and two potential protein kinase C phosphorylation sites at T81 and S85. SIGP-42 shares 12% identity with human chemokine receptor (GI 2104517). The fragment of SEQ ID NO: 119 from about nucleotide 585 to about nucleotide 630 is useful for hybridization. Northern analysis shows the expression of this sequence in hematopoietic/immune, reproductive, and neural cDNA libraries. Approximately 50% of these libraries are associated with neoplastic disorders and 38% with immune response.

[0178] Nucleic acids encoding SIGP-43 of the present invention were first identified in Incyte Clone 1969426 from the breast tissue cDNA library (BRSTNOT04) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 120, was derived from Incyte Clones 1969426 (BRSTNOT04), 2373191 (ADRENOT07), 1225516 (COLNTUT02), 1555912 (BLADTUT04), 1449240 (PLACNOT02), and shotgun sequences SAZA01457 and SAZA00207.

[0179] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 43. SIGP-43 is 235 amino acids in length and has one potential N-glycosylation site at N146; one potential glycosaminoglycan attachment site at S82; and four potential protein kinase C phosphorylation sites at T16, T43, S228, and S231. The fragment of SEQ ID NO: 120 from about nucleotide 243 to about nucleotide 282 is useful for hybridization. Northern analysis shows the expression of this sequence in neural, reproductive, hematopoietic/immune, cardiovascular, gastrointestinal, and muscle cDNA libraries. Approximately 46% of these libraries are associated with neoplastic disorders and 28% with immune response.

[0180] Nucleic acids encoding SIGP-44 of the present invention were first identified in Incyte Clone 1969948 from the umbilical cord cDNA library (UCMCL5T01) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 121, was derived from Incyte Clones 1969948 (UCMCL5T01) and shotgun sequences SATA01513 and SATA00507.

[0181] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 44. SIGP-44 is 203 amino acids in length and has three potential casein kinase II phosphorylation sites at T23, S114, and S120; one potential protein kinase C phosphorylation site at T105; and one potential tyrosine kinase phosphorylation site at Y47. The fragment of SEQ ID NO: 121 from about nucleotide 162 to about nucleotide 216 is useful for hybridization. Northern analysis shows the expression of this sequence in gastrointestinal, hematopoietic/immune, reproductive, and cardiovascular cDNA libraries. Approximately 35% of these libraries are associated with neoplastic disorders and 24% with immune response.

[0182] Nucleic acids encoding SIGP-45 of the present invention were first identified in Incyte Clone 1988911 from the lung cDNA library (LUNGAST01) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 122, was derived from Incyte Clones 1988911 (LUNGAST01), 860576 (BRAITUT03), 3188894 (THYMNON04), 1466606 (PANCTUT02), 1920945 (BRSTTUT01), 1502970 (BRAITUT07), and shotgun sequence SAZC00040.

[0183] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 45. SIGP-45 is 359 amino acids in length and has nine potential casein kinase II phosphorylation sites at S34, S47, S115, T120, T141, S157, S182, S214, and S331; three potential protein kinase C phosphorylation sites at S34, T259, and S325; and one potential tyrosine kinase phosphorylation site at Y241. SIGP-45 shares 16% identity with rat myosin heavy chain (GI 56649). The fragment of SEQ ID NO: 122 from about nucleotide 477 to about nucleotide 558 is useful for hybridization. Northern analysis shows the expression of this sequence in reproductive, hematopoietic/immune, gastrointestinal, and cardiovascular cDNA libraries. Approximately 47% of these libraries are associated with neoplastic disorders, 33% with immune response, and 20% with fetal development.

[0184] Nucleic acids encoding SIGP-46 of the present invention were first identified in Incyte Clone 2061561 from the ovary cDNA library (OVARNOT03) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 123, was derived from Incyte Clones 2061561 (OVARNOT03), 2208104 (SINTFET03 ), 2058750 (OVARNOT03), and shotgun sequences SAZA00915, SAZA00150, and SAZA00799.

[0185] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 46. SIGP-46 is 150 amino acids in length and has two potential amidation sites at F57 and W74; one potential cAMP- and cGMP-dependent protein kinase phosphorylation site at T62; two potential casein kinase II phosphorylation sites at T101 and T110; and two potential protein kinase C phosphorylation sites at T28 and T97. The fragment of SEQ ID NO: 123 from about nucleotide 82 to about nucleotide 168 is useful for hybridization. Northern analysis shows the expression of this sequence in reproductive, neural, gastrointestinal, and cardiovascular cDNA libraries. Approximately 54% of these libraries are associated with neoplastic disorders and 22% with immune response.

[0186] Nucleic acids encoding SIGP-47 of the present invention were first identified in Incyte Clone 2084489 from the pancreas cDNA library (PANCNOT04) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 124, was derived from Incyte Clones 2084489 (PANCNOT04) and shotgun sequences SAJA00837, SAJA00793, SAJA01402, SAJA01533, and SAJA01490.

[0187] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 47. SIGP-47 is 402 amino acids in length and has one potential N-glycosylation site at N191; seven potential cAMP- and cGMP-dependent protein kinase phosphorylation sites at S22, S23, T80, S81, S202, S248, and S382; twenty-two potential casein kinase II phosphorylation sites at S8, S35, S56, S107, T152, S166, S170, S202, S206, S208, T212, S214, S216, T244, S252, S256, T264, T287, S288, T327, S362, S387; ten potential protein kinase C phosphorylation sites at S16, S116, S140, T180, S193, S194, T236, T244, S252, and S387; and one potential tyrosine kinase phosphorylation site at Y361. SIGP-47 shares 28% identity with an A. thaliana protein of unknown function (GI 2262136). The most conserved region, residues 296 to 386 of SIGP-47, shares 70% identity with residues 299 to 386 of the A. thaliana protein. In addition, the potential amidation site at A314 in SIGP-47 is conserved as one potential amidation site at Q317 in the A. thaliana protein; and four potential protein kinase C or cAMP- and cGMP dependent protein kinase phosphorylation sites at S193, T236, S252 and Y361 in SIGP-47 are conserved as potential phosphorylation sites at S165, S219, T247, and Y364 respectively in the A. thaliana protein. The fragment of SEQ ID NO: 124 from about nucleotide 468 to about nucleotide 531 is useful for hybridization. Northern analysis shows the expression of this sequence in neural, gastrointestinal and cardiovascular cDNA libraries. Approximately 50% of these libraries are associated with neoplastic disorders and 20% with trauma.

[0188] Nucleic acids encoding SIGP-48 of the present invention were first identified in Incyte Clone 2203226 from the fetal spleen cDNA library (SPLNFET02) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 125, was derived from Incyte Clones 2203226 (SPLNFET02), 2215960 (SINTFET03), 1291348 (BRAINOT11), 1874915 (LEUKNOT02), and 275828 (TESTNOT03).

[0189] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 48. SIGP-48 is 311 amino acids in length and has one potential amidation site at V117; one potential casein kinase II phosphorylation site at T215; and three potential protein kinase C phosphorylation sites at T13, S18, and T263. SIGP-48 shares 32% identity with a human putative Rab5 interacting protein (GI 1911776). The fragment of SEQ ID NO: 125 from about nucleotide 747 to about nucleotide 846 is useful for hybridization. Northern analysis shows the expression of this sequence in reproductive, cardiovascular, neural, and gastrointestinal cDNA libraries. Approximately 44% of these libraries are associated with neoplastic disorders, 30% with fetal/proliferative cells and tissues, and 23% with immune response.

[0190] Nucleic acids encoding SIGP-49 of the present invention were first identified in Incyte Clone 2232884 from the prostate cDNA library (PROSNOT16) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 126, was derived from Incyte Clones 2232884 (PROSNOT16), 2728528 (OVARTUT05), 2232884 (PROSNOT16), and shotgun sequences SASA00238 and SASA00455.

[0191] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 49. SIGP-49 is 316 amino acids in length and has one potential N-glycosylation site at N140; five potential casein kinase II phosphorylation sites at S3, T8, S29, S85, and T198; and two potential protein kinase C phosphorylation sites at T28 and S60. The fragment of SEQ ID NO: 126 from about nucleotide 180 to about nucleotide 279 is useful for hybridization. Northern analysis shows the expression of this sequence in reproductive, urologic, and neural cDNA libraries. Approximately 77% of these libraries are associated with neoplastic disorders.

[0192] Nucleic acids encoding SIGP-50 of the present invention were first identified in Incyte Clone 2328134 from the colon cDNA library (COLNNOT11) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 127, was derived from Incyte Clones 2328134 (COLNNOT11), 1870180 (SKINBIT01), 081403 (SYNORAB01), and 851547 (NGANNOT01).

[0193] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 50. SIGP-50 is 346 amino acids in length and has two potential cAMP- and cGMP-dependent protein kinase phosphorylation sites at residues S43 and S217; one potential casein kinase II phosphorylation site at residue T96; and five potential protein kinase C phosphorylation sites at residues T2, T15, T39, T247, and S301. SIGP-50 shares 33% identity with the human putative rab5-interacting protein (GI 1911776) and the casein kinase II phosphorylation site at residue T96. The fragment of SEQ ID NO: 127 encoding the potential extracellular ligand binding domain from about nucleotide 16 to about nucleotide 76 is useful for hybridization. Northern analysis shows the expression of this sequence in reproductive, gastrointestinal, cardiovascular, and neural cDNA libraries. Approximately 44% of these libraries are associated with cancer, 28% are associated with immune response, and 20% with fetal disorders.

[0194] Nucleic acids encoding SIGP-51 of the present invention were first identified in Incyte Clone 2382718 from the pancreatic cDNA library (ISLTNOT01) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 128, was derived from Incyte Clones 2382718 (ISLTNOT01), 3472492 (LUNGNOT27), 014756 (THP1PLB01), 1731885 (BRSTTUT08), 1889866 (BLADTUT07), and 1447744 (PLACNOT02).

[0195] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 51. SIGP-51 is 299 amino acids in length and has one potential N-glycosylation site at residue N 185; one cAMP- and cGMP-dependent protein kinase phosphorylation site at T273; nine potential casein kinase II phosphorylation sites at S34, S82, T100, S118, T152, S154, T193, S203, and S287; eight potential protein kinase C phosphorylation sites at S57, T69, T95, S179, T269, S274, S275, and S284; and a potential signal peptide sequence from M1 to G27. SIGP-51 shares 26% identity with a human antigen precursor protein (GI 1814277); the protein kinase C phosphorylation sites at residues S57 and T69; and the casein kinase II phosphorylation site at residue T100. The fragment of SEQ ID NO: 128 encoding the potential extracellular ligand binding domain from about nucleotide 88 to about nucleotide 148 is useful for hybridization. Northern analysis shows the expression of this sequence in reproductive, gastrointestinal, and cardiovascular cDNA libraries. Approximately 48% of these libraries are associated with cancer, 29% are associated with immune response, and 20% with fetal disorders.

[0196] Nucleic acids encoding SIGP-52 of the present invention were first identified in Incyte Clone 2452208 from the cardiovascular cDNA library (ENDANOT01) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 129, was derived from Incyte Clones 2452280 (ENDANOT01), 1505094 (BRAITUT07), 1521239 (BLADTUT04), and 1309844 (COLNFET02).

[0197] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 52. SIGP-52 is 351 amino acids in length and has two potential N-glycosylation sites at N241 and N337; two potential cAMP- and cGMP-dependent protein kinase phosphorylation sites at S201 and T318; six potential casein kinase II phosphorylation sites at S9, S136, T162, T252, S270, and S302; eight potential protein kinase C phosphorylation sites at T25, S34, T37, S64, S87, S112, S 141, and S322; and one potential cell attachment sequence at R280GD. The fragment of SEQ ID NO: 129 encoding the potential extracellular ligand binding domain from about nucleotide 97 to about nucleotide 157 is useful for hybridization. Northern analysis shows the expression of this sequence in reproductive, gastrointestinal, cardiovascular, and neural cDNA libraries. Approximately 33% of these libraries are associated with cancer, 33% are associated with immune response, and 26% with fetal disorders.

[0198] Nucleic acids encoding SIGP-53 of the present invention were first identified in Incyte Clone 2457825 from the aortic endothelial cell cDNA library (ENDANOT01) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 130, was derived from Incyte Clone 2457825 (ENDANOT01) and shotgun sequences SASA00641, SASA02817, SASA01973, SASA03121, SASA01350, and SASA00693.

[0199] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 53. SIGP-53 is 662 amino acids in length and has three potential cAMP- and cGMP-dependent protein kinase phosphorylation sites at S555, S578, and S652; ten potential casein kinase II phosphorylation sites at S67, T151, T215, S241, S470, S471, S482, S556, T589, and T618; one potential leucine zipper pattern from L572 to L593; four potential protein kinase C phosphorylation sites at T2, T21, S80, and T503; and one potential LIM domain signature site from C402 to L436. SIGP-53 shares 10% identity with the C. elegans protein encoded by W04D2.1 (GI 1418625); and the casein kinase II phosphorylation site at residue S241. The fragment of SEQ ID NO: 130 encoding the potential extracellular ligand binding domain from about nucleotide 88 to about nucleotide 148 is useful for hybridization. Northern analysis shows the expression of this sequence in hematopoietic, gastrointestinal, reproductive, and cardiovascular cDNA libraries. Approximately 43% of these libraries are associated with cancer, 35% are associated with immune response, and 22% with fetal disorders.

[0200] Nucleic acids encoding SIGP-54 of the present invention were first identified in Incyte Clone 2470740 from the hematopoietic cDNA library (THP1NOT03) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 131, was derived from Incyte Clone 2470740 (THP1NOT03).

[0201] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 54. SIGP-54 is 115 amino acids in length and has one potential protein kinase C phosphorylation site at S85; and one potential insulin family signature site from C23 to C37. The fragment of SEQ ID NO: 131 encoding the potential extracellular ligand binding domain from about nucleotide 151 to about nucleotide 211 is useful for hybridization. Northern analysis shows the expression of this sequence in neural and developmental cDNA libraries. Approximately 33% of these libraries are associated with cancer and 33% are associated with fetal disorders.

[0202] Nucleic acids encoding SIGP-55 of the present invention were first identified in Incyte Clone 2479092 from the aortic endothelial cell cDNA library (SMCANOT01) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 132, was derived from Incyte Clone 2479092 (SMCANOT01) and 1981954 (LUNGTUT03).

[0203] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 55. SIGP-55 is 157 amino acids in length and has one potential casein kinase II phosphorylation site at S31; one potential tyrosine kinase phosphorylation site at K150; and a potential signal peptide sequence from M1 to A26. The fragment of SEQ ID NO: 132 encoding the potential extracellular ligand binding domain from about nucleotide 97 to about nucleotide 157 is useful for hybridization. Northern analysis shows the expression of this sequence in reproductive, gastrointestinal, hematopoietic, and urologic cDNA libraries. Approximately 47% of these libraries are associated with cancer and 29% with immune response.

[0204] Nucleic acids encoding SIGP-56 of the present invention were first identified in Incyte Clone 2480544 from the aortic smooth muscle cell cDNA library (SMCANOT01) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 133, was derived from Incyte Clones 2480544 (SMCANOT01), 2472409 (THP1NOT03), 1516031 (PANCTUT01), 855817 (NGANNOT01), 1865287 (PROSNOT19), and 677835 (CRBLNOT01).

[0205] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 56. SIGP-56 is 197 amino acids in length and has one potential N glycosylation site at N38; one potential casein kinase II phosphorylation site at S123; two potential protein kinase C phosphorylation sites at T71 and S82; and a potential signal peptide sequence from M1 to A27. SIGP-56 shares 15% identity with a Phaseolus vulgaris protein involved in the stress response (GI 169345) and shows conservation of proline and tyrosine residues in the C-terminal region. The fragment of SEQ ID NO: 133 from about nucleotide 125 to about nucleotide 160 is useful for hybridization. Northern analysis shows the expression of this sequence in neural, reproductive, and cardiovascular cDNA libraries. Approximately 49% of these libraries are associated with neoplastic disorders and 14% with immune response.

[0206] Nucleic acids encoding SIGP-57 of the present invention were first identified in Incyte Clone 2518547 from the brain tumor cDNA library (BRAITUT21) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 134, was derived from Incyte Clones 2518547 (BRAITUT21), 1509622 (LUNGNOT14), 1562945 (SPLNNOT04), 1640136 (UTRSNOT06), and 1432014 (BEPINON01).

[0207] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 57. SIGP-57 is 245 amino acids in length and has one potential casein kinase II phosphorylation site at S27; and two potential protein kinase C phosphorylation sites at S5 and T229. SIGP-57 shares 36% identity with a human protein that binds a regulatory element of the c-myc gene (GI 33969). In addition, the potential protein kinase C phosphorylation site at T229 is conserved as a potential protein kinase A phosphorylation site at S176 in the human protein. The fragment of SEQ ID NO: 134 from about nucleotide 742 to about nucleotide 775 is useful for hybridization. Northern analysis shows the expression of this sequence in hematopoietic, reproductive, and neural cDNA libraries. Approximately 50% of these libraries are associated with neoplastic disorders and 28% with immune response.

[0208] Nucleic acids encoding SIGP-58 of the present invention were first identified in Incyte Clone 2530650 from the gallbladder cDNA library (GBLANOT02) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 135, was derived from Incyte Clones 2530650 (GBLANOT02), 2617724 (GBLANOT01), 3105644 (BRSTTUT15), 2903466 (DRGCNOT01), 1545010 (PROSTUT04), 2313837 (NGANNOT01), 1804413 (SINTNOT13), 3207379 (PENCNOT03), 2347051 (TESTTUT02), 2602493 (UTRSNOT10), 1259341 (MENITUT03), and 81943 (SYNORAB01).

[0209] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 58. SIGP-58 is 310 amino acids in length and has one potential N glycosylation site at N206; one potential cAMP- and cGMP-dependent protein kinase phosphorylation site at T97; five potential casein kinase II phosphorylation sites at S62, S156, S214, S222, and T274; five potential protein kinase C phosphorylation sites at T150, T167, T208, T265, and S273; one potential tyrosine kinase phosphorylation site at Y96; one thyroglobulin type-1 repeat signature from F109 to G143; and a potential signal peptide sequence from M1 to A21. SIGP-58 shares 18% identity with bovine thyroglobulin (GI 2204111) and 46% identity between F109 and G143, the thyroglobulin type-1 repeat signature. The fragment of SEQ ID NO: 135 from about nucleotide 92 to about nucleotide 127 is useful for hybridization. Northern analysis shows the expression of this sequence in reproductive and cardiovascular cDNA libraries. Approximately 67% of these libraries are associated with neoplastic disorders and 19% with immune response.

[0210] Nucleic acids encoding SIGP-59 of the present invention were first identified in Incyte Clone 2652271 from the thymus cDNA library (THYMNOT04) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 136, was derived from Incyte Clones 2652271 (THYMNOT04), 2742813 (BRSTTUT14), 763431 (BRAITUT02), 1272403 (TESTTUT02), 1240531 (LUNGNOT03), and 1318448 (BLADNOT04).

[0211] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 59. SIGP-59 is 256 amino acids in length and has three potential N glycosylation sites at N76, N106, and N212; three potential casein kinase II phosphorylation sites at T46, S188, and T204; two potential protein kinase C phosphorylation sites at S130 and S221; two potential ribonuclease T2 family histidine active sites from W62 to P69 and from F110 to C121; and a potential signal peptide sequence from M1 to A24. SIGP-59 shares 24% identity with Solanum lycopersicum ribonuclease LE (GI 895855); 80% identity between W62 and P75, one of the two ribonuclease T2 family histidine active sites; and 92% identity between F110 and C121, the second of the two ribonuclease T2 family histidine active sites. The fragment of SEQ ID NO: 136 from about nucleotide 462 to about nucleotide 494 is useful for hybridization. Northern analysis shows the expression of this sequence in reproductive, hematopoietic, and gastrointestinal cDNA libraries. Approximately 53% of these libraries are associated with neoplastic disorders and 28% with immune response.

[0212] Nucleic acids encoding SIGP-60 of the present invention were first identified in Incyte Clone 2746976 from the lung tumor cDNA library (LUNGTUT1) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 137, was derived from Incyte Clones 2746976 (LUNGTUT11), 488049 (HNT2AGT01), 1907738 (CONNTUT01), 782645 (MYOMNOT01), and 823864 (PROSNOT06).

[0213] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 60. SIGP-60 is 160 amino acids in length and has one potential cAMP- and cGMP-dependent protein kinase phosphorylation site at T31; four potential casein kinase HI phosphorylation sites at S23, S47, S96, and S152; four potential protein kinase C phosphorylation sites at S23, T125, S126, and T149; and a clathrin adaptor complex small chain signature from I56 to F66. SIGP-60 shares 84% identity with mouse clathrin-associated protein 19 (GI 191983) and 91% identity with the clathrin adaptor complex small chain signature between I56 and F66. In addition, all potential casein kinase II and protein kinase C phosphorylation sites are conserved between SIGP-60 and the mouse protein. The fragments of SEQ ID NO: 137 from about nucleotide 144 to about nucleotide 170 and from about nucleotide 495 to about nucleotide 521 are useful for hybridization. Northern analysis shows the expression of this sequence in hematopoietic, cardiovascular, and reproductive cDNA libraries. Approximately 39% of these libraries are associated with neoplastic disorders and 39% with immune response.

[0214] Nucleic acids encoding SIGP-61 of the present invention were first identified in Incyte Clone 2753496 from the THP-1 promonocyte cDNA library (THP1AZS08) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 138, was derived from Incyte Clones 2753496 (THP1AZS08), 2642512 (LUNGTUT08), 1367244 (SCORNON02), 474458 (MMLR1DT01), 1349777 (LATRTUT02), 1380831 (BRAITUT08), and 832934 (PROSTUT04).

[0215] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 61. SIGP-61 is 341 amino acids in length and has one potential N glycosylation site at N66; four potential casein kinase II phosphorylation sites at T157, T207, S296, and S335; two potential protein kinase C phosphorylation sites at S159 and S296; and one potential tyrosine kinase phosphorylation site at Y184. SIGP-61 shares 17% identity with Schizosaccharomyces pombe BEM46, a protein involved in cell polarity (GI 987286) and the potential phosphorylation sites at T157 and S296. The fragment of SEQ ID NO: 138 from about nucleotide 79 to about nucleotide 114 is useful for hybridization. Northern analysis shows the expression of this sequence in reproductive, gastrointestinal, and neural cDNA libraries. Approximately 52% of these libraries are associated with neoplastic disorders and 25% with immune response.

[0216] Nucleic acids encoding SIGP-62 of the present invention were first identified in Incyte Clone 2781553 from the ovarian tumor cDNA library (OVARTUT03) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 139, was derived from Incyte Clones 2781553 (OVARTUT03), 1413079 (BRAINOT12), 894971 (BRSTNOT05), 2696043 (UTRSNOT12), 1267806 (BRAINOT09), 1961608 (BRSTNOT04), 1755817 (LIVRTUT01), 1793882 (PROSTUT05), 1251515 (LUNGFET03), 1560984 (SPLNNOT04), and 1872574 (LEUKNOT02).

[0217] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 62. SIGP-62 is 430 amino acids in length and has one potential cAMP- and cGMP-dependent protein kinase phosphorylation site at S387; thirteen potential casein kinase II phosphorylation sites at S182, S214, S235, T248, S258, T266, T275, T294, S313, T356, S387, T404, and S413; six potential protein kinase C phosphorylation sites at T71, S168, S235, S306, T356, and S374; and a mitochondrial energy transfer protein signature from P114 to L122. Northern analysis shows the expression of this sequence in reproductive, neural, and hematopoietic cDNA libraries. Approximately 47% of these libraries are associated with neoplastic disorders and 19% with immune response.

[0218] Nucleic acids encoding SIGP-63 of the present invention were first identified in Incyte Clone 2821925 from the adrenal tumor cDNA library (ADRETUT06) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 140, was derived from Incyte Clones 2821925 (ADRETUT06), 933799 (CERVNOT01), and 136467 (SYNORAB01).

[0219] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 63. SIGP-63 is 143 amino acids in length and has one potential cAMP- and cGMP-dependent protein kinase phosphorylation site at S109; three potential casein kinase II phosphorylation sites at S36, S80, and T84; five potential protein kinase C phosphorylation sites at T31, T55, T70, S109, and T122; and a potential signal peptide sequence from M1 to A21. Northern analysis shows the expression of this sequence in reproductive, musculoskeletal and cardiovascular cDNA libraries. Approximately 50% of these libraries are associated with neoplastic disorders and 27% with immune response.

[0220] Nucleic acids encoding SIGP-64 of the present invention were first identified in Incyte Clone 2879068 from the uterine tumor cDNA library (UTRSTUT05) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 141, was derived from Incyte Clones 2879068 (UTRSTUT05), 2910155 (KIDNTUT15), 488673 (HNT2AGT01), 1285407 (COLNNOT16), 1415890 (BRAINOT12), 1352662 (LATRTUT02), 41046 (TBLYNOT01), and 2686554 (LUNGNOT23).

[0221] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 64. SIGP-64 is 301 amino acids in length and has two potential N glycosylation sites at N20 and N251; five potential casein kinase II phosphorylation sites at S8, S41, T125, T161, and T163; five potential protein kinase C phosphorylation sites at T40, S41, T59, T66, and S181; one potential tyrosine kinase phosphorylation site at Y176; one potential glycosaminoglycan attachment site at S253; and two putative RNP-1 RNA-binding signatures from R70 to F77 and from R155 to Y162. SIGP-64 shares 59% identity with human heterogeneous nuclear ribonucleoprotein D (GI 870749); 100% identity between R70 and F77, one of the two RNP-1 RNA-binding signatures; and 89% identity between R155 and Y162, the second of the two RNP-1 RNA-binding signatures. In addition, eight potential phosphorylation sites are conserved between SIGP-64 and the human ribonucleoprotein. The fragments of SEQ ID NO: 141 from about nucleotide 207 to about nucleotide 248 and from about nucleotide 726 to about nucleotide 752 are useful for hybridization. Northern analysis shows the expression of this sequence in reproductive, neural, hematopoietic, and gastrointestinal cDNA libraries. Approximately 48% of these libraries are associated with neoplastic disorders and 24% with immune response.

[0222] Nucleic acids encoding SIGP-65 of the present invention were first identified in Incyte Clone 2886757 from the small intestine cDNA library (SINJNOT02) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 142, was derived from Incyte Clones 2886757 (SINJNOT02), 2230747 (PROSNOT16), and 899432 (BRSTTUT03).

[0223] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 65. SIGP-65 is 233 amino acids in length and has two potential N-glycosylation sites at N82 and N196; one potential casein kinase II phosphorylation site at S 170; and two potential protein kinase C phosphorylation sites at S102 and T134. SIGP-65 shares 22% identity with S. cerevisiae protein encoded by YOL135c (GI 1420026), and the potential casein kinase II phosphorylation site at S170 is conserved between the two proteins. The fragment of SEQ ID NO: 142 from about nucleotide 99 to about nucleotide 137 is useful for hybridization. Northern analysis shows the expression of this sequence in reproductive, cardiovascular, and gastrointestinal cDNA libraries. Approximately 59% of these libraries are associated with neoplastic disorders.

[0224] Nucleic acids encoding SIGP-66 of the present invention were first identified in Incyte Clone 2964329 from the cervical spinal cord cDNA library (SCORNOT04) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 143, was derived from Incyte Clones 2964329, (SCORNOT04), 1274814 (TESITUT02), 746049 (BRAITUT01), 1395667 (THYRNOT03), 1362944 (LUNGNOT12), and 2589 (HMC1NOT01).

[0225] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 66. SIGP-66 is 354 amino acids in length and has one potential cAMP- and cGMP-dependent protein kinase phosphorylation site at S346; two potential casein kinase II phosphorylation sites at S164 and T180; six potential protein kinase C phosphorylation sites at S43, S135, S150, S164, S172, and S201; and one potential tyrosine kinase phosphorylation site at Y182. SIGP-66 shares 12% identity with S. cerevisiae mitochondrial internal membrane carrier protein (GI 311667). In addition, one potential protein kinase C site is conserved between these molecules. The fragment of SEQ ID NO: 143 from about nucleotide 416 to about nucleotide 442 is useful for hybridization. Northern analysis shows the expression of this sequence in reproductive, neural, hematopoietic/immune, gastrointestinal, and cardiovascular cDNA libraries. Approximately 46% of these libraries are associated with neoplastic disorders and 26% with immune response. Nucleic acids encoding SIGP-67 of the present invention were first identified in Incyte Clone 2965248 from the cervical spinal cord cDNA library (SCORNOT04) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 144, was derived from Incyte Clones 2965248 (SCORNOT04), 485746 (HNT2RAT01), 865684 (BRAITUT03), 1459157 (COLNFET02), 1597772 (BRAINOT14), 531430 (BRAINOT03), 725362 (SYNOOAT01), 1620429 (BRAITUT13), and 190305 (SYNORAB01).

[0226] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 67 SIGP-67 is 235 amino acids in length and has seven potential cAMP- and cGMP-dependent protein kinase phosphorylation sites at S50, T80, T98, T126, S135, S136, and T194; three potential casein kinase II phosphorylation sites at S60, T80, and S81; six potential protein kinase C phosphorylation sites at S114, T119, T137, S142, S146, and S174; and a strathmin 1 family signature from P75 to E84. SIGP-67 shares 44% identity with human strathmin homolog SCG10/neuron-specific growth-associated protein in Alzheimer's disease (GI 1478503), and 71% identity between M1 and A107. In addition, one potential cAMP- and cGMP-dependent protein kinase phosphorylation site, one potential casein kinase II phosphorylation site, the strathmin 1 family signature, and the hydrophobic transmembrane domains are conserved between these molecules. TM1 extends from about L15 to about F25; and TM2, from about G196 to about P212. The fragments of SEQ ID NO: 144 from about nucleotide 158 to about nucleotide 196 and from about nucleotide 614 to about nucleotide 643 are useful for hybridization. Northern analysis shows the expression of this sequence in neural, reproductive, gastrointestinal, and hematopoietic/immune cDNA libraries. Approximately 50% of these libraries are associated with neoplastic disorders and 19% with immune response.

[0227] Nucleic acids encoding SIGP-68 of the present invention were first identified in Incyte Clone 3000534 from the Th2 T lymphocyte cDNA library (TLYMNOT06) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 145, was derived from Incyte Clones 3000534 (TLYMNOT06), 1830964 (THP1AZT01), 1329136 (PANCNOT07), and 2910083 (KIDNTUT15).

[0228] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 68. SIGP-68 is 221 amino acids in length and has two potential casein kinase II phosphorylation sites at T31 and T70; one potential glycosaminoglycan attachment site at S62; three potential protein kinase C phosphorylation sites at T111, T146, and T199; and an endoplasmic reticulum targeting sequence at H218DEL. SIGP-68 shares 61 % identity with the human stroma cell-derived secretory factor-2 (GI 1741868). In addition, one potential protein kinase C phosphorylation site and the hydrophobic transmembrane domains are conserved between these molecules. TM1 extends from about A10 to about G27; and TM2, from about T31 to about L45. The cysteines at C38, C92, C100, and C149 are conserved between both molecules. The fragments of SEQ ID NO: 145 from about nucleotide 89 to about nucleotide 118 and from about nucleotide 608 to about nucleotide 643 are useful for hybridization. Northern analysis shows the expression of this sequence in hematopoietic/immune, reproductive, cardiovascular, and gastrointestinal cDNA libraries. Approximately 41% of these libraries are associated with neoplastic disorders and 31% with immune response. neoplastic disorders and 24% with immune response.

[0229] Nucleic acids encoding SIGP-70 of the present invention were first identified in Incyte Clone 3057669 from the pons cDNA library (PONSAZT01) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 147, was derived from Incyte Clones 3057669 (PONSAZT01), 548211 (BEPINOT01), 3702516 (PENCNOT07), 3581270 (293TF3T01), 495191 (HNT2NOT01), 2784427 (BRSTNOT13), 1515961 (PANCTUT01), 3552333 (SYNONOT01), 2838668 (DRGLNOT01), 14600680 (COLNFET02), and 285677 (EOSIHET02).

[0230] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 70. SIGP-70 is 371 amino acids in length and has three potential N-glycosylation sites at N70, N125, and N362; eleven potential casein kinase II phosphorylation sites at T22, S66, S72, S73, S102, T160, T201, T215, T278, T285, and S316; seven potential protein kinase C phosphorylation sites at S72, T79, S99, T127, S134, S257, and T299; and one protein kinase signature and profile from L188 to F200. Northern analysis shows the expression of this sequence in gastrointestinal, reproductive, and neural cDNA libraries. Approximately 54% of these libraries are associated with neoplastic disorders and 14% with immune response.

[0231] Nucleic acids encoding SIGP-71 of the present invention were first identified in Incyte Clone 3088178 from the aorta cDNA library (HEAONOT03) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 148, was derived from Incyte Clones 3088178 (HEAONOT03), 589421 (UTRSNOT01), 2059958 (OVARNOT03), 1550631 (PROSNOT06), and 1271480 (TESTTUT02).

[0232] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 71. SIGP-71 is 402 amino acids in length and has two potential N glycosylation sites at N13 and N366; two potential cAMP- and cGMP-dependent protein kinase phosphorylation sites at T50 and S51; five potential casein kinase II phosphorylation sites at T50, S51, S52, S56, and S246; one potential glycosaminoglycan attachment site at S247; eight potential protein kinase C phosphorylation sites at T45, T46, S224, S240, S259, T279, S338, and S376; one potential tyrosine kinase phosphorylation site at Y273; and one beta-transducin family Trp-Asp repeat signature from V243 to V257. SIGP-71 shares 22% identity with S. cerevisiae protein encoded by HRE594 (GI 498997; truncated sequence). In addition, one potential N-glycosylation site, and two potential casein kinase II phosphorylation sites are conserved between these molecules. The fragment of SEQ ID NO: 148 from about nucleotide 725 to about nucleotide 766 is useful for hybridization. Northern analysis shows the expression of this sequence in reproductive, neural, cardiovascular, and hematopoietic/immune cDNA libraries. Approximately 51% of these libraries are associated with neoplastic disorders and 23% with immune response.

[0233] Nucleic acids encoding SIGP-72 of the present invention were first identified in Incyte Clone 3094321 from the breast cDNA library (BRSTNOT19) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 149, was derived from Incyte Clones 3094321 (BRSTNOT19), 2517422H1 (BRAITUT21), 2101110 (BRAITUT02), 1303603 (PLACNOT02), 2675275 (KIDNNOT19), 1988065 (LUNGAST01), 34101 (THP1NOB01), 1815156 (PROSNOT20), 602724 (BRSTTUT01), and 1485067 (CORPNOT02).

[0234] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 72. SIGP-72 is 640 amino acids in length and has four potential N-glycosylation sites at N295, N513, N568, and N619; two potential cAMP- and cGMP-dependent protein kinase phosphorylation sites at S239 and S507; sixteen potential casein kinase II phosphorylation sites at S42, T178, T220, S229, S239, T247, S289, S350, S372, S446, T463, S492, T580, S592, S604, and S625; nine potential protein kinase C phosphorylation sites at T150, T166, T174, S239, T328, S407, T451, S609, and S621; one potential tyrosine kinase phosphorylation site at Y265; and one cytochrome c family heme-binding site signature at C158YECHP. SIGP-72 shares 33% identity with an essential yeast ubiquitin-activating enzyme homolog (GI 793879). In addition, one potential N-glycosylation site, one potential casein kinase II phosphorylation site, and six potential protein kinase C phosphorylation sites are conserved between these molecules. The fragments of SEQ ID NO: 149 from about nucleotide 382 to about nucleotide 423 and from about nucleotide 1087 to about nucleotide 1113 are useful for hybridization. Northern analysis shows the expression of this sequence in reproductive, hematopoietic/immune, cardiovascular, and gastrointestinal cDNA libraries. Approximately 48% of these libraries are associated with neoplastic disorders and 24% with immune response.

[0235] Nucleic acids encoding SIGP-73 of the present invention were first identified in Incyte Clone 3115936 from the lung cDNA library (LUNGTUT13) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 150, was derived from Incyte Clones 3115936 (LUNGTUT13) 2359411 (LUNGFET05), 2189762 (PROSNOT26), 1449756 (PLACNOT02), 541212 (LNODNOT02), 079364 (SYNORAB01), 864877 (BRAITUT03), 2697958 (UTRSNOT12), 1818830 (PROSNOT20), 1966765 (BRSTNOT04), 998279 (KIDNTUT01), 1961616 (BRSTNOT04), and 1431515 (BEPINON01).

[0236] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 73. SIGP-73 is 237 amino acids in length and has five potential casein kinase II phosphorylation sites at S43, S47, S72, S131, and T177; and three potential protein kinase C phosphorylation sites at S39, S125, and T202. SIGP-73 shares 44% identity with t yeast Rer1p protein, which ensures correct localization of Sec12p integral membrane protein of the endoplasmic reticulum (GI 517174). In addition, the hydrophobic transmembrane domains are conserved among these molecules. TM1 extends from about A82 to about P P126; and TM2, from about A166 to about M203. The fragment of SEQ ID NO: 150 from about nucleotide 585 to about nucleotide 623 is useful for hybridization. Northern analysis shows the expression of this sequence in reproductive, neural, cardiovascular, gastrointestinal, and hematopoietic/ immune cDNA libraries. Approximately 48% of these libraries are associated with neoplastic disorders and 24% with immune response.

[0237] Nucleic acids encoding SIGP-74 of the present invention were first identified in Incyte Clone 3116522 from the lung cDNA library (LUNGTUT13) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 151, was derived from Incyte Clones 3116522 (LUNGTUT13), 2523149 (BRAITUT21), 1513583 (PANCTUT01), 834017 (PROSNOT07), 1631796 (COLNNOT19), 1502736 (BRAITUT07), and 78850 (SYNORAB01).

[0238] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 74. SIGP-74 is 432 amino acids in length and has three potential casein kinase II phosphorylation sites at S144, S257, and S317; three potential protein kinase C phosphorylation sites at T68, S231, and T372; and one potential tyrosine kinase phosphorylation site at Y240. SIGP-74 shares 28% identity with the human UDP-galactose transporter isoform (GI 1669560). In addition, one potential protein kinase C phosphorylation site and the hydrophobic transmembrane domains are conserved between these molecules. TM4 extends from about Q108 to about G127; TM5, from about S152 to about L173; TM6, from about K205 to about K228; TM7, from about T242 to about S257; TM8, from about T268 to about S283; TM9, from about A294 to about T328; and TM10, from about A338 to about V409. The fragment of SEQ ID NO: 151 from about nucleotide 710 to about nucleotide 736 is useful for hybridization. Northern analysis shows the expression of this sequence in reproductive, gastrointestinal, cardiovascular, hematopoietic/immune, and urologic cDNA libraries. Approximately 54% of these libraries are associated with neoplastic disorders and 25% with immune response.

[0239] Nucleic acids encoding SIGP-75 of the present invention were first identified in Incyte Clone 3117184 from the lung cDNA library (LUNGTUT13) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 152, was derived from Incyte Clones 3117184 (LUNGTUT13), 2494724 (ADRETUT05), and 1922002 (BRSTTUT01).

[0240] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 75. SIGP-75 is 252 amino acids in length and has one potential N-glycosylation site at N93; one potential cAMP- and cGMP-dependent protein kinase phosphorylation site at S179; one potential casein kinase II phosphorylation site at T189; and five potential protein kinase C phosphorylation sites at S95, S115, S123, T140, and T200. SIGP-75 shares 39% identity with C. elegans protein encoded by WO4D2.6 (GI 1418628). In addition, one potential N-glycosylation site, and three potential protein kinase C phosphorylation sites are conserved between the molecules. The fragment of SEQ ID NO: 152 from about nucleotide 567 to about nucleotide 593 is useful for hybridization. Northern analysis shows the expression of this sequence in cardiovascular, gastrointestinal, hematopoietic/immune, and reproductive cDNA libraries. Approximately 50% of these libraries are associated with neoplastic disorders and 20% with immune response.

[0241] Nucleic acids encoding SIGP-76 of the present invention were first identified in Incyte Clone 3125156 from the lymph node cDNA library (LNODNOT05) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 153, was derived from Incyte Clones 3125156 (LNODNOT05), 1417459 (BRAINOT12), 1567861 (UTRSNOT05), 154233 (THP1PLB02), 872652 (LUNGAST01), 2525803 (BRAITUT21), and 1209172 (BRSTNOT02).

[0242] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 76. SIGP-76 is 523 amino acids in length and has one potential N glycosylation sites at N186; nine potential casein kinase II phosphorylation sites at S63, T85, S179, S188, T210, S231, T269, T295, and S474; one potential glycosaminoglycan attachment site at S335; ten potential protein kinase C phosphorylation sites at T9, S159, S172, S179, T246, S263, S283, S416, S447, and S498; two potential tyrosine kinase phosphorylation sites at Y106 and Y170; and one tyrosine specific protein phosphatase active site at V331. SIGP-76 shares 21% identity with human T-cell protein tyrosine phosphatase (GI 804750), the N186 glycosylation site, the phosphorylation sites at S179, S188, T210, T246, S263, T295, S416, and Y170; and 50% identity between P324 and F344, the region of the tyrosine specific protein phosphatase active site. The fragments of SEQ ID NO: 153 from about nucleotide 64 to about nucleotide 183 and from about nucleotide 1087 to about nucleotide 1119 are useful for hybridization. Northern analysis shows the expression of this sequence in neural, reproductive, and gastrointestinal cDNA libraries. Approximately 55% of these libraries are associated with neoplastic disorders and 22% with immune response.

[0243] Nucleic acids encoding SIGP-77 of the present invention were first identified in Incyte Clone 3129120 from the lung tumor cDNA library (LUNGTUT12) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO: 154, was derived from Incyte Clones 3129120 (LUNGTUT12), 3744590 (THYMNOT08), 1512939 (PANCTUT01), 3220539 (COLNNON03), 1435889 (PANCNOT08), 1452745 (PENITUT01), 874548 (LUNGAST01), 1524326 (UCMCL5T01), and 811239 (LUNGNOT04).

[0244] In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO: 77. SIGP-77 is 621 amino acids in length and has two potential N glycosylation sites at N203 and N517; one potential protein kinase A or G phosphorylation site at S84; five potential casein kinase II phosphorylation sites at T45, T185, T233, T278, and S573; seven potential protein kinase C phosphorylation sites at T45, T95, S109, S299, T318, S324, and T482; and one potential leucine zipper motif from L332 to L353. SIGP-77 shares 27% identity and the phosphorylation site at T318 with S. cerevisiae membrane protein important for endocytosis (GI 1256890). The fragments of SEQ ID NO: 154 from about nucleotide 64 to about nucleotide 183 and from about nucleotide 1087 to about nucleotide 1119 are useful for hybridization. Northern analysis shows the expression of this sequence in reproductive, neural, gastrointestinal, and cardiovascular cDNA libraries. Approximately 53% of these libraries are associated with neoplastic disorders and 17% with immune response.

[0245] The invention also encompasses SIGP variants. A preferred SIGP variant is one which has at least about 80%, more preferably at least about 90%, and most preferably at least about 95% amino acid sequence identity to the SIGP amino acid sequence, and which contains at least one functional or structural characteristic of SIGP.

[0246] The invention also encompasses polynucleotides which encode SIGP. Accordingly, any nucleic acid sequence which encodes the amino acid sequence of SIGP can be used to produce recombinant molecules which express SIGP. In a particular embodiment, the invention encompasses a polynucleotide comprising a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 78-154.

[0247] It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of polynucleotide sequences encoding SIGP, some bearing minimal homology to the polynucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the invention contemplates each and every possible variation of polynucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the polynucleotide sequence of naturally occurring SIGP, and all such variations are to be considered as being specifically disclosed.

[0248] Although nucleotide sequences which encode SIGP and its variants are preferably capable of hybridizing to the nucleotide sequence of the naturally occurring SIGP under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding SIGP or its derivatives possessing a different codon usage. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for altering the nucleotide sequence encoding SIGP and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

[0249] The invention also encompasses production of DNA sequences which encode SIGP and SIGP derivatives, or fragments thereof, entirely by synthetic chemistry. After production, the synthetic sequence may be inserted into any of the many available expression vectors and cell systems using reagents that are well known in the art. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding SIGP or any fragment thereof.

[0250] Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to the claimed polynucleotide sequences, and, in particular, to those shown in SEQ ID NO: 78-154, under various conditions of stringency (Wahl and Berger (1987) Methods Enzymol 152:399-407; Kimmel (1987) Methods Enzymol 152:507-511).

[0251] Methods for DNA sequencing are well known and generally available in the art and may be used to practice any of the embodiments of the invention. The methods may employ such enzymes as the Klenow fragment of DNA polymerase I, SEQUENASE, Taq polymerase, thermostable T7 polymerase (Amersham Pharmacia Biotech (APB), Piscataway N.J.), or combinations of polymerases and proofreading exonucleases such as those found in the ELONGASE Amplification system (Life Technologies, Gaithersburg Md.). Preferably, the process is automated with machines such as the MICROLAB 2200 (Hamilton, Reno Nev.), DNA ENGINE thermal cycler (MJ Research, Watertown Mass.) and the CATALYST and 373 and 377 PRISM DNA sequencing systems (ABI).

[0252] The nucleic acid sequences encoding SIGP may be extended utilizing a partial nucleotide sequence and employing various methods known in the art to detect upstream sequences, such as promoters and regulatory elements. For example, one method which may be employed, restriction-site PCR, uses universal primers to retrieve unknown sequence adjacent to a known locus (Sarkar (1993) PCR Methods Applic 2:318-322). In particular, genomic DNA is first amplified in the presence of a primer complementary to a linker sequence within the vector and a primer specific to the region predicted to encode the gene. The amplified sequences are then subjected to a second round of PCR with the same linker primer and another specific primer internal to the first one. Products of each round of PCR are transcribed with an appropriate RNA polymerase and sequenced using reverse transcriptase.

[0253] Inverse PCR may also be used to amplify or extend sequences using divergent primers based on a known region (Triglia et al. (1988) Nucleic Acids Res 16:8186). The primers may be designed using commercially available software such as OLIGO software (Molecular Biology Insights, Cascade Colo.) or another appropriate program to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68° C. to 72° C. The method uses several restriction enzymes to generate a fragment in the known region of a gene. The fragment is then circularized by intramolecular ligation and used as a PCR template.

[0254] Another method which may be used is capture PCR, which involves PCR amplification of DNA fragments adjacent to a known sequence in human and yeast artificial chromosome DNA (Lagerstrom et al. (1991) PCR Methods Applic 1:111-119). In this method, multiple restriction enzyme digestions and ligations may be used to place an engineered double-stranded sequence into an unknown fragment of the DNA molecule before performing PCR. Other methods which may be used to retrieve unknown sequences are known in the art (Parker et al. (1991) Nucleic Acids Res 19:3055-3060). Additionally, one may use PCR, nested primers, and PROMOTERFINDER libraries (Clontech, Palo Alto Calif.) to walk genomic DNA. This process avoids the need to screen libraries and is useful in finding intron/exon junctions.

[0255] When screening for full-length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. Also, random-primed libraries are preferable in that they will include more sequences which contain the 5′ regions of genes. Use of a randomly primed library may be especially preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5′ non-transcribed regulatory regions.

[0256] Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different fluorescent dyes (one for each nucleotide) which are laser activated, and a charge coupled device camera for detection of the emitted wavelengths. Output/light intensity may be converted to electrical signal using appropriate software (GENOTYPER and SEQUENCE NAVIGATOR, ABI), and the entire process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for the sequencing of small pieces of DNA which might be present in limited amounts in a particular sample.

[0257] In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode SIGP may be used in recombinant DNA molecules to direct expression of SIGP, or fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode the same or a functionally equivalent amino acid sequence may be produced, and these sequences may be used to clone and express SIGP.

[0258] As will be understood by those of skill in the art, it may be advantageous to produce SIGP-encoding nucleotide sequences possessing non-naturally occurring codons. For example, codons preferred by a particular prokaryotic or eukaryotic host can be selected to increase the rate of protein expression or to produce an RNA transcript having desirable properties, such as a half-life which is longer than that of a transcript generated from the naturally occurring sequence.

[0259] The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter SIGP-encoding sequences for a variety of reasons including, but not limited to, alterations which modify the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, site-directed mutagenesis may be used to insert new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, introduce mutations, and so forth.

[0260] In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences encoding SIGP may be ligated to a heterologous sequence to encode a fusion protein. For example, to screen peptide libraries for inhibitors of SIGP activity, it may be useful to encode a chimeric SIGP protein that can be recognized by a commercially available antibody. A fusion protein may also be engineered to contain a cleavage site located between the SIGP encoding sequence and the heterologous protein sequence, so that SIGP may be cleaved and purified away from the heterologous moiety.

[0261] In another embodiment, sequences encoding SIGP may be synthesized, in whole or in part, using chemical methods well known in the art (Caruthers et al. (1980) Nucleic Acids Symp Ser (7) 215-223, and Horn et al. (1980) Nucleic Acids Symp Ser (7) 225-232). Alternatively, the protein itself may be produced using chemical methods to synthesize the amino acid sequence of SIGP, or a fragment thereof. For example, peptide synthesis can be performed using various solid-phase techniques (Roberge et al. (1995) Science 269:202-204). Automated synthesis may be achieved using the 431A Peptide synthesizer (ABI).

[0262] The newly synthesized peptide may be purified by preparative high performance liquid chromatography (Chiez and Regnier (1990) Methods Enzymol 182:392-421). The composition of the synthetic peptides may be confirmed by amino acid analysis or by sequencing (Creighton (1983) Proteins, Structures and Molecular Properties, W H Freeman, New York N.Y.). Additionally, the amino acid sequence of SIGP, or any part thereof, may be altered during direct synthesis and/or combined with sequences from other proteins, or any part thereof, to produce a variant polypeptide.

[0263] In order to express a biologically active SIGP, the nucleotide sequences encoding SIGP or derivatives thereof may be inserted into appropriate expression vector, i.e., a vector which contains the necessary elements for the transcription and translation of the inserted coding sequence.

[0264] Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding SIGP and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. See especially, Sambrook et al. (1989; Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview N.Y., ch. 4, 8, and 16-17) or Ausubel et al. (1995, and periodic supplements, Current Protocols in Molecular Biology, John Wiley & Sons, New York N.Y., ch. 9, 13, and 16).

[0265] A variety of expression vector/host systems may be utilized to contain and express sequences encoding SIGP. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with virus expression vectors (baculovirus); plant cell systems transformed with virus expression vectors such as cauliflower mosaic virus (CaMV) or tobacco mosaic virus (TMV) or with bacterial expression vectors (Ti or pBR322 plasmids); or animal cell systems. The invention is not limited by the host cell employed.

[0266] The “control elements” or “regulatory sequences” are those non-translated regions (enhancers, promoters, and 5′ and 3′ untranslated regions) of the vector and polynucleotide sequences encoding SIGP which interact with host cellular proteins to carry out transcription and translation. Such elements may vary in their strength and specificity. Depending on the vector system and host utilized, any number of transcription and translation elements, including constitutive and inducible promoters, may be used. For example, when cloning in bacterial systems, inducible promoters such as the hybrid lacZ promoter of the BLUESCRIPT phagemid (Stratagene, La Jolla Calif.) or PSPORT1 plasmid (Life Technologies) may be used. The baculovirus polyhedrin promoter may be used in insect cells. Promoters or enhancers derived from the genomes of plant cells (heat shock, RUBISCO, and storage protein genes) or from plant viruses (viral promoters or leader sequences) may be cloned into the vector. In mammalian cell systems, promoters from mammalian genes or from mammalian viruses are preferable. If it is necessary to generate a cell line that contains multiple copies of the sequence encoding SIGP, vectors based on SV40 or EBV may be used with an appropriate selectable marker.

[0267] In bacterial systems, a number of expression vectors may be selected depending upon the use intended for SIGP. For example, when large quantities of SIGP are needed for the induction of antibodies, vectors which direct high level expression of fusion proteins that are readily purified may be used. Such vectors include, but are not limited to, multifunctional E. coli cloning and expression vectors such as BLUESCRIPT phagemid (Stratagene), in which the sequence encoding SIGP may be ligated into the vector in frame with sequences for the amino-terminal Met and the subsequent 7 residues of β-galactosidase so that a hybrid protein is produced, and pIN vectors (Van Heeke and Schuster (1989) J Biol Chem 264:5503-5509). pGEX vectors (APB) may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. Proteins made in such systems may be designed to include heparin, thrombin, or factor XA protease cleavage sites so that the cloned polypeptide of interest can be released from the GST moiety at will.

[0268] In the yeast Saccharomyces cerevisiae, a number of vectors containing constitutive or inducible promoters, such as alpha factor, alcohol oxidase, and PGH, may be used (Ausubel, supra; Grant et al. (1987) Methods Enzymol 153:516-544).

[0269] In cases where plant expression vectors are used, the expression of sequences encoding SIGP may be driven by any of a number of promoters. For example, viral promoters such as the 35S and 19S promoters of CaMV may be used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) EMBO J 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used (Coruzzi et al. (1984) EMBO J 3:1671-1680; Broglie et al. (1984) Science 224:838-843; and Winter et al. (1991) Results Probl Cell Differ 17:85-105). These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. Such techniques are described in a number of generally available reviews (Hobbs or Murry (1992) In: McGraw Hill Yearbook of Science and Technology McGraw Hill, New York, N.Y.; pp. 191-196).

[0270] An insect system may also be used to express SIGP. For example, in one such system, Autographa californica nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in Spodoptera frugiperda cells or in Trichoplusia larvae. The sequences encoding SIGP may be cloned into a non-essential region of the virus, such as the polyhedrin gene, and placed under control of the polyhedrin promoter. Successful insertion of sequences encoding SIGP will render the polyhedrin gene inactive and produce recombinant virus lacking coat protein. The recombinant viruses may then be used to infect, for example, S. frugiperda cells or Trichoplusia larvae in which SIGP may be expressed (Engelhard et al. (1994) Proc Nat Acad Sci 91:3224-3227).

[0271] In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, sequences encoding SIGP may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain a viable virus which is capable of expressing SIGP in infected host cells (Logan and Shenk (1984) Proc Natl Acad Sci 81:3655-3659). In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells.

[0272] Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained and expressed in a plasmid. HACs of about 6 kb to 10 Mb are constructed and delivered via conventional delivery methods (liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes.

[0273] Specific initiation signals may also be used to achieve more efficient translation of sequences encoding SIGP. Such signals include the ATG initiation codon and adjacent sequences. In cases where sequences encoding SIGP and its initiation codon and upstream sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals including the ATG initiation codon should be provided. Furthermore, the initiation codon should be in the correct reading frame to ensure translation of the entire insert. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate for the particular cell system used (Scharf et al. (1994) Results Probl Cell Differ 20:125-162).

[0274] In addition, a host cell strain may be chosen for its ability to modulate expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a “prepro” form of the protein may also be used to facilitate correct insertion, folding, and/or function. Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (CHO, HeLa, MDCK, HEK293, and WI38), are available from the ATCC (Manassas, Va.) and may be chosen to ensure the correct modification and processing of the foreign protein.

[0275] For long term, high yield production of recombinant proteins, stable expression is preferred. For example, cell lines capable of stably expressing SIGP can be transformed using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for about 1 to 2 days in enriched media before being switched to selective media. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be proliferated using tissue culture techniques appropriate to the cell type.

[0276] Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase genes and adenine phosphoribosyltransferase genes, which can be employed in tk⁻ or apr⁻ cells, respectively (Wigler et al. (1977) Cell 11:223-232; Lowy et al. (1980) Cell 22:817-823). Also, antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection. For example, dhfr confers resistance to methotrexate; npt confers resistance to the aminoglycosides neomycin and G-418; and als or pat confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively (Wigler et al. (1980) Proc Natl Acad Sci 77:3567-3570; Colbere-Garapin et al (1981) J Mol Biol 150:1-14; and Murry, supra). Additional selectable genes have been described, trpB, which allows cells to utilize indole in place of tryptophan, or hisD, which allows cells to utilize histinol in place of histidine (Hartman and Mulligan (1988) Proc Natl Acad Sci 85:8047-8051). Recently, the use of visible markers has gained popularity with such markers as anthocyanins, β glucuronidase and its substrate GUS, luciferase and its substrate luciferin. Green fluorescent proteins (GFP; Clontech, Palo Alto, Calif.) are also used (Chalfie et al. (1994) Science 263:802-805). These markers can be used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system (Rhodes et al. (1995) Methods Mol Bio. 55:121-131).

[0277] Although the presence/absence of marker gene expression suggests that the gene of interest is also present, the presence and expression of the gene may need to be confirmed. For example, if the sequence encoding SIGP is inserted within a marker gene sequence, transformed cells containing sequences encoding SIGP can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding SIGP under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

[0278] Alternatively, host cells which contain the nucleic acid sequence encoding SIGP and express SIGP may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein sequences.

[0279] The presence of polynucleotide sequences encoding SIGP can be detected by DNA-DNA or DNA-RNA hybridization or amplification using probes or fragments or fragments of polynucleotides encoding SIGP. Nucleic acid amplification based assays involve the use of oligonucleotides or oligomers based on the sequences encoding SIGP to detect transformants containing DNA or RNA encoding SIGP.

[0280] A variety of protocols for detecting and measuring the expression of SIGP, using either polyclonal or monoclonal antibodies specific for the protein, are known in the art. Examples of such techniques include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on SIGP is preferred, but a competitive binding assay may be employed. These and other assays are well described in the art (Hampton et al. (1990) Serological Methods, a Laboratory Manual, APS Press, St Paul Minn., Section IV; Maddox et al. (1983) J Exp Med 158:1211-1216).

[0281] A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding SIGP include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide. Alternatively, the sequences encoding SIGP, or any fragments thereof, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits, such as those provided by APB. Reporter molecules or labels which may be used for ease of detection include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

[0282] Host cells transformed with nucleotide sequences encoding SIGP may be cultured under conditions for the expression and recovery of the protein from cell culture. The protein produced by a transformed cell may be secreted or contained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode SIGP may be designed to contain signal sequences which direct secretion of SIGP through a prokaryotic or eukaryotic cell membrane. Other constructions may be used to join sequences encoding SIGP to nucleotide sequences encoding a polypeptide domain which will facilitate purification of soluble proteins. Such purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex, Seattle Wash.). The inclusion of cleavable linker sequences, such as those specific for Factor XA (APB) or enterokinase (Invitrogen, San Diego Calif.), between the purification domain and the SIGP encoding sequence may be used to facilitate purification. One such expression vector provides for expression of a fusion protein containing SIGP and a nucleic acid encoding 6 histidine residues preceding a thioredoxin or an enterokinase cleavage site. The histidine residues facilitate purification on immobilized metal ion affinity chromatography (Porath et al. (1992) Prot Exp Purif 3:263-281). The enterokinase cleavage site provides a means for purifying SIGP from the fusion protein (Kroll et al. (1993) DNA Cell Biol 12:441-453).

[0283] Fragments of SIGP may be produced not only by recombinant production, but also by direct peptide synthesis using solid-phase techniques.(Creighton (1984) Protein: Structures and Molecular Properties, W H Freeman, New York N.Y., pp. 55-60). Protein synthesis may be performed by manual techniques or by automation. Automated synthesis may be achieved, for example, using the 43 1A peptide synthesizer (ABI). Various fragments of SIGP may be synthesized separately and then combined to produce the full length molecule.

[0284] THERAPEUTICS

[0285] The expression of the human signal peptide-containing proteins of the invention (SIGP) is closely associated with cell proliferation. Therefore, in cancers or immune response where SIGP is an activator, transcription factor, or enhancer, and is promoting cell proliferation, it is desirable to decrease the expression of SIGP. In conditions where SIGP is an inhibitor or suppressor and is controlling or decreasing cell proliferation, it is desirable to provide the protein or to increase the expression of SIGP.

[0286] In one embodiment, where SIGP is an inhibitor, SIGP or a fragment or derivative thereof may be administered to a subject to treat a cancer such as adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, and teratocarcinoma. Such cancers include, but are not limited to, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus.

[0287] In another embodiment, a pharmaceutical composition comprising purified SIGP may be used to treat a cancer including, but not limited to, those listed above.

[0288] In another embodiment, an agonist which is specific for SIGP may be administered to a subject to treat a cancer including, but not limited to, those cancers listed above.

[0289] In another further embodiment, a vector capable of expressing SIGP, or a fragment or a derivative thereof, may be administered to a subject to treat a cancer including, but not limited to, those cancers listed above.

[0290] In a further embodiment where SIGP is promoting cell proliferation, antagonists which decrease the expression or activity of SIGP may be administered to a subject to treat a cancer such as adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, and teratocarcinoma. Such cancers include, but are not limited to, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus. In one aspect, antibodies which specifically bind SIGP may be used directly as an antagonist or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissue which express SIGP.

[0291] In another embodiment, a vector expressing the complement of the polynucleotide encoding SIGP may be administered to a subject to treat a cancer including, but not limited to, those cancers listed above.

[0292] In yet another embodiment where SIGP is promoting leukocyte activity or proliferation, antagonists which decrease the activity of SIGP may be administered to a subject to treat an immune response. Such responses include, but are not limited to, disorders such as AIDS, Addison's disease, adult respiratory distress syndrome, allergies, anemia, asthma, atherosclerosis, bronchitis, cholecystitus, Crohn's disease, ulcerative colitis, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, atrophic gastritis, glomerulonephritis, gout, Graves' disease, hypereosinophilia, irritable bowel syndrome, lupus erythematosus, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, rheumatoid arthritis, scleroderma, Sjögren's syndrome, and autoimmune thyroiditis; complications of cancer, hemodialysis, extracorporeal circulation; viral, bacterial, fungal, parasitic, protozoal, and helminthic infections; and trauma. In one aspect, antibodies which specifically bind SIGP may be used directly as an antagonist or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissue which express SIGP.

[0293] In another embodiment, a vector expressing the complement of the polynucleotide encoding SIGP may be administered to a subject to treat an immune response including, but not limited to, those listed above.

[0294] In other embodiments, any of the proteins, antagonists, antibodies, agonists, complementary sequences, or vectors of the invention may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

[0295] An antagonist of SIGP may be produced using methods which are generally known in the art. In particular, purified SIGP may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind SIGP. Antibodies to SIGP may also be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies, those which inhibit dimer formation, are especially preferred for therapeutic use.

[0296] For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others may be immunized by injection with SIGP or with any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, KLH, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and Corynebacterium parvum are especially preferable.

[0297] It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to SIGP have an amino acid sequence consisting of at least about 5 amino acids, and, more preferably, of at least about 10 amino acids. It is also preferable that these oligopeptides, peptides, or fragments are identical to a portion of the amino acid sequence of the natural protein and contain the entire amino acid sequence of a small, naturally occurring molecule. Short stretches of SIGP amino acids may be fused with those of another protein, such as KLH, and antibodies to the chimeric molecule may be produced.

[0298] Monoclonal antibodies to SIGP may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique (Kohler et al. (1975) Nature 256:495-497; Kozbor et al. (1985) J Immunol. Methods 81:31-42; Cote et al. (1983) Proc Natl Acad Sci 80:2026-2030; and Cole et al. (1984) Mol Cell Biol 62:109-120).

[0299] In addition, techniques developed for the production of “chimeric antibodies,” such as the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used (Morrison et al. (1984) Proc Natl Acad Sci 81:6851-6855; Neuberger et al. (1984) Nature 312:604-608; and Takeda et al. (1985) Nature 314:452-454). Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce SIGP-specific single chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries (Burton (1991) Proc Natl Acad Sci 88:10134-10137).

[0300] Antibodies may also be produced by inducing in vivo production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature (Orlandi et al. (1989) Proc Natl Acad Sci 86: 3833-3837; Winter et al. (1991) Nature 349:293-299).

[0301] Antibody fragments which contain specific binding sites for SIGP may also be generated. For example, such fragments include, but are not limited to, F(ab′)2 fragments produced by pepsin digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the F(ab′)2 fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity (Huse et al. (1989) Science 246:1275-1281).

[0302] Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between SIGP and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering SIGP epitopes is preferred, but a competitive binding assay may also be employed (Maddox, supra).

[0303] In another embodiment of the invention, the polynucleotides encoding SIGP, or any fragment or complement thereof, may be used for therapeutic purposes. In one aspect, the complement of the polynucleotide encoding SIGP may be used in situations in which it would be desirable to block the transcription of the mRNA. In particular, cells may be transformed with sequences complementary to polynucleotides encoding SIGP. Thus, complementary molecules or fragments may be used to modulate SIGP activity, or to achieve regulation of gene function. Such technology is now well known in the art, and sense or antisense oligonucleotides or larger fragments can be designed from various locations along the coding or control regions of sequences encoding SIGP.

[0304] Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. Methods which are well known to those skilled in the art can be used to construct vectors which will express nucleic acid sequences complementary to the polynucleotides of the gene encoding SIGP (Sambrook, supra; and Ausubel, supra).

[0305] Genes encoding SIGP can be turned off by transforming a cell or tissue with expression vectors which express high levels of a polynucleotide, or fragment thereof, encoding SIGP. Such constructs may be used to introduce untranslatable sense or antisense sequences into a cell. Even in the absence of integration into the DNA, such vectors may continue to transcribe RNA molecules until they are disabled by endogenous nucleases. Transient expression may last for a month or more with a non-replicating vector, and may last even longer if appropriate replication elements are part of the vector system.

[0306] As mentioned above, modifications of gene expression can be obtained by designing complementary sequences or antisense molecules (DNA, RNA, or PNA) to the control, 5′, or regulatory regions of the gene encoding SIGP. Oligonucleotides derived from the transcription initiation site, for example between about positions −10 and +10 around the start site, are preferred. Similarly, inhibition can be achieved using triple helix base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature (Gee et al. (1994) In: Huber and Carr, Molecular and Immunologic Approaches, Futura Publishing, Mt. Kisco N.Y., pp. 163-177). A complementary sequence or antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

[0307] Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. For example, engineered hammerhead motif ribozyme molecules may specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding SIGP.

[0308] Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites, including the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides, corresponding to the region of the target gene containing the cleavage site, may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

[0309] Complementary ribonucleic acid molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of nucleic acid molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding SIGP. Such DNA sequences may be incorporated into a wide variety of vectors with RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA constructs that synthesize complementary RNA, constitutively or inducibly, can be introduced into cell lines, cells, or tissues.

[0310] RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5′ and/or 3′ ends of the molecule, or the use of phosphorothioate or 2′O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

[0311] Many methods for introducing vectors into cells or tissues are available for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection, by liposome injections, or by polycationic amino polymers may be achieved using methods which are well known in the art (Goldman et al. (1997) Nature Biotechnol 15:462-466).

[0312] Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as dogs, cats, cows, horses, rabbits, monkeys, and most preferably, humans.

[0313] An additional embodiment of the invention relates to the administration of a pharmaceutical or sterile composition, in conjunction with a pharmaceutically acceptable carrier, for any of the therapeutic effects discussed above. Such pharmaceutical compositions may consist of SIGP, antibodies to SIGP, and mimetics, agonists, antagonists, or inhibitors of SIGP. The compositions may be administered alone or in combination with at least one other agent, such as a stabilizing compound, which may be administered in any sterile, biocompatible pharmaceutical carrier including, but not limited to, saline, buffered saline, dextrose, and water. The compositions may be administered to a patient alone, or in combination with other agents, drugs, or hormones.

[0314] The pharmaceutical compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

[0315] In addition to the active ingredients, these pharmaceutical compositions may contain pharmaceutically-acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Further details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing, Easton Pa.).

[0316] Pharmaceutical compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages for oral administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

[0317] Pharmaceutical preparations for oral use can be obtained through combining active compounds with solid excipient and processing the resultant mixture of granules (optionally, after grinding) to obtain tablets or dragee cores. Excipients include carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, and sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose; gums, including arabic and tragacanth; and proteins, such as gelatin and collagen. If desired, disintegrating or solubilizing agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, and alginic acid or a salt thereof, such as sodium alginate. If desired, auxiliaries can be added.

[0318] Dragee cores may be used in conjunction with coatings, such as concentrated sugar solutions, which may also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, i.e., dosage.

[0319] Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with fillers or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in liquids, such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers.

[0320] Pharmaceutical formulations for parenteral administration may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiologically buffered saline. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Lipophilic solvents or vehicles include fatty oils, such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate, triglycerides, or liposomes. Non-lipid polycationic amino polymers may also be used for delivery. Optionally, the suspension may also contain stabilizers or agents to increase the solubility of the compounds and allow for the preparation of highly concentrated solutions.

[0321] For topical or nasal administration, penetrants appropriate to the particular barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

[0322] The pharmaceutical compositions of the present invention may be manufactured by conventional means known in the art such as mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes.

[0323] The pharmaceutical composition may be provided as a salt and can be formed with many acids, including but not limited to, hydrochloric, sulfuric, acetic, lactic, tartaric, malic, and succinic acid. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms. In other cases, the preferred preparation may be a lyophilized powder which may contain any or all of the following: 1 mM to 50 mM histidine, 0.1% to 2% sucrose, and 2% to 7% mannitol, at a pH range of 4.5 to 5.5, that is combined with buffer prior to use.

[0324] After pharmaceutical compositions have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition. For administration of SIGP, such labeling would include amount, frequency, and method of administration.

[0325] Pharmaceutical compositions for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

[0326] For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays of neoplastic cells or in animal models such as mice, rats, rabbits, dogs, or pigs. An animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

[0327] A therapeutically effective dose refers to that amount of active ingredient, for example SIGP or fragments thereof, antibodies of SIGP, and agonists, antagonists or inhibitors of SIGP, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating the ED50 (the dose therapeutically effective in 50% of the population) or LD50 (the dose lethal to 50% of the population) statistics. The dose ratio of therapeutic to toxic effects is the therapeutic index. Pharmaceutical compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies are used to formulate a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that includes the ED50 with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, the sensitivity of the patient, and the route of administration.

[0328] The exact dosage will be determined by the practitioner, in light of factors related to the subject requiring treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and gender of the subject, time and frequency of administration, drug combination(s), reaction sensitivities, and response to therapy. Long-acting pharmaceutical compositions may be administered every 3 to 4 days, every week, or biweekly depending on the half-life and clearance rate of the particular formulation.

[0329] Normal dosage amounts may vary from about 0.1 μg to 100,000 μg, up to a total dose of about 1 gram, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

[0330] DIAGNOSTICS

[0331] In another embodiment, antibodies which specifically bind SIGP may be used for the diagnosis of disorders characterized by expression of SIGP, or in assays to monitor patients being treated with SIGP or agonists, antagonists, or inhibitors of SIGP. Antibodies useful for diagnostic purposes may be prepared in the same manner as described above for therapeutics. Diagnostic assays for SIGP include methods which utilize the antibody and a label to detect SIGP in human body fluids or in extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by covalent or non-covalent attachment of a reporter molecule. A wide variety of reporter molecules, several of which are described above, are known in the art and may be used.

[0332] A variety of protocols for measuring SIGP, including ELISAs, RIAs, and FACS, are known in the art and provide a basis for diagnosing altered or abnormal levels of SIGP expression. Normal or standard values for SIGP expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, preferably human, with antibody to SIGP under conditions for complex formation The amount of standard complex formation may be quantitated by various methods, preferably by photometric means. Quantities of SIGP expressed in subject, control, and disease samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

[0333] In another embodiment of the invention, the polynucleotides encoding SIGP may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantitate gene expression in biopsied tissues in which expression of SIGP may be correlated with disease. The diagnostic assay may be used to determine absence, presence, and excess expression of SIGP, and to monitor regulation of SIGP levels during therapeutic intervention.

[0334] In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding SIGP or closely related molecules may be used to identify nucleic acid sequences which encode SIGP. The specificity of the probe, whether it is made from a highly specific region such as the 5′ regulatory region or from a less specific region such as a conserved motif, and the stringency of the hybridization or amplification (maximal, high, intermediate, or low), will determine whether the polynucleotide identifies only naturally occurring sequences encoding SIGP, alleles, or related sequences.

[0335] Probes may also be used for the detection of related sequences, and should preferably contain at least 50% of the nucleotides from any of the SIGP encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and may be derived from the sequence of SEQ ID NOs: 78-154, or from genomic sequences including promoters, enhancers, and introns of the SIGP gene.

[0336] Means for producing specific hybridization probes for DNAs encoding SIGP include the cloning of polynucleotide sequences encoding SIGP or SIGP derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by means of the addition of the appropriate RNA polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a variety of reporter groups, for example, by radionuclides such as ³²P or ³⁵S, or by enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

[0337] Polynucleotide sequences encoding SIGP may be used for the diagnosis of a disorder associated with either increased or decreased expression of SIGP. Examples of such a disorder include, but are not limited to, cancers such as adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and cancers of the adrenal gland, bladder, bone, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, bone marrow, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; neuronal disorders such as akathesia, Alzheimer's disease, amnesia, amyotrophic lateral sclerosis, bipolar disorder, catatonia, cerebral neoplasms, dementia, depression, Down's syndrome, tardive dyskinesia, dystonias, epilepsy, Huntington's disease, multiple sclerosis, neurofibromatosis, Parkinson's disease, paranoid psychoses, schizophrenia, and Tourette's disorder; and immunological disorders such as AIDS, Addison's disease, adult respiratory distress syndrome, allergies, anemia, asthma, atherosclerosis, bronchitis, cholecystitus, Crohn's disease, ulcerative colitis, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, atrophic gastritis, glomerulonephritis, gout, Graves' disease, hypereosinophilia, irritable bowel syndrome, lupus erythematosus, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, rheumatoid arthritis, scleroderma, Sjögren's syndrome, and thyroiditis. The polynucleotide sequences encoding SIGP may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; in dipstick, pin, and multiwell assays; and in microarrays utilizing fluids or tissues from patients to detect altered SIGP expression. Such qualitative or quantitative methods are well known in the art.

[0338] In a particular aspect, the nucleotide sequences encoding SIGP may be useful in assays that detect the presence of associated disorders, particularly those mentioned above. The nucleotide sequences encoding SIGP may be labeled by standard methods and added to a fluid or tissue sample from a patient under conditions for the formation of hybridization complexes. After an incubation period, the sample is washed and the signal is quantitated and compared with a standard value. If the amount of signal in the patient sample is significantly altered in comparison to a control sample then the presence of altered levels of nucleotide sequences encoding SIGP in the sample indicates the presence of the associated disorder. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or to monitor the treatment of an individual patient.

[0339] In order to provide a basis for the diagnosis of a disorder associated with expression of SIGP, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, encoding SIGP, under conditions for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with values from an experiment in which a known amount of a purified polynucleotide is used. Standard values obtained in this manner may be compared with values obtained from samples from patients who are symptomatic for a disorder. Deviation from standard values is used to establish the presence of a disorder.

[0340] Once the presence of a disorder is established and a treatment protocol is initiated, hybridization assays may be repeated on a regular basis to determine if the level of expression in the patient begins to approximate that which is observed in the normal subject. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

[0341] With respect to cancer, the presence of a relatively high amount of transcript in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ aggressive treatment earlier thereby preventing the development or further progression of the cancer.

[0342] Additional diagnostic uses for oligonucleotides designed from the sequences encoding SIGP may involve the use of PCR. These oligomers may be chemically synthesized, generated enzymatically, or produced in vitro. Oligomers will preferably contain a fragment of a polynucleotide encoding SIGP, or a fragment of a polynucleotide complementary to the polynucleotide encoding SIGP, and will be employed under optimized conditions for identification of a specific gene or condition. Oligomers may also be employed under less stringent conditions for detection or quantitation of closely related DNA or RNA sequences.

[0343] Methods which may also be used to quantitate the expression of SIGP include radiolabeling or biotinylating nucleotides, coamplification of a control nucleic acid, and interpolating results from standard curves (Melby et a. (1993) J Immunol Methods 159:235-244; Duplaa et al. (1993) Anal Biochem 229-236). The speed of quantitation of multiple samples may be accelerated by running the assay in a multiwell format where the oligomer of interest is presented in various dilutions and a spectrophotometric or calorimetric response gives rapid quantitation.

[0344] In further embodiments, oligonucleotides or longer fragments derived from any of the polynucleotide sequences described herein may be used as targets in a microarray. The microarray can be used to monitor the expression level of large numbers of genes simultaneously and to identify genetic variants, mutations, and polymorphisms. This information may be used to determine gene function, to understand the genetic basis of a disorder, to diagnose a disorder, and to develop and monitor the activities of therapeutic agents.

[0345] In one embodiment, the microarray is prepared and used according to methods known in the art. See, for example, Chee et al. (1995) PCT application WO95/11995; Lockhart et al. (1996) Nat Biotech 14:1675-1680; and Schena et al. (1996) Proc Natl Acad Sci 913:10614-10619.

[0346] The microarray is preferably composed of a large number of unique single-stranded nucleic acid sequences, usually either synthetic antisense oligonucleotides or fragments of cDNAs. The oligonucleotides are preferably about 6 to 60 nucleotides in length, more preferably about 15 to 30 nucleotides in length, and most preferably about 20 to 25 nucleotides in length. It may be preferable to use oligonucleotides which are about 7 to 10 nucleotides in length. The microarray may contain oligonucleotides which cover the known 5′ or 3′ sequence, sequential oligonucleotides which cover the full length sequence, or unique oligonucleotides selected from particular areas along the length of the sequence. Polynucleotides used in the microarray may be oligonucleotides specific to a gene or genes of interest. Oligonucleotides can also be specific to one or more unidentified cDNAs associated with a particular cell type or tissue type. It may be appropriate to use pairs of oligonucleotides on a microarray. The first oligonucleotide in each pair differs from the second oligonucleotide by one nucleotide. This nucleotide is preferably located in the center of the sequence. The second oligonucleotide serves as a control. The number of oligonucleotide pairs may range from about 2 to 1,000,000.

[0347] In order to produce oligonucleotides for use on a microarray, the gene of interest is examined using a computer algorithm which starts at the 5′ end, or, more preferably, at the 3′ end of the nucleotide sequence. The algorithm identifies oligomers of defined length that are unique to the gene, have a GC content within a range for hybridization, and lack secondary structure that may interfere with hybridization. In one aspect, the oligomers may be synthesized on a substrate using a light-directed chemical process (Chee, supra).

[0348] In another aspect, the oligonucleotides may be synthesized on the surface of the substrate using a chemical coupling procedure and an ink jet application apparatus (Baldeschweiler et al. (1995) PCT application WO95/251116). An array analogous to a dot or slot blot (HYBRIDOT apparatus, Life Technologies) may be used to arrange and link cDNA fragments or oligonucleotides to the surface of a substrate using a vacuum system or thermal, UV, mechanical, or chemical bonding procedures. An array may also be produced by hand or by using available devices, materials, and machines, e.g. multichannel pipetters or robotic instruments. The array may contain from 2 to 1,000,000 or any other feasible number of oligonucleotides.

[0349] In order to conduct sample analysis using the microarrays, polynucleotides are extracted from a sample. The sample may be obtained from any bodily fluid including but not limited to blood, urine, saliva, phlegm, gastric juices, cultured cells, biopsies, or other tissue preparations. To produce probes, the polynucleotides extracted from the sample are used to produce nucleic acid sequences complementary to the nucleic acids on the microarray. If the microarray contains cDNAs, antisense RNAs (aRNAs) are appropriate probes. Therefore, in one aspect, mRNA is reverse-transcribed to cDNA. The cDNA, in the presence of fluorescent label, is used to produce fragment or oligonucleotide aRNA probes. The fluorescently labeled probes are incubated with the microarray so that the probes hybridize to the microarray oligonucleotides. Nucleic acid sequences used as probes can include polynucleotides, fragments, and complementary or antisense sequences produced using restriction enzymes, PCR, or other methods known in the art.

[0350] Hybridization conditions can be adjusted so that hybridization occurs with varying degrees of complementarity. A scanner can be used to determine the levels and patterns of fluorescence after removal of any nonhybridized probes. The degree of complementarity and the relative abundance of each oligonucleotide sequence on the microarray can be assessed through analysis of the scanned images. A detection system may be used to measure the absence, presence, or level of hybridization for any of the sequences (Heller et al. (1997) Proc Natl Acad Sci 94:2150-2155).

[0351] In another embodiment of the invention, nucleic acid sequences encoding SIGP may be used to generate hybridization probes useful in mapping the naturally occurring genomic sequence. The sequences may be mapped to a particular chromosome, to a specific region of a chromosome, or to artificial chromosome constructions such as human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions, or single chromosome cDNA libraries (Price (1993) Blood Rev 7:127-134; Trask (1991) Trends Genet 7:149-154).

[0352] Fluorescent in situ hybridization (FISH) may be correlated with other physical chromosome mapping techniques and genetic map data (Heinz-Ulrich et al. (1995) In: Meyers Molecular Biology and Biotechnology, VCH Publishers, New York N.Y., pp. 965-968). Examples of genetic map data can be found in various scientific journals or at the Online Mendelian Inheritance in Man (OMIM) site. Correlation between the location of the gene encoding SIGP on a physical chromosomal map and a specific disorder, or a predisposition to a specific disorder, may help define the region of DNA associated with that disorder. The nucleotide sequences of the invention may be used to detect differences in gene sequences among normal, carrier, and affected individuals.

[0353] In situ hybridization of chromosomal preparations and physical mapping techniques, such as linkage analysis using established chromosomal markers, may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the number or arm of a particular human chromosome is not known. New sequences can be assigned to chromosomal arms by physical mapping. This provides valuable information to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the disease or syndrome has been crudely localized by genetic linkage to a particular genomic region such as AT to 11q22-23, any sequences mapping to that area may represent associated or regulatory genes for further investigation (Gatti et al. (1988) Nature 336:577-580). The nucleotide sequence of the subject invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc., among normal, carrier, or affected individuals.

[0354] In another embodiment of the invention, SIGP, its catalytic or immunogenic fragments, or oligopeptides thereof can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes between SIGP and the agent being tested may be measured.

[0355] Another technique for drug screening provides for high throughput screening of compounds having binding affinity to the protein of interest (Geysen, et al. (1984) PCT application WO84/03564). In this method, large numbers of different small test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The test compounds are reacted with SIGP, or fragments thereof, and washed. Bound SIGP is then detected by methods well known in the art. Purified SIGP can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

[0356] In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding SIGP specifically compete with a test compound for binding SIGP. In this manner, antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with SIGP.

[0357] In additional embodiments, the nucleotide sequences which encode SIGP may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.

[0358] The examples below are provided to illustrate the subject invention and are not included for the purpose of limiting the invention.

EXAMPLES

[0359] For purposes of example, the preparation and sequencing of the SPLNNOT04 cDNA library, from which Incyte Clones 1534876 and 1559131 were isolated, is described. Preparation and sequencing of cDNAs in libraries in the LIFESEQ database (Incte Genomics, Palo Alto Calif.) have varied over time, and the gradual changes involved use of kits, plasmids, and machinery available at the particular time the library was made and analyzed.

I. SPLNNOT04 cDNA Library Construction

[0360] The SPLNNOT04 cDNA library was constructed from microscopically normal spleen tissue obtained from a 2-year-old Hispanic male who died of cerebral anoxia. The patient's serologies and past medical history were negative.

[0361] The frozen tissue was homogenized and lysed using a POLYTRON homogenizer (Brinkmann Instruments, Westbury N.J.) in guanidinium isothiocyanate solution. The lysate was centrifuged over a 5.7 M CsCl cushion using an SW28 rotor in an L8-70M ultracentrifuge (Beckman Coulter, Fullerton Calif.) for 18 hours at 25,000 rpm at ambient temperature. The RNA was extracted with acid phenol, pH 4.0, precipitated using 0.3 M sodium acetate and 2.5 volumes of ethanol, resuspended in RNAse-free water and DNase treated at 37° C. The RNA extraction and precipitation were repeated as before. The mRNA was then isolated using the OLIGOTEX kit (Qiagen, Chatsworth Calif.) and used to construct the cDNA library.

[0362] The mRNA was handled according to the recommended protocols in the SUPERSCRIPT plasmid system (Life Technologies). cDNA synthesis was initiated with a NotI-oligo d(T) primer. Double-stranded cDNA was blunted, ligated to EcoRI adaptors, digested with NotI, fractionated on a SEPHAROSE CL4B column (APB), and those cDNAs exceeding 400 bp were ligated into the NotI and EcoRI sites of the pINCY 1 plasmid (Incyte Genomics). The plasmid was subsequently transformed into DH5α competent cells (Life Technologies).

II Isolation and Sequencing of cDNA Clones

[0363] Plasmid cDNA was released from the cells and purified using the REAL PREP 96 plasmid kit (Qiagen). The recommended protocol was employed except for the following changes: 1) the bacteria were cultured in 1 ml of sterile TERRIFIC BROTH (BD Biosciences, Sparks Md.) with carbenicillin (carb) at 25 mg/land glycerol at 0.4%; 2) the cultures were inoculated and incubated for 19 hours, and then the cells were lysed with 0.3 ml of lysis buffer; and 3) following isopropanol precipitation, the plasmid DNA pellet was resuspended in 0.1 ml of distilled water. After the last step in the protocol, samples were transferred to a 96-well block for storage at 4° C.

[0364] cDNAs were prepared using a CATALYST 800 (ABI) or a MICROLAB 2200 (Hamilton) in combination with DNA ENGINE thermal cyclers (MJ Research) and sequenced according to the method of Sanger et al. (1975, J Mol Biol 94:441f) using 377 or 373 PRISM DNA sequencing systems (ABI), and reading frame was determined.

III Homology Searching of cDNA Clones and Their Deduced Proteins

[0365] The nucleotide sequences and/or amino acid sequences of the Sequence Listing were used to query sequences in the GenBank, SwissProt, BLOCKS, and Pima II databases. These databases, which contain previously identified and annotated sequences, were searched for regions of homology using BLAST (Basic Local Alignment Search Tool; Altschul (1993) J Mol Evol 36:290-300; Altschul et al. (1990) J Mol Biol 215:403-410).

[0366] BLAST produced alignments of both nucleotide and amino acid sequences to determine sequence similarity. Because of the local nature of the alignments, BLAST was especially useful in determining exact matches or in identifying homologs which may be of prokaryotic (bacterial) or eukaryotic (animal, fungal, or plant) origin. Other algorithms could have been used when dealing with primary sequence patterns and secondary structure gap penalties (Smith et al. (1992) Protein Engineering 5:35-51). The sequences disclosed in this application have lengths of at least 49 nucleotides and have no more than 12% uncalled bases (where N is recorded rather than A, C, G, or T).

[0367] The BLAST approach searched for matches between a query sequence and a database sequence. BLAST evaluated the statistical significance of any matches found, and reported only those matches that satisfy the user-selected threshold of significance. In this application, threshold was set at 10⁻²⁵ for nucleotides and 10⁻⁸ for peptides.

[0368] Incyte nucleotide sequences were searched against the GenBank databases for primate (pri), rodent (rod), and other mammalian sequences (mam), and deduced amino acid sequences from the same clones were then searched against GenBank functional protein databases, mammalian (mamp), vertebrate (vrtp), and eukaryote (eukp), for homology.

IV Northern Analysis

[0369] Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound (Sambrook, supra, ch. 7; Ausubel, supra, ch. 4 and 16).

[0370] Analogous computer techniques applying BLAST are used to search for identical or related molecules in nucleotide databases such as GenBank or LIFESEQ database (Incyte Genomics). This analysis is much faster than multiple membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or homologous.

[0371] The basis of the search is the product score, which is defined as: $\frac{\% \quad {sequence}\quad {identity} \times \% \quad {maximum}\quad {BLAST}\quad {score}}{100}$

[0372] The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. For example, with a product score of 40, the match will be exact within a 1% to 2% error, and, with a product score of 70, the match will be exact. Homologous molecules are usually identified by selecting those which show product scores between 15 and 40, although lower scores may identify related molecules.

[0373] The results of northern analysis are reported as a list of libraries in which the transcript encoding SIGP occurs. Abundance and percent abundance are also reported. Abundance directly reflects the number of times a particular transcript is represented in a cDNA library, and percent abundance is abundance divided by the total number of sequences examined in the cDNA library.

V Extension of SIGP Encoding Polynucleotides

[0374] The nucleic acid sequence of one of the polynucleotides of the present invention was used to design oligonucleotide primers for extending a partial nucleotide sequence to full length. One primer was synthesized to initiate extension of an antisense polynucleotide, and the other was synthesized to initiate extension of a sense polynucleotide. Primers were used to facilitate the extension of the known sequence “outward” generating amplicons containing new unknown nucleotide sequence for the region of interest. The initial primers were designed from the cDNA using OLIGO software (Molecular Biology Insights), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68° C. to about 72° C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.

[0375] Selected human cDNA libraries (Life Technologies) were used to extend the sequence. If more than one extension is necessary or desired, additional sets of primers are designed to further extend the known region.

[0376] High fidelity amplification was obtained by following the instructions for the XL-PCR kit (ABI) and thoroughly mixing the enzyme and reaction mix. PCR was performed using the DNA ENGINE thermal cycler (MJ Research), beginning with 40 pmol of each primer and the recommended concentrations of all other components of the kit, with the following parameters: Step 1, 94° C. for 1 min (initial denaturation); Step 2, 65° C. for 1 min; Step 3, 68° C. for 6 min; Step 4, 94° C. for 15 sec; Step 5, 65° C. for 1 min; Step 6, 68° C. for 7 min; Step 7, repeat steps 4 through 6 for an additional 15 cycles; Step 8, 94° C. for 15 sec; Step 9, 65° C. for 1 min; Step 10, 68° C. for 7:15 min; Step 11, repeat steps 8 through 10 for an additional 12 cycles; Step 12, 72° C. for 8 min; and Step 13, 4° C. (and holding).

[0377] A 5 μl to 10 μl aliquot of the reaction mixture was analyzed by electrophoresis on a low concentration (about 0.6% to 0.8%) agarose mini-gel to determine which reactions were successful in extending the sequence. Bands thought to contain the largest products were excised from the gel, purified using QIAQUICK kit (Qiagen), and trimmed of overhangs using Kienow enzyme to facilitate religation and cloning.

[0378] After ethanol precipitation, the products were redissolved in 13 μl of ligation buffer, 1 μT4-DNA ligase (15 units) and 1 μl T4 polynucleotide kinase were added, and the mixture was incubated at room temperature for 2 to 3 hours, or overnight at 16° C. Competent E. coli cells (in 40 μl of appropriate media) were transformed with 3 μl of ligation mixture and cultured in 80 μl of SOC medium (Sambrook, supra, Appendix A, p. 2). After incubation for one hour at 37° C., the E. coli mixture was plated on Luria Bertani (LB) agar (Sambrook, supra, Appendix A, p. 1) containing 2x carb. The following day, several colonies were randomly picked from each plate and cultured in 150 μl of liquid LB/2x carb medium placed in an individual well of an appropriate commercially-available sterile 96-well microtiter plate. The following day, 5 μl of each overnight culture was transferred into a non-sterile 96-well plate and, after dilution 1:10 with water, 5 μl from each sample was transferred into a PCR array.

[0379] For PCR amplification, 18 μl of concentrated PCR reaction mix (3.3x) containing 4 units of rTth DNA polymerase, a vector primer, and one or both of the gene specific primers used for the extension reaction were added to each well. Amplification was performed using the following conditions: Step 1, 94° C. for 60 sec; Step 2, 94° C. for 20 sec; Step 3, 55° C. for 30 sec; Step 4, 72° C. for 90 sec; Step 5, repeat steps 2 through 4 for an additional 29 cycles; Step 6, 72° C. for 180 sec; and Step 7, 4° C. (and holding).

[0380] Aliquots of the PCR reactions were run on agarose gels together with molecular weight markers.

[0381] The sizes of the PCR products were compared to the original partial cDNAs, and appropriate clones were selected, ligated into plasmid, and sequenced.

[0382] In like manner, the nucleotide sequence of one of the nucleotide sequences of the present invention were used to obtain 5′ regulatory sequences using the procedure above, oligonucleotides designed for 5′ extension, and an appropriate genomic library.

VI Labeling and Use of Individual Hybridization Probes

[0383] Hybridization probes derived from one of the nucleotide sequences of the present invention are employed to screen cDNAs, genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base pairs, is specifically described, essentially the same procedure is used with larger nucleotide fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO software (Molecular Biology Insights) and labeled by combining 50 pmol of each oligomer, 250 ,μCi of [γ-³²P] adenosine triphosphate (APB), and T4 polynucleotide kinase (PerkinElmer Life Sciences, Boston Mass.). The labeled oligonucleotides are purified using a SEPHADEX G-25 superfine resin column (APB). An aliquot containing 10⁷ counts per minute of the labeled probe is used in a typical membrane-based hybridization analysis of human genomic DNA digested with one of the following endonucleases: Ase I, Bgl II, Eco RI, Pst I, Xba 1, or Pvu II (PerkinElmer Life Sciences).

[0384] The DNA from each digest is fractionated on a 0.7 percent agarose gel and transferred to NYTRAN PLUS membranes (Schleicher & Schuell, Durham N.H.). Hybridization is carried out for 16 hours at 40° C. To remove nonspecific signals, blots are sequentially washed at room temperature under increasingly stringent conditions up to 0.1×saline sodium citrate and 0.5% sodium dodecyl sulfate. After XOMAT AR film (Eastman Kodak, Rochester N.Y.) is exposed to the blots for several hours, hybridization patterns are compared.

VII Microarrays

[0385] To produce oligonucleotides for a microarray, one of the nucleotide sequences of the present invention is examined using a computer algorithm which starts at the 3′ end of the nucleotide sequence. For each, the algorithm identifies oligomers of defined length that are unique to the nucleic acid sequence, have a GC content within a range for hybridization, and lack secondary structure that would interfere with hybridization. The algorithm identifies approximately 20 oligonucleotides corresponding to each nucleic acid sequence. For each sequence-specific oligonucleotide, a pair of oligonucleotides is synthesized in which the first oligonucleotides differs from the second oligonucleotide by one nucleotide in the center of the sequence. The oligonucleotide pairs can be arranged on a substrate, e.g. a silicon chip, using a light-directed chemical process (Chee, supra).

[0386] In the alternative, a chemical coupling procedure and an ink jet device can be used to synthesize oligomers on the surface of a substrate (Baldeschweiler, supra.) An array analogous to a dot or slot blot may also be used to arrange and operably-link fragments or oligonucleotides to the surface of a substrate using or thermal, UV, mechanical, or chemical bonding procedures, or a vacuum system. A typical array may be produced by hand or using available methods and machines and contain any appropriate number of elements. After hybridization, nonhybridized probes are removed and a scanner used to determine the levels and patterns of fluorescence. The degree of complementarity and the relative abundance of each oligonucleotide sequence on the substrate may be assessed through analysis of the scanned images.

VIII Complementary Polynucleotides

[0387] Sequences complementary to the SIGP-encoding sequences, or any parts thereof, are used to detect, decrease, or inhibit expression of naturally occurring SIGP. Although use of oligonucleotides comprising from about 15 to 30 base pairs is described, essentially the same procedure is used with smaller or with larger sequence fragments. Appropriate oligonucleotides are designed using Oligo 4.06 software and the coding sequence of SIGP. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5′ sequence and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the SIGP-encoding transcript.

IX Expression of SIGP

[0388] Expression of SIGP is accomplished by subcloning the cDNA into an appropriate vector and transforming the vector into host cells. This vector contains a β-galactosidase promoter upstream of the cloning site, operably-associated with the cDNA of interest (Sambrook, supra, pp. 404-433; Rosenberg et al. (1983) Methods Enzymol 101:123-138).

[0389] Induction of an isolated, transformed bacterial strain with isopropyl beta-D-thiogalactopyranoside (IPTG) using standard methods produces a fusion protein which consists of the first 8 residues of β-galactosidase, about 5 to 15 residues of linker, and the full length protein. The signal residues direct the secretion of SIGP into bacterial growth media which can be used directly in the following assay for activity.

X Production of SIGP Specific Antibodies

[0390] SIGP purified using PAGE electrophoresis (Harrington (1990) Methods Enzymol 182:488-495), or other purification techniques, is used to immunize rabbits and to produce antibodies using standard protocols. The SIGP amino acid sequence is analyzed using LASERGENE software (DNASTAR) to determine regions of high immunogenicity, and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Methods for selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are well described in the art (Ausubel et al. supra, ch. 11).

[0391] Typically, the oligopeptides are 15 residues in length, and are synthesized using an 431A Peptide synthesizer (ABI) using Fmoc-chemistry and coupled to KLH (Sigma-Aldrich, St. Louis Mo.) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester to increase immunogenicity (Ausubel, supra). Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. Resulting antisera are tested for antipeptide activity, for example, by binding the peptide to plastic, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio-iodinated goat anti-rabbit IgG.

XI Purification of Naturally Occurring SIGP Using Specific Antibodies

[0392] Naturally occurring or recombinant SIGP is purified by immunoaffinity chromatography using antibodies specific for SIGP. An immunoaffinity column is constructed by covalently coupling anti-SIGP antibody to an activated chromatographic resin, such as CNBr-activated SEPHAROSE resin (APB). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

[0393] Media containing SIGP are passed over the immunoaffinity column, and the column is washed under conditions, high ionic strength buffers in the presence of detergent, that allow the preferential absorbance of SIGP. The column is eluted under conditions that disrupt antibody/SIGP binding (a buffer of pH 2-3 or a high concentration of a chaotrope such as urea or thiocyanate ion) and SIGP is collected.

XII Identification of Molecules Which Interact with SIGP

[0394] SIGP, or biologically active fragments thereof, are labeled with ¹²⁵I Bolton-Hunter reagent (Bolton et al. (1973) Biochem J 133:529-533). Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled SIGP, washed, and any wells with labeled SIGP complex are assayed. Data obtained using different concentrations of SIGP are used to calculate values for the number, affinity, and association of SIGP with the candidate molecules.

[0395] Various modifications and variations of the described methods and systems of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

0 SEQUENCE LISTING W (1) GENERAL INFORMATION: (iii) NUMBER OF SEQUENCES: 154 (2) INFORMATION FOR SEQ ID NO: 1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 348 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: HEARNOT01 (B) CLONE: 305841 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1 : Met Ala Ala Thr Leu Gly Pro Leu Gly Ser Trp Gln Gln Trp Arg 5 10 15 Arg Cys Leu Ser Ala Arg Asp Gly Ser Arg Met Leu Leu Leu Leu 20 25 30 Leu Leu Leu Gly Ser Gly Gln Gly Pro Gln Gln Val Gly Ala Gly 35 40 45 Gln Thr Phe Glu Tyr Leu Lys Arg Glu His Ser Leu Ser Lys Pro 50 55 60 Tyr Gln Gly Val Gly Thr Gly Ser Ser Ser Leu Trp Asn Leu Met 65 70 75 Gly Asn Ala Met Val Met Thr Gln Tyr Ile Arg Leu Thr Pro Asp 80 85 90 Met Gln Ser Lys Gln Gly Ala Leu Trp Asn Arg Val Pro Cys Phe 95 100 105 Leu Arg Asp Trp Glu Leu Gln Val His Phe Lys Ile His Gly Gln 110 115 120 Gly Lys Lys Asn Leu His Gly Asp Gly Leu Ala Ile Trp Tyr Thr 125 130 135 Lys Asp Arg Met Gln Pro Gly Pro Val Phe Gly Asn Met Asp Lys 140 145 150 Phe Val Gly Leu Gly Val Phe Val Asp Thr Tyr Pro Asn Glu Glu 155 160 165 Lys Gln Gln Glu Arg Val Phe Pro Tyr Ile Ser Ala Met Val Asn 170 175 180 Asn Gly Ser Leu Ser Tyr Asp His Glu Arg Asp Gly Arg Pro Thr 185 190 195 Glu Leu Gly Gly Cys Thr Ala Ile Val Arg Asn Leu His Tyr Asp 200 205 210 Thr Phe Leu Val Ile Arg Tyr Val Lys Arg His Leu Thr Ile Met 215 220 225 Met Asp Ile Asp Gly Lys His Glu Trp Arg Asp Cys Ile Glu Val 230 235 240 Pro Gly Val Arg Leu Pro Arg Gly Tyr Tyr Phe Gly Thr Ser Ser 245 250 255 Ile Thr Gly Asp Leu Ser Asp Asn His Asp Val Ile Ser Leu Lys 260 265 270 Leu Phe Glu Leu Thr Val Glu Arg Thr Pro Glu Glu Glu Lys Leu 275 280 285 His Arg Asp Val Phe Leu Pro Ser Val Asp Asn Met Lys Leu Pro 290 295 300 Glu Met Thr Ala Pro Leu Pro Pro Leu Ser Gly Leu Ala Leu Phe 305 310 315 Leu Ile Val Phe Phe Ser Leu Val Phe Ser Val Phe Ala Ile Val 320 325 330 Ile Gly Ile Ile Leu Tyr Asn Lys Trp Gln Glu Gln Ser Arg Lys 335 340 345 Arg Phe Tyr (2) INFORMATION FOR SEQ ID NO: 2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 194 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: EOSIHET02 (B) CLONE: 322866 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2 : Met Gly Met Ser Ser Leu Lys Leu Leu Lys Tyr Val Leu Phe Phe 5 10 15 Phe Asn Leu Leu Phe Trp Ile Cys Gly Cys Cys Ile Leu Gly Phe 20 25 30 Gly Ile Tyr Leu Leu Ile His Asn Asn Phe Gly Val Leu Phe His 35 40 45 Asn Leu Pro Ser Leu Thr Leu Gly Asn Val Phe Val Ile Val Gly 50 55 60 Ser Ile Ile Met Val Val Ala Phe Leu Gly Cys Met Gly Ser Ile 65 70 75 Lys Glu Asn Lys Cys Leu Leu Met Ser Phe Phe Ile Leu Leu Leu 80 85 90 Ile Ile Leu Leu Ala Glu Val Thr Leu Ala Ile Leu Leu Phe Val 95 100 105 Tyr Glu Gln Lys Leu Asn Glu Tyr Val Ala Lys Gly Leu Thr Asp 110 115 120 Ser Ile His Arg Tyr His Ser Asp Asn Ser Thr Lys Ala Ala Trp 125 130 135 Asp Ser Ile Gln Ser Phe Leu Gln Cys Cys Gly Ile Asn Gly Thr 140 145 150 Ser Asp Leu Asp Ser Gly Ser Pro Ala Ser Cys Pro Ser Asp Arg 155 160 165 Lys Val Glu Gly Cys Tyr Ala Lys Glu Asp Phe Gly Phe Ile Gln 170 175 180 Phe Pro Val Tyr Arg Asn His His His Leu Cys Met Cys Asp 185 190 (2) INFORMATION FOR SEQ ID NO: 3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 342 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: BEPINOT01 (B) CLONE: 546656 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3 : Met Ser Leu His Gly Lys Arg Lys Glu Ile Tyr Lys Tyr Glu Ala 5 10 15 Pro Trp Thr Val Tyr Ala Met Asn Trp Ser Val Arg Pro Asp Lys 20 25 30 Arg Phe Arg Leu Ala Leu Gly Ser Phe Val Glu Glu Tyr Asn Asn 35 40 45 Lys Val Gln Leu Val Gly Leu Asp Glu Glu Ser Ser Glu Phe Ile 50 55 60 Cys Arg Asn Thr Phe Asp His Pro Tyr Pro Thr Thr Lys Leu Met 65 70 75 Trp Ile Pro Asp Thr Lys Gly Val Tyr Pro Asp Leu Leu Ala Thr 80 85 90 Ser Gly Asp Tyr Leu Arg Val Trp Arg Val Gly Glu Thr Glu Thr 95 100 105 Arg Leu Glu Cys Leu Leu Asn Asn Asn Lys Asn Ser Asp Phe Cys 110 115 120 Ala Pro Leu Thr Ser Phe Asp Trp Asn Glu Val Asp Pro Tyr Leu 125 130 135 Leu Gly Thr Ser Ser Ile Asp Thr Thr Cys Thr Ile Trp Gly Leu 140 145 150 Glu Thr Gly Gln Val Leu Gly Arg Val Asn Leu Val Ser Gly His 155 160 165 Val Lys Thr Gln Leu Ile Ala His Asp Lys Glu Val Tyr Asp Ile 170 175 180 Ala Phe Ser Arg Ala Gly Gly Gly Arg Asp Met Phe Ala Ser Val 185 190 195 Gly Ala Asp Gly Ser Val Arg Met Phe Asp Leu Arg His Leu Glu 200 205 210 His Ser Thr Ile Ile Tyr Glu Asp Pro Gln His His Pro Leu Leu 215 220 225 Arg Leu Cys Trp Asn Lys Gln Asp Pro Asn Tyr Leu Ala Thr Met 230 235 240 Ala Met Asp Gly Met Glu Val Val Ile Leu Asp Val Arg Val Pro 245 250 255 Cys Thr Pro Val Ala Arg Leu Asn Asn His Arg Ala Cys Val Asn 260 265 270 Gly Ile Ala Trp Ala Pro His Ser Ser Cys His Ile Cys Thr Ala 275 280 285 Ala Asp Asp His Gln Ala Leu Ile Trp Asp Ile Gln Gln Met Pro 290 295 300 Arg Ala Ile Glu Asp Pro Ile Leu Ala Tyr Thr Ala Glu Gly Glu 305 310 315 Ile Asn Asn Val Gln Trp Ala Ser Thr Gln Pro Asp Trp Ile Ala 320 325 330 Ile Cys Tyr Asn Asn Cys Leu Glu Ile Leu Arg Val 335 340 (2) INFORMATION FOR SEQ ID NO: 4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 656 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: SYNORAT03 (B) CLONE: 693453 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4 : Met Glu Glu Leu Asp Gly Glu Pro Thr Val Thr Leu Ile Pro Gly 5 10 15 Val Asn Ser Lys Lys Asn Gln Met Tyr Phe Asp Trp Gly Pro Gly 20 25 30 Glu Met Leu Val Cys Glu Thr Ser Phe Asn Lys Lys Glu Lys Ser 35 40 45 Glu Met Val Pro Ser Cys Pro Phe Ile Tyr Ile Ile Arg Lys Asp 50 55 60 Val Asp Val Tyr Ser Gln Ile Leu Arg Lys Leu Phe Asn Glu Ser 65 70 75 His Gly Ile Phe Leu Gly Leu Gln Arg Ile Asp Glu Glu Leu Thr 80 85 90 Gly Lys Ser Arg Lys Ser Gln Leu Val Arg Val Ser Lys Asn Tyr 95 100 105 Arg Ser Val Ile Arg Ala Cys Met Glu Glu Met His Gln Val Ala 110 115 120 Ile Ala Ala Lys Asp Pro Ala Asn Gly Arg Gln Phe Ser Ser Gln 125 130 135 Val Ser Ile Leu Ser Ala Met Glu Leu Ile Trp Asn Leu Cys Glu 140 145 150 Ile Leu Phe Ile Glu Val Ala Pro Ala Gly Pro Leu Leu Leu His 155 160 165 Leu Leu Asp Trp Val Arg Leu His Val Cys Glu Val Asp Ser Leu 170 175 180 Ser Ala Asp Val Leu Gly Ser Glu Asn Pro Ser Lys His Asp Ser 185 190 195 Phe Trp Asn Leu Val Thr Ile Leu Val Leu Gln Gly Arg Leu Asp 200 205 210 Glu Ala Arg Gln Met Leu Ser Lys Glu Ala Asp Ala Ser Pro Ala 215 220 225 Ser Ala Gly Ile Cys Arg Ile Met Gly Asp Leu Met Arg Thr Met 230 235 240 Pro Ile Leu Ser Pro Gly Asn Thr Gln Thr Leu Thr Glu Leu Glu 245 250 255 Leu Lys Trp Gln His Trp His Glu Glu Cys Glu Arg Tyr Leu Gln 260 265 270 Asp Ser Thr Phe Ala Thr Ser Pro His Leu Glu Ser Leu Leu Lys 275 280 285 Ile Met Leu Gly Asp Glu Ala Ala Leu Leu Glu Gln Lys Glu Leu 290 295 300 Leu Ser Asn Trp Tyr His Phe Leu Val Thr Arg Leu Leu Tyr Ser 305 310 315 Asn Pro Thr Val Lys Pro Ile Asp Leu His Tyr Tyr Ala Gln Ser 320 325 330 Ser Leu Asp Leu Phe Leu Gly Gly Glu Ser Ser Pro Glu Pro Leu 335 340 345 Asp Asn Ile Leu Leu Ala Ala Phe Glu Phe Asp Ile His Gln Val 350 355 360 Ile Lys Glu Cys Ser Ile Ala Leu Ser Asn Trp Trp Phe Val Ala 365 370 375 His Leu Thr Asp Leu Leu Asp His Cys Lys Leu Leu Gln Ser His 380 385 390 Asn Leu Tyr Phe Gly Ser Asn Met Arg Glu Phe Leu Leu Leu Glu 395 400 405 Tyr Ala Ser Gly Leu Phe Ala His Pro Ser Leu Trp Gln Leu Gly 410 415 420 Val Asp Tyr Phe Asp Tyr Cys Pro Glu Leu Gly Arg Val Ser Leu 425 430 435 Glu Leu His Ile Glu Arg Ile Pro Leu Asn Thr Glu Gln Lys Ala 440 445 450 Leu Lys Val Leu Arg Ile Cys Glu Gln Arg Gln Met Thr Glu Gln 455 460 465 Val Arg Ser Ile Cys Lys Ile Leu Ala Met Lys Ala Val Arg Asn 470 475 480 Asn Arg Leu Gly Ser Ala Leu Ser Trp Ser Ile Arg Ala Lys Asp 485 490 495 Ala Ala Phe Ala Thr Leu Val Ser Asp Arg Phe Leu Arg Asp Tyr 500 505 510 Cys Glu Arg Gly Cys Phe Ser Asp Leu Asp Leu Ile Asp Asn Leu 515 520 525 Gly Pro Ala Met Met Leu Ser Asp Arg Leu Thr Phe Leu Gly Lys 530 535 540 Tyr Arg Glu Phe His Arg Met Tyr Gly Glu Lys Arg Phe Ala Asp 545 550 555 Ala Ala Ser Leu Leu Leu Ser Leu Met Thr Ser Arg Ile Ala Pro 560 565 570 Arg Ser Phe Trp Met Thr Leu Leu Thr Asp Ala Leu Pro Leu Leu 575 580 585 Glu Gln Lys Gln Val Ile Phe Ser Ala Glu Gln Thr Tyr Glu Leu 590 595 600 Met Arg Cys Leu Glu Asp Leu Thr Ser Arg Arg Pro Val His Gly 605 610 615 Glu Ser Asp Thr Glu Gln Leu Gln Asp Asp Asp Ile Glu Thr Thr 620 625 630 Lys Val Glu Met Leu Arg Leu Ser Leu Ala Arg Asn Leu Ala Arg 635 640 645 Ala Ile Ile Arg Glu Gly Ser Leu Glu Gly Ser 650 655 (2) INFORMATION FOR SEQ ID NO: 5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 236 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: BRAITUT03 (B) CLONE: 866885 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5 : Met Ala Pro Asp Pro Trp Phe Ser Thr Tyr Asp Ser Thr Cys Gln 5 10 15 Ile Ala Gln Glu Ile Ala Glu Lys Ile Gln Gln Arg Asn Gln Tyr 20 25 30 Glu Arg Lys Gly Glu Lys Ala Pro Lys Leu Thr Val Thr Ile Arg 35 40 45 Ala Leu Leu Gln Asn Leu Lys Glu Lys Ile Ala Leu Leu Lys Asp 50 55 60 Leu Leu Leu Arg Ala Val Ser Thr His Gln Ile Thr Gln Leu Glu 65 70 75 Gly Asp Arg Arg Gln Asn Leu Leu Asp Asp Leu Val Thr Arg Glu 80 85 90 Arg Leu Leu Leu Ala Ser Phe Lys Asn Glu Gly Ala Glu Pro Asp 95 100 105 Leu Ile Arg Ser Ser Leu Met Ser Glu Glu Ala Lys Arg Gly Ala 110 115 120 Pro Asn Pro Trp Leu Phe Glu Glu Pro Glu Glu Thr Arg Gly Leu 125 130 135 Gly Phe Asp Glu Ile Arg Gln Gln Gln Gln Lys Ile Ile Gln Glu 140 145 150 Gln Asp Ala Gly Leu Asp Ala Leu Ser Ser Ile Ile Ser Arg Gln 155 160 165 Lys Gln Met Gly Gln Glu Ile Gly Asn Glu Leu Asp Glu Gln Asn 170 175 180 Glu Ile Ile Asp Asp Leu Ala Asn Leu Val Glu Asn Thr Asp Glu 185 190 195 Lys Leu Arg Asn Glu Thr Arg Arg Val Asn Met Val Asp Arg Lys 200 205 210 Ser Ala Ser Cys Gly Met Ile Met Val Ile Leu Leu Leu Leu Val 215 220 225 Ala Ile Val Val Val Ala Val Trp Pro Thr Asn 230 235 (2) INFORMATION FOR SEQ ID NO: 6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 195 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: LUNGNOT03 (B) CLONE: 1242271 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6 : Met Leu Leu Asp Thr Val Gln Lys Val Phe Gln Lys Met Leu Glu 5 10 15 Cys Ile Ala Arg Ser Phe Arg Lys Gln Pro Glu Glu Gly Leu Arg 20 25 30 Leu Leu Tyr Ser Val Gln Arg Pro Leu His Glu Phe Ile Thr Ala 35 40 45 Val Gln Ser Arg His Thr Asp Thr Pro Val His Arg Gly Val Leu 50 55 60 Ser Thr Leu Ile Ala Gly Pro Val Val Glu Ile Ser His Gln Leu 65 70 75 Arg Lys Val Ser Asp Val Glu Glu Leu Thr Pro Pro Glu His Leu 80 85 90 Ser Asp Leu Pro Pro Phe Ser Arg Cys Leu Ile Gly Ile Ile Ile 95 100 105 Lys Ser Ser Asn Val Val Arg Ser Phe Leu Asp Glu Leu Lys Ala 110 115 120 Cys Val Ala Ser Asn Asp Ile Glu Gly Ile Val Cys Leu Thr Ala 125 130 135 Ala Val His Ile Ile Leu Val Ile Asn Ala Gly Lys His Lys Ser 140 145 150 Ser Lys Val Arg Glu Val Ala Ala Thr Val His Arg Lys Leu Lys 155 160 165 Thr Phe Met Glu Ile Thr Leu Glu Glu Asp Ser Ile Glu Arg Phe 170 175 180 Leu Tyr Glu Ser Ser Ser Arg Thr Leu Gly Glu Leu Leu Asn Ser 185 190 195 (2) INFORMATION FOR SEQ ID NO: 7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 608 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: LUNGFET03 (B) CLONE: 1255027 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7 : Met Thr Lys Thr Asp Glu Thr Thr Leu Val Ala Ser Trp Glu Thr 5 10 15 Arg Glu Lys Thr Ala Lys Thr Thr Leu Phe Leu Pro Leu Glu Phe 20 25 30 Trp Ser Tyr Lys Ala Glu Val Pro His Leu Pro Glu Leu Ala Tyr 35 40 45 Ser Ala Arg Ser Lys Met Ala Glu Leu Asn Thr His Val Asn Val 50 55 60 Lys Glu Lys Ile Tyr Ala Val Arg Ser Val Val Pro Asn Lys Ser 65 70 75 Asn Asn Glu Ile Val Leu Val Leu Gln Gln Phe Asp Phe Asn Val 80 85 90 Asp Lys Ala Val Gln Ala Phe Val Asp Gly Ser Ala Ile Gln Val 95 100 105 Leu Lys Glu Trp Asn Met Thr Gly Lys Lys Lys Asn Asn Lys Arg 110 115 120 Lys Arg Ser Lys Ser Lys Gln His Gln Gly Asn Lys Asp Ala Lys 125 130 135 Asp Lys Val Glu Arg Pro Glu Ala Gly Pro Leu Gln Pro Gln Pro 140 145 150 Pro Gln Ile Gln Asn Gly Pro Met Asn Gly Cys Glu Lys Asp Ser 155 160 165 Ser Ser Thr Asp Ser Ala Asn Glu Lys Pro Ala Leu Ile Pro Arg 170 175 180 Glu Lys Lys Ile Ser Ile Leu Glu Glu Pro Ser Lys Ala Leu Arg 185 190 195 Gly Val Thr Glu Gly Asn Arg Leu Leu Gln Gln Lys Leu Ser Leu 200 205 210 Asp Gly Asn Pro Lys Pro Ile His Gly Thr Thr Glu Arg Ser Asp 215 220 225 Gly Leu Gln Trp Ser Ala Glu Gln Pro Cys Asn Pro Ser Lys Pro 230 235 240 Lys Ala Lys Thr Ser Pro Val Lys Ser Asn Thr Pro Ala Ala His 245 250 255 Leu Glu Ile Lys Pro Asp Glu Leu Ala Lys Lys Arg Gly Pro Asn 260 265 270 Ile Glu Lys Ser Val Lys Asp Leu Gln Arg Cys Thr Val Ser Leu 275 280 285 Thr Arg Tyr Arg Val Met Ile Lys Glu Glu Val Asp Ser Ser Val 290 295 300 Lys Lys Ile Lys Ala Ala Phe Ala Glu Leu His Asn Cys Ile Ile 305 310 315 Asp Lys Glu Val Ser Leu Met Ala Glu Met Asp Lys Val Lys Glu 320 325 330 Glu Ala Met Glu Ile Leu Thr Ala Arg Gln Lys Lys Ala Glu Glu 335 340 345 Leu Lys Arg Leu Thr Asp Leu Ala Ser Gln Met Ala Glu Met Gln 350 355 360 Leu Ala Glu Leu Arg Ala Glu Ile Lys His Phe Val Ser Glu Arg 365 370 375 Lys Tyr Asp Glu Glu Leu Gly Lys Ala Ala Arg Phe Ser Cys Asp 380 385 390 Ile Glu Gln Leu Lys Ala Gln Ile Met Leu Cys Gly Glu Ile Thr 395 400 405 His Pro Lys Asn Asn Tyr Ser Ser Arg Thr Pro Cys Ser Ser Leu 410 415 420 Leu Pro Leu Leu Asn Ala His Ala Ala Thr Ser Gly Lys Gln Ser 425 430 435 Asn Phe Ser Arg Lys Ser Ser Thr His Asn Lys Pro Ser Glu Gly 440 445 450 Lys Ala Ala Asn Pro Lys Met Val Ser Ser Leu Pro Ser Thr Ala 455 460 465 Asp Pro Ser His Gln Thr Met Pro Ala Asn Lys Gln Asn Gly Ser 470 475 480 Ser Asn Gln Arg Arg Arg Phe Asn Pro Gln Tyr His Asn Asn Arg 485 490 495 Leu Asn Gly Pro Ala Lys Ser Gln Gly Ser Gly Asn Glu Ala Glu 500 505 510 Pro Leu Gly Lys Gly Asn Ser Arg His Glu His Arg Arg Gln Pro 515 520 525 His Asn Gly Phe Arg Pro Lys Asn Lys Gly Gly Ala Lys Asn Gln 530 535 540 Glu Ala Ser Leu Gly Met Lys Thr Pro Glu Ala Pro Ala His Ser 545 550 555 Glu Lys Pro Arg Arg Arg Gln His Ala Ala Asp Thr Ser Glu Ala 560 565 570 Arg Pro Phe Arg Gly Ser Val Gly Arg Val Ser Gln Cys Asn Leu 575 580 585 Cys Pro Thr Arg Ile Glu Val Ser Thr Asp Ala Ala Val Leu Ser 590 595 600 Val Pro Ala Val Thr Leu Val Ala 605 (2) INFORMATION FOR SEQ ID NO: 8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 267 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: TESTTUT02 (B) CLONE: 1273453 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8 : Met Val Ile Ser Trp His Leu Ala Ser Asp Met Asp Cys Val Val 5 10 15 Thr Leu Thr Thr Asp Ala Ala Arg Arg Ile Tyr Asp Glu Thr Gln 20 25 30 Gly Arg Gln Gln Val Leu Pro Leu Asp Ser Ile Tyr Lys Lys Thr 35 40 45 Leu Pro Asp Trp Lys Arg Ser Leu Pro His Phe Arg Asn Gly Lys 50 55 60 Leu Tyr Phe Lys Pro Ile Gly Asp Pro Val Phe Ala Arg Asp Leu 65 70 75 Leu Thr Phe Pro Asp Asn Val Glu His Cys Glu Thr Val Phe Gly 80 85 90 Met Leu Leu Gly Asp Thr Ile Ile Leu Asp Asn Leu Asp Ala Ala 95 100 105 Asn His Tyr Arg Lys Glu Val Val Lys Ile Thr His Cys Pro Thr 110 115 120 Leu Leu Thr Arg Asp Gly Asp Arg Ile Arg Ser Asn Gly Lys Phe 125 130 135 Gly Gly Leu Gln Asn Lys Ala Pro Pro Met Asp Lys Leu Arg Gly 140 145 150 Met Val Phe Gly Ala Pro Val Pro Lys Gln Cys Leu Ile Leu Gly 155 160 165 Glu Gln Ile Asp Leu Leu Gln Gln Tyr Arg Ser Ala Val Cys Lys 170 175 180 Leu Asp Ser Val Asn Lys Asp Leu Asn Ser Gln Leu Glu Tyr Leu 185 190 195 Arg Thr Pro Asp Met Arg Lys Lys Lys Gln Glu Leu Asp Glu His 200 205 210 Glu Lys Asn Leu Lys Leu Ile Glu Glu Lys Leu Gly Met Thr Pro 215 220 225 Ile Arg Lys Cys Asn Asp Ser Leu Arg His Ser Pro Lys Val Glu 230 235 240 Thr Thr Asp Cys Pro Val Pro Pro Lys Arg Met Arg Arg Glu Ala 245 250 255 Thr Arg Gln Asn Arg Ile Ile Thr Lys Thr Asp Val 260 265 (2) INFORMATION FOR SEQ ID NO: 9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 285 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: TESTTUT02 (B) CLONE: 1275261 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9 : Met Val Met Arg Pro Leu Trp Ser Leu Leu Leu Trp Glu Ala Leu 5 10 15 Leu Pro Ile Thr Val Thr Gly Ala Gln Val Leu Ser Lys Val Gly 20 25 30 Gly Ser Val Leu Leu Val Ala Ala Arg Pro Pro Gly Phe Gln Val 35 40 45 Arg Glu Ala Ile Trp Arg Ser Leu Trp Pro Ser Glu Glu Leu Leu 50 55 60 Ala Thr Phe Phe Arg Gly Ser Leu Glu Thr Leu Tyr His Ser Arg 65 70 75 Phe Leu Gly Arg Ala Gln Leu His Ser Asn Leu Ser Leu Glu Leu 80 85 90 Gly Pro Leu Glu Ser Gly Asp Ser Gly Asn Phe Ser Val Leu Met 95 100 105 Val Asp Thr Arg Gly Gln Pro Trp Thr Gln Thr Leu Gln Leu Lys 110 115 120 Val Tyr Asp Ala Val Pro Arg Pro Val Val Gln Val Phe Ile Ala 125 130 135 Val Glu Arg Asp Ala Gln Pro Ser Lys Thr Cys Gln Val Phe Leu 140 145 150 Ser Cys Trp Ala Pro Asn Ile Ser Glu Ile Thr Tyr Ser Trp Arg 155 160 165 Arg Glu Thr Thr Met Asp Phe Gly Met Glu Pro His Ser Leu Phe 170 175 180 Thr Asp Gly Gln Val Leu Ser Ile Ser Leu Gly Pro Gly Asp Arg 185 190 195 Asp Val Ala Tyr Ser Cys Ile Val Ser Asn Pro Val Ser Trp Asp 200 205 210 Leu Ala Thr Val Thr Pro Trp Asp Ser Cys His His Glu Ala Ala 215 220 225 Pro Gly Lys Ala Ser Tyr Lys Asp Val Leu Leu Val Val Val Pro 230 235 240 Val Ser Leu Leu Leu Met Leu Val Thr Leu Phe Ser Ala Trp His 245 250 255 Trp Cys Pro Cys Ser Gly Lys Lys Lys Lys Asp Val His Ala Asp 260 265 270 Arg Val Gly Pro Glu Thr Glu Asn Pro Leu Val Gln Asp Leu Pro 275 280 285 (2) INFORMATION FOR SEQ ID NO: 10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 76 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: COLNNOT16 (B) CLONE: 1281682 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10 : Met Pro Phe Thr Arg Pro Leu Lys His Phe Val Ser Leu Leu His 5 10 15 Pro Ser Ala Ser Gln Val His Asn Ala Gly Gln His Gln Lys Leu 20 25 30 Lys Thr Leu Glu Lys Ala Cys Gly Leu Ala Leu Gly Glu Gly Arg 35 40 45 Glu Gln Asn Leu Cys Thr Ser Leu Phe Asn Leu Glu Ile Arg His 50 55 60 Pro Arg Asp Ala Ile Ile Phe Cys Val Ser Ile Val Val Pro Leu 65 70 75 Ser (2) INFORMATION FOR SEQ ID NO: 11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 147 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: BRSTNOT07 (B) CLONE: 1298305 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11 : Met Thr Ala Ser Thr Gly His Leu Gly Leu Gly Trp Ser Ala Arg 5 10 15 Pro Cys Pro Cys Gly Thr Leu Gly Ser Cys Phe Leu Ser Leu Phe 20 25 30 Ala Ala Leu Leu Trp Leu Ala Ala Ala Val Leu Gln Ala Cys Val 35 40 45 Gly His Ser Asp Glu Gly Cys Gly Ala Ser Gln Cys Arg Arg Ala 50 55 60 Ala Leu Gly Ile Val Pro Ser Pro Val Ser Val Leu Arg Thr Tyr 65 70 75 Pro Gly Leu His His Gln Asp Pro Val Phe Gly Phe Arg Arg Pro 80 85 90 Ser Met Gly Lys Thr Arg His Gln Pro Leu Gln Gln Trp Val Pro 95 100 105 Leu Ala Cys Gly His Gln Leu Gly Asp Pro Gly Ser Gly Pro Leu 110 115 120 Leu Ser Pro Val Ser Leu Cys Cys Gly Phe Trp Ala Val Met Ser 125 130 135 Pro Pro Leu Lys Asp Val Phe Thr Leu Thr Ser Gly 140 145 (2) INFORMATION FOR SEQ ID NO: 12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 261 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: LUNGNOT12 (B) CLONE: 1360501 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12 : Met Glu Leu Leu Gln Val Thr Ile Leu Phe Leu Leu Pro Ser Ile 5 10 15 Cys Ser Ser Asn Ser Thr Gly Val Leu Glu Ala Ala Asn Asn Ser 20 25 30 Leu Val Val Thr Thr Thr Lys Pro Ser Ile Thr Thr Pro Asn Thr 35 40 45 Glu Ser Leu Gln Lys Asn Val Val Thr Pro Thr Thr Gly Thr Thr 50 55 60 Pro Lys Gly Thr Ile Thr Asn Glu Leu Leu Lys Met Ser Leu Met 65 70 75 Ser Thr Ala Thr Phe Leu Thr Ser Lys Asp Glu Gly Leu Lys Ala 80 85 90 Thr Thr Thr Asp Val Arg Lys Asn Asp Ser Ile Ile Ser Asn Val 95 100 105 Thr Val Thr Ser Val Thr Leu Pro Asn Ala Val Ser Thr Leu Gln 110 115 120 Ser Ser Lys Pro Lys Thr Glu Thr Gln Ser Ser Ile Lys Thr Thr 125 130 135 Glu Ile Pro Gly Ser Val Leu Gln Pro Asp Ala Ser Pro Ser Lys 140 145 150 Thr Gly Thr Leu Thr Ser Ile Pro Val Thr Ile Pro Glu Asn Thr 155 160 165 Ser Gln Ser Gln Val Ile Gly Thr Glu Gly Gly Lys Asn Ala Ser 170 175 180 Thr Ser Ala Thr Ser Arg Ser Tyr Ser Ser Ile Ile Leu Pro Val 185 190 195 Val Ile Ala Leu Ile Val Ile Thr Leu Ser Val Phe Val Leu Val 200 205 210 Gly Leu Tyr Arg Met Cys Trp Lys Ala Asp Pro Gly Thr Pro Glu 215 220 225 Asn Gly Asn Asp Gln Pro Gln Ser Asp Lys Glu Ser Val Lys Leu 230 235 240 Leu Thr Val Lys Thr Ile Ser His Glu Ser Gly Glu His Ser Ala 245 250 255 Gln Gly Lys Thr Lys Asn 260 (2) INFORMATION FOR SEQ ID NO: 13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 213 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: LUNGNOT12 (B) CLONE: 1362406 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13 : Met Ala Gly Cys Pro Ala Asp Arg Ser Ile Leu Ala Pro Leu Ala 5 10 15 Trp Asp Leu Gly Leu Leu Leu Leu Phe Val Gly Gln His Ser Leu 20 25 30 Met Ala Ala Glu Arg Val Lys Ala Trp Thr Ser Arg Tyr Phe Gly 35 40 45 Val Leu Gln Arg Ser Leu Tyr Val Ala Cys Thr Ala Leu Ala Leu 50 55 60 Gln Leu Val Met Arg Tyr Trp Glu Pro Ile Pro Lys Gly Pro Val 65 70 75 Leu Trp Glu Ala Arg Ala Glu Pro Trp Ala Thr Trp Val Pro Leu 80 85 90 Leu Cys Phe Val Leu His Val Ile Ser Trp Leu Leu Ile Phe Ser 95 100 105 Ile Leu Leu Val Phe Asp Tyr Ala Glu Leu Met Gly Leu Lys Gln 110 115 120 Val Tyr Tyr His Val Leu Gly Leu Gly Glu Pro Leu Ala Leu Lys 125 130 135 Ser Pro Arg Ala Leu Arg Leu Phe Ser His Leu Arg His Pro Val 140 145 150 Cys Val Glu Leu Leu Thr Val Leu Trp Val Val Pro Thr Leu Gly 155 160 165 Thr Asp Arg Leu Leu Leu Ala Phe Leu Leu Thr Leu Tyr Leu Gly 170 175 180 Leu Ala His Gly Leu Asp Gln Gln Asp Leu Arg Tyr Leu Arg Ala 185 190 195 Gln Leu Gln Arg Lys Leu His Leu Leu Ser Arg Pro Gln Asp Gly 200 205 210 Glu Ala Glu (2) INFORMATION FOR SEQ ID NO: 14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 67 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: LATRTUT02 (B) CLONE: 1405329 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14 : Met Gln Pro Arg Pro Arg Gly Arg Pro Pro Arg Thr Arg Gly Asp 5 10 15 Glu Ala Pro Gln Trp His Leu Pro Asp Ala Ala Ala Leu Leu Pro 20 25 30 Val Arg Leu Pro Leu Ala Val Leu Val Arg Gly Thr Gln Arg Pro 35 40 45 Glu Arg Arg Arg Cys Gly Arg Leu Pro Ala Gly Val Pro Gly Ala 50 55 60 Ala Arg Ser Val Ala Arg Ser 65 (2) INFORMATION FOR SEQ ID NO: 15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 161 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: BRAINOT12 (B) CLONE: 1415223 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15 : Met Leu Ala Pro Gln Arg Thr Arg Ala Pro Ser Pro Arg Ala Ala 5 10 15 Pro Arg Pro Thr Arg Ser Met Leu Pro Ala Ala Met Lys Gly Leu 20 25 30 Gly Leu Ala Leu Leu Ala Val Leu Leu Cys Ser Ala Pro Ala His 35 40 45 Gly Leu Trp Cys Gln Asp Cys Thr Leu Thr Thr Asn Ser Ser His 50 55 60 Cys Thr Pro Lys Gln Cys Gln Pro Ser Asp Thr Val Cys Ala Ser 65 70 75 Val Arg Ile Thr Asp Pro Ser Ser Ser Arg Lys Asp His Ser Val 80 85 90 Asn Lys Met Cys Ala Ser Ser Cys Asp Phe Val Lys Arg His Phe 95 100 105 Phe Ser Asp Tyr Leu Met Gly Phe Ile Asn Ser Gly Ile Leu Lys 110 115 120 Val Asp Val Asp Cys Cys Glu Lys Asp Leu Cys Asn Gly Ala Ala 125 130 135 Gly Ala Gly His Ser Pro Trp Ala Leu Ala Gly Gly Leu Leu Leu 140 145 150 Ser Leu Gly Pro Ala Leu Leu Trp Ala Gly Pro 155 160 (2) INFORMATION FOR SEQ ID NO: 16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 141 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: BRAINOT12 (B) CLONE: 1416553 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16 : Met Trp Ala Gln Arg Val Leu Thr Leu Trp Gln Gly Leu Ser Trp 5 10 15 Gly Arg Pro Pro Ser Gly Pro Gly Ala Met Ala Pro Arg Gly Gln 20 25 30 Ala Asp Leu Leu Pro Ala Val Ser Thr Pro Phe Leu Ile Thr Val 35 40 45 Trp Ser Pro Ser Phe Gly Cys Ser Leu Arg Cys Val Leu Gly Ser 50 55 60 Ser Glu Pro Glu Ala Ser Phe Trp Lys Pro Ala Val Leu Pro Ala 65 70 75 Pro Val Gln Lys Pro Leu Ser Pro Ala Phe Pro Gln Ala Gly Val 80 85 90 Gly Val Gly Gly Leu Cys Pro Ser Ser Leu Thr Leu Glu Arg Trp 95 100 105 Glu Ala Gly Asn Leu His Leu Gly Ala Trp Ala Pro Pro Leu Cys 110 115 120 Ala Ser Gly Phe Pro Ala Pro Gly Arg Gly Cys Ser Pro Ser Trp 125 130 135 Thr Pro Ala Cys Pro Ser 140 (2) INFORMATION FOR SEQ ID NO: 17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 152 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: KIDNNOT09 (B) CLONE: 1418517 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17 : Met Glu Asp Glu Glu Val Ala Glu Ser Trp Glu Glu Ala Ala Asp 5 10 15 Ser Gly Glu Ile Asp Arg Arg Leu Glu Lys Lys Leu Lys Ile Thr 20 25 30 Gln Lys Glu Ser Arg Lys Ser Lys Ser Pro Pro Lys Val Pro Ile 35 40 45 Val Ile Gln Asp Asp Ser Leu Pro Ala Gly Pro Pro Pro Gln Ile 50 55 60 Ile Leu Lys Arg Pro Thr Ser Asn Gly Val Val Ser Ser Pro 65 70 75 Asn Ser Thr Ser Arg Pro Thr Leu Pro Val Lys Ser Leu Ala Gln 80 85 90 Arg Glu Ala Glu Tyr Ala Glu Ala Arg Lys Arg Ile Leu Gly Ser 95 100 105 Ala Ser Pro Glu Glu Glu Gln Glu Lys Pro Ile Leu Asp Arg Pro 110 115 120 Thr Arg Ile Ser Gln Pro Glu Asp Ser Arg Gln Pro Asn Asn Val 125 130 135 Ile Arg Gln Pro Leu Gly Pro Asp Gly Ser Gln Gly Phe Lys Gln 140 145 150 Arg Arg (2) INFORMATION FOR SEQ ID NO: 18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 742 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: PANCNOT08 (B) CLONE: 1438165 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18 : Met Ala Ser Val His Glu Ser Leu Tyr Phe Asn Pro Met Met Thr 5 10 15 Asn Gly Val Val His Ala Asn Val Phe Gly Ile Lys Asp Trp Val 20 25 30 Thr Pro Tyr Lys Ile Ala Val Leu Val Leu Leu Asn Glu Met Ser 35 40 45 Arg Thr Gly Glu Gly Ala Val Ser Leu Met Glu Arg Arg Arg Leu 50 55 60 Asn Gln Leu Leu Leu Pro Leu Leu Gln Gly Pro Asp Ile Thr Leu 65 70 75 Ser Lys Leu Tyr Lys Leu Ile Glu Glu Ser Cys Pro Gln Leu Ala 80 85 90 Asn Ser Val Gln Ile Arg Ile Lys Leu Met Ala Glu Gly Glu Leu 95 100 105 Lys Asp Met Glu Gln Phe Phe Asp Asp Leu Ser Asp Ser Phe Ser 110 115 120 Gly Thr Glu Pro Glu Val His Lys Thr Ser Val Val Gly Leu Phe 125 130 135 Leu Arg His Met Ile Leu Ala Tyr Ser Lys Leu Ser Phe Ser Gln 140 145 150 Val Phe Lys Leu Tyr Thr Ala Leu Gln Gln Tyr Phe Gln Asn Gly 155 160 165 Glu Lys Lys Thr Val Glu Asp Ala Asp Met Glu Leu Thr Ser Arg 170 175 180 Asp Glu Gly Glu Arg Lys Met Glu Lys Glu Glu Leu Asp Val Ser 185 190 195 Val Arg Glu Glu Glu Val Ser Cys Ser Gly Pro Leu Ser Gln Lys 200 205 210 Gln Ala Glu Phe Phe Leu Ser Gln Gln Ala Ser Leu Leu Lys Asn 215 220 225 Asp Glu Thr Lys Ala Leu Thr Pro Ala Ser Leu Gln Lys Glu Leu 230 235 240 Asn Asn Leu Leu Lys Phe Asn Pro Asp Phe Ala Glu Ala His Tyr 245 250 255 Leu Ser Tyr Leu Asn Asn Leu Arg Val Gln Asp Val Phe Ser Ser 260 265 270 Thr His Ser Leu Leu His Tyr Phe Asp Arg Leu Ile Leu Thr Gly 275 280 285 Ala Glu Ser Lys Ser Asn Gly Glu Glu Gly Tyr Gly Arg Ser Leu 290 295 300 Arg Tyr Ala Ala Leu Asn Leu Ala Ala Leu His Cys Arg Phe Gly 305 310 315 His Tyr Gln Gln Ala Glu Leu Ala Leu Gln Glu Ala Ile Arg Ile 320 325 330 Ala Gln Glu Ser Asn Asp His Val Cys Leu Gln His Cys Leu Ser 335 340 345 Trp Leu Tyr Val Leu Gly Gln Lys Arg Ser Asp Ser Tyr Val Leu 350 355 360 Leu Glu His Ser Val Lys Lys Ala Val His Phe Gly Leu Pro Arg 365 370 375 Ala Phe Ala Gly Lys Thr Ala Asn Lys Leu Met Asp Ala Leu Lys 380 385 390 Asp Ser Asp Leu Leu His Trp Lys His Ser Leu Ser Glu Leu Ile 395 400 405 Asp Ile Ser Ile Ala Gln Lys Thr Ala Ile Trp Arg Leu Tyr Gly 410 415 420 Arg Ser Thr Met Ala Leu Gln Gln Ala Gln Met Leu Leu Ser Met 425 430 435 Asn Ser Leu Glu Ala Val Asn Ala Gly Val Gln Gln Asn Asn Thr 440 445 450 Glu Ser Phe Ala Val Ala Leu Cys His Leu Ala Glu Leu His Ala 455 460 465 Glu Gln Gly Cys Phe Ala Ala Ala Ser Glu Val Leu Lys His Leu 470 475 480 Lys Glu Arg Phe Pro Pro Asn Ser Gln His Ala Gln Leu Trp Met 485 490 495 Leu Cys Asp Gln Lys Ile Gln Phe Asp Arg Ala Met Asn Asp Gly 500 505 510 Lys Tyr His Leu Ala Asp Ser Leu Val Thr Gly Ile Thr Ala Leu 0 515 520 525 Asn Ser Ile Glu Gly Val Tyr Arg Lys Ala Val Val Leu Gln Ala 530 535 540 Gln Asn Gln Met Ser Glu Ala His Lys Leu Leu Gln Lys Leu Leu 545 550 555 Val His Cys Gln Lys Leu Lys Asn Thr Glu Met Val Ile Ser Val 560 565 570 Leu Leu Ser Val Ala Glu Leu Tyr Trp Arg Ser Ser Ser Pro Thr 575 580 585 Ile Ala Leu Pro Met Leu Leu Gln Ala Leu Ala Leu Ser Lys Glu 590 595 600 Tyr Arg Leu Gln Tyr Leu Ala Ser Glu Thr Val Leu Asn Leu Ala 605 610 615 Phe Ala Gln Leu Ile Leu Gly Ile Pro Glu Gln Ala Leu Ser Leu 620 625 630 Leu His Met Ala Ile Glu Pro Ile Leu Ala Asp Gly Ala Ile Leu 635 640 645 Asp Lys Gly Arg Ala Met Phe Leu Val Ala Lys Cys Gln Val Ala 650 655 660 Ser Ala Ala Ser Tyr Asp Gln Pro Lys Lys Ala Glu Ala Leu Glu 665 670 675 Ala Ala Ile Glu Asn Leu Asn Glu Ala Lys Asn Tyr Phe Ala Lys 680 685 690 Val Asp Cys Lys Glu Arg Ile Arg Asp Val Val Tyr Phe Gln Ala 695 700 705 Arg Leu Tyr His Thr Leu Gly Lys Thr Gln Glu Arg Asn Arg Cys 710 715 720 Ala Met Leu Phe Arg Gln Leu His Gln Glu Leu Pro Ser His Gly 725 730 735 Val Pro Leu Ile Asn His Leu 740 (2) INFORMATION FOR SEQ ID NO: 19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 805 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: THYRNOT03 (B) CLONE: 1440381 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19 : Met Asp Gly Ile Leu Asp Glu Ser Leu Leu Glu Thr Cys Pro Ile 5 10 15 Gln Ser Pro Leu Gln Val Phe Ala Gly Met Gly Gly Leu Ala Leu 20 25 30 Ile Ala Glu Arg Leu Pro Met Leu Tyr Pro Glu Val Ile Gln Gln 35 40 45 Val Ser Ala Pro Val Val Thr Ser Thr Thr Gln Glu Lys Pro Tyr 50 55 60 Asp Ser Asp Gln Phe Glu Trp Val Thr Ile Glu Gln Ser Gly Glu 65 70 75 Leu Val Tyr Glu Ala Pro Glu Thr Val Ala Ala Glu Pro Pro Pro 80 85 90 Ile Lys Ser Ala Val Gln Thr Met Ser Pro Ile Pro Ala His Ser 95 100 105 Leu Ala Ala Phe Gly Leu Phe Leu Arg Leu Pro Gly Tyr Ala Glu 110 115 120 Val Leu Leu Lys Glu Arg Lys His Ala Gln Cys Leu Leu Arg Leu 125 130 135 Val Leu Gly Val Thr Asp Asp Gly Glu Gly Ser His Ile Leu Gln 140 145 150 Ser Pro Ser Ala Asn Val Leu Pro Thr Leu Pro Phe His Val Leu 155 160 165 Arg Ser Leu Phe Ser Thr Thr Pro Leu Thr Thr Asp Asp Gly Val 170 175 180 Leu Leu Arg Arg Met Ala Leu Glu Ile Gly Ala Leu His Leu Ile 185 190 195 Leu Val Cys Leu Ser Ala Leu Ser His His Ser Pro Arg Val Pro 200 205 210 Asn Ser Ser Val Asn Gln Thr Glu Pro Gln Val Ser Ser Ser His 215 220 225 Asn Pro Thr Ser Thr Glu Glu Gln Gln Leu Tyr Trp Ala Lys Gly 230 235 240 Thr Gly Phe Gly Thr Gly Ser Thr Ala Ser Gly Trp Asp Val Glu 245 250 255 Gln Ala Leu Thr Lys Gln Arg Leu Glu Glu Glu His Val Thr Cys 260 265 270 Leu Leu Gln Val Leu Ala Ser Tyr Ile Asn Pro Val Ser Ser Ala 275 280 285 Val Asn Gly Glu Ala Gln Ser Ser His Glu Thr Arg Gly Gln Asn 290 295 300 Ser Asn Ala Leu Pro Ser Val Leu Leu Glu Leu Leu Ser Gln Ser 305 310 315 Cys Leu Ile Pro Ala Met Ser Ser Tyr Leu Arg Asn Asp Ser Val 320 325 330 Leu Asp Met Ala Arg His Val Pro Leu Tyr Arg Ala Leu Leu Glu 335 340 345 Leu Leu Arg Ala Ile Ala Ser Cys Ala Ala Met Val Pro Leu Leu 350 355 360 Leu Pro Leu Ser Thr Glu Asn Gly Glu Glu Glu Glu Glu Gln Ser 365 370 375 Glu Cys Gln Thr Ser Val Gly Thr Leu Leu Ala Lys Met Lys Thr 380 385 390 Cys Val Asp Thr Tyr Thr Asn Arg Leu Arg Ser Lys Arg Glu Asn 395 400 405 Val Lys Thr Gly Val Lys Pro Asp Ala Ser Asp Gln Glu Pro Glu 410 415 420 Gly Leu Thr Leu Leu Val Pro Asp Ile Gln Lys Thr Ala Glu Ile 425 430 435 Val Tyr Ala Ala Thr Thr Ser Leu Arg Gln Ala Asn Gln Glu Lys 440 445 450 Asn Trp Val Asn Thr Pro Arg Arg Arg Leu Met Asn Pro Lys Pro 455 460 465 Leu Ser Val Leu Lys Ser Leu Glu Glu Lys Tyr Val Ala Val Met 470 475 480 Lys Lys Leu Gln Phe Asp Thr Phe Glu Met Val Ser Glu Asp Glu 485 490 495 Asp Gly Lys Leu Gly Phe Lys Val Asn Tyr His Tyr Met Ser Gln 500 505 510 Val Lys Asn Ala Asn Asp Ala Asn Ser Ala Ala Arg Ala Arg Arg 515 520 525 Leu Ala Gln Glu Ala Val Thr Leu Ser Thr Ser Leu Pro Leu Ser 530 535 540 Ser Ser Ser Ser Val Phe Val Arg Cys Asp Glu Glu Arg Leu Asp 545 550 555 Ile Met Lys Val Leu Ile Thr Gly Pro Ala Asp Thr Pro Tyr Ala 560 565 570 Asn Gly Cys Phe Glu Phe Asp Val Tyr Phe Pro Gln Asp Tyr Pro 575 580 585 Ser Ser Pro Pro Leu Val Asn Leu Glu Thr Thr Gly Gly His Ser 590 595 600 Val Arg Phe Asn Pro Asn Leu Tyr Asn Asp Gly Lys Val Cys Leu 605 610 615 Ser Ile Leu Asn Thr Trp His Gly Arg Pro Glu Glu Lys Trp Asn 620 625 630 Pro Gln Thr Ser Ser Phe Leu Gln Val Leu Val Ser Val Gln Ser 635 640 645 Leu Ile Leu Val Ala Glu Pro Tyr Phe Asn Glu Pro Gly Tyr Glu 650 655 660 Arg Ser Arg Gly Thr Pro Ser Gly Thr Gln Ser Ser Arg Glu Tyr 665 670 675 Asp Gly Asn Ile Arg Gln Ala Thr Val Lys Trp Ala Met Leu Glu 680 685 690 Gln Ile Arg Asn Pro Ser Pro Cys Phe Lys Glu Val Ile His Lys 695 700 705 His Phe Tyr Leu Lys Arg Val Glu Ile Met Ala Gln Cys Glu Glu 710 715 720 Trp Ile Ala Asp Ile Gln Gln Tyr Ser Ser Asp Lys Arg Val Gly 725 730 735 Arg Thr Met Ser His His Ala Ala Ala Leu Lys Arg His Thr Ala 740 745 750 Gln Leu Arg Glu Glu Leu Leu Lys Leu Pro Cys Pro Glu Gly Leu 755 760 765 Asp Pro Asp Thr Asp Asp Ala Pro Glu Val Cys Arg Ala Thr Thr 770 775 780 Gly Ala Glu Glu Thr Leu Met His Asp Gln Val Lys Pro Ser Ser 785 790 795 Ser Lys Glu Leu Pro Ser Asp Phe Gln Leu 800 805 (2) INFORMATION FOR SEQ ID NO: 20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 195 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: LUNGNOT14 (B) CLONE: 1510839 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20 : Met Lys Ala Ser Gln Cys Cys Cys Cys Leu Ser His Leu Leu Ala 5 10 15 Ser Val Leu Leu Leu Leu Leu Leu Pro Glu Leu Ser Gly Pro Leu 20 25 30 Ala Val Leu Leu Gln Ala Ala Glu Ala Ala Pro Gly Leu Gly Pro 35 40 45 Pro Asp Pro Arg Pro Arg Thr Leu Pro Pro Leu Pro Pro Gly Pro 50 55 60 Thr Pro Ala Gln Gln Pro Gly Arg Gly Leu Ala Glu Ala Ala Gly 65 70 75 Pro Arg Gly Ser Glu Gly Gly Asn Gly Ser Asn Pro Val Ala Gly 80 85 90 Leu Glu Thr Asp Asp His Gly Gly Lys Ala Gly Glu Gly Ser Val 95 100 105 Gly Gly Gly Leu Ala Val Ser Pro Asn Pro Gly Asp Lys Pro Met 110 115 120 Thr Gln Arg Ala Leu Thr Val Leu Met Val Val Ser Gly Ala Val 125 130 135 Leu Val Tyr Phe Val Val Arg Thr Val Arg Met Arg Arg Arg Asn 140 145 150 Arg Lys Thr Arg Arg Tyr Gly Val Leu Asp Thr Asn Ile Glu Asn 155 160 165 Met Glu Leu Thr Pro Leu Glu Gln Asp Asp Glu Asp Asp Asp Asn 170 175 180 Thr Leu Phe Asp Ala Asn His Pro Arg Arg Arg Glu Cys Ala Phe 185 190 195 (2) INFORMATION FOR SEQ ID NO: 21: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 161 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: SPLNNOT04 (B) CLONE: 1534876 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21 : Met Trp Phe Leu Gly Cys Thr Gly Pro Gly Cys Gly Cys Ala Gly 5 10 15 Val Cys Lys Val Val Pro Cys Ile Ser Thr Gly Phe Glu Thr Ser 20 25 30 Gly Pro Cys Pro Ser Ser Arg Glu Gly Phe Leu Phe Phe Leu Thr 35 40 45 Gln Val Thr Phe Gln Pro Phe Gln Phe Pro Ser Phe Ser Ala Leu 50 55 60 Pro Ser Asn Ser Ala Asn Pro Gly Val Gly Ser Gln Gly Gly Arg 65 70 75 Glu Cys Pro Thr Thr Phe Ser Gly Gln Pro Leu Thr Pro Lys Pro 80 85 90 Leu Pro Pro Ser Ile Leu His Pro Leu Pro Ile Gln Pro Lys Cys 95 100 105 Pro Gln Leu Gly Leu Ser Cys Ile Pro Val Glu Gly Pro Leu Pro 110 115 120 Cys Leu Ser Glu Val Arg Leu Cys Cys Val Met Gly Arg Leu Cys 125 130 135 Pro Ser Pro Pro Leu Ala Arg Cys Thr Cys Phe Leu Val Cys Thr 140 145 150 Arg Cys Pro Gly Gly Pro Ser Leu Pro Cys Gln 155 160 (2) INFORMATION FOR SEQ ID NO: 22: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 160 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: SPLNNOT04 (B) CLONE: 1559131 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22 : Met Asp Lys Leu Lys Lys Val Leu Ser Gly Gln Asp Thr Glu Asp 5 10 15 Arg Ser Gly Leu Ser Glu Val Val Glu Ala Ser Ser Leu Ser Trp 20 25 30 Ser Thr Arg Ile Lys Gly Phe Ile Ala Cys Phe Ala Ile Gly Ile 35 40 45 Leu Cys Ser Leu Leu Gly Thr Val Leu Leu Trp Val Pro Arg Lys 50 55 60 Gly Leu His Leu Phe Ala Val Phe Tyr Thr Phe Gly Asn Ile Ala 65 70 75 Ser Ile Gly Ser Thr Ile Phe Leu Met Gly Pro Val Lys Gln Leu 80 85 90 Lys Arg Met Phe Glu Pro Thr Arg Leu Ile Ala Thr Ile Met Val 95 100 105 Leu Leu Cys Phe Ala Leu Thr Leu Cys Ser Ala Phe Trp Trp His 110 115 120 Asn Lys Gly Leu Ala Leu Ile Phe Cys Ile Leu Gln Ser Leu Ala 125 130 135 Leu Thr Trp Tyr Ser Leu Ser Phe Ile Pro Phe Ala Arg Asp Ala 140 145 150 Val Lys Lys Cys Phe Ala Val Cys Leu Ala 155 160 (2) INFORMATION FOR SEQ ID NO: 23: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 76 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: BLADNOT03 (B) CLONE: 1601473 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23 : Met Gln Ala Lys Tyr Ser Ser Thr Arg Asp Met Leu Asp Asp Asp 5 10 15 Gly Asp Thr Thr Met Ser Leu His Ser Gln Ala Ser Ala Thr Thr 20 25 30 Arg His Pro Glu Pro Arg Arg Thr Glu His Arg Ala Pro Ser Ser 35 40 45 Thr Trp Arg Pro Val Ala Leu Thr Leu Leu Thr Leu Cys Leu Val 50 55 60 Leu Leu Ile Gly Leu Ala Ala Leu Gly Leu Leu Cys Lys Ser Ala 65 70 75 Leu (2) INFORMATION FOR SEQ ID NO: 24: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 336 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: BRAITUT12 (B) CLONE: 1615809 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24 : Met Ile Ser Tyr Ile Val Leu Leu Ser Ile Leu Leu Trp Pro Leu 5 10 15 Val Val Tyr His Glu Leu Ile Gln Arg Met Tyr Thr Arg Leu Glu 20 25 30 Pro Leu Leu Met Gln Leu Asp Tyr Ser Met Lys Ala Glu Ala Asn 35 40 45 Ala Leu His His Lys His Asp Lys Arg Lys Arg Gln Gly Lys Asn 50 55 60 Ala Pro Pro Gly Gly Asp Glu Pro Leu Ala Glu Thr Glu Ser Glu 65 70 75 Ser Glu Ala Glu Leu Ala Gly Phe Ser Pro Val Val Asp Val Lys 80 85 90 Lys Thr Ala Leu Ala Leu Ala Ile Thr Asp Ser Glu Leu Ser Asp 95 100 105 Glu Glu Ala Ser Ile Leu Glu Ser Gly Gly Phe Ser Val Ser Arg 110 115 120 Ala Thr Thr Pro Gln Leu Thr Asp Val Ser Glu Asp Leu Asp Gln 125 130 135 Gln Ser Leu Pro Ser Glu Pro Glu Glu Thr Leu Ser Arg Asp Leu 140 145 150 Gly Glu Gly Glu Glu Gly Glu Leu Ala Pro Pro Glu Asp Leu Leu 155 160 165 Gly Arg Pro Gln Ala Leu Ser Arg Gln Ala Leu Asp Ser Glu Glu 170 175 180 Glu Glu Glu Asp Val Ala Ala Lys Glu Thr Leu Leu Arg Leu Ser 185 190 195 Ser Pro Leu His Phe Val Asn Thr His Phe Asn Gly Ala Gly Ser 200 205 210 Pro Gln Asp Gly Val Lys Cys Ser Pro Gly Gly Pro Val Glu Thr 215 220 225 Leu Ser Pro Glu Thr Val Ser Gly Gly Leu Thr Ala Leu Pro Gly 230 235 240 Thr Leu Ser Pro Pro Leu Cys Leu Val Gly Ser Asp Pro Ala Pro 245 250 255 Ser Pro Ser Ile Leu Pro Pro Val Pro Gln Asp Ser Pro Gln Pro 260 265 270 Leu Pro Ala Pro Glu Glu Glu Glu Ala Leu Thr Thr Glu Asp Phe 275 280 285 Glu Leu Leu Asp Gln Gly Glu Leu Glu Gln Leu Asn Ala Glu Leu 290 295 300 Gly Leu Glu Pro Glu Thr Pro Pro Lys Pro Pro Asp Ala Pro Pro 305 310 315 Leu Gly Pro Asp Ile His Ser Leu Val Gln Ser Asp Gln Glu Ala 320 325 330 Gln Ala Val Ala Glu Pro 335 (2) INFORMATION FOR SEQ ID NO: 25: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 150 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: COLNNOT19 (B) CLONE: 1634813 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25 : Met Asn Leu Trp Leu Leu Ala Cys Leu Val Ala Gly Phe Leu Gly 5 10 15 Ala Trp Ala Pro Ala Val His Ala Gln Gly Val Phe Glu Asp Cys 20 25 30 Cys Leu Ala Tyr His Tyr Pro Ile Gly Trp Ala Val Leu Arg Arg 35 40 45 Ala Trp Thr Tyr Arg Ile Gln Glu Val Ser Gly Ser Cys Asn Leu 50 55 60 Pro Ala Ala Ile Phe Tyr Leu Pro Lys Arg His Arg Lys Val Cys 65 70 75 Gly Asn Pro Lys Ser Arg Glu Val Gln Arg Ala Met Lys Leu Leu 80 85 90 Asp Ala Arg Asn Lys Val Phe Ala Lys Leu Arg His Asn Thr Gln 95 100 105 Thr Phe Gln Ala Gly Pro His Ala Val Lys Lys Leu Ser Ser Gly 110 115 120 Asn Ser Lys Leu Ser Ser Ser Lys Phe Ser Asn Pro Ile Ser Ser 125 130 135 Ser Lys Arg Asn Val Ser Leu Leu Ile Ser Ala Asn Ser Gly Leu 140 145 150 (2) INFORMATION FOR SEQ ID NO: 26: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 217 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: UTRSNOT06 (B) CLONE: 1638407 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26 : Met Ala Pro Pro Ala Leu Gln Arg Gly Gln Arg Val Ala Ala Val 5 10 15 Ala Val Gly Ser Gln Ala Val Leu Gln Ile Leu Ser Arg Val Ser 20 25 30 Gly Arg Gln Ala Pro Pro Gln Pro Ser Gly Ser Gly Gly Val Gly 35 40 45 Ala Gly Pro Val Val Val Pro Asp Gly Gly Gly Glu Gly Pro Gln 50 55 60 Pro His Pro Ser Ser Ser Gln Ser Pro Pro Asp Leu Pro Leu Lys 65 70 75 Ala Gly Asp Thr Val Met Gly Lys Gln Ala Gln Arg Asp Ile Arg 80 85 90 Leu Arg Val Arg Ala Glu Tyr Cys Glu His Gly Pro Ala Leu Glu 95 100 105 Gln Gly Val Ala Ser Arg Arg Pro Gln Ala Leu Ala Arg Gln Leu 110 115 120 Asp Val Phe Gly Gln Ala Thr Ala Val Leu Arg Ser Arg Asp Leu 125 130 135 Gly Ser Val Val Cys Asp Ile Lys Phe Ser Glu Leu Ser Tyr Leu 140 145 150 Asp Ala Phe Trp Gly Asp Tyr Leu Ser Gly Ala Leu Leu Gln Ala 155 160 165 Leu Arg Gly Val Phe Leu Thr Glu Ala Leu Arg Glu Ala Val Gly 170 175 180 Arg Glu Ala Val Arg Leu Leu Val Ser Val Asp Glu Ala Asp Tyr 185 190 195 Glu Ala Gly Arg Arg Arg Leu Leu Leu Met Ala Glu Glu Gly Gly 200 205 210 Arg Arg Pro Thr Glu Ala Ser 215 (2) INFORMATION FOR SEQ ID NO: 27: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 504 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: PROSTUT08 (B) CLONE: 1653112 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27 : Met Ser Gln Pro Arg Thr Pro Glu Gln Ala Leu Asp Thr Pro Gly 5 10 15 Asp Cys Pro Pro Gly Arg Arg Asp Glu Asp Ala Gly Glu Gly Ile 20 25 30 Gln Cys Ser Gln Arg Met Leu Ser Phe Ser Asp Ala Leu Leu Ser 35 40 45 Ile Ile Ala Thr Val Met Ile Leu Pro Val Thr His Thr Glu Ile 50 55 60 Ser Pro Glu Gln Gln Phe Asp Arg Ser Val Gln Arg Leu Leu Ala 65 70 75 Thr Arg Ile Ala Val Tyr Leu Met Thr Phe Leu Ile Val Thr Val 80 85 90 Ala Trp Ala Ala His Thr Arg Leu Phe Gln Val Val Gly Lys Thr 95 100 105 Asp Asp Thr Leu Ala Leu Leu Asn Leu Ala Cys Met Met Thr Ile 110 115 120 Thr Phe Leu Pro Tyr Thr Phe Ser Leu Met Val Thr Phe Pro Asp 125 130 135 Val Pro Leu Gly Ile Phe Leu Phe Cys Val Cys Val Ile Ala Ile 140 145 150 Gly Val Val Gln Ala Leu Ile Val Gly Tyr Ala Phe His Phe Pro 155 160 165 His Leu Leu Ser Pro Gln Ile Gln Arg Ser Ala His Arg Ala Leu 170 175 180 Tyr Arg Arg His Val Leu Gly Ile Val Leu Gln Gly Pro Ala Leu 185 190 195 Cys Phe Ala Ala Ala Ile Phe Ser Leu Phe Phe Val Pro Leu Ser 200 205 210 Tyr Leu Leu Met Val Thr Val Ile Leu Leu Pro Tyr Val Ser Lys 215 220 225 Val Thr Gly Trp Cys Arg Asp Arg Leu Leu Gly His Arg Glu Pro 230 235 240 Ser Ala His Pro Val Glu Val Phe Ser Phe Asp Leu His Glu Pro 245 250 255 Leu Ser Lys Glu Arg Val Glu Ala Phe Ser Asp Gly Val Tyr Ala 260 265 270 Ile Val Ala Thr Leu Leu Ile Leu Asp Ile Cys Glu Asp Asn Val 275 280 285 Pro Asp Pro Lys Asp Val Lys Glu Arg Phe Ser Gly Ser Leu Val 290 295 300 Ala Ala Leu Ser Ala Thr Gly Pro Arg Phe Leu Ala Tyr Phe Gly 305 310 315 Ser Phe Ala Thr Val Gly Leu Leu Trp Phe Ala His His Ser Leu 320 325 330 Phe Leu His Val Arg Lys Ala Thr Arg Ala Met Gly Leu Leu Asn 335 340 345 Thr Leu Ser Leu Ala Phe Val Gly Gly Leu Pro Leu Ala Tyr Gln 350 355 360 Gln Thr Ser Ala Phe Ala Arg Gln Pro Arg Asp Glu Leu Glu Arg 365 370 375 Val Arg Val Ser Cys Thr Ile Ile Phe Leu Ala Ser Ile Phe Gln 380 385 390 Leu Ala Met Trp Thr Thr Ala Leu Leu His Gln Ala Glu Thr Leu 395 400 405 Gln Pro Ser Val Trp Phe Gly Gly Arg Glu His Val Leu Met Phe 410 415 420 Ala Lys Leu Ala Leu Tyr Pro Cys Ala Ser Leu Leu Ala Phe Ala 425 430 435 Ser Thr Cys Leu Leu Ser Arg Phe Ser Val Gly Ile Phe His Leu 440 445 450 Met Gln Ile Ala Val Pro Cys Ala Phe Leu Leu Leu Arg Leu Leu 455 460 465 Val Gly Leu Ala Leu Ala Thr Leu Arg Val Leu Arg Gly Leu Ala 470 475 480 Arg Pro Glu His Pro Pro Pro Ala Pro Thr Gly Gln Asp Asp Pro 485 490 495 Gln Ser Gln Leu Leu Pro Ala Pro Cys 500 (2) INFORMATION FOR SEQ ID NO: 28: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 320 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: BRSTNOT09 (B) CLONE: 1664634 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28 : Met Ala Ala Arg Leu Asp Gly Gly Phe Ala Ala Val Ser Arg Ala 5 10 15 Phe His Glu Ile Arg Ala Arg Asn Pro Ala Phe Gln Pro Gln Thr 20 25 30 Leu Met Asp Phe Gly Ser Gly Thr Gly Ser Val Thr Trp Ala Ala 35 40 45 His Ser Ile Trp Gly Gln Ser Leu Arg Glu Tyr Met Cys Val Asp 50 55 60 Arg Ser Ala Ala Met Leu Val Leu Ala Glu Lys Leu Leu Thr Gly 65 70 75 Gly Ser Glu Ser Gly Glu Pro Tyr Ile Pro Gly Val Phe Phe Arg 80 85 90 Gln Phe Leu Pro Val Ser Pro Lys Val Gln Phe Asp Val Val Val 95 100 105 Ser Ala Phe Ser Leu Ser Asp Gln Leu Leu Thr Phe Ile Leu Ser 110 115 120 Cys Asn Ser Ser Leu Leu His Ile Phe Pro Phe Cys Glu Gln Val 125 130 135 Leu Val Glu Asn Gly Thr Lys Ala Gly His Ser Leu Leu Met Asp 140 145 150 Ala Arg Asp Leu Val Leu Lys Gly Lys Glu Lys Ser Pro Leu Asp 155 160 165 Pro Arg Pro Gly Phe Val Phe Ala Pro Cys Pro His Glu Leu Pro 170 175 180 Cys Pro Gln Leu Thr Asn Leu Ala Cys Ser Phe Ser Gln Ala Tyr 185 190 195 His Pro Ile Pro Phe Ser Trp Asn Lys Lys Pro Lys Glu Glu Lys 200 205 210 Phe Ser Met Val Ile Leu Ala Arg Gly Ser Pro Glu Glu Ala His 215 220 225 Arg Trp Pro Arg Ile Thr Gln Pro Val Leu Lys Arg Pro Arg His 230 235 240 Val His Cys His Leu Cys Cys Pro Asp Gly His Met Gln His Ala 245 250 255 Val Leu Thr Ala Arg Arg His Gly Arg Tyr Gly Gly Cys Asp Gln 260 265 270 Asn Gln Trp Asp Val Ala Gly Ser Cys Ser Pro Arg Gln His Leu 275 280 285 Phe Pro Gln Gly Phe Val Ser Leu Cys Pro Cys Gln Leu Leu Gly 290 295 300 Arg Ser Phe Thr Cys Ala Tyr Ser Val Cys Val Ser Ser Ile Tyr 305 310 315 Gly Ser Gly Ser Leu 320 (2) INFORMATION FOR SEQ ID NO: 29: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 117 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: PROSTUT10 (B) CLONE: 1690990 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29 : Met Asp Asn Lys Gly Ile Tyr Pro Gly Ala Val Phe Tyr His Asp 5 10 15 Ser Phe Thr Glu Ser Arg Val Val Leu Leu Arg Ile Arg Thr Leu 20 25 30 Val Pro Tyr Ser Pro Pro Asp Cys Pro Thr Thr Thr Thr Ala Tyr 35 40 45 Ser Pro Phe Pro Asn His Gly Gln Gln Ile Glu Leu Leu Thr Glu 50 55 60 Val Ser Phe Arg Trp Ile Ser Gln Pro Phe Pro His Arg Pro His 65 70 75 Arg Glu Thr Val Thr Asp Cys Tyr Ser Pro Asn Thr Gln Val Lys 80 85 90 Ser Asn Ala Gly Arg Asn Asn Ser Lys Ser Phe Asn Phe Leu Ile 95 100 105 Leu Leu Leu Lys Ile Leu Thr Glu Ala Ser Arg Phe 110 115 (2) INFORMATION FOR SEQ ID NO: 30: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 298 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: DUODNOT02 (B) CLONE: 1704050 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30 : Met Ala Arg Arg Ser Arg His Arg Leu Leu Leu Leu Leu Leu Arg 5 10 15 Tyr Leu Val Val Ala Leu Gly Tyr His Lys Ala Tyr Gly Phe Ser 20 25 30 Ala Pro Lys Asp Gln Gln Val Val Thr Ala Val Glu Tyr Gln Glu 35 40 45 Ala Ile Leu Ala Cys Lys Thr Pro Lys Lys Thr Val Ser Ser Arg 50 55 60 Leu Glu Trp Lys Lys Leu Gly Arg Ser Val Ser Phe Val Tyr Tyr 65 70 75 Gln Gln Thr Leu Gln Gly Asp Phe Lys Asn Arg Ala Glu Met Ile 80 85 90 Asp Phe Asn Ile Arg Ile Lys Asn Val Thr Arg Ser Asp Ala Gly 95 100 105 Lys Tyr Arg Cys Glu Val Ser Ala Pro Ser Glu Gln Gly Gln Asn 110 115 120 Leu Glu Glu Asp Thr Val Thr Leu Glu Val Leu Val Ala Pro Ala 125 130 135 Val Pro Ser Cys Glu Val Pro Ser Ser Ala Leu Ser Gly Thr Val 140 145 150 Val Glu Leu Arg Cys Gln Asp Lys Glu Gly Asn Pro Ala Pro Glu 155 160 165 Tyr Thr Trp Phe Lys Asp Gly Ile Arg Leu Leu Glu Asn Pro Arg 170 175 180 Leu Gly Ser Gln Ser Thr Asn Ser Ser Tyr Thr Met Asn Thr Lys 185 190 195 Thr Gly Thr Leu Gln Phe Asn Thr Val Ser Lys Leu Asp Thr Gly 200 205 210 Glu Tyr Ser Cys Glu Ala Arg Asn Ser Val Gly Tyr Arg Arg Cys 215 220 225 Pro Gly Lys Arg Met Gln Val Asp Asp Leu Asn Ile Ser Gly Ile 230 235 240 Ile Ala Ala Val Val Val Val Ala Leu Val Ile Ser Val Cys Gly 245 250 255 Leu Gly Val Cys Tyr Ala Gln Arg Lys Gly Tyr Phe Ser Lys Glu 260 265 270 Thr Ser Phe Gln Lys Ser Asn Ser Ser Ser Lys Ala Thr Thr Met 275 280 285 Ser Glu Asn Asp Phe Lys His Thr Lys Ser Phe Ile Ile 290 295 (2) INFORMATION FOR SEQ ID NO: 31: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 118 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: PROSNOT16 (B) CLONE: 1711840 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31 : Met Gln His Arg Gly Phe Leu Leu Leu Thr Leu Leu Ala Leu Leu 5 10 15 Ala Leu Thr Ser Ala Val Ala Lys Lys Gln Asp Lys Val Lys Lys 20 25 30 Gly Gly Pro Gly Ser Glu Cys Ala Glu Trp Ala Trp Gly Pro Cys 35 40 45 Thr Pro Ser Ser Lys Gly Phe Ala Ala Val Gly Phe Pro Arg Gly 50 55 60 Pro Pro Trp Gly Gly Pro Arg Thr Gln Pro Ala Val Leu Val Glu 65 70 75 Arg Val Ala Pro Gly Lys Leu Glu Arg Lys Glu Phe Trp Ala Pro 80 85 90 Gly Leu Trp Lys Val Gly Gln Ile Phe Trp Lys Lys Thr Trp Arg 95 100 105 Val Cys Arg Ser Val Lys Trp Gly Arg Gly Gln Lys Asn 110 115 (2) INFORMATION FOR SEQ ID NO: 32: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 248 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32 : Met Gln Thr Cys Pro Leu Ala Phe Pro Gly His Val Ser Gln Ala 5 10 15 Leu Gly Thr Leu Leu Phe Leu Ala Ala Ser Leu Ser Ala Gln Asn 20 25 30 Glu Gly Trp Asp Ser Pro Ile Cys Thr Glu Gly Val Val Ser Val 35 40 45 Ser Trp Gly Glu Asn Thr Val Met Ser Cys Asn Ile Ser Asn Ala 50 55 60 Phe Ser His Val Asn Ile Lys Leu Arg Ala His Gly Gln Glu Ser 65 70 75 Ala Ile Phe Asn Glu Val Ala Pro Gly Tyr Phe Ser Arg Asp Gly 80 85 90 Trp Gln Leu Gln Val Gln Gly Gly Val Ala Gln Leu Val Ile Lys 95 100 105 Gly Ala Arg Asp Ser His Ala Gly Leu Tyr Met Trp His Leu Val 110 115 120 Gly His Gln Arg Asn Asn Arg Gln Val Thr Leu Glu Val Ser Gly 125 130 135 Ala Glu Pro Gln Ser Ala Pro Asp Thr Gly Phe Trp Pro Val Pro 140 145 150 Ala Val Val Thr Ala Val Phe Ile Leu Leu Val Ala Leu Val Met 155 160 165 Phe Ala Trp Tyr Arg Cys Arg Cys Ser Gln Gln Arg Arg Glu Lys 170 175 180 Lys Phe Phe Leu Leu Glu Pro Gln Met Lys Val Ala Ala Leu Arg 185 190 195 Ala Gly Ala Gln Gln Gly Leu Ser Arg Ala Ser Ala Glu Leu Trp 200 205 210 Thr Pro Asp Ser Glu Pro Thr Pro Arg Pro Leu Ala Leu Val Phe 215 220 225 Lys Pro Ser Pro Leu Gly Ala Leu Glu Leu Leu Ser Pro Gln Pro 230 235 240 Leu Phe Pro Tyr Ala Ala Asp Pro 245 (2) INFORMATION FOR SEQ ID NO: 33: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 150 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: STOMTUT02 (B) CLONE: 1750632 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33 : Met Leu Glu Glu Gly Ser Phe Arg Gly Arg Thr Ala Asp Phe Val 5 10 15 Phe Met Phe Leu Phe Gly Gly Val Leu Met Thr Val Ser Phe Pro 20 25 30 Gln Ala Leu Glu Pro Arg Ala Arg Ala Pro Arg Arg Pro Ala Cys 35 40 45 Val Gly Pro Gly Ala Asn Thr Ala Met Pro Glu Arg Asp Thr Val 50 55 60 Ala Val Ser Ser Leu Ala Pro Phe Leu Pro Trp Ala Leu Met Gly 65 70 75 Phe Ser Leu Leu Leu Gly Asn Ser Ile Leu Val Asp Leu Leu Gly 80 85 90 Ile Ala Val Gly His Ile Tyr Tyr Phe Leu Glu Asp Val Phe Pro 95 100 105 Asn Gln Pro Gly Gly Lys Arg Leu Leu Gln Thr Pro Gly Phe Leu 110 115 120 Lys Leu Leu Leu Asp Ala Pro Ala Glu Asp Pro Asn Tyr Leu Pro 125 130 135 Leu Pro Glu Glu Gln Pro Gly Pro His Leu Pro Pro Pro Gln Gln 140 145 150 (2) INFORMATION FOR SEQ ID NO: 34: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 431 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34 : Met Trp Ala Leu Gly Gln Ala Gly Phe Ala Asn Leu Thr Glu Gly 5 10 15 Leu Lys Val Trp Leu Gly Ile Met Leu Pro Val Leu Gly Ile Lys 20 25 30 Ser Leu Ser Pro Phe Ala Ile Thr Tyr Leu Asp Arg Leu Leu Leu 35 40 45 Met His Pro Asn Leu Thr Lys Gly Phe Gly Met Ile Gly Pro Lys 50 55 60 Asp Phe Phe Pro Leu Leu Asp Phe Ala Tyr Met Pro Asn Asn Ser 65 70 75 Leu Thr Pro Ser Leu Gln Glu Gln Leu Cys Gln Leu Tyr Pro Arg 80 85 90 Leu Lys Met Leu Ala Phe Gly Ala Lys Pro Asp Ser Thr Leu His 95 100 105 Thr Tyr Phe Pro Ser Phe Leu Ser Arg Ala Thr Pro Ser Cys Pro 110 115 120 Pro Glu Met Lys Lys Glu Leu Leu Ser Ser Leu Thr Glu Cys Leu 125 130 135 Thr Val Asp Pro Leu Ser Ala Ser Val Trp Arg Gln Leu Tyr Pro 140 145 150 Lys His Leu Ser Gln Ser Ser Leu Leu Leu Glu His Leu Leu Ser 155 160 165 Ser Trp Glu Gln Ile Pro Lys Lys Val Gln Lys Ser Leu Gln Glu 170 175 180 Thr Ile Gln Ser Leu Lys Leu Thr Asn Gln Glu Leu Leu Arg Lys 185 190 195 Gly Ser Ser Asn Asn Gln Asp Val Val Thr Cys Asp Met Ala Cys 200 205 210 Lys Gly Leu Leu Gln Gln Val Gln Gly Pro Arg Leu Pro Trp Thr 215 220 225 Arg Leu Leu Leu Leu Leu Leu Val Phe Ala Val Gly Phe Leu Cys 230 235 240 His Asp Leu Arg Ser His Ser Ser Phe Gln Ala Ser Leu Thr Gly 245 250 255 Arg Leu Leu Arg Ser Ser Gly Phe Leu Pro Ala Ser Gln Gln Ala 260 265 270 Cys Ala Lys Leu Tyr Ser Tyr Ser Leu Gln Gly Tyr Ser Trp Leu 275 280 285 Gly Glu Thr Leu Pro Leu Trp Gly Ser His Leu Leu Thr Val Val 290 295 300 Arg Pro Ser Leu Gln Leu Ala Trp Ala His Thr Asn Ala Thr Val 305 310 315 Ser Phe Leu Ser Ala His Cys Ala Ser His Leu Ala Trp Phe Gly 320 325 330 Asp Ser Leu Thr Ser Leu Ser Gln Arg Leu Gln Ile Gln Leu Pro 335 340 345 Asp Ser Val Asn Gln Leu Leu Arg Tyr Leu Arg Glu Leu Pro Leu 350 355 360 Leu Phe His Gln Asn Val Leu Leu Pro Leu Trp His Leu Leu Leu 365 370 375 Glu Ala Leu Ala Trp Ala Gln Glu His Cys His Glu Ala Cys Arg 380 385 390 Gly Glu Val Thr Trp Asp Cys Met Lys Thr Gln Leu Ser Glu Ala 395 400 405 Val His Trp Thr Trp Leu Cys Leu Gln Asp Ile Thr Val Ala Phe 410 415 420 Leu Asp Trp Ala Leu Ala Leu Ile Ser Gln Gln 425 430 (2) INFORMATION FOR SEQ ID NO: 35: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 278 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: PROSNOT20 (B) CLONE: 1818761 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35 : Met Gln Trp Leu Arg Val Arg Glu Ser Pro Gly Glu Ala Thr Gly 5 10 15 His Arg Val Thr Met Gly Thr Ala Ala Leu Gly Pro Val Trp Ala 20 25 30 Ala Leu Leu Leu Phe Leu Leu Met Cys Glu Ile Pro Met Val Glu 35 40 45 Leu Thr Phe Asp Arg Ala Val Ala Ser Gly Cys Gln Arg Cys Cys 50 55 60 Asp Ser Glu Asp Pro Leu Asp Pro Ala His Val Ser Ser Ala Ser 65 70 75 Ser Ser Gly Arg Pro His Ala Leu Pro Glu Ile Arg Pro Tyr Ile 80 85 90 Asn Ile Thr Ile Leu Lys Gly Asp Lys Gly Asp Pro Gly Pro Met 95 100 105 Gly Leu Pro Gly Tyr Met Gly Arg Glu Gly Pro Gln Gly Glu Pro 110 115 120 Gly Pro Gln Gly Ser Lys Gly Asp Lys Gly Glu Met Gly Ser Pro 125 130 135 Gly Ala Pro Cys Gln Lys Arg Phe Phe Ala Phe Ser Val Gly Arg 140 145 150 Lys Thr Ala Leu His Ser Gly Glu Asp Phe Gln Thr Leu Leu Phe 155 160 165 Glu Arg Val Phe Val Asn Leu Asp Gly Cys Phe Asp Met Ala Thr 170 175 180 Gly Gln Phe Ala Ala Pro Leu Arg Gly Ile Tyr Phe Phe Ser Leu 185 190 195 Asn Val His Ser Trp Asn Tyr Lys Glu Thr Tyr Val His Ile Met 200 205 210 His Asn Gln Lys Glu Ala Val Ile Leu Tyr Ala Gln Pro Ser Glu 215 220 225 Arg Ser Ile Met Gln Ser Gln Ser Val Met Leu Asp Leu Ala Tyr 230 235 240 Gly Asp Arg Val Trp Val Arg Leu Phe Lys Arg Gln Arg Glu Asn 245 250 255 Ala Ile Tyr Ser Asn Asp Phe Asp Thr Tyr Ile Thr Phe Ser Gly 260 265 270 His Leu Ile Lys Ala Glu Asp Asp 275 (2) INFORMATION FOR SEQ ID NO: 36: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 286 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: GBLATUT01 (B) CLONE: 1824469 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36 : Met Glu Glu Lys Arg Arg Arg Ala Arg Val Gln Gly Ala Trp Ala 5 10 15 Ala Pro Val Lys Ser Gln Ala Ile Ala Gln Pro Ala Thr Thr Ala 20 25 30 Lys Ser His Leu His Gln Lys Pro Gly Gln Thr Trp Lys Asn Lys 35 40 45 Glu His His Leu Ser Asp Arg Glu Phe Val Phe Lys Glu Pro Gln 50 55 60 Gln Val Val Arg Arg Ala Pro Glu Pro Arg Val Ile Asp Arg Glu 65 70 75 Gly Val Tyr Glu Ile Ser Leu Ser Pro Thr Gly Val Ser Arg Val 80 85 90 Cys Leu Tyr Pro Gly Phe Val Asp Val Lys Glu Ala Asp Trp Ile 95 100 105 Leu Glu Gln Leu Cys Gln Asp Val Pro Trp Lys Gln Arg Thr Gly 110 115 120 Ile Arg Glu Asp Ile Thr Tyr Gln Gln Pro Arg Leu Thr Ala Trp 125 130 135 Tyr Gly Glu Leu Pro Tyr Thr Tyr Ser Arg Ile Thr Met Glu Pro 140 145 150 Asn Pro His Trp His Pro Val Leu Arg Thr Leu Lys Asn Arg Ile 155 160 165 Glu Glu Asn Thr Gly His Thr Phe Asn Ser Leu Leu Cys Asn Leu 170 175 180 Tyr Arg Asn Glu Lys Asp Ser Val Asp Trp His Ser Asp Asp Glu 185 190 195 Pro Ser Leu Gly Arg Cys Pro Ile Ile Ala Ser Leu Ser Phe Gly 200 205 210 Ala Thr Arg Thr Phe Glu Met Arg Lys Lys Pro Pro Pro Glu Glu 215 220 225 Asn Gly Asp Tyr Thr Tyr Val Glu Arg Val Lys Ile Pro Leu Asp 230 235 240 His Gly Thr Leu Leu Ile Met Glu Gly Ala Thr Gln Ala Asp Trp 245 250 255 Gln His Arg Val Pro Lys Glu Tyr His Ser Arg Glu Pro Arg Val 260 265 270 Asn Leu Thr Phe Arg Thr Val Tyr Pro Asp Pro Arg Gly Ala Pro 275 280 285 Trp (2) INFORMATION FOR SEQ ID NO: 37: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 404 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: PROSNOT19 (B) CLONE: 1864292 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 37 : Met Lys Met Glu Glu Ala Val Gly Lys Val Glu Glu Leu Ile Glu 5 10 15 Ser Glu Ala Pro Pro Lys Ala Ser Glu Gln Glu Thr Ala Lys Glu 20 25 30 Glu Asp Gly Ser Val Glu Leu Glu Ser Gln Val Gln Lys Asp Gly 35 40 45 Val Ala Asp Ser Thr Val Ile Ser Ser Met Pro Cys Leu Leu Met 50 55 60 Glu Leu Arg Arg Asp Ser Ser Glu Ser Gln Leu Ala Ser Thr Glu 65 70 75 Ser Asp Lys Pro Thr Thr Gly Arg Val Tyr Glu Ser Asp Pro Ser 80 85 90 Asn His Cys Met Leu Ser Pro Ser Ser Ser Gly His Leu Ala Asp 95 100 105 Ser Asp Thr Leu Ser Ser Ala Glu Glu Asn Glu Pro Ser Gln Ala 110 115 120 Glu Thr Ala Val Glu Gly Asp Pro Ser Gly Val Ser Gly Ala Thr 125 130 135 Val Gly Arg Lys Ser Arg Arg Ser Arg Ser Glu Ser Glu Thr Ser 140 145 150 Thr Met Ala Ala Lys Lys Asn Arg Gln Ser Ser Asp Lys Gln Asn 155 160 165 Gly Arg Val Ala Lys Val Lys Gly His Arg Ser Gln Lys His Lys 170 175 180 Glu Arg Ile Arg Leu Leu Arg Gln Lys Arg Glu Ala Ala Ala Arg 185 190 195 Lys Lys Tyr Asn Leu Leu Gln Asp Ser Ser Thr Ser Asp Ser Asp 200 205 210 Leu Thr Cys Asp Ser Ser Thr Ser Ser Ser Asp Asp Asp Glu Glu 215 220 225 Val Ser Gly Ser Ser Lys Thr Ile Thr Ala Glu Ile Pro Asp Gly 230 235 240 Pro Pro Val Val Ala His Tyr Asp Met Ser Asp Thr Asn Ser Asp 245 250 255 Pro Glu Val Val Asn Val Asp Asn Leu Leu Ala Ala Ala Val Val 260 265 270 Gln Glu His Ser Asn Ser Val Gly Gly Gln Asp Thr Gly Ala Thr 275 280 285 Trp Arg Thr Ser Gly Leu Leu Glu Glu Leu Asn Ala Glu Ala Gly 290 295 300 His Leu Asp Pro Gly Phe Leu Ala Ser Asp Lys Thr Ser Ala Gly 305 310 315 Asn Ala Pro Leu Asn Glu Glu Ile Asn Ile Ala Ser Ser Asp Ser 320 325 330 Glu Val Glu Ile Val Gly Val Gln Glu His Ala Arg Cys Val His 335 340 345 Pro Arg Gly Gly Val Ile Gln Ser Val Ser Ser Trp Lys His Gly 350 355 360 Ser Gly Thr Gln Tyr Val Ser Thr Arg Gln Thr Gln Ser Trp Thr 365 370 375 Ala Val Thr Pro Gln Gln Thr Trp Ala Ser Pro Ala Glu Val Val 380 385 390 Asp Leu Thr Leu Asp Glu Asp Ser Arg Arg Lys Tyr Leu Leu 395 400 (2) INFORMATION FOR SEQ ID NO: 38: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 405 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: THP1NOT01 (B) CLONE: 1866437 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 38 : Met Phe Val Gln Glu Glu Lys Ile Phe Ala Gly Lys Val Leu Arg 5 10 15 Leu His Ile Cys Ala Ser Asp Gly Ala Glu Trp Leu Glu Glu Ala 20 25 30 Thr Glu Asp Thr Ser Val Glu Lys Leu Lys Glu Arg Cys Leu Lys 35 40 45 His Cys Ala His Gly Ser Leu Glu Asp Pro Lys Ser Ile Thr His 50 55 60 His Lys Leu Ile His Ala Ala Ser Glu Arg Val Leu Ser Asp Ala 65 70 75 Arg Thr Ile Leu Glu Glu Asn Ile Gln Asp Gln Asp Val Leu Leu 80 85 90 Leu Lys Lys Lys Arg Ala Pro Ser Pro Leu Pro Lys Met Ala Asp 95 100 105 Val Ser Ala Glu Glu Lys Lys Lys Gln Asp Gln Lys Ala Pro Asp 110 115 120 Lys Glu Ala Ile Leu Arg Ala Thr Ala Asn Leu Pro Ser Tyr Asn 125 130 135 Met Asp Arg Ala Ala Val Gln Thr Asn Met Arg Asp Phe Gln Thr 140 145 150 Glu Leu Arg Lys Ile Leu Val Ser Leu Ile Glu Val Ala Gln Lys 155 160 165 Leu Leu Ala Leu Asn Pro Asp Ala Val Glu Leu Phe Lys Lys Ala 170 175 180 Asn Ala Met Leu Asp Glu Asp Glu Asp Glu Arg Val Asp Glu Ala 185 190 195 Ala Leu Arg Gln Leu Thr Glu Met Gly Phe Pro Glu Asn Arg Ala 200 205 210 Thr Lys Ala Leu Gln Leu Asn His Met Ser Val Pro Gln Ala Met 215 220 225 Glu Trp Leu Ile Glu His Ala Glu Asp Pro Thr Ile Asp Thr Pro 230 235 240 Leu Pro Gly Gln Ala Pro Pro Glu Ala Glu Gly Ala Thr Ala Ala 245 250 255 Ala Ser Glu Ala Ala Ala Gly Ala Ser Ala Thr Asp Glu Glu Ala 260 265 270 Arg Asp Glu Leu Thr Glu Ile Phe Lys Lys Ile Arg Arg Lys Arg 275 280 285 Glu Phe Arg Ala Asp Ala Arg Ala Val Ile Ser Leu Met Glu Met 290 295 300 Gly Phe Asp Glu Lys Glu Val Ile Asp Ala Leu Arg Val Asn Asn 305 310 315 Asn Gln Gln Asn Ala Ala Cys Glu Trp Leu Leu Gly Asp Arg Lys 320 325 330 Pro Ser Pro Glu Glu Leu Asp Lys Gly Ile Asp Pro Asp Ser Pro 335 340 345 Leu Phe Gln Ala Ile Leu Asp Asn Pro Val Val Gln Leu Gly Leu 350 355 360 Thr Asn Pro Lys Thr Leu Leu Ala Phe Glu Asp Met Leu Glu Asn 365 370 375 Pro Leu Asn Ser Thr Gln Trp Met Asn Asp Pro Glu Thr Gly Pro 380 385 390 Val Met Leu Gln Ile Ser Arg Ile Phe Gln Thr Leu Asn Arg Thr 395 400 405 (2) INFORMATION FOR SEQ ID NO: 39: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 177 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: SKINBIT01 (B) CLONE: 1871375 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 39 : Met Val Met His Asn Ser Asp Pro Asn Leu His Leu Leu Ala Glu 5 10 15 Gly Ala Pro Ile Asp Trp Gly Glu Glu Tyr Ser Asn Ser Gly Gly 20 25 30 Gly Gly Ser Pro Ala Pro Ala Pro Arg Ser Gln Pro Pro Ser Arg 35 40 45 Lys Ser Asp Gly Ala Pro Ser Arg Trp Ser Leu Trp Ser Arg Met 50 55 60 Arg Arg Trp Gly Cys Pro Leu Arg Leu Ala Leu Ser His His His 65 70 75 Leu Arg Pro Arg Thr Val Ser Leu Arg Ser Glu Ala Cys Trp Pro 80 85 90 Lys Val Cys Gly Leu Arg Ala Pro His Gln Pro Ala Pro Cys Ser 95 100 105 Thr Gly Pro Pro Leu Gly Arg Val Pro Ser Leu Arg Pro Pro Pro 110 115 120 Arg Pro Pro Arg Arg Leu Pro His Pro Ser Ser Ile Ser Cys Leu 125 130 135 Glu Arg Leu Trp Thr Leu Gly Pro Pro Ser Pro Ala Thr Arg Arg 140 145 150 Leu Glu Ser Arg Cys Pro Ala Pro Ala Ala Thr Pro Pro Ser Thr 155 160 165 Pro Pro Pro Arg Xaa Xaa Phe Lys Gly Cys Lys Asn 170 175 (2) INFORMATION FOR SEQ ID NO: 40: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 197 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: LEUKNOT03 (B) CLONE: 1880830 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 40 : Met Ile Thr Cys Arg Val Cys Gln Ser Leu Ile Asn Val Glu Gly 5 10 15 Lys Met His Gln His Val Val Lys Cys Gly Val Cys Asn Glu Ala 20 25 30 Thr Pro Ile Lys Asn Ala Pro Pro Gly Lys Lys Tyr Val Arg Cys 35 40 45 Pro Cys Asn Cys Leu Leu Ile Cys Lys Val Thr Ser Gln Arg Ile 50 55 60 Ala Cys Pro Arg Pro Tyr Cys Lys Arg Ile Ile Asn Leu Gly Pro 65 70 75 Val His Pro Gly Pro Leu Ser Pro Glu Pro Gln Pro Met Gly Val 80 85 90 Arg Val Ile Cys Gly His Cys Lys Asn Thr Phe Leu Trp Thr Glu 95 100 105 Phe Thr Asp Arg Thr Leu Ala Arg Cys Pro His Cys Arg Lys Val 110 115 120 Ser Ser Ile Gly Arg Arg Tyr Pro Arg Lys Arg Cys Ile Cys Cys 125 130 135 Phe Leu Leu Gly Leu Leu Leu Ala Val Thr Ala Thr Gly Leu Ala 140 145 150 Phe Gly Thr Trp Lys His Ala Arg Arg Tyr Gly Gly Ile Tyr Ala 155 160 165 Ala Trp Ala Phe Val Ile Leu Leu Ala Val Leu Cys Leu Gly Arg 170 175 180 Ala Leu Tyr Trp Ala Cys Met Lys Val Ser His Pro Val Gln Asn 185 190 195 Phe Ser (2) INFORMATION FOR SEQ ID NO: 41: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 302 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: OVARNOT07 (B) CLONE: 1905325 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 41 : Met Leu Lys Asp Ile Ile Lys Glu Tyr Thr Asp Val Tyr Pro Glu 5 10 15 Ile Ile Glu Arg Ala Gly Tyr Ser Leu Glu Lys Val Phe Gly Ile 20 25 30 Gln Leu Lys Glu Ile Asp Lys Asn Asp His Leu Tyr Ile Leu Leu 35 40 45 Ser Thr Leu Glu Pro Thr Asp Ala Gly Ile Leu Gly Thr Thr Lys 50 55 60 Asp Ser Pro Lys Leu Gly Leu Leu Met Val Leu Leu Ser Ile Ile 65 70 75 Phe Met Asn Gly Asn Arg Ser Ser Glu Ala Val Ile Trp Glu Val 80 85 90 Leu Arg Lys Leu Gly Leu Arg Pro Gly Ile His His Ser Leu Phe 95 100 105 Gly Asp Val Lys Lys Leu Ile Thr Asp Glu Phe Val Lys Gln Lys 110 115 120 Tyr Leu Asp Tyr Ala Arg Val Pro Asn Ser Asn Pro Pro Glu Tyr 125 130 135 Glu Phe Phe Trp Gly Leu Arg Ser Tyr Tyr Glu Thr Ser Lys Met 140 145 150 Lys Val Leu Lys Phe Ala Cys Lys Val Gln Lys Lys Asp Pro Lys 155 160 165 Glu Trp Ala Ala Gln Tyr Arg Glu Ala Met Glu Ala Asp Leu Lys 170 175 180 Ala Ala Ala Glu Ala Ala Ala Glu Ala Lys Ala Arg Ala Glu Ile 185 190 195 Arg Ala Arg Met Gly Ile Gly Leu Gly Ser Glu Asn Ala Ala Gly 200 205 210 Pro Cys Asn Trp Asp Glu Ala Asp Ile Gly Pro Trp Ala Lys Ala 215 220 225 Arg Ile Gln Ala Gly Ala Glu Ala Lys Ala Lys Ala Gln Glu Ser 230 235 240 Gly Ser Ala Ser Thr Gly Ala Ser Thr Ser Thr Asn Asn Ser Ala 245 250 255 Ser Ala Ser Ala Ser Thr Ser Gly Gly Phe Ser Ala Gly Ala Ser 260 265 270 Leu Thr Ala Thr Leu Thr Phe Gly Leu Phe Ala Gly Leu Gly Gly 275 280 285 Ala Gly Ala Ser Thr Ser Gly Ser Ser Gly Ala Cys Gly Phe Ser 290 295 300 Tyr Lys (2) INFORMATION FOR SEQ ID NO: 42: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 164 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: BRSTTUT01 (B) CLONE: 1919931 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 42 : Met Arg Thr Leu Glu Asn Gln Gly Phe Lys Ile Leu Pro Phe Leu 5 10 15 Gly Val Lys Glu Val Trp Gln Lys Gln Asn Lys Leu Ile Ser Arg 20 25 30 Phe Ile Thr Cys Gln Phe Phe Leu Tyr Asn Phe Leu Asp Ser Gly 35 40 45 Ser Ile Trp Val Gln Ala Asp Phe Pro Pro Ile Leu Gln Cys Gly 50 55 60 Cys Phe Leu Phe His Pro Trp Thr Leu Gln Glu Ile Ala Pro Cys 65 70 75 Phe Cys Leu Cys Ile Thr Glu Lys Gly Ser Met Lys Val Ala Gln 80 85 90 Val Arg Pro Phe His Cys Pro Pro Gly Ala Gly Phe Ala Leu Pro 95 100 105 Ile Leu Gly Leu Leu Gln Gly Leu Val Ile Leu His Ser Pro Leu 110 115 120 His Ile Ser Gln Val Ser Ala Gln Lys Ser Pro Phe Gly Gly Val 125 130 135 Ser Thr Cys His Cys Val Cys Lys Ser Ser Phe Ser Phe Phe Leu 140 145 150 Ala His Leu Thr Leu Val Met Ser Leu Ile Thr Thr Thr Ile 155 160 (2) INFORMATION FOR SEQ ID NO: 43: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 235 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: BRSTNOT04 (B) CLONE: 1969426 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 43 : Met Ser Pro Thr Leu Ser Ser Ile Thr Gln Gly Val Pro Leu Asp 5 10 15 Thr Ser Lys Leu Ser Thr Asp Gln Arg Leu Pro Pro Tyr Pro Tyr 20 25 30 Ser Ser Pro Ser Leu Val Leu Pro Thr Gln Pro His Thr Pro Lys 35 40 45 Ser Leu Gln Gln Pro Gly Leu Pro Ser Gln Ser Cys Ser Val Gln 50 55 60 Ser Ser Gly Gly Gln Pro Pro Gly Arg Gln Ser His Tyr Gly Thr 65 70 75 Pro Tyr Pro Pro Gly Pro Ser Gly His Gly Gln Gln Ser Tyr His 80 85 90 Arg Pro Met Ser Asp Phe Asn Leu Gly Asn Leu Glu Gln Phe Ser 95 100 105 Met Glu Ser Pro Ser Ala Ser Leu Val Leu Asp Pro Pro Gly Phe 110 115 120 Ser Glu Gly Pro Gly Phe Leu Gly Gly Glu Gly Pro Met Gly Gly 125 130 135 Pro Gln Asp Pro His Thr Phe Asn His Gln Asn Leu Thr His Cys 140 145 150 Ser Arg His Gly Ser Gly Pro Asn Ile Ile Leu Thr Gly Asp Ser 155 160 165 Ser Pro Gly Phe Ser Lys Glu Ile Ala Ala Ala Leu Ala Gly Val 170 175 180 Pro Gly Phe Glu Val Ser Ala Ala Gly Leu Glu Leu Gly Leu Gly 185 190 195 Leu Glu Asp Glu Leu Arg Met Glu Pro Leu Gly Leu Glu Gly Leu 200 205 210 Asn Met Leu Ser Asp Pro Cys Ala Leu Leu Pro Asp Pro Ala Val 215 220 225 Glu Glu Ser Phe Arg Ser Asp Arg Leu Gln 230 235 (2) INFORMATION FOR SEQ ID NO: 44: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 203 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: UCMCL5T01 (B) CLONE: 1969948 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 44 : Met Asn Tyr Phe Pro Leu Ala Pro Phe Asn Gln Leu Leu Gln Lys 5 10 15 Asp Ile Ile Ser Glu Leu Leu Thr Ser Asp Asp Met Lys Asn Ala 20 25 30 Tyr Lys Leu His Thr Leu Asp Thr Cys Leu Lys Leu Asp Asp Thr 35 40 45 Val Tyr Leu Arg Asp Ile Ala Leu Ser Leu Pro Gln Leu Pro Arg 50 55 60 Glu Leu Pro Ser Ser His Thr Asn Ala Lys Val Ala Glu Val Leu 65 70 75 Ser Ser Leu Leu Gly Gly Glu Gly His Phe Ser Lys Asp Val His 80 85 90 Leu Pro His Asn Tyr His Ile Asp Phe Glu Ile Arg Met Asp Thr 95 100 105 Asn Arg Asn Gln Val Leu Pro Leu Ser Asp Val Asp Thr Thr Ser 110 115 120 Ala Thr Asp Ile Gln Arg Val Ala Val Leu Cys Val Ser Arg Ser 125 130 135 Ala Tyr Cys Leu Gly Ser Ser His Pro Arg Gly Phe Leu Ala Met 140 145 150 Lys Met Arg His Leu Asn Ala Met Gly Phe His Val Ile Leu Val 155 160 165 Asn Asn Trp Glu Met Asp Lys Leu Glu Met Glu Asp Ala Val Thr 170 175 180 Phe Leu Lys Thr Lys Ile Tyr Ser Val Glu Ala Leu Pro Val Ala 185 190 195 Ala Val Asn Val Gln Ser Thr Gln 200 (2) INFORMATION FOR SEQ ID NO: 45: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 359 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: LUNGAST01 (B) CLONE: 1988911 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 45 : Met Glu Arg Gly Asn Val Leu Ser Arg Ala Pro Ser Arg Ala His 5 10 15 Gly Thr His Phe Gly Asp Asp Arg Phe Glu Asp Leu Glu Glu Ala 20 25 30 Asn Pro Phe Ser Phe Arg Glu Phe Leu Lys Thr Lys Asn Leu Gly 35 40 45 Leu Ser Lys Glu Asp Pro Ala Ser Arg Ile Tyr Ala Lys Glu Ala 50 55 60 Ser Arg His Ser Leu Gly Leu Asp His Asn Ser Pro Pro Ser Gln 65 70 75 Thr Gly Gly Tyr Gly Leu Glu Tyr Gln Gln Pro Phe Phe Glu Asp 80 85 90 Pro Thr Gly Ala Gly Asp Leu Leu Asp Glu Glu Glu Asp Glu Asp 95 100 105 Thr Gly Trp Ser Gly Ala Tyr Leu Pro Ser Ala Ile Glu Gln Thr 110 115 120 His Pro Glu Arg Val Pro Ala Gly Thr Ser Pro Cys Ser Thr Tyr 125 130 135 Leu Ser Phe Phe Ser Thr Pro Ser Glu Leu Ala Gly Pro Glu Ser 140 145 150 Leu Pro Ser Trp Ala Leu Ser Asp Thr Asp Ser Arg Val Ser Pro 155 160 165 Ala Ser Pro Ala Gly Ser Pro Ser Ala Asp Phe Ala Val His Gly 170 175 180 Glu Ser Leu Gly Asp Arg His Leu Arg Thr Leu Gln Ile Ser Tyr 185 190 195 Asp Ala Leu Lys Asp Glu Asn Ser Lys Leu Arg Arg Lys Leu Asn 200 205 210 Glu Val Gln Ser Phe Ser Glu Ala Gln Thr Glu Met Val Arg Thr 215 220 225 Leu Glu Arg Lys Leu Glu Ala Lys Met Ile Lys Glu Glu Ser Asp 230 235 240 Tyr His Asp Leu Glu Ser Val Val Gln Gln Val Glu Gln Asn Leu 245 250 255 Glu Leu Met Thr Lys Arg Ala Val Lys Ala Glu Asn His Val Val 260 265 270 Lys Leu Lys Gln Glu Ile Ser Leu Leu Gln Ala Gln Val Ser Asn 275 280 285 Phe Gln Arg Glu Asn Glu Ala Leu Arg Cys Gly Gln Gly Ala Ser 290 295 300 Leu Thr Val Val Lys Gln Asn Ala Asp Val Ala Leu Gln Asn Leu 305 310 315 Arg Val Val Met Asn Ser Ala Gln Ala Ser Ile Lys Gln Leu Val 320 325 330 Ser Gly Ala Glu Thr Leu Asn Leu Val Ala Glu Ile Leu Lys Ser 335 340 345 Ile Asp Arg Ile Ser Glu Val Lys Asp Glu Glu Glu Asp Ser 350 355 (2) INFORMATION FOR SEQ ID NO: 46: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 150 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: OVARNOT03 (B) CLONE: 2061561 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 46 : Met Gly Gly Lys Pro His Lys Glu Pro Arg Ala Lys Gly Pro Leu 5 10 15 Ser Ile Phe Tyr Pro Gly Ser Thr Ala Pro Val Ile Thr Gln Arg 20 25 30 Thr Pro Xaa Ala Ala Leu Lys Pro Pro Pro Ile Lys Gly Ala Gly 35 40 45 Pro Thr Ile Ala Pro Ile Lys Gly Xaa Xaa Asn Phe Gly Lys Arg 50 55 60 Pro Thr Val Thr Xaa Pro Xaa Trp Xaa Ile Ser Pro Asn Trp Gly 65 70 75 Lys Arg Gly Xaa Cys Xaa Xaa Xaa Gly Ile Lys Trp Val Xaa Pro 80 85 90 Arg Val Ser Gln Ala Arg Thr Phe Lys Thr Thr Ala Asn Glu Leu 95 100 105 Xaa Phe Xaa Asp Thr Phe Glu Glu Xaa Xaa Arg Xaa Xaa His Ala 110 115 120 Xaa Val Ser Xaa Glu Pro Gln Pro Arg Cys Pro Leu Gly Glu Ser 125 130 135 Arg Ser Leu Gly Ala Ala Val Cys Arg Trp Asp Ser Phe Asp Phe 140 145 150 (2) INFORMATION FOR SEQ ID NO: 47: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 402 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: PANCNOT04 (B) CLONE: 2084489 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 47 : Met Pro Pro Val Ser Arg Ser Ser Tyr Ser Glu Asp Ile Val Gly 5 10 15 Ser Arg Arg Arg Arg Arg Ser Ser Ser Gly Ser Pro Pro Ser Pro 20 25 30 Gln Ser Arg Cys Ser Ser Trp Asp Gly Cys Ser Arg Ser His Ser 35 40 45 Arg Gly Arg Glu Gly Leu Arg Pro Pro Trp Ser Glu Leu Asp Val 50 55 60 Gly Ala Leu Tyr Pro Phe Ser Arg Ser Gly Ser Arg Gly Arg Leu 65 70 75 Pro Arg Phe Arg Asn Tyr Ala Phe Ala Ser Ser Trp Ser Thr Ser 80 85 90 Tyr Ser Gly Tyr Arg Tyr His Arg His Cys Tyr Ala Glu Glu Arg 95 100 105 Gln Ser Ala Glu Asp Tyr Glu Lys Glu Glu Ser His Arg Gln Arg 110 115 120 Arg Leu Lys Glu Arg Glu Arg Ile Gly Glu Leu Gly Ala Pro Glu 125 130 135 Val Trp Gly Pro Ser Pro Lys Phe Pro Gln Leu Asp Ser Asp Glu 140 145 150 His Thr Pro Val Glu Asp Glu Glu Glu Val Thr His Gln Lys Ser 155 160 165 Ser Ser Ser Asp Ser Asn Ser Glu Glu His Arg Lys Lys Lys Thr 170 175 180 Ser Arg Ser Arg Asn Lys Lys Lys Arg Lys Asn Lys Ser Ser Lys 185 190 195 Arg Lys His Arg Lys Tyr Ser Asp Ser Asp Ser Asn Ser Glu Ser 200 205 210 Asp Thr Asn Ser Asp Ser Asp Asp Asp Lys Lys Arg Val Lys Ala 215 220 225 Lys Lys Lys Lys Lys Lys Lys Lys His Lys Thr Lys Lys Lys Lys 230 235 240 Asn Lys Lys Thr Lys Lys Glu Ser Ser Asp Ser Ser Cys Lys Asp 245 250 255 Ser Glu Glu Asp Leu Ser Glu Ala Thr Trp Met Glu Gln Pro Asn 260 265 270 Val Ala Asp Thr Met Asp Leu Ile Gly Pro Glu Ala Pro Ile Ile 275 280 285 His Thr Ser Gln Asp Glu Lys Pro Leu Lys Tyr Gly His Ala Leu 290 295 300 Leu Pro Gly Glu Gly Ala Ala Met Ala Glu Tyr Val Lys Ala Gly 305 310 315 Lys Arg Ile Pro Arg Arg Gly Glu Ile Gly Leu Thr Ser Glu Glu 320 325 330 Ile Gly Ser Phe Glu Cys Ser Gly Tyr Val Met Ser Gly Ser Arg 335 340 345 His Arg Arg Met Glu Ala Val Arg Leu Arg Lys Glu Asn Gln Ile 350 355 360 Tyr Ser Ala Asp Glu Lys Arg Ala Leu Ala Ser Phe Asn Gln Glu 365 370 375 Glu Arg Arg Lys Arg Glu Ser Lys Ile Leu Ala Ser Phe Arg Glu 380 385 390 Met Val His Lys Lys Thr Lys Glu Lys Asp Asp Lys 395 400 (2) INFORMATION FOR SEQ ID NO: 48: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 311 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: SPLNFET02 (B) CLONE: 2203226 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 48 : Met His Pro Ala Gly Leu Ala Ala Ala Ala Ala Gly Thr Pro Arg 5 10 15 Leu Pro Ser Lys Arg Arg Ile Pro Val Ser Gln Pro Gly Met Ala 20 25 30 Asp Pro His Gln Leu Phe Asp Asp Thr Ser Ser Ala Gln Ser Arg 35 40 45 Gly Tyr Gly Ala Gln Arg Ala Pro Gly Gly Leu Ser Tyr Pro Ala 50 55 60 Ala Ser Pro Thr Pro His Ala Ala Phe Leu Ala Asp Pro Val Ser 65 70 75 Asn Met Ala Met Ala Tyr Gly Ser Ser Leu Ala Ala Gln Gly Lys 80 85 90 Glu Leu Val Asp Lys Asn Ile Asp Arg Phe Ile Pro Ile Thr Lys 95 100 105 Leu Lys Tyr Tyr Phe Ala Val Asp Thr Met Tyr Val Gly Arg Lys 110 115 120 Leu Gly Leu Leu Phe Phe Pro Tyr Leu His Gln Asp Trp Glu Val 125 130 135 Gln Tyr Gln Gln Asp Thr Pro Val Ala Pro Arg Phe Asp Val Asn 140 145 150 Ala Pro Asp Leu Tyr Ile Pro Ala Met Ala Phe Ile Thr Tyr Val 155 160 165 Leu Val Ala Gly Leu Ala Leu Gly Thr Gln Asp Arg Phe Ser Pro 170 175 180 Asp Leu Leu Gly Leu Gln Ala Ser Ser Ala Leu Ala Trp Leu Thr 185 190 195 Leu Glu Val Leu Ala Ile Leu Leu Ser Leu Tyr Leu Val Thr Val 200 205 210 Asn Thr Asp Leu Thr Thr Ile Asp Leu Val Ala Phe Leu Gly Tyr 215 220 225 Lys Tyr Val Gly Met Ile Gly Gly Val Leu Met Gly Leu Leu Phe 230 235 240 Gly Lys Ile Gly Tyr Tyr Leu Val Leu Gly Trp Cys Cys Val Ala 245 250 255 Ile Phe Val Phe Met Ile Arg Thr Leu Arg Leu Lys Ile Leu Ala 260 265 270 Asp Ala Ala Ala Glu Gly Val Pro Val Arg Gly Ala Arg Asn Gln 275 280 285 Leu Arg Met Tyr Leu Thr Met Ala Val Ala Ala Ala Gln Pro Met 290 295 300 Leu Met Tyr Trp Leu Thr Phe His Leu Val Arg 305 310 (2) INFORMATION FOR SEQ ID NO: 49: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 316 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: PROSNOT16 (B) CLONE: 2232884 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 49 : Met Ala Ser Ala Asp Glu Leu Thr Phe His Glu Phe Glu Glu Ala 5 10 15 Thr Asn Leu Leu Ala Asp Thr Pro Asp Ala Ala Thr Thr Ser Arg 20 25 30 Ser Asp Gln Leu Thr Pro Gln Gly His Val Ala Val Ala Val Gly 35 40 45 Ser Gly Gly Ser Tyr Gly Ala Glu Asp Glu Val Glu Glu Glu Ser 50 55 60 Asp Lys Ala Ala Leu Leu Gln Glu Gln Gln Gln Gln Gln Gln Pro 65 70 75 Gly Phe Trp Thr Phe Ser Tyr Tyr Gln Ser Phe Phe Asp Val Asp 80 85 90 Thr Ser Gln Val Leu Asp Arg Ile Lys Gly Ser Leu Leu Pro Arg 95 100 105 Pro Gly His Asn Phe Val Arg His His Leu Arg Asn Arg Pro Asp 110 115 120 Leu Tyr Gly Pro Phe Trp Ile Cys Ala Thr Leu Ala Phe Val Leu 125 130 135 Ala Val Thr Gly Asn Leu Thr Leu Val Leu Ala Gln Arg Arg Asp 140 145 150 Pro Ser Ile His Tyr Ser Pro Gln Phe His Lys Val Thr Val Ala 155 160 165 Gly Ile Ser Ile Tyr Cys Tyr Ala Trp Leu Val Pro Leu Ala Leu 170 175 180 Trp Gly Phe Leu Arg Trp Arg Lys Gly Val Gln Glu Arg Met Gly 185 190 195 Pro Tyr Thr Phe Leu Glu Thr Val Cys Ile Tyr Gly Tyr Ser Leu 200 205 210 Phe Val Phe Ile Pro Met Val Val Leu Trp Leu Ile Pro Val Pro 215 220 225 Trp Leu Gln Trp Leu Phe Gly Ala Leu Ala Leu Gly Leu Ser Ala 230 235 240 Ala Gly Leu Val Phe Thr Leu Trp Pro Val Val Arg Glu Asp Thr 245 250 255 Arg Leu Val Ala Thr Val Leu Leu Ser Val Val Val Leu Leu His 260 265 270 Ala Leu Leu Ala Met Gly Cys Lys Leu Tyr Phe Phe Gln Ser Leu 275 280 285 Pro Pro Glu Asn Val Ala Pro Pro Pro Gln Ile Thr Ser Leu Pro 290 295 300 Ser Asn Ile Ala Leu Ser Pro Thr Leu Pro Gln Ser Leu Ala Pro 305 310 315 Ser (2) INFORMATION FOR SEQ ID NO: 50: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 346 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: COLNNOT11 (B) CLONE: 2328134 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 50 : Met Thr Pro Arg Thr Trp Trp Pro Arg Pro Ala Gly Trp Gly Thr 5 10 15 Cys Arg Ala Ala Gly Trp Pro Arg Ser Val Pro Trp Ala Arg Thr 20 25 30 Ala Ala Ser Leu Val Phe Val Pro Thr Arg Arg Arg Ser Gly Pro 35 40 45 Ser Gly Thr Ala Ser Val Ala Ala Met Ala Tyr His Ser Gly Tyr 50 55 60 Gly Ala His Gly Ser Lys His Arg Ala Arg Ala Ala Pro Asp Pro 65 70 75 Pro Pro Leu Phe Asp Asp Thr Ser Gly Gly Tyr Ser Ser Gln Pro 80 85 90 Gly Gly Tyr Pro Ala Thr Gly Ala Asp Val Ala Phe Ser Val Asn 95 100 105 His Leu Leu Gly Asp Pro Met Ala Asn Val Ala Met Ala Tyr Gly 110 115 120 Ser Ser Ile Ala Ser His Gly Lys Asp Met Val His Lys Glu Leu 125 130 135 His Arg Phe Val Ser Val Ser Lys Leu Lys Tyr Phe Phe Ala Val 140 145 150 Asp Thr Ala Tyr Val Ala Lys Lys Leu Gly Leu Leu Val Phe Pro 155 160 165 Tyr Thr His Gln Asn Trp Glu Val Gln Tyr Ser Arg Asp Ala Pro 170 175 180 Leu Pro Pro Arg Gln Asp Leu Asn Ala Pro Asp Leu Tyr Ile Pro 185 190 195 Thr Met Ala Phe Ile Thr Tyr Val Leu Leu Ala Gly Met Ala Leu 200 205 210 Gly Ile Gln Lys Arg Phe Ser Pro Glu Val Leu Gly Leu Cys Ala 215 220 225 Ser Thr Ala Leu Val Trp Val Val Met Glu Val Leu Ala Leu Leu 230 235 240 Leu Gly Leu Tyr Leu Ala Thr Val Arg Ser Asp Leu Ser Thr Phe 245 250 255 His Leu Leu Ala Tyr Ser Gly Tyr Lys Tyr Val Gly Met Ile Leu 260 265 270 Ser Val Leu Thr Gly Leu Leu Phe Gly Ser Asp Gly Tyr Tyr Val 275 280 285 Ala Leu Ala Trp Thr Ser Ser Ala Leu Met Tyr Phe Ile Val Arg 290 295 300 Ser Leu Arg Thr Ala Ala Leu Gly Pro Asp Ser Met Gly Gly Pro 305 310 315 Val Pro Arg Gln Arg Leu Gln Leu Tyr Leu Thr Leu Gly Ala Ala 320 325 330 Ala Phe Gln Pro Leu Ile Ile Tyr Trp Leu Thr Phe His Leu Val 335 340 345 Arg (2) INFORMATION FOR SEQ ID NO: 51: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 299 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: ISLTNOT01 (B) CLONE: 2382718 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 51 : Met Gly Thr Lys Ala Gln Val Glu Arg Lys Leu Leu Cys Leu Phe 5 10 15 Ile Leu Ala Ile Leu Leu Cys Ser Leu Ala Leu Gly Ser Val Thr 20 25 30 Val His Ser Ser Glu Pro Glu Val Arg Ile Pro Glu Asn Asn Pro 35 40 45 Val Lys Leu Ser Cys Ala Tyr Ser Gly Phe Ser Ser Pro Arg Val 50 55 60 Glu Trp Lys Phe Asp Gln Gly Asp Thr Thr Arg Leu Val Cys Tyr 65 70 75 Asn Asn Lys Ile Thr Ala Ser Tyr Glu Asp Arg Val Thr Phe Leu 80 85 90 Pro Thr Gly Ile Thr Phe Lys Ser Val Thr Arg Glu Asp Thr Gly 95 100 105 Thr Tyr Thr Cys Met Val Ser Glu Glu Gly Gly Asn Ser Tyr Gly 110 115 120 Glu Val Lys Val Lys Leu Ile Val Leu Val Pro Pro Ser Lys Pro 125 130 135 Thr Val Asn Ile Pro Ser Ser Ala Thr Ile Gly Asn Arg Ala Val 140 145 150 Leu Thr Cys Ser Glu Gln Asp Gly Ser Pro Pro Ser Glu Tyr Thr 155 160 165 Trp Phe Lys Asp Gly Ile Val Met Pro Thr Asn Pro Lys Ser Thr 170 175 180 Arg Ala Phe Ser Asn Ser Ser Tyr Val Leu Asn Pro Thr Thr Gly 185 190 195 Glu Leu Val Phe Asp Pro Leu Ser Ala Ser Asp Thr Gly Glu Tyr 200 205 210 Ser Cys Glu Ala Arg Asn Gly Tyr Gly Thr Pro Met Thr Ser Asn 215 220 225 Ala Val Arg Met Glu Ala Val Glu Arg Asn Val Gly Val Ile Val 230 235 240 Ala Ala Val Leu Val Thr Leu Ile Leu Leu Gly Ile Leu Val Phe 245 250 255 Gly Ile Trp Phe Ala Tyr Ser Arg Gly His Phe Asp Arg Thr Lys 260 265 270 Lys Gly Thr Ser Ser Lys Lys Val Ile Tyr Ser Gln Pro Ser Ala 275 280 285 Arg Ser Glu Gly Glu Phe Lys Gln Thr Ser Ser Phe Leu Val 290 295 (2) INFORMATION FOR SEQ ID NO: 52: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 351 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: ENDANOT01 (B) CLONE: 2452208 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 52 : Met Ala Ser Thr Gly Ser Gln Ala Ser Asp Ile Asp Glu Ile Phe 5 10 15 Gly Phe Phe Asn Asp Gly Glu Pro Pro Thr Lys Lys Pro Arg Lys 20 25 30 Leu Leu Pro Ser Leu Lys Thr Lys Lys Pro Arg Glu Leu Val Leu 35 40 45 Val Ile Gly Thr Gly Ile Ser Ala Ala Val Ala Pro Gln Val Pro 50 55 60 Ala Leu Lys Ser Trp Lys Gly Leu Ile Gln Ala Leu Leu Asp Ala 65 70 75 Ala Ile Asp Phe Asp Leu Leu Glu Asp Glu Glu Ser Lys Lys Phe 80 85 90 Gln Lys Cys Leu His Glu Asp Lys Asn Leu Val His Val Ala His 95 100 105 Asp Leu Ile Gln Lys Leu Ser Pro Arg Thr Ser Asn Val Arg Ser 110 115 120 Thr Phe Phe Lys Asp Cys Leu Tyr Glu Val Phe Asp Asp Leu Glu 125 130 135 Ser Lys Met Glu Asp Ser Gly Lys Gln Leu Leu Gln Ser Val Leu 140 145 150 His Leu Met Glu Asn Gly Ala Leu Val Leu Thr Thr Asn Phe Asp 155 160 165 Asn Leu Leu Glu Leu Tyr Ala Ala Asp Gln Gly Lys Gln Leu Glu 170 175 180 Ser Leu Asp Leu Thr Asp Glu Lys Lys Val Leu Glu Trp Ala Gln 185 190 195 Glu Lys Arg Lys Leu Ser Val Leu His Ile His Gly Val Tyr Thr 200 205 210 Asn Pro Ser Gly Ile Val Leu His Pro Ala Gly Tyr Gln Asn Val 215 220 225 Leu Arg Asn Thr Glu Val Met Arg Glu Ile Gln Lys Leu Tyr Glu 230 235 240 Asn Lys Ser Phe Leu Phe Leu Gly Cys Gly Trp Thr Val Asp Asp 245 250 255 Thr Thr Phe Gln Ala Leu Phe Leu Glu Ala Val Lys His Lys Ser 260 265 270 Asp Leu Glu His Phe Met Leu Val Arg Arg Gly Asp Val Asp Glu 275 280 285 Phe Lys Lys Leu Arg Glu Asn Met Leu Asp Lys Gly Ile Lys Val 290 295 300 Ile Ser Tyr Gly Asp Asp Tyr Ala Asp Leu Pro Glu Tyr Phe Lys 305 310 315 Arg Leu Thr Cys Glu Ile Ser Thr Arg Gly Thr Ser Ala Gly Met 320 325 330 Val Arg Glu Gly Gln Leu Asn Gly Ser Ser Ala Ala His Ser Glu 335 340 345 Ile Arg Gly Cys Ser Thr 350 (2) INFORMATION FOR SEQ ID NO: 53: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 662 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: ENDANOT01 (B) CLONE: 2457825 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 53 : Met Thr Ala Lys Lys Gln Cys Leu Leu Arg Leu Gly Val Leu Arg 5 10 15 Gln Asp Trp Pro Asp Thr Asn Arg Leu Leu Gly Ser Ala Asn Val 20 25 30 Val Pro Glu Ala Leu Gln Arg Phe Thr Arg Ala Ala Ala Asp Phe 35 40 45 Ala Thr His Gly Lys Leu Gly Lys Leu Glu Phe Ala Gln Asp Ala 50 55 60 His Gly Gln Pro Asp Val Ser Ala Phe Asp Phe Thr Ser Met Met 65 70 75 Arg Ala Glu Ser Ser Ala Arg Val Gln Glu Lys His Gly Ala Arg 80 85 90 Leu Leu Leu Gly Leu Val Gly Asp Cys Leu Val Glu Pro Phe Trp 95 100 105 Pro Leu Gly Thr Gly Val Ala Arg Gly Phe Leu Ala Ala Phe Asp 110 115 120 Ala Ala Trp Met Val Lys Arg Trp Ala Glu Gly Ala Glu Ser Leu 125 130 135 Glu Val Leu Ala Glu Arg Glu Ser Leu Tyr Gln Leu Leu Ser Gln 140 145 150 Thr Ser Pro Glu Asn Met His Arg Asn Val Ala Gln Tyr Gly Leu 155 160 165 Asp Pro Ala Thr Arg Tyr Pro Asn Leu Asn Leu Arg Ala Val Thr 170 175 180 Pro Asn Gln Val Arg Asp Leu Tyr Asp Val Leu Ala Lys Glu Pro 185 190 195 Val Gln Arg Asp Asn Asp Lys Thr Asp Thr Gly Met Pro Ala Thr 200 205 210 Gly Ser Ala Gly Thr Gln Glu Glu Leu Leu Arg Trp Cys Gln Glu 215 220 225 Gln Thr Ala Gly Tyr Pro Gly Val His Val Ser Asp Leu Ser Ser 230 235 240 Ser Trp Ala Asp Gly Leu Ala Leu Cys Ala Leu Val Tyr Arg Leu 245 250 255 Gln Pro Gly Leu Leu Glu Pro Ser Glu Leu Gln Gly Leu Gly Ala 260 265 270 Leu Glu Ala Thr Ala Trp Ala Leu Lys Val Ala Glu Asn Glu Leu 275 280 285 Gly Ile Thr Pro Val Val Ser Ala Gln Ala Val Val Ala Gly Ser 290 295 300 Asp Pro Leu Gly Leu Ile Ala Tyr Leu Ser His Phe His Ser Ala 305 310 315 Phe Lys Ser Met Ala His Ser Pro Gly Pro Val Ser Gln Ala Ser 320 325 330 Pro Gly Thr Ser Ser Ala Val Leu Phe Leu Ser Lys Leu Gln Arg 335 340 345 Thr Leu Gln Arg Ser Arg Ala Lys Glu Asn Ala Glu Asp Ala Gly 350 355 360 Gly Lys Lys Leu Arg Leu Glu Met Glu Ala Glu Thr Pro Ser Thr 365 370 375 Glu Val Pro Pro Asp Pro Glu Pro Gly Val Pro Leu Thr Pro Pro 380 385 390 Ser Gln His Gln Glu Ala Gly Ala Gly Asp Leu Cys Ala Leu Cys 395 400 405 Gly Glu His Leu Tyr Val Leu Glu Arg Leu Cys Val Asn Gly His 410 415 420 Phe Phe His Arg Ser Cys Phe Arg Cys His Thr Cys Glu Ala Thr 425 430 435 Leu Trp Pro Gly Gly Tyr Glu Gln His Pro Gly Ser Arg Thr Ser 440 445 450 Gln Phe Phe Phe Ser Ala Leu Val Ala Met Glu Lys Glu Glu Lys 455 460 465 Glu Ser Pro Phe Ser Ser Glu Glu Glu Glu Glu Asp Val Pro Leu 470 475 480 Asp Ser Asp Val Glu Gln Ala Leu Gln Thr Phe Ala Lys Thr Ser 485 490 495 Gly Thr Met Asn Asn Tyr Pro Thr Trp Arg Arg Thr Leu Leu Arg 500 505 510 Arg Ala Lys Glu Glu Glu Met Lys Arg Phe Cys Lys Ala Gln Thr 515 520 525 Ile Gln Arg Arg Leu Asn Glu Ile Glu Ala Ala Leu Arg Glu Leu 530 535 540 Glu Ala Glu Gly Val Lys Leu Glu Leu Ala Leu Arg Arg Gln Ser 545 550 555 Ser Ser Pro Glu Gln Gln Lys Lys Leu Trp Val Gly Gln Leu Leu 560 565 570 Gln Leu Val Asp Lys Lys Asn Ser Leu Val Ala Glu Glu Ala Glu 575 580 585 Leu Met Ile Thr Val Gln Glu Leu Asn Leu Glu Glu Lys Gln Trp 590 595 600 Gln Leu Asp Gln Glu Leu Arg Gly Tyr Met Asn Arg Glu Glu Asn 605 610 615 Leu Lys Thr Ala Ala Asp Arg Gln Ala Glu Asp Gln Val Leu Arg 620 625 630 Lys Leu Val Asp Leu Val Asn Gln Arg Asp Ala Leu Ile Arg Phe 635 640 645 Gln Glu Glu Arg Arg Leu Ser Glu Leu Ala Leu Gly Thr Gly Ala 650 655 660 Gln Gly (2) INFORMATION FOR SEQ ID NO: 54: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 115 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: THP1NOT03 (B) CLONE: 2470740 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 54 : Met Ala Ser Trp Pro Ala Ser Pro Leu Gln Trp Gly Pro Pro Leu 5 10 15 Ala Ser Cys Pro Ser Cys Cys Cys Cys Cys Phe His Cys Trp Gln 20 25 30 Pro Arg Val Gly Val Ala Cys Arg Gln Arg Cys Trp Pro Leu Arg 35 40 45 Trp Gly Trp Trp Val Trp Gly Pro Pro Thr Cys Ser Phe Val Gln 50 55 60 Pro Cys Thr Cys Pro Pro Val Phe Ser Tyr Ser Trp Pro Arg Val 65 70 75 Pro His Trp Gly Pro Ser Trp Xaa Met Ser Trp Arg Arg Arg Leu 80 85 90 Met Gly Val Pro Leu Gly Leu Trp Asn Cys Leu Val Leu Lys Leu 95 100 105 Xaa Gln Gly Leu Ala Pro Thr Ser Gly Gly 110 115 (2) INFORMATION FOR SEQ ID NO: 55: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 157 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: SMCANOT01 (B) CLONE: 2479092 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 55 : Met Glu Ala Leu Arg Arg Ala His Glu Val Ala Leu Arg Leu Leu 5 10 15 Leu Cys Arg Pro Trp Ala Ser Arg Ala Ala Ala Arg Pro Lys Pro 20 25 30 Ser Ala Ser Glu Val Leu Thr Arg His Leu Leu Gln Arg Arg Leu 35 40 45 Pro His Trp Thr Ser Phe Cys Val Pro Tyr Ser Ala Val Arg Asn 50 55 60 Asp Gln Phe Gly Leu Ser His Phe Asn Trp Pro Val Gln Gly Ala 65 70 75 Asn Tyr His Val Leu Arg Thr Gly Cys Phe Pro Phe Ile Lys Tyr 80 85 90 His Cys Ser Lys Ala Pro Trp Gln Asp Leu Ala Arg Gln Asn Arg 95 100 105 Phe Phe Thr Ala Leu Lys Val Val Asn Leu Gly Ile Pro Thr Leu 110 115 120 Leu Tyr Gly Leu Gly Ser Trp Leu Phe Ala Arg Val Thr Glu Thr 125 130 135 Val His Thr Ser Tyr Gly Pro Ile Thr Val Tyr Phe Leu Asn Lys 140 145 150 Glu Asp Glu Gly Ala Met Tyr 155 (2) INFORMATION FOR SEQ ID NO: 56: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 197 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: SMCANOT01 (B) CLONE: 2480544 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 56 : Met Pro Pro Ala Gly Leu Arg Arg Ala Ala Pro Leu Thr Ala Ile 5 10 15 Ala Leu Leu Val Leu Gly Ala Pro Leu Val Leu Ala Gly Glu Asp 20 25 30 Cys Leu Trp Tyr Leu Asp Arg Asn Gly Ser Trp His Pro Gly Phe 35 40 45 Asn Cys Glu Phe Phe Thr Phe Cys Cys Gly Thr Cys Tyr His Arg 50 55 60 Tyr Cys Cys Arg Asp Leu Thr Leu Leu Ile Thr Glu Arg Gln Gln 65 70 75 Lys His Cys Leu Ala Phe Ser Pro Lys Thr Ile Ala Gly Ile Ala 80 85 90 Ser Ala Val Ile Leu Phe Val Ala Val Val Ala Thr Thr Ile Cys 95 100 105 Cys Phe Leu Cys Ser Cys Cys Tyr Leu Tyr Arg Arg Arg Gln Gln 110 115 120 Leu Gln Ser Pro Phe Glu Gly Gln Glu Ile Pro Met Thr Gly Ile 125 130 135 Pro Val Gln Pro Val Tyr Pro Tyr Pro Gln Asp Pro Lys Ala Gly 140 145 150 Pro Ala Pro Pro Gln Pro Gly Phe Met Tyr Pro Pro Ser Gly Pro 155 160 165 Ala Pro Gln Tyr Pro Leu Tyr Pro Ala Gly Pro Pro Val Tyr Asn 170 175 180 Pro Ala Ala Pro Pro Pro Tyr Met Pro Pro Gln Pro Ser Tyr Pro 185 190 195 Gly Ala (2) INFORMATION FOR SEQ ID NO: 57: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 245 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: BRAITUT21 (B) CLONE: 2518547 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 57 : Met Gly Gly Ala Ser Arg Arg Val Glu Ser Gly Ala Trp Ala Tyr 5 10 15 Leu Ser Pro Leu Val Leu Arg Lys Glu Leu Glu Ser Leu Val Glu 20 25 30 Asn Glu Gly Ser Glu Val Leu Ala Leu Pro Glu Leu Pro Ser Ala 35 40 45 His Pro Ile Ile Phe Trp Asn Leu Leu Trp Tyr Phe Gln Arg Leu 50 55 60 Arg Leu Pro Ser Ile Leu Pro Gly Leu Val Leu Ala Ser Cys Asp 65 70 75 Gly Pro Ser His Ser Gln Ala Pro Ser Pro Trp Leu Thr Pro Asp 80 85 90 Pro Ala Ser Val Gln Val Arg Leu Leu Trp Asp Val Leu Thr Pro 95 100 105 Asp Pro Asn Ser Cys Pro Pro Leu Tyr Val Leu Trp Arg Val His 110 115 120 Ser Gln Ile Pro Gln Arg Val Val Trp Pro Gly Pro Val Pro Ala 125 130 135 Ser Leu Ser Leu Ala Leu Leu Glu Ser Val Leu Arg His Val Gly 140 145 150 Leu Asn Glu Val His Lys Ala Val Gly Leu Leu Leu Glu Thr Leu 155 160 165 Gly Pro Pro Pro Thr Gly Leu His Leu Gln Arg Gly Ile Tyr Arg 170 175 180 Glu Ile Leu Phe Leu Thr Met Ala Ala Leu Gly Lys Asp His Val 185 190 195 Asp Ile Val Ala Phe Asp Lys Lys Tyr Lys Ser Ala Phe Asn Lys 200 205 210 Leu Ala Ser Ser Met Gly Lys Glu Glu Leu Arg His Arg Arg Ala 215 220 225 Gln Met Pro Thr Pro Lys Ala Ile Asp Cys Arg Lys Cys Phe Gly 230 235 240 Ala Pro Pro Glu Cys 245 (2) INFORMATION FOR SEQ ID NO: 58: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 310 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: GBLANOT02 (B) CLONE: 2530650 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 58 : Met Leu Leu Pro Gln Leu Cys Trp Leu Pro Leu Leu Ala Gly Leu 5 10 15 Leu Pro Pro Val Pro Ala Gln Lys Phe Ser Ala Leu Thr Phe Leu 20 25 30 Arg Val Asp Gln Asp Lys Asp Lys Asp Cys Ser Leu Asp Cys Ala 35 40 45 Gly Ser Pro Gln Lys Pro Leu Cys Ala Ser Asp Gly Arg Thr Phe 50 55 60 Leu Ser Arg Cys Glu Phe Gln Arg Ala Lys Cys Lys Asp Pro Gln 65 70 75 Leu Glu Ile Ala Tyr Arg Gly Asn Cys Lys Asp Val Ser Arg Cys 80 85 90 Val Ala Glu Arg Lys Tyr Thr Gln Glu Gln Ala Arg Lys Glu Phe 95 100 105 Gln Gln Val Phe Ile Pro Glu Cys Asn Asp Asp Gly Thr Tyr Ser 110 115 120 Gln Val Gln Cys His Ser Tyr Thr Gly Tyr Cys Trp Cys Val Thr 125 130 135 Pro Asn Gly Arg Pro Ile Ser Gly Thr Ala Val Ala His Lys Thr 140 145 150 Pro Arg Cys Pro Gly Ser Val Asn Glu Lys Leu Pro Gln Arg Glu 155 160 165 Gly Thr Gly Lys Thr Asp Asp Ala Ala Ala Pro Ala Leu Glu Thr 170 175 180 Gln Pro Gln Gly Asp Glu Glu Asp Ile Ala Ser Arg Tyr Pro Thr 185 190 195 Leu Trp Thr Glu Gln Val Lys Ser Arg Gln Asn Lys Thr Asn Lys 200 205 210 Asn Ser Val Ser Ser Cys Asp Gln Glu His Gln Ser Ala Leu Glu 215 220 225 Glu Ala Lys Gln Pro Lys Asn Asp Asn Val Val Ile Pro Glu Cys 230 235 240 Ala His Gly Gly Leu Tyr Lys Pro Val Gln Cys His Pro Ser Thr 245 250 255 Gly Tyr Cys Trp Cys Val Leu Val Asp Thr Gly Arg Pro Ile Pro 260 265 270 Gly Thr Ser Thr Arg Tyr Glu Gln Pro Lys Cys Asp Asn Thr Gly 275 280 285 Gln Gly Pro Pro Ser Gln Ser Pro Gly Pro Val Gln Gly Pro Pro 290 295 300 Ala Thr Arg Leu Ser Gly Cys Gln Lys Ala 305 310 (2) INFORMATION FOR SEQ ID NO: 59: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 256 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: THYMNOT04 (B) CLONE: 2652271 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 59 : Met Arg Pro Ala Ala Leu Arg Gly Ala Leu Leu Gly Cys Leu Cys 5 10 15 Leu Ala Leu Leu Cys Leu Gly Gly Ala Asp Lys Arg Leu Arg Asp 20 25 30 Asn His Glu Trp Lys Lys Leu Ile Met Val Gln His Trp Pro Glu 35 40 45 Thr Val Cys Glu Lys Ile Gln Asn Asp Cys Arg Asp Pro Pro Asp 50 55 60 Tyr Trp Thr Ile His Gly Leu Trp Pro Asp Lys Ser Glu Gly Cys 65 70 75 Asn Arg Ser Trp Pro Phe Asn Leu Glu Glu Ile Lys Asp Leu Leu 80 85 90 Pro Glu Met Arg Ala Tyr Trp Pro Asp Val Ile His Ser Phe Pro 95 100 105 Asn Arg Ser Arg Phe Trp Lys His Glu Trp Glu Lys His Gly Thr 110 115 120 Cys Ala Ala Gln Val Asp Ala Leu Asn Ser Gln Lys Lys Tyr Phe 125 130 135 Gly Arg Ser Leu Glu Leu Tyr Arg Glu Leu Asp Leu Asn Ser Val 140 145 150 Leu Leu Lys Leu Gly Ile Lys Pro Ser Ile Asn Tyr Tyr Gln Val 155 160 165 Ala Asp Phe Lys Asp Ala Leu Ala Arg Val Tyr Gly Val Ile Pro 170 175 180 Lys Ile Gln Cys Leu Pro Pro Ser Gln Asp Glu Glu Val Gln Thr 185 190 195 Ile Gly Gln Ile Glu Leu Cys Leu Thr Lys Gln Asp Gln Gln Leu 200 205 210 Gln Asn Cys Thr Glu Pro Gly Glu Gln Pro Ser Pro Lys Gln Glu 215 220 225 Val Trp Leu Ala Asn Gly Ala Ala Glu Ser Arg Gly Leu Arg Val 230 235 240 Cys Glu Asp Gly Pro Val Phe Tyr Pro Pro Pro Lys Lys Thr Lys 245 250 255 His (2) INFORMATION FOR SEQ ID NO: 60: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 160 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: LUNGTUT11 (B) CLONE: 2746976 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 60 : Met Gln Phe Met Leu Leu Phe Ser Arg Gln Gly Lys Leu Arg Leu 5 10 15 Gln Lys Trp Tyr Val Pro Leu Ser Asp Lys Glu Lys Arg Lys Ile 20 25 30 Thr Arg Glu Leu Val Gln Thr Val Leu Ala Arg Lys Pro Lys Met 35 40 45 Cys Ser Phe Leu Glu Trp Arg Asp Leu Lys Ile Val Tyr Lys Arg 50 55 60 Tyr Ala Ser Leu Tyr Phe Cys Cys Ala Ile Glu Asp Gln Asp Asn 65 70 75 Glu Leu Ile Thr Leu Glu Ile Ile His Arg Tyr Val Glu Leu Leu 80 85 90 Asp Lys Tyr Phe Gly Ser Val Cys Glu Leu Asp Ile Ile Phe Asn 95 100 105 Phe Glu Lys Ala Tyr Phe Ile Leu Asp Glu Phe Leu Leu Gly Gly 110 115 120 Glu Val Gln Glu Thr Ser Lys Lys Asn Val Leu Lys Ala Ile Glu 125 130 135 Gln Ala Asp Leu Leu Gln Glu Asp Ala Lys Glu Ala Glu Thr Pro 140 145 150 Arg Ser Val Leu Glu Glu Ile Gly Leu Thr 155 160 (2) INFORMATION FOR SEQ ID NO: 61: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 341 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: THP1AZS08 (B) CLONE: 2753496 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 61 : Met Lys Arg Ala Leu Gly Arg Arg Lys Gly Val Trp Leu Arg Leu 5 10 15 Arg Lys Ile Leu Phe Cys Val Leu Gly Leu Tyr Ile Ala Ile Pro 20 25 30 Phe Leu Ile Lys Leu Cys Pro Gly Ile Gln Ala Lys Leu Ile Phe 35 40 45 Leu Asn Phe Val Arg Val Pro Tyr Phe Ile Asp Leu Lys Lys Pro 50 55 60 Gln Asp Gln Gly Leu Asn His Thr Cys Asn Tyr Tyr Leu Gln Pro 65 70 75 Glu Glu Asp Val Thr Ile Gly Val Trp His Thr Val Pro Ala Val 80 85 90 Trp Trp Lys Asn Ala Gln Gly Lys Asp Gln Met Trp Tyr Glu Asp 95 100 105 Ala Leu Ala Ser Ser His Pro Ile Ile Leu Tyr Leu His Gly Asn 110 115 120 Ala Gly Thr Arg Gly Gly Asp His Arg Val Glu Leu Tyr Lys Val 125 130 135 Leu Ser Ser Leu Gly Tyr His Val Val Thr Phe Asp Tyr Arg Gly 140 145 150 Trp Gly Asp Ser Val Gly Thr Pro Ser Glu Arg Gly Met Thr Tyr 155 160 165 Asp Ala Leu His Val Phe Asp Trp Ile Lys Ala Arg Ser Gly Asp 170 175 180 Asn Pro Val Tyr Ile Trp Gly His Ser Leu Gly Thr Gly Val Ala 185 190 195 Thr Asn Leu Val Arg Arg Leu Cys Glu Arg Glu Thr Pro Pro Asp 200 205 210 Ala Leu Ile Leu Glu Ser Pro Phe Thr Asn Ile Arg Glu Glu Ala 215 220 225 Lys Ser His Pro Phe Ser Val Ile Tyr Arg Tyr Phe Pro Gly Phe 230 235 240 Asp Trp Phe Phe Leu Asp Pro Ile Thr Ser Ser Gly Ile Lys Phe 245 250 255 Ala Asn Asp Glu Asn Val Lys His Ile Ser Cys Pro Leu Leu Ile 260 265 270 Leu His Ala Glu Asp Asp Pro Val Val Pro Phe Gln Leu Gly Arg 275 280 285 Lys Leu Tyr Ser Ile Ala Ala Pro Ala Arg Ser Phe Arg Asp Phe 290 295 300 Lys Val Gln Phe Val Pro Phe His Ser Asp Leu Gly Tyr Arg His 305 310 315 Lys Tyr Ile Tyr Lys Ser Pro Glu Leu Pro Arg Ile Leu Arg Glu 320 325 330 Phe Leu Gly Lys Ser Glu Pro Glu His Gln His 335 340 (2) INFORMATION FOR SEQ ID NO: 62: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 430 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: OVARTUT03 (B) CLONE: 2781553 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 62 : Met Ala Glu Gly Glu Asp Val Gly Trp Trp Arg Ser Trp Leu Gln 5 10 15 Gln Ser Tyr Gln Ala Val Lys Glu Lys Ser Ser Glu Ala Leu Glu 20 25 30 Phe Met Lys Arg Asp Leu Thr Glu Phe Thr Gln Val Val Gln His 35 40 45 Asp Thr Ala Cys Thr Ile Ala Ala Thr Ala Ser Val Val Lys Glu 50 55 60 Lys Leu Ala Thr Glu Gly Ser Ser Gly Ala Thr Glu Lys Met Lys 65 70 75 Lys Gly Leu Ser Asp Phe Leu Gly Val Ile Ser Asp Thr Phe Ala 80 85 90 Pro Ser Pro Asp Lys Thr Ile Asp Cys Asp Val Ile Thr Leu Met 95 100 105 Gly Thr Pro Ser Gly Thr Ala Glu Pro Tyr Asp Gly Thr Lys Ala 110 115 120 Arg Leu Tyr Ser Leu Gln Ser Asp Pro Ala Thr Tyr Cys Asn Glu 125 130 135 Pro Asp Gly Pro Pro Glu Leu Phe Asp Ala Trp Leu Ser Gln Phe 140 145 150 Cys Leu Glu Glu Lys Lys Gly Glu Ile Ser Glu Leu Leu Val Gly 155 160 165 Ser Pro Ser Ile Arg Ala Leu Tyr Thr Lys Met Val Pro Ala Ala 170 175 180 Val Ser His Ser Glu Phe Trp His Arg Tyr Phe Tyr Lys Val His 185 190 195 Gln Leu Glu Gln Glu Gln Ala Arg Arg Asp Ala Leu Lys Gln Arg 200 205 210 Ala Glu Gln Ser Ile Ser Glu Glu Pro Gly Trp Glu Glu Glu Glu 215 220 225 Glu Glu Leu Met Gly Ile Ser Pro Ile Ser Pro Lys Glu Ala Lys 230 235 240 Val Pro Val Ala Lys Ile Ser Thr Phe Pro Glu Gly Glu Pro Gly 245 250 255 Pro Gln Ser Pro Cys Glu Glu Asn Leu Val Thr Ser Val Glu Pro 260 265 270 Pro Ala Glu Val Thr Pro Ser Glu Ser Ser Glu Ser Ile Ser Leu 275 280 285 Val Thr Gln Ile Ala Asn Pro Ala Thr Ala Pro Glu Ala Arg Val 290 295 300 Leu Pro Lys Asp Leu Ser Gln Lys Leu Leu Glu Ala Ser Leu Glu 305 310 315 Glu Gln Gly Leu Ala Val Asp Val Gly Glu Thr Gly Pro Ser Pro 320 325 330 Pro Ile His Ser Lys Pro Leu Thr Pro Ala Gly His Thr Gly Gly 335 340 345 Pro Glu Pro Arg Pro Pro Ala Arg Val Glu Thr Leu Arg Glu Glu 350 355 360 Ala Pro Thr Asp Leu Arg Val Phe Glu Leu Asn Ser Asp Ser Gly 365 370 375 Lys Ser Thr Pro Ser Asn Asn Gly Lys Lys Gly Ser Ser Thr Asp 380 385 390 Ile Ser Glu Asp Trp Glu Lys Asp Phe Asp Leu Asp Met Thr Glu 395 400 405 Glu Glu Val Gln Met Ala Leu Ser Lys Val Asp Ala Ser Gly Glu 410 415 420 Leu Glu Asp Val Glu Trp Glu Asp Trp Glu 425 430 (2) INFORMATION FOR SEQ ID NO: 63: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 143 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: ADRETUT06 (B) CLONE: 2821925 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 63 : Met Gly Pro Val Arg Leu Gly Ile Leu Leu Phe Leu Phe Leu Ala 5 10 15 Val His Glu Ala Trp Ala Gly Met Leu Lys Glu Glu Asp Asp Asp 20 25 30 Thr Glu Arg Leu Pro Ser Lys Cys Glu Val Cys Lys Leu Leu Ser 35 40 45 Thr Glu Leu Gln Ala Glu Leu Ser Arg Thr Gly Arg Ser Arg Glu 50 55 60 Val Leu Glu Leu Gly Gln Val Leu Asp Thr Gly Lys Arg Lys Arg 65 70 75 His Val Pro Tyr Ser Val Ser Glu Thr Arg Leu Glu Glu Ala Leu 80 85 90 Glu Asn Leu Cys Glu Arg Ile Leu Asp Tyr Ser Val His Ala Glu 95 100 105 Arg Lys Gly Ser Leu Arg Tyr Ala Lys Gly Gln Ser Gln Thr Met 110 115 120 Ala Thr Leu Lys Gly Leu Val Gln Lys Gly Val Lys Val Asp Leu 125 130 135 Gly Ile Pro Leu Glu Leu Leu Gly 140 (2) INFORMATION FOR SEQ ID NO: 64: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 301 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: UTRSTUT05 (B) CLONE: 2879068 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 64 : Met Glu Asp Met Asn Glu Tyr Ser Asn Ile Glu Glu Phe Ala Glu 5 10 15 Gly Ser Lys Ile Asn Ala Ser Lys Asn Gln Gln Asp Asp Gly Lys 20 25 30 Met Phe Ile Gly Gly Leu Ser Trp Asp Thr Ser Lys Lys Asp Leu 35 40 45 Thr Glu Tyr Leu Ser Arg Phe Gly Glu Val Val Asp Cys Thr Ile 50 55 60 Lys Thr Asp Pro Val Thr Gly Arg Ser Arg Gly Phe Gly Phe Val 65 70 75 Leu Phe Lys Asp Ala Ala Ser Val Asp Lys Val Leu Glu Leu Lys 80 85 90 Glu His Lys Leu Asp Gly Lys Leu Ile Asp Pro Lys Arg Ala Lys 95 100 105 Ala Leu Lys Gly Lys Glu Pro Pro Lys Lys Val Phe Val Gly Gly 110 115 120 Leu Ser Pro Asp Thr Ser Glu Glu Gln Ile Lys Glu Tyr Phe Gly 125 130 135 Ala Phe Gly Glu Ile Glu Asn Ile Glu Leu Pro Met Asp Thr Lys 140 145 150 Thr Asn Glu Arg Arg Gly Phe Cys Phe Ile Thr Tyr Thr Asp Glu 155 160 165 Glu Pro Val Lys Lys Leu Leu Glu Ser Arg Tyr His Gln Ile Gly 170 175 180 Ser Gly Lys Cys Glu Ile Lys Val Ala Gln Pro Lys Glu Val Tyr 185 190 195 Arg Gln Gln Gln Gln Gln Gln Lys Gly Gly Arg Gly Ala Ala Ala 200 205 210 Gly Gly Arg Gly Gly Thr Arg Gly Arg Gly Arg Gly Gln Gly Gln 215 220 225 Asn Trp Asn Gln Gly Phe Asn Asn Tyr Tyr Asp Gln Gly Tyr Gly 230 235 240 Asn Tyr Asn Ser Ala Tyr Gly Gly Asp Gln Asn Tyr Ser Gly Tyr 245 250 255 Gly Gly Tyr Asp Tyr Thr Gly Tyr Asn Tyr Gly Asn Tyr Gly Tyr 260 265 270 Gly Gln Gly Tyr Ala Asp Tyr Ser Gly Gln Gln Ser Thr Tyr Gly 275 280 285 Lys Ala Ser Arg Gly Gly Gly Asn His Gln Asn Asn Tyr Gln Pro 290 295 300 Tyr (2) INFORMATION FOR SEQ ID NO: 65: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 233 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: SINJNOT02 (B) CLONE: 2886757 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 65 : Met Gly Glu Pro Gln Gln Val Ser Ala Leu Pro Pro Pro Pro Met 5 10 15 Gln Tyr Ile Lys Glu Tyr Thr Asp Glu Asn Ile Gln Glu Gly Leu 20 25 30 Ala Pro Lys Pro Pro Pro Pro Ile Lys Asp Ser Tyr Met Met Phe 35 40 45 Gly Asn Gln Phe Gln Cys Asp Asp Leu Ile Ile Arg Pro Leu Glu 50 55 60 Ser Gln Gly Ile Glu Arg Leu His Pro Met Gln Phe Asp His Lys 65 70 75 Lys Glu Leu Arg Lys Leu Asn Met Ser Ile Leu Ile Asn Phe Leu 80 85 90 Asp Leu Leu Asp Ile Leu Ile Arg Ser Pro Gly Ser Ile Lys Arg 95 100 105 Glu Glu Lys Leu Glu Asp Leu Lys Leu Leu Phe Val His Val His 110 115 120 His Leu Ile Asn Glu Tyr Arg Pro His Gln Ala Arg Glu Thr Leu 125 130 135 Arg Val Met Met Glu Val Gln Lys Arg Gln Arg Leu Glu Thr Ala 140 145 150 Glu Arg Phe Gln Lys His Leu Glu Arg Val Ile Glu Met Ile Gln 155 160 165 Asn Cys Leu Ala Ser Leu Pro Asp Asp Leu Pro His Ser Glu Ala 170 175 180 Gly Met Arg Val Lys Thr Glu Pro Met Asp Ala Asp Asp Ser Asn 185 190 195 Asn Cys Thr Gly Gln Asn Glu His Gln Arg Glu Asn Ser Gly His 200 205 210 Arg Arg Asp Gln Ile Ile Glu Lys Asp Ala Ala Leu Cys Val Leu 215 220 225 Ile Asp Glu Met Asn Glu Arg Pro 230 (2) INFORMATION FOR SEQ ID NO: 66: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 354 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: SCORNOT04 (B) CLONE: 2964329 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 66 : Met Ala Gly Ala Gly Ala Gly Ala Gly Ala Arg Gly Gly Ala Ala 5 10 15 Ala Gly Val Glu Ala Arg Ala Arg Asp Pro Pro Pro Ala His Arg 20 25 30 Ala His Pro Arg His Pro Arg Pro Ala Ala Gln Pro Ser Ala Arg 35 40 45 Arg Met Asp Gly Gly Ser Gly Gly Leu Gly Ser Gly Asp Asn Ala 50 55 60 Pro Thr Thr Glu Ala Leu Phe Val Ala Leu Gly Ala Gly Val Thr 65 70 75 Ala Leu Ser His Pro Leu Leu Tyr Val Lys Leu Leu Ile Gln Val 80 85 90 Gly His Glu Pro Met Pro Pro Thr Leu Gly Thr Asn Val Leu Gly 95 100 105 Arg Lys Val Leu Tyr Leu Pro Ser Phe Phe Thr Tyr Ala Lys Tyr 110 115 120 Ile Val Gln Val Asp Gly Lys Ile Gly Leu Phe Arg Gly Leu Ser 125 130 135 Pro Arg Leu Met Ser Asn Ala Leu Ser Thr Val Thr Arg Gly Ser 140 145 150 Met Lys Lys Val Phe Pro Pro Asp Glu Ile Glu Gln Val Ser Asn 155 160 165 Lys Asp Asp Met Lys Thr Ser Leu Lys Lys Val Val Lys Glu Thr 170 175 180 Ser Tyr Glu Met Met Met Gln Cys Val Ser Arg Met Leu Ala His 185 190 195 Pro Leu His Val Ile Ser Met Arg Cys Met Val Gln Phe Val Gly 200 205 210 Arg Glu Ala Lys Tyr Ser Gly Val Leu Ser Ser Ile Gly Lys Ile 215 220 225 Phe Lys Glu Glu Gly Leu Leu Gly Phe Phe Val Gly Leu Ile Pro 230 235 240 His Leu Leu Gly Asp Val Val Phe Leu Trp Gly Cys Asn Leu Leu 245 250 255 Ala His Phe Ile Asn Ala Tyr Leu Val Asp Asp Ser Phe Ser Gln 260 265 270 Ala Leu Ala Ile Arg Ser Tyr Thr Lys Phe Val Met Gly Ile Ala 275 280 285 Val Ser Met Leu Thr Tyr Pro Phe Leu Leu Val Gly Asp Leu Met 290 295 300 Ala Val Asn Asn Cys Gly Leu Gln Ala Gly Leu Pro Pro Tyr Ser 305 310 315 Pro Val Phe Lys Ser Trp Ile His Cys Trp Lys Tyr Leu Ser Val 320 325 330 Gln Gly Gln Leu Phe Arg Gly Ser Ser Leu Leu Phe Arg Arg Val 335 340 345 Ser Ser Gly Ser Cys Phe Ala Leu Glu 350 (2) INFORMATION FOR SEQ ID NO: 67: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 235 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: SCORNOT04 (B) CLONE: 2965248 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 67 : Met Ala Ser Thr Ile Ser Ala Tyr Lys Glu Lys Met Lys Glu Leu 5 10 15 Ser Val Leu Ser Leu Ile Cys Ser Cys Phe Tyr Thr Gln Pro His 20 25 30 Pro Asn Thr Val Tyr Gln Tyr Gly Asp Met Glu Val Lys Gln Leu 35 40 45 Asp Lys Arg Ala Ser Gly Gln Ser Phe Glu Val Ile Leu Lys Ser 50 55 60 Pro Ser Asp Leu Ser Pro Glu Ser Pro Met Leu Ser Ser Pro Pro 65 70 75 Lys Lys Lys Asp Thr Ser Leu Glu Glu Leu Gln Lys Arg Leu Glu 80 85 90 Ala Ala Glu Glu Arg Arg Lys Thr Gln Glu Ala Gln Val Leu Lys 95 100 105 Gln Leu Ala Asp Gly Ala Ser Thr Ser Ala Arg Cys Cys Thr Arg 110 115 120 Arg Trp Arg Arg Ile Thr Thr Ser Ala Ala Arg Arg Arg Arg Ser 125 130 135 Ser Thr Thr Arg Trp Ser Ser Ala Arg Arg Ser Ala Arg His Thr 140 145 150 Trp Pro His Cys Ala Ser Gly Cys Ala Arg Arg Ser Cys Thr Arg 155 160 165 Pro Arg Cys Ala Gly Thr Arg Ser Ser Glu Lys Arg Cys Arg Ala 170 175 180 Lys Gly Pro Gly Arg Ala Ala Pro Ile Leu Arg Arg Asn Thr Phe 185 190 195 Gly Phe Trp Phe Cys Phe Val His Leu Cys Leu Asp Ala Thr Phe 200 205 210 Val Pro Pro Pro Pro Pro Gln Pro Pro Ala Ser Cys Phe Ser Ser 215 220 225 Ala Leu Ser Arg Pro Ala Leu Ser Ser Trp 230 235 (2) INFORMATION FOR SEQ ID NO: 68: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 221 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: TLYMNOT06 (B) CLONE: 3000534 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 68 : Met Trp Ser Ala Gly Arg Gly Gly Ala Ala Trp Pro Val Leu Leu 5 10 15 Gly Leu Leu Leu Ala Leu Leu Val Pro Gly Gly Gly Ala Ala Lys 20 25 30 Thr Gly Ala Glu Leu Val Thr Cys Gly Ser Val Leu Lys Leu Leu 35 40 45 Asn Thr His His Arg Val Arg Leu His Ser His Asp Ile Lys Tyr 50 55 60 Gly Ser Gly Ser Gly Gln Gln Ser Val Thr Gly Val Glu Ala Ser 65 70 75 Asp Asp Ala Asn Ser Tyr Trp Arg Ile Arg Gly Gly Ser Glu Gly 80 85 90 Gly Cys Pro Arg Gly Ser Pro Val Arg Cys Gly Gln Ala Val Arg 95 100 105 Leu Thr His Val Leu Thr Gly Lys Asn Leu His Thr His His Phe 110 115 120 Pro Ser Pro Leu Ser Asn Asn Gln Glu Val Ser Ala Phe Gly Glu 125 130 135 Asp Gly Glu Gly Asp Asp Leu Asp Leu Trp Thr Val Arg Cys Ser 140 145 150 Gly Gln His Trp Glu Arg Glu Ala Ala Val Arg Phe Gln His Val 155 160 165 Gly Thr Ser Val Phe Leu Ser Val Thr Gly Glu Gln Tyr Gly Ser 170 175 180 Pro Ile Arg Gly Gln His Glu Val His Gly Met Pro Ser Ala Asn 185 190 195 Thr His Asn Thr Trp Lys Ala Met Glu Gly Ile Phe Ile Lys Pro 200 205 210 Ser Val Glu Pro Ser Ala Gly His Asp Glu Leu 215 220 (2) INFORMATION FOR SEQ ID NO: 69: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 483 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: HEAANOT01 (B) CLONE: 3046870 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 69 : Met Lys Ala Phe His Thr Phe Cys Val Val Leu Leu Val Phe Gly 5 10 15 Ser Val Ser Glu Ala Lys Phe Asp Asp Phe Glu Asp Glu Glu Asp 20 25 30 Ile Val Glu Tyr Asp Asp Asn Asp Phe Ala Glu Phe Glu Asp Val 35 40 45 Met Glu Asp Ser Val Thr Glu Ser Pro Gln Arg Val Ile Ile Thr 50 55 60 Glu Asp Asp Glu Asp Glu Thr Thr Val Glu Leu Glu Gly Gln Asp 65 70 75 Glu Asn Gln Glu Gly Asp Phe Glu Asp Ala Asp Thr Gln Glu Gly 80 85 90 Asp Thr Glu Ser Glu Pro Tyr Asp Asp Glu Glu Phe Glu Gly Tyr 95 100 105 Glu Asp Lys Pro Asp Thr Ser Ser Ser Lys Asn Lys Asp Pro Ile 110 115 120 Thr Ile Val Asp Val Pro Ala His Leu Gln Asn Ser Trp Glu Ser 125 130 135 Tyr Tyr Leu Glu Ile Leu Met Val Thr Gly Leu Leu Ala Tyr Ile 140 145 150 Met Asn Tyr Ile Ile Gly Lys Asn Lys Asn Ser Arg Leu Ala Gln 155 160 165 Ala Trp Phe Asn Thr His Arg Glu Leu Leu Glu Ser Asn Phe Thr 170 175 180 Leu Val Gly Asp Asp Gly Thr Asn Lys Glu Ala Thr Ser Thr Gly 185 190 195 Lys Leu Asn Gln Glu Asn Glu His Ile Tyr Asn Leu Trp Cys Ser 200 205 210 Gly Arg Val Cys Cys Glu Gly Met Leu Ile Gln Leu Arg Phe Leu 215 220 225 Lys Arg Gln Asp Leu Leu Asn Val Leu Ala Arg Met Met Arg Pro 230 235 240 Val Ser Asp Gln Val Gln Ile Lys Val Thr Met Asn Asp Glu Asp 245 250 255 Met Asp Thr Tyr Val Phe Ala Val Gly Thr Arg Lys Ala Leu Val 260 265 270 Arg Leu Gln Lys Glu Met Gln Asp Leu Ser Glu Phe Cys Ser Asp 275 280 285 Lys Pro Lys Ser Gly Ala Lys Tyr Gly Leu Pro Asp Ser Leu Ala 290 295 300 Ile Leu Ser Glu Met Gly Glu Val Thr Asp Gly Met Met Asp Thr 305 310 315 Lys Met Val His Phe Leu Thr His Tyr Ala Asp Lys Ile Glu Ser 320 325 330 Val His Phe Ser Asp Gln Phe Ser Gly Pro Lys Ile Met Gln Glu 335 340 345 Glu Gly Gln Pro Leu Lys Leu Pro Asp Thr Lys Arg Thr Leu Leu 350 355 360 Phe Thr Phe Asn Val Pro Gly Ser Gly Asn Thr Tyr Pro Lys Asp 365 370 375 Met Glu Ala Leu Leu Pro Leu Met Asn Met Val Ile Tyr Ser Ile 380 385 390 Asp Lys Ala Lys Lys Phe Arg Leu Asn Arg Glu Gly Lys Gln Lys 395 400 405 Ala Asp Lys Asn Arg Ala Arg Val Glu Glu Asn Phe Leu Lys Leu 410 415 420 Thr His Val Gln Arg Gln Glu Ala Ala Gln Ser Arg Arg Glu Glu 425 430 435 Lys Lys Arg Ala Glu Lys Glu Arg Ile Met Asn Glu Glu Asp Pro 440 445 450 Glu Lys Gln Arg Arg Leu Glu Glu Ala Ala Leu Arg Arg Glu Gln 455 460 465 Lys Lys Leu Glu Lys Lys Gln Met Lys Met Lys Gln Ile Lys Val 470 475 480 Lys Ala Met (2) INFORMATION FOR SEQ ID NO: 70: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 371 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: PONSAZT01 (B) CLONE: 3057669 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 70 : Met Asp His Glu Asp Ile Ser Glu Ser Val Asp Ala Ala Tyr Asn 5 10 15 Leu Gln Asp Ser Cys Leu Thr Asp Cys Asp Val Glu Asp Gly Thr 20 25 30 Met Asp Gly Asn Asp Glu Gly His Ser Phe Glu Leu Cys Pro Ser 35 40 45 Glu Ala Ser Pro Tyr Val Arg Ser Arg Glu Arg Thr Ser Ser Ser 50 55 60 Ile Val Phe Glu Asp Ser Gly Cys Asp Asn Ala Ser Ser Lys Glu 65 70 75 Glu Pro Lys Thr Asn Arg Leu His Ile Gly Asn His Cys Ala Asn 80 85 90 Lys Leu Thr Ala Phe Lys Pro Thr Ser Ser Lys Ser Ser Ser Glu 95 100 105 Ala Thr Leu Ser Ile Ser Pro Pro Arg Pro Thr Thr Leu Ser Leu 110 115 120 Asp Leu Thr Lys Asn Thr Thr Glu Lys Leu Gln Pro Ser Ser Pro 125 130 135 Lys Val Tyr Leu Tyr Ile Gln Met Gln Leu Cys Arg Lys Glu Asn 140 145 150 Leu Lys Asp Trp Met Asn Gly Arg Cys Thr Ile Glu Glu Arg Glu 155 160 165 Arg Ser Val Cys Leu His Ile Phe Leu Gln Ile Ala Glu Ala Val 170 175 180 Glu Phe Leu His Ser Lys Gly Leu Met His Arg Asp Leu Lys Pro 185 190 195 Ser Asn Ile Phe Phe Thr Met Asp Asp Val Val Lys Val Gly Asp 200 205 210 Phe Gly Leu Val Thr Ala Met Asp Gln Asp Glu Glu Glu Gln Thr 215 220 225 Val Leu Thr Pro Met Pro Ala Tyr Ala Arg His Thr Gly Gln Val 230 235 240 Gly Thr Lys Leu Tyr Met Ser Pro Glu Gln Ile His Gly Asn Ser 245 250 255 Tyr Ser His Lys Val Asp Ile Phe Ser Leu Gly Leu Ile Leu Phe 260 265 270 Glu Leu Leu Tyr Pro Phe Ser Thr Gln Met Glu Arg Val Arg Thr 275 280 285 Leu Thr Asp Val Arg Asn Leu Lys Phe Pro Pro Leu Phe Thr Gln 290 295 300 Lys Tyr Pro Cys Glu Tyr Val Met Val Gln Asp Met Leu Ser Pro 305 310 315 Ser Pro Met Glu Arg Pro Glu Ala Ile Asn Ile Ile Glu Asn Ala 320 325 330 Val Phe Glu Asp Leu Asp Phe Pro Gly Lys Thr Val Leu Arg Gln 335 340 345 Arg Ser Arg Ser Leu Ser Ser Ser Gly Thr Lys His Ser Arg Gln 350 355 360 Ser Asn Asn Ser His Ser Pro Leu Pro Ser Asn 365 370 (2) INFORMATION FOR SEQ ID NO: 71: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 402 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: HEAONOT03 (B) CLONE: 3088178 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 71 : Met Met Asn Asn Arg Phe Arg Lys Asp Met Met Lys Asn Ala Ser 5 10 15 Glu Ser Lys Leu Ser Lys Asp Asn Leu Lys Lys Arg Leu Lys Glu 20 25 30 Glu Phe Gln His Ala Met Gly Gly Val Pro Ala Trp Ala Glu Thr 35 40 45 Thr Lys Arg Lys Thr Ser Ser Asp Asp Glu Ser Glu Glu Asp Glu 50 55 60 Asp Asp Leu Leu Gln Arg Thr Gly Asn Phe Ile Ser Thr Ser Thr 65 70 75 Ser Leu Pro Arg Gly Ile Leu Lys Met Lys Asn Cys Gln His Ala 80 85 90 Asn Ala Glu Arg Pro Thr Val Ala Arg Ile Ser Ser Val Gln Phe 95 100 105 His Pro Gly Ala Gln Ile Val Met Val Ala Gly Leu Asp Asn Ala 110 115 120 Val Ser Leu Phe Gln Val Asp Gly Lys Thr Asn Pro Lys Ile Gln 125 130 135 Ser Ile Tyr Leu Glu Arg Phe Pro Ile Phe Lys Ala Cys Phe Ser 140 145 150 Ala Asn Gly Glu Glu Val Leu Ala Thr Ser Thr His Ser Lys Val 155 160 165 Leu Tyr Val Tyr Asp Met Leu Ala Gly Lys Leu Ile Pro Val His 170 175 180 Gln Val Arg Gly Leu Lys Glu Lys Ile Val Arg Ser Phe Glu Val 185 190 195 Ser Pro Asp Gly Ser Phe Leu Leu Ile Asn Gly Ile Ala Gly Tyr 200 205 210 Leu His Leu Leu Ala Met Lys Thr Lys Glu Leu Ile Gly Ser Met 215 220 225 Lys Ile Asn Gly Arg Val Ala Ala Ser Thr Phe Ser Ser Asp Ser 230 235 240 Lys Lys Val Tyr Ala Ser Ser Gly Asp Gly Glu Val Tyr Val Trp 245 250 255 Asp Val Asn Ser Arg Lys Cys Leu Asn Arg Phe Val Asp Glu Gly 260 265 270 Ser Leu Tyr Gly Leu Ser Ile Ala Thr Ser Arg Asn Gly Gln Tyr 275 280 285 Val Ala Cys Gly Ser Asn Cys Gly Val Val Asn Ile Tyr Asn Gln 290 295 300 Asp Ser Cys Leu Gln Glu Thr Asn Pro Lys Pro Ile Lys Ala Ile 305 310 315 Met Asn Leu Val Thr Gly Val Thr Ser Leu Thr Phe Asn Pro Thr 320 325 330 Thr Glu Ile Leu Ala Ile Ala Ser Glu Lys Met Lys Glu Ala Val 335 340 345 Arg Leu Val His Leu Pro Ser Cys Thr Val Phe Ser Asn Phe Pro 350 355 360 Val Ile Lys Asn Lys Asn Ile Ser His Val His Thr Met Asp Phe 365 370 375 Ser Pro Arg Ser Gly Tyr Phe Ala Leu Gly Asn Glu Lys Gly Lys 380 385 390 Ala Leu Met Tyr Arg Leu His His Tyr Ser Asp Phe 395 400 (2) INFORMATION FOR SEQ ID NO: 72: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 640 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: BRSTNOT19 (B) CLONE: 3094321 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 72 : Met Ala Leu Ser Arg Gly Leu Pro Arg Glu Leu Ala Glu Ala Val 5 10 15 Ala Gly Gly Arg Val Leu Val Val Gly Ala Gly Gly Ile Gly Cys 20 25 30 Glu Leu Leu Lys Asn Leu Val Leu Thr Gly Phe Ser His Ile Asp 35 40 45 Leu Ile Asp Leu Asp Thr Ile Asp Val Ser Asn Leu Asn Arg Gln 50 55 60 Phe Leu Phe Gln Lys Lys His Val Gly Arg Ser Lys Ala Gln Val 65 70 75 Ala Lys Glu Ser Val Leu Gln Phe Tyr Pro Lys Ala Asn Ile Val 80 85 90 Ala Tyr His Asp Ser Ile Met Asn Pro Asp Tyr Asn Val Glu Phe 95 100 105 Phe Arg Gln Phe Ile Leu Val Met Asn Ala Leu Asp Asn Arg Ala 110 115 120 Ala Arg Asn His Val Asn Arg Met Cys Leu Ala Ala Asp Val Pro 125 130 135 Leu Ile Glu Ser Gly Thr Ala Gly Tyr Leu Gly Gln Val Thr Thr 140 145 150 Ile Lys Lys Gly Val Thr Glu Cys Tyr Glu Cys His Pro Lys Pro 155 160 165 Thr Gln Arg Thr Phe Pro Gly Cys Thr Ile Arg Asn Thr Pro Ser 170 175 180 Glu Pro Ile His Cys Ile Val Trp Ala Lys Tyr Leu Phe Asn Gln 185 190 195 Leu Phe Gly Glu Glu Asp Ala Asp Gln Glu Val Ser Pro Asp Arg 200 205 210 Ala Asp Pro Glu Ala Ala Trp Glu Pro Thr Glu Ala Glu Ala Arg 215 220 225 Ala Arg Ala Ser Asn Glu Asp Gly Asp Ile Lys Arg Ile Ser Thr 230 235 240 Lys Glu Trp Ala Lys Ser Thr Gly Tyr Asp Pro Val Lys Leu Phe 245 250 255 Thr Lys Leu Phe Lys Asp Asp Ile Arg Tyr Leu Leu Thr Met Asp 260 265 270 Lys Leu Trp Arg Lys Arg Lys Pro Pro Val Pro Leu Asp Trp Ala 275 280 285 Glu Val Gln Ser Gln Gly Glu Glu Thr Asn Ala Ser Asp Gln Gln 290 295 300 Asn Glu Pro Gln Leu Gly Leu Lys Asp Gln Gln Val Leu Asp Val 305 310 315 Lys Ser Tyr Ala Arg Leu Phe Ser Lys Ser Ile Glu Thr Leu Arg 320 325 330 Val His Leu Ala Glu Lys Gly Asp Gly Ala Glu Leu Ile Trp Asp 335 340 345 Lys Asp Asp Pro Ser Ala Met Asp Phe Val Thr Ser Ala Ala Asn 350 355 360 Leu Arg Met His Ile Phe Ser Met Asn Met Lys Ser Arg Phe Asp 365 370 375 Ile Lys Ser Met Ala Gly Asn Ile Ile Pro Ala Ile Ala Thr Thr 380 385 390 Asn Ala Val Ile Ala Gly Leu Ile Val Leu Glu Gly Leu Lys Ile 395 400 405 Leu Ser Gly Lys Ile Asp Gln Cys Arg Thr Ile Phe Leu Asn Lys 410 415 420 Gln Pro Asn Pro Arg Lys Lys Leu Leu Val Pro Cys Ala Leu Asp 425 430 435 Pro Pro Asn Pro Asn Cys Tyr Val Cys Ala Ser Lys Pro Glu Val 440 445 450 Thr Val Arg Leu Asn Val His Lys Val Thr Val Leu Thr Leu Gln 455 460 465 Asp Lys Ile Val Lys Glu Lys Phe Ala Met Val Ala Pro Asp Val 470 475 480 Gln Ile Glu Asp Gly Lys Gly Thr Ile Leu Ile Ser Ser Glu Glu 485 490 495 Gly Glu Thr Glu Ala Asn Asn His Lys Lys Leu Ser Glu Phe Gly 500 505 510 Ile Arg Asn Gly Ser Arg Leu Gln Ala Asp Asp Phe Leu Gln Asp 515 520 525 Tyr Thr Leu Leu Ile Asn Ile Leu His Ser Glu Asp Leu Gly Lys 530 535 540 Asp Val Glu Phe Glu Val Val Gly Asp Ala Pro Glu Lys Val Gly 545 550 555 Pro Lys Gln Ala Glu Asp Ala Ala Lys Ser Ile Thr Asn Gly Ser 560 565 570 Asp Asp Gly Ala Gln Pro Ser Thr Ser Thr Ala Gln Glu Gln Asp 575 580 585 Asp Val Leu Ile Val Asp Ser Asp Glu Glu Asp Ser Ser Asn Asn 590 595 600 Ala Asp Val Ser Glu Glu Glu Arg Ser Arg Lys Arg Lys Leu Asp 605 610 615 Glu Lys Glu Asn Leu Ser Ala Lys Arg Ser Arg Ile Glu Gln Lys 620 625 630 Glu Glu Leu Asp Asp Val Ile Ala Leu Asp 635 640 (2) INFORMATION FOR SEQ ID NO: 73: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 237 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: LUNGTUT13 (B) CLONE: 3115936 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 73 : Met Asp Lys Ile Leu Asn Val Glu Glu Thr Tyr Leu Thr Val Leu 5 10 15 Val Lys Ile Gly Pro Gly Phe His Thr Arg Glu Cys Phe Leu Leu 20 25 30 Lys Ser Ile Leu Cys Phe Ser Pro Ser Tyr Arg Met Ser Glu Gly 35 40 45 Asp Ser Val Gly Glu Ser Val His Gly Lys Pro Ser Val Val Tyr 50 55 60 Arg Phe Phe Thr Arg Leu Gly Gln Ile Tyr Gln Ser Trp Leu Asp 65 70 75 Lys Ser Thr Pro Tyr Thr Ala Val Arg Trp Val Val Thr Leu Gly 80 85 90 Leu Ser Phe Val Tyr Met Ile Arg Val Tyr Leu Leu Gln Gly Trp 95 100 105 Tyr Ile Val Thr Tyr Ala Leu Gly Ile Tyr His Leu Asn Leu Phe 110 115 120 Ile Ala Phe Leu Ser Pro Lys Val Asp Pro Ser Leu Met Glu Asp 125 130 135 Ser Asp Asp Gly Pro Ser Leu Pro Thr Lys Gln Asn Glu Glu Phe 140 145 150 Arg Pro Phe Ile Arg Arg Leu Pro Glu Phe Lys Phe Trp His Ala 155 160 165 Ala Thr Lys Gly Ile Leu Val Ala Met Val Cys Thr Phe Phe Asp 170 175 180 Ala Phe Asn Val Pro Val Phe Trp Pro Ile Leu Val Met Tyr Phe 185 190 195 Ile Met Leu Phe Cys Ile Thr Met Lys Arg Gln Ile Lys His Met 200 205 210 Ile Lys Tyr Arg Tyr Ile Pro Phe Thr His Gly Lys Arg Arg Tyr 215 220 225 Arg Gly Lys Glu Asp Ala Gly Lys Ala Phe Ala Ser 230 235 (2) INFORMATION FOR SEQ ID NO: 74: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 432 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: LUNGTUT13 (B) CLONE: 3116522 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 74 : Met Asp Ala Arg Trp Trp Ala Val Val Val Leu Ala Ala Phe Pro 5 10 15 Ser Leu Gly Ala Gly Gly Glu Thr Pro Glu Ala Pro Pro Glu Ser 20 25 30 Trp Thr Gln Leu Trp Phe Phe Arg Phe Val Val Asn Ala Ala Gly 35 40 45 Tyr Ala Ser Phe Met Val Pro Gly Tyr Leu Leu Val Gln Tyr Phe 50 55 60 Arg Arg Lys Asn Tyr Leu Glu Thr Gly Arg Gly Leu Cys Phe Pro 65 70 75 Leu Val Lys Ala Cys Val Phe Gly Asn Glu Pro Lys Ala Ser Asp 80 85 90 Glu Val Pro Leu Ala Pro Arg Thr Glu Ala Ala Glu Thr Thr Pro 95 100 105 Met Trp Gln Ala Leu Lys Leu Leu Phe Cys Ala Thr Gly Leu Gln 110 115 120 Val Ser Tyr Leu Thr Trp Gly Val Leu Gln Glu Arg Val Met Thr 125 130 135 Arg Ser Tyr Gly Ala Thr Ala Thr Ser Pro Gly Glu Arg Phe Thr 140 145 150 Asp Ser Gln Phe Leu Val Leu Met Asn Arg Val Leu Ala Leu Ile 155 160 165 Val Ala Gly Leu Ser Cys Val Leu Cys Lys Gln Pro Arg His Gly 170 175 180 Ala Pro Met Tyr Arg Tyr Ser Phe Ala Ser Leu Ser Asn Val Leu 185 190 195 Ser Ser Trp Cys Gln Tyr Glu Ala Leu Lys Phe Val Ser Phe Pro 200 205 210 Thr Gln Val Leu Ala Lys Ala Ser Lys Val Ile Pro Val Met Leu 215 220 225 Met Gly Lys Leu Val Ser Arg Arg Ser Tyr Glu His Trp Glu Tyr 230 235 240 Leu Thr Ala Thr Leu Ile Ser Ile Gly Val Ser Met Phe Leu Leu 245 250 255 Ser Ser Gly Pro Glu Pro Arg Ser Ser Pro Ala Thr Thr Leu Ser 260 265 270 Gly Leu Ile Leu Leu Ala Gly Tyr Ile Ala Phe Asp Ser Phe Thr 275 280 285 Ser Asn Trp Gln Asp Ala Leu Phe Ala Tyr Lys Met Ser Ser Val 290 295 300 Gln Met Met Phe Gly Val Asn Phe Phe Ser Cys Leu Phe Thr Val 305 310 315 Gly Ser Leu Leu Glu Gln Gly Ala Leu Leu Glu Gly Thr Arg Phe 320 325 330 Met Gly Arg His Ser Glu Phe Ala Ala His Ala Leu Leu Leu Ser 335 340 345 Ile Cys Ser Ala Cys Gly Gln Leu Phe Ile Phe Tyr Thr Ile Gly 350 355 360 Gln Phe Gly Ala Ala Val Phe Thr Ile Ile Met Thr Leu Arg Gln 365 370 375 Ala Phe Ala Ile Leu Leu Ser Cys Leu Leu Tyr Gly His Thr Val 380 385 390 Thr Val Val Gly Gly Leu Gly Val Ala Val Val Phe Ala Ala Leu 395 400 405 Leu Leu Arg Val Tyr Ala Arg Gly Arg Leu Lys Gln Arg Gly Lys 410 415 420 Lys Ala Val Pro Val Glu Ser Pro Val Gln Lys Val 425 430 (2) INFORMATION FOR SEQ ID NO: 75: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 252 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: LUNGTUT13 (B) CLONE: 3117184 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 75 : Met Ser Phe Pro Pro His Leu Asn Arg Pro Pro Met Gly Ile Pro 5 10 15 Ala Leu Pro Pro Gly Thr Pro Pro Pro Gln Phe Pro Gly Phe Pro 20 25 30 Pro Pro Val Pro Pro Gly Thr Pro Met Ile Pro Val Pro Met Ser 35 40 45 Ile Met Ala Pro Ala Pro Thr Val Leu Val Pro Thr Val Ser Met 50 55 60 Val Gly Lys His Leu Gly Ala Arg Lys Asp His Pro Gly Leu Lys 65 70 75 Ala Lys Glu Asn Asp Glu Asn Cys Gly Pro Thr Thr Thr Val Phe 80 85 90 Val Gly Asn Ile Ser Glu Lys Ala Ser Asp Met Leu Ile Arg Gln 95 100 105 Leu Leu Ala Lys Cys Gly Leu Val Leu Ser Trp Lys Arg Val Gln 110 115 120 Gly Ala Ser Gly Lys Leu Gln Ala Phe Gly Phe Cys Glu Tyr Lys 125 130 135 Glu Pro Glu Ser Thr Leu Arg Ala Leu Arg Leu Leu His Asp Leu 140 145 150 Gln Ile Gly Glu Lys Lys Leu Leu Val Lys Val Asp Ala Lys Thr 155 160 165 Lys Ala Gln Leu Asp Glu Trp Lys Ala Lys Lys Lys Ala Ser Asn 170 175 180 Gly Asn Ala Arg Pro Glu Thr Val Thr Asn Asp Asp Glu Glu Ala 185 190 195 Leu Asp Glu Glu Thr Lys Arg Arg Asp Gln Met Ile Lys Gly Ala 200 205 210 Ile Glu Val Leu Ile Arg Glu Tyr Ser Ser Glu Leu Asn Ala Pro 215 220 225 Ser Gln Glu Ser Asp Ser His Pro Arg Lys Lys Lys Lys Glu Lys 230 235 240 Lys Glu Asp Ile Phe Gly Arg Phe Gln Trp Ala His 245 250 (2) INFORMATION FOR SEQ ID NO: 76: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 523 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: LNODNOT05 (B) CLONE: 3125156 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 76 : Met Gly Pro Gln Ala Ala Pro Leu Thr Ile Arg Gly Pro Ser Ser 5 10 15 Ala Gly Gln Ser Thr Pro Ser Pro His Leu Val Pro Ser Pro Ala 20 25 30 Pro Ser Pro Gly Pro Gly Pro Val Pro Pro Arg Pro Pro Ala Ala 35 40 45 Glu Pro Pro Pro Cys Leu Arg Arg Gly Ala Ala Ala Ala Asp Leu 50 55 60 Leu Ser Ser Ser Pro Glu Ser Gln His Gly Gly Thr Gln Ser Pro 65 70 75 Gly Gly Gly Gln Pro Leu Leu Gln Pro Thr Lys Val Asp Ala Ala 80 85 90 Glu Gly Arg Arg Pro Gln Ala Leu Arg Leu Ile Glu Arg Asp Pro 95 100 105 Tyr Glu His Pro Glu Arg Leu Arg Gln Leu Gln Gln Glu Leu Glu 110 115 120 Ala Phe Arg Gly Gln Leu Gly Asp Val Gly Ala Leu Asp Thr Val 125 130 135 Trp Arg Glu Leu Gln Asp Ala Gln Glu His Asp Ala Arg Gly Arg 140 145 150 Ser Ile Ala Ile Ala Arg Cys Tyr Ser Leu Lys Asn Arg His Gln 155 160 165 Asp Val Met Pro Tyr Asp Ser Asn Arg Val Val Leu Arg Ser Gly 170 175 180 Lys Asp Asp Tyr Ile Asn Ala Ser Cys Val Glu Gly Leu Ser Pro 185 190 195 Tyr Cys Pro Pro Leu Val Ala Thr Gln Ala Pro Leu Pro Gly Thr 200 205 210 Ala Ala Asp Phe Trp Leu Met Val His Glu Gln Lys Val Ser Val 215 220 225 Ile Val Met Leu Val Ser Glu Ala Glu Met Glu Lys Gln Lys Val 230 235 240 Ala Arg Tyr Phe Pro Thr Glu Arg Gly Gln Pro Met Val His Gly 245 250 255 Ala Leu Ser Leu Ala Leu Ser Ser Val Arg Ser Thr Glu Thr His 260 265 270 Val Glu Arg Val Leu Ser Leu Gln Phe Arg Asp Gln Ser Leu Lys 275 280 285 Arg Ser Leu Val His Leu His Phe Pro Thr Trp Pro Glu Leu Gly 290 295 300 Leu Pro Asp Ser Pro Ser Asn Leu Leu Arg Phe Ile Gln Glu Val 305 310 315 His Ala His Tyr Leu His Gln Arg Pro Leu His Thr Pro Ile Ile 320 325 330 Val His Cys Ser Ser Gly Val Gly Arg Thr Gly Ala Phe Ala Leu 335 340 345 Leu Tyr Ala Ala Val Gln Glu Val Glu Ala Gly Asn Gly Ile Pro 350 355 360 Glu Leu Pro Gln Leu Val Arg Arg Met Arg Gln Gln Arg Lys His 365 370 375 Met Leu Gln Glu Lys Leu His Leu Arg Phe Cys Tyr Glu Ala Val 380 385 390 Val Arg His Val Glu Gln Val Leu Gln Arg His Gly Val Pro Pro 395 400 405 Pro Cys Lys Pro Leu Ala Ser Ala Ser Ile Ser Gln Lys Asn His 410 415 420 Leu Pro Gln Asp Ser Gln Asp Leu Val Leu Gly Gly Asp Val Pro 425 430 435 Ile Ser Ser Ile Gln Ala Thr Ile Ala Lys Leu Ser Ile Arg Pro 440 445 450 Pro Gly Gly Leu Glu Ser Pro Val Ala Ser Leu Pro Gly Pro Ala 455 460 465 Glu Pro Pro Gly Leu Pro Pro Ala Ser Leu Pro Glu Ser Thr Pro 470 475 480 Ile Pro Ser Ser Ser Gln Thr Pro Phe Pro Pro His Tyr Leu Arg 485 490 495 Leu Pro Ser Leu Arg Arg Ser Arg Gln Cys Leu Lys Pro Pro Ala 500 505 510 Arg Gly Pro Pro Pro Pro Pro Trp Asn Cys Trp Pro Pro 515 520 (2) INFORMATION FOR SEQ ID NO: 77: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 621 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: LUNGTUT12 (B) CLONE: 3129120 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 77 : Met Gly Leu Leu Ser Asp Pro Val Arg Arg Arg Ala Leu Ala Arg 5 10 15 Leu Val Leu Arg Leu Asn Ala Pro Leu Cys Val Leu Ser Tyr Val 20 25 30 Ala Gly Ile Ala Trp Phe Leu Ala Leu Val Phe Pro Pro Leu Thr 35 40 45 Gln Arg Thr Tyr Met Ser Glu Asn Ala Met Gly Ser Thr Met Val 50 55 60 Glu Glu Gln Phe Ala Gly Gly Asp Arg Ala Arg Ala Phe Ala Arg 65 70 75 Asp Phe Ala Ala His Arg Lys Lys Ser Gly Ala Leu Pro Val Ala 80 85 90 Trp Leu Glu Arg Thr Met Arg Ser Val Gly Leu Glu Val Tyr Thr 95 100 105 Gln Ser Phe Ser Arg Lys Leu Pro Phe Pro Asp Glu Thr His Glu 110 115 120 Arg Tyr Met Val Ser Gly Thr Asn Val Tyr Gly Ile Leu Arg Ala 125 130 135 Pro Arg Ala Ala Ser Thr Glu Ser Leu Val Leu Thr Val Pro Cys 140 145 150 Gly Ser Asp Ser Thr Asn Ser Gln Ala Val Gly Leu Leu Leu Ala 155 160 165 Leu Ala Ala His Phe Arg Gly Gln Ile Tyr Trp Ala Lys Asp Ile 170 175 180 Val Phe Leu Val Thr Glu His Asp Leu Leu Gly Thr Glu Ala Trp 185 190 195 Leu Glu Ala Tyr His Asp Val Asn Val Thr Gly Met Gln Ser Ser 200 205 210 Pro Leu Gln Gly Arg Ala Gly Ala Ile Gln Ala Ala Val Ala Leu 215 220 225 Glu Leu Ser Ser Asp Val Val Thr Ser Leu Asp Val Ala Val Glu 230 235 240 Gly Leu Asn Gly Gln Leu Pro Asn Leu Asp Leu Leu Asn Leu Phe 245 250 255 Gln Thr Phe Cys Gln Lys Gly Gly Leu Leu Cys Thr Leu Gln Gly 260 265 270 Lys Leu Gln Pro Glu Asp Trp Thr Ser Leu Asp Gly Pro Leu Gln 275 280 285 Gly Leu Gln Thr Leu Leu Leu Met Val Leu Arg Gln Ala Ser Gly 290 295 300 Arg Pro His Gly Ser His Gly Leu Phe Leu Arg Tyr Arg Val Glu 305 310 315 Ala Leu Thr Leu Arg Gly Ile Asn Ser Phe Arg Gln Tyr Lys Tyr 320 325 330 Asp Leu Val Ala Val Gly Lys Ala Leu Glu Gly Met Phe Arg Lys 335 340 345 Leu Asn His Leu Leu Glu Arg Leu His Gln Ser Phe Phe Leu Tyr 350 355 360 Leu Leu Pro Gly Leu Ser Arg Phe Val Ser Ile Gly Leu Tyr Met 365 370 375 Pro Ala Val Gly Phe Leu Leu Leu Val Leu Gly Leu Lys Ala Leu 380 385 390 Glu Leu Trp Met Gln Leu His Glu Ala Gly Met Gly Leu Glu Glu 395 400 405 Pro Gly Gly Ala Pro Gly Pro Ser Val Pro Leu Pro Pro Ser Gln 410 415 420 Gly Val Gly Leu Ala Ser Leu Val Ala Pro Leu Leu Ile Ser Gln 425 430 435 Ala Met Gly Leu Ala Leu Tyr Val Leu Pro Val Leu Gly Gln His 440 445 450 Val Ala Thr Gln His Phe Pro Val Ala Glu Ala Glu Ala Val Val 455 460 465 Leu Thr Leu Leu Ala Ile Tyr Ala Ala Gly Leu Ala Leu Pro His 470 475 480 Asn Thr His Arg Val Val Ser Thr Gln Ala Pro Asp Arg Gly Trp 485 490 495 Met Ala Leu Lys Leu Val Ala Leu Ile Tyr Leu Ala Leu Gln Leu 500 505 510 Gly Cys Ile Ala Leu Thr Asn Phe Ser Leu Gly Phe Leu Leu Ala 515 520 525 Thr Thr Met Val Pro Thr Ala Ala Leu Ala Lys Pro His Gly Pro 530 535 540 Arg Thr Leu Tyr Ala Ala Leu Leu Val Leu Thr Ser Pro Ala Ala 545 550 555 Thr Leu Leu Gly Ser Leu Phe Leu Trp Arg Glu Leu Gln Glu Ala 560 565 570 Pro Leu Ser Leu Ala Glu Gly Trp Gln Leu Phe Leu Ala Ala Leu 575 580 585 Ala Gln Gly Val Leu Glu His His Thr Tyr Gly Ala Leu Leu Phe 590 595 600 Pro Leu Leu Ser Leu Gly Leu Tyr Pro Cys Trp Leu Leu Phe Trp 605 610 615 Asn Val Leu Phe Trp Lys 620 (2) INFORMATION FOR SEQ ID NO: 78: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2347 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: HEARNOT01 (B) CLONE: 305841 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 78 : CCCTCGAGAA GATGGCGGCG ACTCTGGGAC CCCTTGGGTC GTGGCAGCAG TGGCGGCGAT 60 GTTTGTCGGC TCGGGATGGG TCCAGGATGT TACTCCTTCT TCTTTTGTTG GGGTCTGGGC 120 AGGGGCCACA GCAAGTCGGG GCGGGTCAAA CGTTCGAGTA CTTGAAACGG GAGCACTCGC 180 TGTCGAAGCC CTACCAGGGT GTGGGCACAG GCAGTTCCTC ACTGTGGAAT CTGATGGGCA 240 ATGCCATGGT GATGACCCAG TATATCCGCC TTACCCCAGA TATGCAAAGT AAACAGGGTG 300 CCTTGTGGAA CCGGGTGCCA TGTTTCCTGA GAGACTGGGA GTTGCAGGTG CACTTCAAAA 360 TCCATGGACA AGGAAAGAAG AATCTGCATG GGGATGGCTT GGCAATCTGG TACACAAAGG 420 ATCGGATGCA GCCAGGGCCT GTGTTTGGAA ACATGGACAA ATTTGTGGGG CTGGGAGTAT 480 TTGTAGACAC CTACCCCAAT GAGGAGAAGC AGCAAGAGCG GGTATTCCCC TACATCTCAG 540 CCATGGTGAA CAACGGCTCC CTCAGCTATG ATCATGAGCG GGATGGGCGG CCTACAGAGC 600 TGGGAGGCTG CACAGCCATT GTCCGCAATC TTCATTACGA CACCTTCCTG GTGATTCGCT 660 ACGTCAAGAG GCATTTGACG ATAATGATGG ATATTGATGG CAAGCATGAG TGGAGGGACT 720 GCATTGAAGT GCCCGGAGTC CGCCTGCCCC GCGGCTACTA CTTCGGCACC TCCTCCATCA 780 CTGGGGATCT CTCAGATAAT CATGATGTCA TTTCCTTGAA GTTGTTTGAA CTGACAGTGG 840 AGAGAACCCC AGAAGAGGAA AAGCTCCATC GAGATGTGTT CTTGCCCTCA GTGGACAATA 900 TGAAGCTGCC TGAGATGACA GCTCCACTGC CGCCCCTGAG TGGCCTGGCC CTCTTCCTCA 960 TCGTCTTTTT CTCCCTGGTG TTTTCTGTAT TTGCCATAGT CATTGGTATC ATACTCTACA 1020 ACAAATGGCA GGAACAGAGC CGAAAGCGCT TCTACTGAGC CCTCCTGCTG CCACCACTTT 1080 TGTGACTGTC ACCCATGAGG TATGGAAGGA GCAGGCACTG GCCTGAGCAT GCAGCCTGGA 1140 GAGTGTTCTT GTCTCTAGCA GCTGGTTGGG GACTATATTC TGTCACTGGA GTTTTGAATG 1200 CAGGGACCCC GCATTCCCAT GGTTGTGCAT GGGGACATCT AACTCTGGTC TGGGAAGCCA 1260 CCCACCCCAG GGCAATGCTG CTGTGATGTG CCTTTCCCTG CAGTCCTTCC ATGTGGGAGC 1320 AGAGGTGTGA AGAGAATTTA CGTGGTTGTG ATGCCAAAAT CACAGAACAG AATTTCATAG 1380 CCCAGGCTGC CGTGTTGTTT GACTCAGAAG GCCCTTCTAC TTCAGTTTTG AATCCACAAA 1440 GAATTAAAAA CTGGTAACAC CACAGGCTTT CTGACCATCC ATTCGTTGGG TTTTGCATTT 1500 GACCCAACCC TCTGCCTACC TGAGGAGCTT TCTTTGGAAA CCAGGATGGA AACTTCTTCC 1560 CTGCCTTACC TTCCTTTCAC TCCATTCATT GTCCTCTCTG TGTGCAACCT GAGCTGGGAA 1620 AGGCATTTGG ATGCCTCTCT GTTGGGGCCT GGGGCTGCAG AACACACCTG CGTTTCACTG 1680 GCCTTCATTA GGTGGCCCTA GGGAGATGGC TTTCTGCTTT GGATCACTGT TCCCTAGCAT 1740 GGGTCTTGGG TCTATTGGCA TGTCCATGGC CTTCCCAATC AAGTCTCTTC AGGCCCTCAG 1800 TGAAGTTTGG CTAAAGGTTG GTGTAAAAAT CAAGAGAAGC CTGGAAGACA TCATGGATGC 1860 CATGGATTAG CTGTGCAACT GACCAGCTCC AGGTTTGATC AAACCAAAAG CAACATTTGT 1920 CATGTGGTCT GACCATGTGG AGATGTTTCT GGACTTGCTA GAGCCTGCTT AGCTGCATGT 1980 TTTGTAGTTA CGATTTTTGG AATCCCACTT TGAGTGCTGA AAGTGTAAGG AAGCTTTCTT 2040 CTTACACCTT GGGCTTGGAT ATTGCCCAGA GAAGAAATTT GGCTTTTTTT TTCTTAATGG 2100 ACAAGAGACA GTTGCTGTTC TCATGTTCCA AGTCTGAGAG CAACAGACCC TCATCATCTG 2160 TGCCTGGAAG AGTTCACTGT CATTGAGCAG CACAGCCTGA GTGCTGGCCT CTGTCAACCC 2220 TTATTCCACT GCCTTATTTG ACAAGGGGTT ACATGCTGCT CACCTTACTG CCCTGGGATT 2280 AAATCAGTTA CAGGCCAGAG TCTCCTTGGA GGGCCTGGAA CTCTGAGTCC TCCTATGAAC 2340 CTCTGTA 2347 (2) INFORMATION FOR SEQ ID NO: 79: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1529 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: EOSIHET02 (B) CLONE: 322866 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 79 : CCCACGCGTC CGCCAGCCTT GTCTCGGCCA CCTCAAGGAT AATCACTAAA TTCTGCCGAA 60 AGGACTGAGG AACGGTGCCT GGAAAAGGGC AAGAATATCA CGGCATGGGC ATGAGTAGCT 120 TGAAACTGCT GAAGTATGTC CTGTTTTTCT TCAACTTGCT CTTTTGGATC TGTGGCTGCT 180 GCATTTTGGG CTTTGGGATC TACCTGCTGA TCCACAACAA CTTCGGAGTG CTCTTCCATA 240 ACCTGCCCTC CCTCACGCTG GGCAATGTGT TTGTCATCGT GGGCTCTATT ATCATGGTAG 300 TTGCCTTCCT GGGCTGCATG GGCTCTATCA AGGAAAACAA GTGTCTGCTT ATGTCGTTCT 360 TCATCCTGCT GCTGATTATC CTCCTTGCTG AGGTGACCTT GGCCATCCTG CTCTTTGTAT 420 ATGAACAGAA GCTGAATGAG TATGTGGCTA AGGGTCTGAC CGACAGCATC CACCGTTACC 480 ACTCAGACAA TAGCACCAAG GCAGCGTGGG ACTCCATCCA GTCATTTCTG CAGTGTTGTG 540 GTATAAATGG CACGAGTGAT TTGGACAGTG GCTCACCAGC ATCTTGCCCC TCAGATCGAA 600 AAGTGGAGGG GTGCTATGCG AAAGAAGACT TTGGTTTCAT TCAATTTCCT GTATATCGGA 660 ATCATCACCA TCTGTGTATG TGTGATTGAG GTGTTGGGGG ATGTCCTTTG CACTGACCCT 720 GAACTGCCAG ATTGACAAAA CCAGCCAGAC CATAGGGCTA TGATCTGCAG TAGTTCTGTG 780 GTGAAGAGAC TTGTTTCATC TCCGGAAATG CAAAACCATT TATAGCATGA AGCCCTACAT 840 GATCACTGCA GGATGATCCT CCTCCCATCC TTTCCCTTTT TAGGTCCCTG TCTTATACAA 900 CCAGAGAAGT GGGTGTTGGC CAGGCACATC CCATCTCAGG CAGCAAGACA ATCTTTCACT 960 CACTGACGGC AGCAGCCATG TCTCTCAAAG TGGTGAAACT AATATCTGAG CATCTTTTAG 1020 ACAAGAGAGG CAAAGACAAA CTGGATTTAA TGGCCCAACA TCAAAGGGTG AACCCAGGAT 1080 ATGAATTTTT GCATCTTCCC ATTGTCGAAT TAGTCTCCAG CCTCTAAATA ATGCCCAGTC 1140 TTCTCCCCAA AGTCAAGCAA GAGACTAGTT GAAGGGAGTT CTGGGGCCAG GCTCACTGGA 1200 CCATTGTCAC AACCCTCTGT TTCTCTTTGA CTAAGTGCCC TGGCTACAGG AATTACACAG 1260 TTCTCTTTCT CCAAAGGGCA AGATCTCATT TCAATTTCTT TATTAGAGGG CCTTATTGAT 1320 GTGTTCTAAG TCTTTCCAGA AAAAAACTAT CCAGTGATTT ATATCCTGAT TTCAACCAGT 1380 CACTTAGCTG ATAATCACAG TAAGAAGACT TCTGGTATTA TCTCTCTATC AGATAAGATT 1440 TTGTTAATGT ACTATTTTAC TCTTCAATAA ATAAAACAGT TTATTATCTC AAAAAAAAAA 1500 AAAAAAAAAA AAAAAAAAAA AAAAAAAAA 1529 (2) INFORMATION FOR SEQ ID NO: 80: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4387 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: BEPINOT01 (B) CLONE: 546656 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 80 : GCATCCCCGC TTCCGGGTTA GGCCGTTCCT GCCCGCCCCC TCCTCTCCTC CCTTCGGACC 60 CATAGATCTC AGGCTCGGCT CCCCGCCCGC CGCAGCCCAC TGTTGACCCG GCCCGTACTG 120 CGGCCCCGTG GCCACCATGT CCCTGCACGG CAAACGGAAG GAGATCTACA AGTATGAAGC 180 GCCCTGGACA GTCTACGCGA TGAACTGGAG TGTGCGGCCC GATAAGCGCT TTCGCTTGGC 240 GCTGGGCAGC TTCGTGGAGG AGTACAACAA CAAGGTTCAG CTTGTTGGTT TAGATGAGGA 300 GAGTTCAGAG TTTATTTGCA GAAACACCTT TGACCACCCA TACCCCACCA CAAAGCTCAT 360 GTGGATCCCT GACACAAAAG GCGTCTATCC AGACCTACTG GCAACAAGCG GTGACTATCT 420 CCGTGTGTGG AGGGTTGGTG AAACAGAGAC CAGGCTGGAG TGTTTGCTAA ACAATAATAA 480 GAACTCTGAT TTCTGTGCTC CCCTGACCTC CTTTGACTGG AATGAGGTGG ATCCTTATCT 540 TTTAGGTACC TCAAGCATTG ATACGACATG CACCATCTGG GGGCTGGAGA CAGGGCAGGT 600 GTTAGGGCGA GTGAATCTCG TGTCTGGCCA CGTGAAGACC CAGCTGATCG CCCATGACAA 660 AGAGGTCTAT GATATTGCAT TTAGCCGGGC CGGGGGTGGC AGGGACATGT TTGCCTCTGT 720 GGGTGCTGAT GGCTCGGTGC GGATGTTTGA CCTCCGCCAT CTAGAACACA GCACCATCAT 780 TTACGAAGAC CCACAGCATC ACCCACTGCT TCGCCTCTGC TGGAACAAGC AGGACCCTAA 840 CTACCTGGCC ACCATGGCCA TGGATGGAAT GGAGGTGGTG ATTCTAGATG TCCGGGTTCC 900 CTGCACACCT GTCGCCAGGT TAAACAACCA TCGAGCATGT GTCAATGGCA TTGCTTGGGC 960 CCCACATTCA TCCTGCCACA TCTGCACTGC AGCGGATGAC CACCAGGCTC TCATCTGGGA 1020 CATCCAGCAA ATGCCCCGAG CCATTGAGGA CCCTATCCTG GCCTACACAG CTGAAGGAGA 1080 GATCAACAAT GTGCAGTGGG CATCAACTCA GCCCGACTGG ATCGCCATCT GCTACAACAA 1140 CTGCCTGGAG ATACTCAGAG TGTAGTGTTG GTGGCGCTGT GCCCACGAGG CAGGGGCTTT 1200 TGTATTTCCT GCCTCTGCCC CACCCCCAAA GTAAGAAGAA ACATGTTTCC AGTGGCCAGT 1260 ATGTCTTTCA TTGCTTTGCA CCCACTGTTA CCAGAAGCTG CTCTAGGAGT TCCTGGCCAG 1320 TCACCCCATC GCCCTCTGTG GCAGACTCAG TGCTGTGTGG CGCCTCCTCA GCCCAGGGCT 1380 GAGTTTTAAG ATTTTCTCTC CTTTCCTCTT CTCCTTTGGT TCCTCAATTA AAAAATGTGT 1440 GTATATTTGT TTGTCAGGCG TTGTGTTGAG GAGCAGTTCA CGCACTGGCT GTGTCTATTC 1500 CTCTGCCCAG GTGTCTCTGT TTGCTGCCCA AGGCAGCAGT TCATGTCTCG TCCATGTCCA 1560 TGTTCGTGTT AGCACTTACG TGGGAACAAA TACCAATTTG TCTTTTCTCC TAGTATCAGT 1620 GTGTTTAACA AATTTTAACT TTGTATATTT GTTATCTATC AGGCTAATTT TTTTATGAAA 1680 AGAATTTTAC TCTCCTGCTT CATTTCTTTG TCTTATAGTC CTCCCTCTTT GCACCTTCTT 1740 CTCTTCCCTC AGTGCCTGGA GCTGGTACTG GGCCCCTGGG CCCCATGAGC AGTTTGCCTT 1800 CTTGAGTCAC TGCCTGTGTA GTACATACCT GACCGGGAGT CCAAACCACC TTGGTGCTCT 1860 GAAGTCCACT GACTCATCAC ACCTTTCTTA GCCTGGCTCC TCTCAAGGGC ATTCTGGGCT 1920 TGTAAACAGA CATAGGAAGC CTCTGTTTAC CCTGAAGCAC CACTGTCCAG CCCATTGGTT 1980 CCCACTGGCA GCATGGTAGA GCTGAGAGAA ACAGGCTCTC AGGGTACCTG ACTTGAGGGG 2040 AATCGTTTCA TGAAGCTGAA CTTCAAGCAT ATTTCCAGTA CATTCTTTCA GAGTCTGTTT 2100 TTCCATCCAA ATATAAGCCC CAGGCCATTC CACTTAGTGT CTTTTCAATG ATAGGCAAGA 2160 ATGATATCTG AGTTGAACTT CGGTGCTTCT GTTGTTTGAG TTTACTGTGC CTGGTGGTAT 2220 ATTGGGCATT CTTTGGATTG AGTGTTCTGA GGTGAGAGAG TCTTCCCGAG GCATCCTGTC 2280 TGTGCTTCCA ACCCTGAACA AGACCTTACA TGAGAGATGG ACTGATGGAC TGCGGCAATC 2340 CTGGGCTGTC AAGTGGATAG ATAGTTAAAA AGCATTATAC TGTGGGTAAT GAAAAGGGAG 2400 GAAAAAAAAA GAAGGAAAAG GAATTATAGA CCCCCAGGGT CAGCCAGTTA AGAGCTCTAC 2460 CCACACCTGT CAACCCCTCT CTCCCCCAGT TTAGGTTCTG AGCAGTATTG GACTTGTAGC 2520 CTGCAGTTGT CTTTTGACTT GCAGGCCGCA GGTGTCTTTC TGTTATGTGA ATGAGTTCCA 2580 TGGAGGGGCA TATGTGTGAT TCCACCGTTA GATGAGCCCT TGGGGCAGGC AGTTTGGGAT 2640 GTGCTCTTGG GGGAAAGTTG GCTGTTTCCT TGCGCTCTGC TCCTACCCGA AGGTTTTTAA 2700 GTCCCTCTGA ATTGCTCATC TGAGATTAGT AGAGTAGCAG GCCTGAAGGA TGATGGTTTT 2760 GTCCTCTTTG GTTCTCACCT GCTTGAGAAG TAAAACAGTA ACTTTGTTCT TCTGGGCCCT 2820 TAAGCTTTTT TGGTTAAGTC TTCCTTTTCA GAAGTAGATG TCATTATATG CCAAAAGTCT 2880 AGCTCTTTGC TTTACCATAC AGGGACCTGT CCCAAAGAAA AAGGCTCTTT TTTTAGCCAG 2940 CATATTTCCC CTTCTACCCT TTTACTTTGT TGTTCTGATT TTAGGACTCT GGCTGGCCAT 3000 GTGCTTGTGG TTGCCTCTCC TGCATTTGCC ACTGGATTTG CACTGCATCG TTTGGAGATA 3060 CAAAGCGAGC AGTTCTTGGT CAGAACCCTC CTCTGCTTTT CATTGTGTTT GATAATGGTT 3120 ACTGGGTCCT TCTCTCAAGG GTAGCAAGGC CAAGCTGATG GCTGCTTGTT TAGGAGGCCA 3180 TCAGTTCCTT CCTGTGGAGA AGGGTCTGAA ATGGAAGTCA GTGGTAGAAG GGGCTGGTCT 3240 GCTGGGCAGG GCTTACATCC ACTGAGTTCT AAGATTCCTT TCCTGATCTG CACCTACGCC 3300 TGGTCTGTAT GGTGGAATTT GTCAGCTGGA ACTCAGAAAC AACAACTTGA AAAAAAAATA 3360 ATAATTAGAA CATATTTGCA TAAGATAGCT ATTTACTCTG GAAACCAACA ACTTTTGAGA 3420 TTTCCCTTGC CCTGTGGACG CCCAGCTCCT GTCATCCTTC CTTAGGTCCT GCAGTACAGT 3480 CTTCCCCTGA ATGCCACCGG GGACCCAGGG GGACTCCACC CCCCTAAGCA AGCACACACA 3540 TACTCACAGT TGATGAGTTG CTGGTCTTTG AGTCCCAGCT CTCTTACCCT CCCTTTACTC 3600 CACCAGCCCG ACGACCCATG ACTGAGGAGG GGATTTCTAC AGTCTCAGGA TTTAGAAAGT 3660 CTGTAAGCCA TCCATGCTCC AGAAAGCACC GATCTGTTGT AGTTGCAAAA ACAACTCTGT 3720 AATTTGTTGA GGTTCTCAAA CTGACAGCCA GCGAGACTGG GTGGGAGGCC CTGGATCTGT 3780 TCTCCCTGAC TGCGGGAGGA GCAGCCACTA GGACTTTAGC AGGAAGCCCA CATGGAGGCT 3840 CCGCCAGGCT GTGGCCCAGC TGGTGATGGC CCTTTTGCTC CTGGCAGCCT GAGGCACAGC 3900 TGCCTGTATT GTCCTCATCT GTTCTGACTG AAGGATGGAG GTGCTGAATA AATTAGGCCT 3960 CAGGCCTCTA CCACCAGAGA GCTGGAGAAT GGGTCCACGT CATTCAAGGA CCTGAATTTT 4020 TTATGCTCAG GAGCATTGGA ATCCTCTTCT TCCAGGGAGG AATTAGCCTG CAAGGTTAGG 4080 ACTTGAAGAG GGAAGGTATT TAATAACTGG GCGAGGATGG GTGTGGTGGC TCACACCTGT 4140 AATCCCAGCA TTTTGGGAGG CTGAGGTGGC CAGATCCCAA GGTCAGAAGA TCGAGACCAT 4200 CCTGGCTAAC ATGGTGAAAC CCCATCTCTA CTAAAAATAC AAAAAAAAAT TAGCCGGGGG 4260 TGGTGGCGGG TACCTGTAGT CCTAGCTACT TGGGAGGCTG AGGCAGGAGA ATGGCGTGAA 4320 CCTGGGAGGT GGAGCTTGCA GTGAGCCAAG ATCGTCCACT CACTGCAGCC TGGCGACAGA 4380 GCAAGCG 4387 (2) INFORMATION FOR SEQ ID NO: 81: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2117 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: SYNORAT03 (B) CLONE: 693453 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 81 : GCCTGAGCGG GAAGCATTGG CGTCCGAGCG ACTTCTAGGA GCCTGGGGTT CGGCGCTATG 60 GAGGAGCTCG ATGGCGAGCC AACAGTCACT TTGATTCCAG GCGTGAATTC CAAGAAGAAC 120 CAAATGTATT TTGACTGGGG TCCAGGGGAG ATGCTGGTAT GTGAAACCTC CTTCAACAAA 180 AAAGAAAAAT CAGAGATGGT GCCAAGTTGC CCCTTTATCT ATATCATCCG TAAGGATGTA 240 GATGTTTACT CTCAAATCTT GAGAAAACTC TTCAATGAAT CCCATGGAAT CTTTCTGGGC 300 CTCCAGAGAA TTGACGAAGA GTTGACTGGA AAATCCAGAA AATCTCAATT GGTTCGAGTG 360 AGTAAAAACT ACCGATCAGT CATCAGAGCA TGTATGGAGG AAATGCACCA GGTTGCAATT 420 GCTGCTAAAG ATCCAGCCAA TGGCCGCCAG TTCAGCAGCC AGGTCTCCAT TTTGTCAGCA 480 ATGGAGCTCA TCTGGAACCT GTGTGAGATT CTTTTTATTG AAGTGGCCCC AGCTGGCCCT 540 CTCCTCCTCC ATCTCCTTGA CTGGGTCCGG CTCCATGTGT GCGAGGTGGA CAGTTTGTCG 600 GCAGATGTTC TGGGCAGTGA GAATCCAAGC AAACATGACA GCTTCTGGAA CTTGGTGACC 660 ATCTTGGTGC TGCAGGGCCG GCTGGATGAG GCCCGACAGA TGCTCTCCAA GGAAGCCGAT 720 GCCAGCCCCG CCTCTGCAGG CATATGCCGA ATCATGGGGG ACCTGATGAG GACAATGCCC 780 ATTCTTAGTC CTGGGAACAC CCAGACACTG ACAGAGCTGG AGCTGAAGTG GCAGCACTGG 840 CACGAGGAAT GTGAGCGGTA CCTCCAGGAC AGCACATTCG CCACCAGCCC TCACCTGGAG 900 TCTCTCTTGA AGATTATGCT GGGAGACGAA GCTGCCTTGT TAGAGCAGAA GGAACTTCTG 960 AGTAATTGGT ATCATTTCCT AGTGACTCGG CTCTTGTACT CCAATCCCAC AGTAAAACCC 1020 ATTGATCTGC ACTACTATGC CCAGTCCAGC CTGGACCTGT TTCTGGGAGG TGAGAGCAGC 1080 CCAGAACCCC TGGACAACAT CTTGTTGGCA GCCTTTGAGT TTGACATCCA TCAAGTAATC 1140 AAAGAGTGCA GCATCGCCCT GAGCAACTGG TGGTTTGTGG CCCACCTGAC AGACCTGCTG 1200 GACCACTGCA AGCTCCTCCA GTCACACAAC CTCTATTTCG GTTCCAACAT GAGAGAGTTC 1260 CTCCTGCTGG AGTACGCCTC GGGACTGTTT GCTCATCCCA GCCTGTGGCA GCTGGGGGTC 1320 GATTACTTTG ATTACTGCCC CGAGCTGGGC CGAGTCTCCC TGGAGCTGCA CATTGAGCGG 1380 ATACCTCTGA ACACCGAGCA GAAAGCCCTG AAGGTGCTGC GGATCTGTGA GCAGCGGCAG 1440 ATGACTGAAC AAGTTCGCAG CATTTGTAAG ATCTTAGCCA TGAAAGCCGT CCGCAACAAT 1500 CGCCTGGGTT CTGCCCTCTC TTGGAGCATC CGTGCTAAGG ATGCCGCCTT TGCCACGCTC 1560 GTGTCAGACA GGTTCCTCAG GGATTACTGT GAGCGAGGCT GCTTTTCTGA TTTGGATCTC 1620 ATTGACAACC TGGGGCCAGC CATGATGCTC AGTGACCGAC TGACATTCCT GGGAAAGTAT 1680 CGCGAGTTCC ACCGTATGTA CGGGGAGAAG CGTTTTGCCG ACGCAGCTTC TCTCCTTCTG 1740 TCCTTGATGA CGTCTCGGAT TGCCCCTCGG TCTTTCTGGA TGACTCTGCT GACAGATGCC 1800 TTGCCCCTTT TGGAACAGAA ACAGGTGATT TTCTCAGCAG AACAGACTTA TGAGTTGATG 1860 CGGTGTCTGG AGGACTTGAC GTCAAGAAGA CCTGTGCATG GAGAATCTGA TACCGAGCAG 1920 CTCCAGGATG ATGACATAGA GACCACCAAG GTGGAAATGC TGAGACTTTC TCTGGCACGA 1980 AATCTTGCTC GGGCAATTAT AAGAGAAGGC TCACTGGAAG GTTCCTGAGA ACTGCTTCAA 2040 TGTGGTATCT TTGTATGGCA ATGTATATAG ATTTTTTAAA AGAATAAATG TTGTTTGCAA 2100 AAAAAAAAAA AAAAAAA 2117 (2) INFORMATION FOR SEQ ID NO: 82: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 846 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: BRAITUT03 (B) CLONE: 866885 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 82 : GGCGGGCGGA GTCTGCAGGA TGGCACCGGA CCCCTGGTTC TCCACATACG ATTCTACTTG 60 TCAAATTGCC CAAGAAATTG CTGAGAAAAT TCAACAACGA AATCAATATG AAAGAAAAGG 120 TGAAAAGGCA CCAAAGCTTA CCGTGACAAT CAGAGCTTTG TTGCAGAACC TGAAGGAAAA 180 GATCGCCCTT TTGAAGGACT TATTGCTAAG AGCTGTGTCA ACACATCAGA TAACACAGCT 240 TGAAGGGGAC CGAAGACAGA ACCTCTTGGA TGATCTTGTA ACTCGAGAGA GACTACTTCT 300 GGCATCCTTT AAGAATGAGG GTGCCGAACC AGATCTAATC AGGTCCAGCC TGATGAGTGA 360 AGAGGCTAAG CGAGGAGCAC CCAACCCTTG GCTCTTTGAG GAGCCAGAGG AGACCAGAGG 420 CTTGGGTTTT GATGAAATCC GGCAACAGCA GCAGAAAATT ATCCAAGAAC AGGATGCAGG 480 CCTTGATGCC CTTTCCTCTA TCATAAGTCG CCAAAAACAA ATGGGGCAGG AAATTGGGAA 540 TGAATTGGAT GAACAAAATG AGATAATTGA CGACCTTGCC AACCTAGTGG AGAACACAGA 600 TGAAAAACTT CGCAATGAAA CCAGGCGGGT AAACATGGTG GACAGAAAGT CAGCCTCTTG 660 TGGGATGATC ATGGTGATTT TACTGCTGCT TGTGGCTATC GTGGTTGTTG CAGTCTGGCC 720 GACCAACTGA TGGCAGTAAA GAGACCACCA GCAGTGACAC CTGGCAATGA CAGATGCAAG 780 CCCAACACCC TTTTGGTACG CAAAACCTGC TCTCAATAAA TTCCCCCAAA GCTCTGAAAA 840 AAAAAA 846 (2) INFORMATION FOR SEQ ID NO: 83: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1011 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: LUNGNOT03 (B) CLONE: 1242271 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 83 : GAAAGAGATA ACTGGAAGTT CCTTGATTCA GAAAACAGAT TCAGATGAAG AAGTTGCAAT 60 GCTGTTGGAC ACAGTCCAGA AAGTATTTCA GAAAATGTTG GAATGTATTG CACGGAGCTT 120 CAGGAAGCAG CCGGAAGAAG GCCTGCGGCT GCTTTATTCT GTTCAGAGGC CTCTTCATGA 180 GTTCATTACT GCTGTTCAGT CTCGGCACAC AGACACCCCT GTGCACCGGG GTGTACTTTC 240 TACTCTGATC GCTGGGCCTG TGGTTGAGAT AAGTCACCAG CTACGGAAGG TTTCTGACGT 300 AGAAGAGCTT ACCCCTCCAG AGCATCTTTC TGATCTTCCA CCATTTTCAA GGTGTTTAAT 360 AGGAATAATA ATAAAGTCTT CGAATGTGGT CAGGTCATTT TTGGATGAAT TAAAGGCATG 420 TGTGGCTTCT AATGATATTG AAGGCATTGT GTGCCTCACG GCTGCTGTGC ATATTATCCT 480 GGTTATTAAT GCAGGTAAAC ATAAAAGCTC AAAAGTGAGG GAGGTTGCAG CCACTGTTCA 540 CAGAAAACTA AAGACATTCA TGGAAATTAC TTTGGAAGAG GATAGCATTG AAAGATTTCT 600 CTATGAATCA TCATCAAGAA CTCTGGGAGA ACTTTTGAAT TCATAACCAA GCCAACATCT 660 CCAGACATGT AAAAATAGGG AAAAGTGATT CAAATTGAAA TGCCTGTGTA TTTTCCTATT 720 GTTTTTAATG TTAATAACCC ATATAATAGG GAAAGGGTGG GATTTTTTTG TGGGAATGTG 780 GGAAGGTGGG GGTTATGGAG GAGATAACTC AAAACTTCTT CAATTTTGCC TAGTGCCTGC 840 GTAAATAATA TATTTAATAT AAAGGACTCC AGGTATGAAT GGTGTAGAAA TCCATGATTC 900 CAAGAAAAAA CACTTTTCTA GCAAACCTGG TTGTTTTTAA AATGACTTTT ATATATGTAA 960 TATTGCTTGG AAACTATGAG TAATAAAGCA ATGACAACAT CAAAAAAAAA A 1011 (2) INFORMATION FOR SEQ ID NO: 84: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2478 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: LUNGFET03 (B) CLONE: 1255027 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 84 : CCCACGCGTC CGCCCACGCG TCCGCAGCGC TGTGTTTGCG AGCGGGAGCG AGGGGCGCCG 60 GCTGGGGTGT GTGCTCCTGA GCTCTTCAGA AACCAGGCTG CTTTCAGGAA CATTGCTGTG 120 GATTCCCAGC TTTCAGACAA CACATGACTA AGACAGATGA GACCACTCTA GTTGCCTCAT 180 GGGAAACTCG GGAAAAGACT GCAAAAACAA CATTGTTTCT CCCTTTGGAA TTCTGGAGTT 240 ATAAGGCAGA GGTCCCCCAT CTTCCCGAAC TGGCCTATTC CGCTAGAAGC AAGATGGCTG 300 AACTCAATAC TCATGTGAAT GTCAAGGAAA AGATCTATGC AGTTAGATCA GTTGTTCCCA 360 ACAAAAGCAA TAATGAAATA GTCCTGGTGC TCCAACAGTT TGATTTTAAT GTGGATAAAG 420 CCGTGCAAGC CTTTGTGGAT GGCAGTGCAA TTCAAGTTCT AAAAGAATGG AATATGACAG 480 GCAAAAAGAA GAACAATAAA AGAAAAAGAA GCAAGTCCAA GCAGCATCAA GGCAACAAAG 540 ATGCTAAAGA CAAGGTGGAG AGGCCTGAGG CAGGGCCCCT GCAGCCGCAG CCACCACAGA 600 TTCAAAACGG CCCCATGAAT GGCTGCGAGA AGGACAGCTC GTCCACAGAT TCTGCTAACG 660 AAAAACCAGC CCTTATCCCT CGTGAGAAAA AGATCTCGAT ACTTGAGGAA CCTTCAAAGG 720 CACTTCGTGG GGTCACAGAA GGCAACAGAC TACTGCAACA GAAACTATCC TTAGATGGGA 780 ACCCCAAACC TATACATGGA ACAACAGAGA GGTCAGATGG CCTACAGTGG TCAGCTGAGC 840 AGCCTTGTAA CCCAAGCAAG CCTAAGGCAA AAACATCTCC TGTTAAGTCC AATACCCCTG 900 CAGCTCATCT TGAAATAAAG CCAGATGAGT TGGCAAAGAA AAGAGGCCCA AATATTGAGA 960 AATCAGTGAA GGATTTGCAA CGCTGCACCG TTTCTCTAAC TAGATATCGC GTCATGATTA 1020 AGGAAGAAGT GGATAGTTCC GTGAAGAAGA TCAAAGCTGC CTTTGCTGAA TTACACAACT 1080 GCATCATTGA CAAAGAAGTT TCATTAATGG CAGAAATGGA TAAAGTTAAA GAAGAAGCCA 1140 TGGAAATCCT GACTGCTCGT CAGAAGAAAG CAGAAGAACT AAAGAGACTC ACTGACCTTG 1200 CCAGTCAGAT GGCAGAGATG CAGCTGGCCG AACTCAGGGC AGAAATTAAG CACTTTGTCA 1260 GCGAGCGTAA ATATGACGAG GAGCTCGGGA AAGCTGCCCG GTTTTCCTGT GACATCGAAC 1320 AGCTGAAGGC CCAAATCATG CTCTGCGGAG AAATTACACA TCCAAAGAAC AACTATTCCT 1380 CAAGAACTCC CTGCAGCTCC CTGCTGCCTC TGCTGAATGC GCACGCAGCA ACCTCTGGGA 1440 AACAGAGTAA CTTTTCCCGA AAATCATCCA CTCACAATAA GCCCTCTGAA GGCAAAGCGG 1500 CAAACCCCAA AATGGTGAGC AGTCTCCCCA GCACCGCCGA CCCCTCTCAC CAGACCATGC 1560 CGGCCAACAA GCAGAATGGA TCTTCTAACC AAAGACGGAG ATTTAATCCA CAGTATCATA 1620 ACAACAGGCT AAATGGGCCT GCCAAGTCGC AGGGCAGTGG GAATGAAGCC GAGCCACTGG 1680 GAAAGGGCAA CAGCCGCCAC GAACACAGAA GACAGCCGCA CAACGGCTTC CGGCCCAAAA 1740 ACAAAGGCGG TGCCAAAAAT CAAGAGGCTT CCTTGGGGAT GAAGACCCCC GAGGCCCCGG 1800 CCCATTCTGA AAAGCCCCGG CGAAGGCAGC ACGCTGCAGA CACCTCGGAG GCCAGGCCCT 1860 TCCGGGGTAG TGTCGGTAGG GTTTCACAGT GCAATCTCTG CCCCACGAGA ATAGAAGTTT 1920 CCACAGATGC AGCAGTTCTC TCAGTCCCGG CTGTGACGTT GGTGGCCTGA GCTAGGAGGA 1980 AAAAGAGCAG TTTTCACTCA GTTTTGGTTC CCTGCCCGAG GTGCTGACCC AATTCGCTGC 2040 CAAAAGAGTG TCAATCAGAA TATACAAATC CCGTATGGTT GTGTCATCCT CTCTTAATCA 2100 TTTTTACTAA TTCTAATAAT CAGCTCTAGC TTGCTTCATA ATTTTCATGG CTTTGCTTGA 2160 TCTGTTGATG CTTTCTCTCA TCAAGACTTT GCAGCATTTT AGCCAGGCAG TATTTACTCA 2220 TTATTAGGAA AATCAAGATG TGGCTGAAGA TCAGAGGCTC AGTTAGCAAC CTGTGTTGTA 2280 GCAGTGATGT CAGTCCATTG ATTGTCTTTA GAGAGTTAAT GTTACAAAAA AGAATTCTTA 2340 ATAATCAGAC AAACATGATC TGCTGAGGAC ACATGCGCTT TTGTAGAATT TAACATCTGG 2400 TGTTTTTCTG AAAAAATATA TATACATATA TTGCTTTATT TGAAACAAAT TAAAATATGC 2460 TGCATTTGAA AAAAAAAA 2478 (2) INFORMATION FOR SEQ ID NO: 85: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1897 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: TESTTUT02 (B) CLONE: 1273453 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 85 : TGCACATCTA GCACAAATTG AAGATGATAG AGCTGCGATG GTTATTTCTT GGCATCTGGC 60 AAGTGACATG GACTGTGTAG TCACCCTAAC CACTGACGCT GCACGTCGTA TCTATGATGA 120 AACCCAAGGT CGTCAGCAGG TGTTGCCCCT TGATTCTATT TACAAGAAGA CTCTTCCAGA 180 TTGGAAAAGA TCTCTACCTC ATTTCCGAAA TGGAAAATTG TATTTTAAAC CCATTGGAGA 240 TCCAGTCTTT GCTCGAGACT TGTTAACATT TCCAGATAAT GTAGAACATT GTGAAACAGT 300 ATTTGGTATG CTGTTAGGAG ACACCATTAT TTTGGATAAT CTGGATGCGG CCAATCATTA 360 TAGAAAAGAG GTTGTTAAAA TTACACACTG TCCTACACTG CTGACCAGAG ATGGAGATCG 420 AATTCGAAGT AATGGAAAGT TTGGGGGCCT TCAGAATAAA GCTCCTCCAA TGGATAAACT 480 TCGGGGAATG GTATTTGGAG CTCCAGTTCC AAAACAGTGT CTGATCTTAG GGGAACAAAT 540 AGATCTTCTT CAGCAGTATC GTTCTGCTGT GTGCAAACTA GACAGTGTGA ATAAGGATCT 600 TAACAGTCAA TTAGAGTACC TTCGCACTCC GGATATGAGG AAGAAAAAGC AAGAACTTGA 660 TGAACATGAG AAAAATCTCA AACTAATAGA GGAAAAACTA GGTATGACTC CCATACGTAA 720 GTGTAATGAC TCATTGCGTC ATTCACCAAA GGTTGAGACG ACAGATTGTC CAGTTCCTCC 780 TAAAAGAATG AGACGAGAAG CTACAAGACA AAATAGGATT ATAACCAAAA CAGATGTATG 840 AGAGGTGACA GAGAGAAGAG GCCATTGGTC TCAGTAAGAA TGCCCTGCTT TCTGCATCTC 900 TGTTTCAGAA GACCAAGAGG GTGACTTACC AGACTGAGTA TTTCTGGGGA CAATACAAGT 960 ACCTGGGCAT GAATTTCCAT TTCGATTCAG ATGGGACTGG AAACAACCAT TCAATTTTAT 1020 GAATCTTACT GGACATTATG GATTTACTGG AATTATTCCA GACATTATGC CCTTTGGTTG 1080 TCACTACCTT GCAAATGTGT AAGAGGAAAA TGTGCTAATG TGGCAGTGAC TGTAAAACTG 1140 GCACATGGCA TTTATTAATC CTGAAGAAAA GTACATGTAC TATTTTTCAG TATAAATATA 1200 ATGAACATGT CAGAACTATT TCTTGAAAAC CTTTTTATTA CTTTTGCGTG AATTTATTTA 1260 ACAAAGATGT TTTGTCTTTT GTGTAAGGGA GGTTCTAGAG GCTAGATGTT TAATTGTAAA 1320 TATGTGAGGA AACTCAATGC AGAATTCAGG ATAAAAATTT TAAAAGCACA GGTATTTGGG 1380 AATTGAAATG TTAAGATACC CAGAACAACA TTAAATCAAT GAGTGAACTT GTGACAGTGG 1440 TAGCATTTCA AATTTCAAAA GACTTATCCT GTGTGTGTGT GTGTGTGTGT ATATATATAT 1500 ATATATATAT AAATATATAT ATATAAAATA TTCAGCAGCA CCAAGTTTTA TAACTATTGT 1560 TTGTTTGACT TTATTAATAC TAGAATATGT AGTCTCAGCC TTAATTTTAC ATTTACATTA 1620 TTTTGTAATT TTTTATTACT ATTTTTAAGG GGTTAAAGAG AACATACATT CTCACATTAG 1680 TGTACTTTCT GGTAGAAAGT TGCTGCAAAA ACATTTGAAA TGTATATTAA CCTAATGTAT 1740 GTCATATATA TGTCTTTGTG TAAGTTCAAG ACTATTGATC TGTGAAGTTA TTTTGTAAGG 1800 ACATACATTT GGTAAGTAAG TTTGTGTCCC AGGAAATGTA TGTGTTTTTA AACCCTTTCT 1860 AAATATGCAG GCCATTAATA AATAAGATTG TGTCTCA 1897 (2) INFORMATION FOR SEQ ID NO: 86: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1488 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: TESTTUT02 (B) CLONE: 1275261 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 86 : CCCACGCGTC CGGGGACATC CTGTTCTGAG TCAAGATTCC TCCTTCTGAA CATGGGACTT 60 TCCAGAAGGA CCACAGCTCC TCCCGTGCAT CCACTCGGCC TGGGAGGTTC TGGATTTTGG 120 CTGTCGAGGG AGTTTGCCTG CCTCTCCAGA GAAAGATGGT CATGAGGCCC CTGTGGAGTC 180 TGCTTCTCTG GGAAGCCCTA CTTCCCATTA CAGTTACTGG TGCCCAAGTG CTGAGCAAAG 240 TCGGGGGCTC GGTGCTGCTG GTGGCAGCGC GTCCCCCTGG CTTCCAAGTC CGTGAGGCTA 300 TCTGGCGATC TCTCTGGCCT TCAGAAGAGC TCCTGGCCAC GTTTTTCCGA GGCTCCCTGG 360 AGACTCTGTA CCATTCCCGC TTCCTGGGCC GAGCCCAGCT ACACAGCAAC CTCAGCCTGG 420 AGCTCGGGCC GCTGGAGTCT GGAGACAGCG GCAACTTCTC CGTGTTGATG GTGGACACAA 480 GGGGCCAGCC CTGGACCCAG ACCCTCCAGC TCAAGGTGTA CGATGCAGTG CCCAGGCCCG 540 TGGTACAAGT GTTCATTGCT GTAGAAAGGG ATGCTCAGCC CTCCAAGACC TGCCAGGTTT 600 TCTTGTCCTG TTGGGCCCCC AACATCAGCG AAATAACCTA TAGCTGGCGA CGGGAGACAA 660 CCATGGACTT TGGTATGGAA CCACACAGCC TCTTCACAGA CGGACAGGTG CTGAGCATTT 720 CCCTGGGACC AGGAGACAGA GATGTGGCCT ATTCCTGCAT TGTCTCCAAC CCTGTCAGCT 780 GGGACTTGGC CACAGTCACG CCCTGGGATA GCTGTCATCA TGAGGCAGCA CCAGGGAAGG 840 CCTCCTACAA AGATGTGCTG CTGGTGGTGG TGCCTGTCTC GCTGCTCCTG ATGCTGGTTA 900 CTCTCTTCTC TGCCTGGCAC TGGTGCCCCT GCTCAGGGAA AAAGAAAAAG GATGTCCATG 960 CTGACAGAGT GGGTCCAGAG ACAGAGAACC CCCTTGTGCA GGATCTGCCA TAAAGGACAA 1020 TATGAACTGA TGCCTGGACT ATCAGTAACC CCACTGCACA GGCACACGAT GCTCTGGGAC 1080 ATAACTGGTG CCTGGAAATC ACCATGGTCC TCATATCTCC CATGGGAATC CTGTCCTGCC 1140 TCGAAGGAGC AGCCTGGGCA GCCATCACAC CACGAGGACA GGAAGCACCA GCACGTTTCA 1200 CACCTCCCCC TTCCCTCTCC CATCTTCTCA TATCCTGGCT CTTCTCTGGG CAAGATGAGC 1260 CAAGCAGAAC ATTCCATCCA GGACACTGGA AGTTCTCCAG GATCCAGATC CATGGGGACA 1320 TTAATAGTCC AAGGCATTCC CTCCCCCACC ACTATTCATA AAGTACTAAC CAACTGGCAC 1380 CAAGAAAAAA TCCTCACTAA CCGCATCATC CGACAACTAA TAATTCACAC TACATCCAAA 1440 CATCACTTAG GCGGCGGGGC CGCCGACTGG TTCCGGGCTT AGGGTGGG 1488 (2) INFORMATION FOR SEQ ID NO: 87: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1357 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: COLNNOT16 (B) CLONE: 1281682 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 87 : CCGACTTTGT AGCATTTTTA TTTAAGCTAA AACAGAGCAC ATGTATATGT ACATAAGACA 60 CATTAAATCT ATAAATACTA TTTATTCATT TTATATAAAC TAATGTAATG GAAAACAAAT 120 TCTTATGACT TTGTGGTTTT ATAGATGTTC TAGAAACTTT GTATGTAGGT ATCTACAAAA 180 TTAGTTCATT CCCCTGAATA TTTTTGCATT CATATTTTTG AGGTCTTGAT GTTTTCAGCC 240 TCTGGCGAAT CTTTTTCATT GAATTTGAAC CATTTGTAAA ATCTGTGATG CTGAAGCAGA 300 GTGTGTCACA AAGTGATGAG AACATTACTA AAATCCACGG ACGCACTGCG ACCTAAGGGC 360 TCAACGGCTG ACTCGGCAGC GGGCAGCCAC CCCACGCTCC CCTGCGGTCA CTCGCACACC 420 ACAGCCTGAA GCTCCCCCAG CGCCTGCACC TCGCACACAG CTAAGGTCAA AGTTCAAACG 480 CACTCCACAC GGAAGCTCAT TCTATACCCG AAGAGCAGTC TCAGAAAGCA AGATTACTTT 540 TGTGTTTTTT AAAAAATGAT TCTTTAATGT ATTTTTCTAA ACATTCTGAT TGGAAGTAGT 600 GGATTCCTAA ATGATTCCAA AGTCATCTGT AATTCTTCTG TTTTTGTTTT GTTCTGTCTT 660 TTCTTCATTT TGGCTTTGGG TGGGGGGAGG GGCAGGTGAC ACAAAGGATT TTTTTTTTTT 720 TTTTTTTTTA ATTTTTGGAA TCTTTTCCAA TAACCAGCTA AAGATTTGCA CTGAAATACA 780 ACTTGTATGC CTTTTGCATT TTTAAAGCCT GCTTCCTGGA TTTAAGCAGA GTGATAGTGT 840 TCAAAGAGCC AGTTCAGCCT GTAACATATT TGAAAAAGAT ATGTCTGCAC TTTGAGGTCC 900 CTTTTGAATG CCATTCACTA GACCTCTCAA GCATTTTGTT TCATTGCTAC ATCCAAGCGC 960 CTCACAAGTC CACAATGCGG GACAGCATCA AAAGCTCAAG ACTTTGGAAA AAGCTTGTGG 1020 GCTTGCACTG GGGGAGGGAA GGGAACAAAA TTTGTGTACT TCTTTGTTTA ATTTAGAAAT 1080 AAGGCATCCA AGAGATGCCA TTATTTTCTG TGTTTCAATT GTTGTGCCTT TGAGTTAAAC 1140 TGCATTTTTG TCTTTTGGTT GAAATCTGAA ATGTACTGTC CCAATATAAA ACAGTAATTA 1200 TTTGACCTTT GCACTGTTTG TCTGGTCCTT TTCAGTTTGA TTGCATATAA ATGTGGAACT 1260 TGATAGATCT CTATATTTTT AATGCACTTG TGATAAACTG GCAGCAGGGT TAGACATTAC 1320 TTTCAAAGCT TGAGGTAGAC CGAGTCAGCA TGCTAGA 1357 (2) INFORMATION FOR SEQ ID NO: 88: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2330 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: BRSTNOT07 (B) CLONE: 1298305 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 88 : CCTACTTGTT CCCACCTTGG GAGAGGACGA TGACTTGGGA GGGACGCGTG AAGGGAGAAG 60 GGGTCCTCCC ATGAGGCTGA GGATGGCCTG AACCTGGAGC AGCGGACCAG GCAGACGGGC 120 TGAAGTGGGG TCCCAAATTC CATGTCCAGA GGTGTGGGGA GCCTGCCTCC CTAGCTCCTG 180 GCCCCTGCCA GGGGCTTACA TCAAAACACC TCAGAGGGCT GCCCTCCAGA GGCTGCACCC 240 AGAACAGTGG GACATGAGCA GGGGTGTGGG CTTGGAGGGT GAAGAGGATG TGGTCCTATC 300 AGATGCTGGG CCTCCTCAGC CATAGCCCCC TGCTCCTACC CCCTGACTGG CTCTTGTGTC 360 CTCACCTCTC ACCCTCTCCT TCCTGGGAGG CCCTGGGAGG TGATCATTGA CACCCAGCCA 420 AGCAGACAGC TGCGGGTGCC CAAGCCCTTG CTGGGCCTGC GCGTGAGGAG TCCCACTGCT 480 TCTAAAGGAA GTCCTGGGCA GGAGGTGGCT TTGGTGGTTG GTTCCAAAGT TGAAAATGCT 540 TGCAGTTTGA CCTTAGAAGA AGTGGGAAGA AGAAGGAGCT CTACAGGGTC AGCTTTGTTT 600 GATTTGTCCA GTCTAAGAAG TCCCATTGCC AAAGCTTTCT GCAGGAGGGT GAATGCCGCA 660 GCTTGGCAGC CCCTGGGTTT CTCTTGGAAA TGGTCAGTTT CCCCTCAAAG TACCCAAAGT 720 AGCCTTGGCT TGAGTTTTTG TCCTTGCCTC CTTTTTAGAG AAGAGGGCAT TTAGACTGCA 780 TTTTCCTGGT TAAAGAAGGT TAAAGCAAAT GTTTATTGCC TTTTCTAGTG AACTAACTCG 840 TAGAGATGTT CTCAGCAGGA AGACAGTCTT AGCACTGTCA CTTAGCAGAT TGCACTTAAG 900 TCCCTTGTGC TGGCCAGATG GCGTGGCTGG TTGCCTTAAT ATGTCCCAGG ACCCCTGACA 960 GGGCTGCCTG GCCTCTCCCT CGTGCTCCTC AAGAGCCCAG TCCATACACT GTGGATGTCA 1020 TTGCTGTCGG GTTAGGAAGT CTTGTCCTAG AACGCCCTGG CTGGTATGAC CACAGTTCAT 1080 GGCGGCTCTT CTCGCTTGGG TCATGGTCAT CTTCCAGCAC CTGCTGTGCT GGGAAGGCCG 1140 AGGATGGGGG CCCAGCACTG TCCAGGCCTG CTGGGGCCTG GCTGGGAGTC CTGTGGGCAG 1200 CATGGAACAT GCAGCTGGGC TTCCTGTGAC CAGGCACCCT CTGGCACTGT TGCTTGCCCT 1260 GTGCCCTGGA CCTTTTCCTG CCCTTCTCCT TCCTCTGCTC CCTTGGGGCT ACCCCTTGGC 1320 CCCTCCTGGT CTGTGCAAAC TCCCTCAGGG AGCCCCCCTG CCCTGTAGCT CTCACTTAAC 1380 TTCCTAGGGG CTGCTGAGCC CACCCAGAGG TTGTTGGAGT TCAGCGGGGC AGCTTGTCTC 1440 CCTTGTCAGC AGGGGCGTAA GGGCTGGGTT TGGCCATACA AGGTTGGCTA CGCCCTCAAT 1500 CCCTGACCGT TCCAGGCACT GAGCTGGGCA CCCACGGAAG GACATGCTGT CCAGACTGTG 1560 ATGACTGCCA GCACAGGGCA TCTCGGGCTT GGCTGGTCTG CGAGGCCTTG CCCCTGTGGA 1620 ACTCTGGGTT CCTGTTTTCT CAGTCTTTTT GCGGCTTTGC TGTGGTTGGC AGCTGCCGTA 1680 CTCCAGGCTT GTGTCGGCCA CTCAGATGAG GGCTGTGGTG CGAGCCAGTG CAGGAGAGCT 1740 GCGCTTGGGA TTGTGCCCTC TCCTGTGTCT GTCCTCCGGA CCTACCCAGG TCTCCACCAT 1800 CAGGACCCTG TCTTTGGGTT TAGAAGACCA AGTATGGGGA AAACCAGACA CCAGCCTCTG 1860 CAGCAATGGG TCCCTCTAGC CTGTGGACAC CAGCTGGGGG ATCCAGGGTC AGGCCCCCTC 1920 CTCTCCCCAG TTTCCCTCTG CTGTGGGTTC TGGGCTGTCA TGTCTCCACC ACTTAAGGAT 1980 GTCTTTACAC TGACTTCAGG ATAGATGCTG GGATGCCTGG GCATGGCCAC ATGTTACATG 2040 TACAGAACTT TGTCTACAGC ACAAATTAAG TTATATAAAC ACAGTGACTG GTATTTAATG 2100 CTGATCTACT ATAAGGTATT CTATATTTAT ATGACTTCAG AGACGCGTAT GTAATAAAGG 2160 ACGCCCTCCC TCCAGTGTCC ACATCCAGTT CACCCCAGAG GGTCGGGCAG GTTGACATAT 2220 TTATTTTTGT CTATTCTGTA GGCTTCCATG TCCAGAATCC TGCTTAAGGT TTTAGGGTAC 2280 CTTCAGTACT TTTTGCAATA AAAGTATTTC CTATCCAAAA AAAAAAAAAA 2330 (2) INFORMATION FOR SEQ ID NO: 89: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2729 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: LUNGNOT12 (B) CLONE: 1360501 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 89 : CTACACCTTT TCCATTTGCT AATAAGGCCC TGCCAGGCTG GGAGGGAATT GTCCCTGCCT 60 GCTTCTGGAG AAAGAAGATA TTGACACCAT CTACGGGCAC CATGGAACTG CTTCAAGTGA 120 CCATTCTTTT TCTTCTGCCC AGTATTTGCA GCAGTAACAG CACAGGTGTT TTAGAGGCAG 180 CTAATAATTC ACTTGTTGTT ACTACAACAA AACCATCTAT AACAACACCA AACACAGAAT 240 CATTACAGAA AAATGTTGTC ACACCAACAA CTGGAACAAC TCCTAAAGGA ACAATCACCA 300 ATGAATTACT TAAAATGTCT CTGATGTCAA CAGCTACTTT TTTAACAAGT AAAGATGAAG 360 GATTGAAAGC CACAACCACT GATGTCAGGA AGAATGACTC CATCATTTCA AACGTAACAG 420 TAACAAGTGT TACACTTCCA AATGCTGTTT CAACATTACA AAGTTCCAAA CCCAAGACTG 480 AAACTCAGAG TTCAATTAAA ACAACAGAAA TACCAGGTAG TGTTCTACAA CCAGATGCAT 540 CACCTTCTAA AACTGGTACA TTAACCTCAA TACCAGTTAC AATTCCAGAA AACACCTCAC 600 AGTCTCAAGT AATAGGCACT GAGGGTGGAA AAAATGCAAG CACTTCAGCA ACCAGCCGGT 660 CTTATTCCAG TATTATTTTG CCGGTGGTTA TTGCTTTGAT TGTAATAACA CTTTCAGTAT 720 TTGTTCTGGT GGGTTTGTAC CGAATGTGCT GGAAGGCAGA TCCGGGCACA CCAGAAAATG 780 GAAATGATCA ACCTCAGTCT GATAAAGAGA GCGTGAAGCT TCTTACCGTT AAGACAATTT 840 CTCATGAGTC TGGTGAGCAC TCTGCACAAG GAAAAACCAA GAACTGACAG CTTGAGGAAT 900 TCTCTCCACA CCTAGGCAAT AATTACGCTT AATCTTCAGC TTCTATGCAC CAAGCGTGGA 960 AAAGGAGAAA GTCCTGCAGA ATCAATCCCG ACTTCCATAC CTGCTGCTGG ACTGTACCAG 1020 ACGTCTGTCC CAGTAAAGTG ATGTCCAGCT GACATGCAAT AATTTGATGG AATCAAAAAG 1080 AACCCCGGGG CTCTCCTGTT CTCTCACATT TAAAAATTCC ATTACTCCAT TTACAGGAGC 1140 GTTCCTAGGA AAAGGAATTT TAGGAGGAGA ATTTGTGAGC AGTGAATCTG ACAGCCCAGG 1200 AGGTGGGCTC GCTGATAGGC ATGACTTTCC TTAATGTTTA AAGTTTTCCG GGCCAAGAAT 1260 TTTTATCCAT GAAGACTTTC CTACTTTTCT CGGTGTTCTT ATATTACCTA CTGTTAGTAT 1320 TTATTGTTTA CCACTATGTT AATGCAGGGA AAAGTTGCAC GTGTATTATT AAATATTAGG 1380 TAGAAATCAT ACCATGCTAC TTTGTACATA TAAGTATTTT ATTCCTGCTT TCGTGTTACT 1440 TTTAATAAAT AACTACTGTA CTCAATACTC TAAAAATACT ATAACATGAC TGTGAAAATG 1500 GCAATGTTAT TGTCTTCCTA TAATTATGAA TATTTTTGGA TGGATTATTA GAATACATGA 1560 ACTCACTAAT GAAAGGCATT TGTAATAAGT CAGAAAGGGA CATAGGATTC ACATATCAGA 1620 CTGTTAGGGG GAGAGTAATT TATCAGTTCT TTGGTCTTTC TATTTGTCAT TCATACTATG 1680 TGATGAAGAT GTAAGTGCAA GGGCATTTAT AACACTATAC TGCATTCATT AAGATAATAG 1740 GATCATGATT TTTCATTAAC TCATTTGATT GATATTATCT CCATGCATTT TTTATTTCTT 1800 TTAGAAATGT AATTATTTGT TCTAGCAATC ATTGCTAACC TCTAGTTTGT AGAAAATCAA 1860 CACTTTATAA ATACATAATT ATGATATTAT TTTTCATTGT ATCACTGTTC TAAAAATACC 1920 ATATGATTAT AGCTGCCACT CCATCAGGAG CAAATTCTTC TGTTAAAAGC TAACTGATCA 1980 ACCTTGACCA CTTTTTTGAC ATGTGAGATC AAAGTGTCAA GTTGGCTGAG GTTTTTTGGA 2040 AAGCTTTAGA ACTAATAAGC TGCTGGTGGC AGCTTTGTAA CGTATGATTA TCTAAGCTGA 2100 TTTTGATGCT AAATTATCTT AGTGATCTAA GGGGCAGTTT AGTGAAGATG GAATCTTGTA 2160 TTTAAAATAG CCTTTTAAAA TTTGTTTTGT GGTGATGTAT TTTGACAACT TCCATCTTTA 2220 GGAGTTATAT AATCACCTTG ATTTTAGTTT CCTGATGTTT GGACTATTTA TAATCAAGGA 2280 CACCAAGCAA GCATAAGCAT ATCTATATTT CTGACTGGTG TCTCTTTGAG AAGGATGGGA 2340 AGTAGAAAAA AAAAAAAGAA AGAAAGGAAA GGAAGAGAGG AGAGAAGAAG GCAGGGATCT 2400 CCACTATGTA TGTTTTCACT TTAGAACTGT TGAGCCCATG CTTAATTTTA ATCTAGAAGT 2460 CTTTAAATGG TGAGACAGTG ACTGGAGCAT GCCAATCAGA GAGCATTTGT CTTCAGAAAA 2520 AAAAAAAATC TGAGTTTGAG ACTAGCCTGG CCAACATGTT GAAACCCCAT ATCTACTAAA 2580 AATACAAAAA TTAGCCTGGT GTGGTGGCGC ACGCCTGTAG TCCCAGCTAC TCTGGAGCCT 2640 GAGGAACGTG AATCGCTTGA ACCCAGAAGA CAGAGGTTGC AGTGAGCTGA GATGGCACTA 2700 TTGCACTCCA GACTGGTGAC ACACGCAGA 2729 (2) INFORMATION FOR SEQ ID NO: 90: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1386 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: LUNGNOT12 (B) CLONE: 1362406 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 90 : GGCCCCTGCA CTGCTCCTGA TCCCTGCTGC CCTCGCCTCT TTCATCCTGG CCTTTGGCAC 60 CGGAGTGGAG TTCGTGCGCT TTACCTCCCT TCGGCCACTT CTTGGAGGGA TCCCGGAGTC 120 TGGTGGTCCG GATGCCCGCC AGGGATGGCT GGCTGCCCTG CAGACCGCAG CATCCTTGCC 180 CCCCTGGCAT GGGATCTGGG GCTCCTGCTT CTATTTGTTG GGCAGCACAG CCTCATGGCA 240 GCTGAAAGAG TGAAGGCATG GACATCCCGG TACTTTGGGG TCCTTCAGAG GTCACTGTAT 300 GTGGCCTGCA CTGCCCTGGC CTTGCAGCTG GTGATGCGGT ACTGGGAGCC CATACCCAAA 360 GGCCCTGTGT TGTGGGAGGC TCGGGCTGAG CCATGGGCCA CCTGGGTGCC GCTCCTCTGC 420 TTTGTGCTCC ATGTCATCTC CTGGCTCCTC ATCTTTAGCA TCCTTCTCGT CTTTGACTAT 480 GCTGAGCTCA TGGGCCTCAA ACAGGTATAC TACCATGTGC TGGGGCTGGG CGAGCCTCTG 540 GCCCTGAAGT CTCCCCGGGC TCTCAGACTC TTCTCCCACC TGCGCCACCC AGTGTGTGTG 600 GAGCTGCTGA CAGTGCTGTG GGTGGTGCCT ACCCTGGGCA CGGACCGTCT CCTCCTTGCT 660 TTCCTCCTTA CCCTCTACCT GGGCCTGGCT CACGGGCTTG ATCAGCAAGA CCTCCGCTAC 720 CTCCGGGCCC AGCTACAAAG AAAACTCCAC CTGCTCTCTC GGCCCCAGGA TGGGGAGGCA 780 GAGTGAGGAG CTCACTCTGG TTACAAGCCC TGTTCTTCCT CTCCCACTGA ATTCTAAATC 840 CTTAACATCC AGGCCCTGGC TGCTTCATGC CAGAGGCCCA AATCCATGGA CTGAAGGAGA 900 TGCCCCTTCT ACTACTTGAG ACTTTATTCT CTGGGTCCAG CTCCATACCC TAAATTCTGA 960 GTTTCAGCCA CTGAACTCCA AGGTCCACTT CTCACCAGCA AGGAAGAGTG GGGTATGGAA 1020 GTCATCTGTC CCTTCACTGT TTAGAGCATG ACACTCTCCC CCTCAACAGC CTCCTGAGAA 1080 GGAAAGGATC TGCCCTGACC ACTCCCCTGG CACTGTTACT TGCCTCTGCG CCTCAGGGGT 1140 CCCCTTCTGC ACCGCTGGCT TCCACTCCAA GAAGGTGGAC CAGGGTCTGC AAGTTCAACG 1200 GTCATAGCTG TCCCTCCAGG CCCCAACCTT GCCTCACCAC TCCCGGCCCT AGTCTCTGCA 1260 CCTCCTTAGG CCCTGCCTCT GGGCTCAGAC CCCAACCTAG TCAAGGGGAT TCTCCTGCTC 1320 TTAACTCGAT GACTTGGGGC TCCCTGCTCT CCCGAGGAAG ATGCTCTGCA GGAAAATAAA 1380 AGTCAG 1386 (2) INFORMATION FOR SEQ ID NO: 91: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 542 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: LATRTUT02 (B) CLONE: 1405329 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 91 : CCCGGGCCAT GCAGCCTCGG CCCCGCGGGC GCCCGCCGCG CACCCGAGGA GATGAGGCTC 60 CGCAATGGCA CCTTCCTGAC GCTGCTGCTC TTCTGCCTGT GCGCCTTCCT CTCGCTGTCC 120 TGGTACGCGG CACTCAGCGG CCAGAAAGGC GACGTTGTGG ACGTTTACCA GCGGGAGTTC 180 CTGGCGCTGC GCGATCGGTT GCACGCAGCT GAGCAGGAGA GCCTCAAGCG CTCCAAGGAG 240 CTCAACCTGG TGCTGGACGA GATCAAGAGG GCCGTGTCAG AAAGGCAGGC GCTGCGAGAC 300 GGAGACGGCA ATCGCACCTG GGGCCGCCTA ACAGAGGACC CCCGATTGAC GCCGTGGAAC 360 GGCTCACACC GGCACGTGCT GCACCTGCCC ACCGTCTTCC ATCACCTGCC ACACCTGCTG 420 GCCAAGGAGA GCAGTCTGCA GCCCGCGGTG CGCGTGGGCC AGGGCCGCAC CGGAGTGTCG 480 GTGGTGATGG GCATCCCGAG CGTGCGGCGC GAGGTGCACT CGTACCTGAC TGACACTCTG 540 CA 542 (2) INFORMATION FOR SEQ ID NO: 92: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 772 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: BRAINOT12 (B) CLONE: 1415223 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 92 : CGAGCCCGGA GTGCGGACAC CCCCGGGATG CTTGCGCCCC AGAGGACCCG CGCCCCAAGC 60 CCCCGCGCCG CCCCCAGGCC CACCCGGAGC ATGCTGCCTG CAGCCATGAA GGGCCTCGGC 120 CTGGCGCTGC TGGCCGTCCT GCTGTGCTCG GCGCCCGCTC ATGGCCTGTG GTGCCAGGAC 180 TGCACCCTGA CCACCAACTC CAGCCATTGC ACCCCAAAGC AGTGCCAGCC GTCCGACACG 240 GTGTGTGCCA GTGTCCGAAT CACCGATCCC AGCAGCAGCA GGAAGGATCA CTCGGTGAAC 300 AAGATGTGTG CCTCCTCCTG TGACTTCGTT AAGCGACACT TTTTCTCAGA CTATCTGATG 360 GGGTTTATTA ACTCTGGGAT CTTAAAGGTC GACGTGGACT GCTGCGAGAA GGATTTGTGC 420 AATGGGGCGG CAGGGGCAGG GCACAGCCCC TGGGCCCTGG CCGGGGGGCT CCTGCTCAGC 480 CTGGGGCCTG CCCTCCTCTG GGCTGGGCCC TGATGTCTCC TGCTTCCCAC GGGGCTTCTG 540 AGCTTGCTCC CCTGAGCCTG TGGCTGCCCT CTCCCCAGCC TGGCGTGGCT GGGGCTGGGG 600 GCAGCCTTGG GCCAGCTCCG TGGCTGTGGC CTGTGGGTCT GAATTCTTCC CCGACGTGAA 660 GCCTNCCTGT CTCTCCGGCA GCTCTGAGTC CCAGGCAGCT GGACATTCCA GGGGAACAAG 720 CCATTNGGCA GGAGGGCTGG GATGAGGTTG GGGGGGACCG GAGGTCCCGG AG 772 (2) INFORMATION FOR SEQ ID NO: 93: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1738 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: BRAINOT12 (B) CLONE: 1416553 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 93 : TGTCCATCCA AAAACCATAA AATCACTGGG TTCCACATCA GCCTCCATGA GGCCAAGCCT 60 TGTACCTGCA AGCTCTTGGC CTAACCATTC CTCTGTCCTC TTCTCTGGCC TGCCTGGGGA 120 GCCCGTGAAG GCCGCACGGG TGCCTCCAGC CTGAGACATC AGGGGAGAGC CTGCAGCTGA 180 GTTCAGCAGA AAGGAGGAAT CCTGGCCCTC AGGAAGAAGA TAGTCACATG TTTTTCTTCC 240 TTGTCCCCAC AGCCCCCAGA ACAACATTCT CCCTGCTGGC AGCCCTTCCA TGTCTCCAAA 300 CCTGGGTCAG AGTGAAAGGA CCTTTGGGGG TGGGTGGGAG CAAAGGGCCC ACCTGCTGGT 360 TGGTGAAAGC AGTGGTGCCG GAGTGCTAGG TACCGCACGA GTAGTGGTGC GGGGGCTTGG 420 GAAGCAGACC AGGGTTGGAC AAAACCCCAT GAGGGCGGGG AGCTGGAAGA AAAGTCTCTT 480 GGGGACCTCT GGGGCAAGGA GCTGAGAAGT CCTGCAGCAC CAGGTGAGAC TTGCTTACAG 540 TGGATGCCAC TTCTAGGCCT CTGGACCGCA GATGCCCTCC TCCCTCCTGC ACACCTGGCC 600 TCCTGGGCCT CCAGGTAAAG AGAGAGAGCC AGCCCAGCCC TGTTTCCCCT CAGTCCTCCT 660 TTGCTCCTGC TGCTTCTCCC AACAGCCCAC TGTTAGGAGG TAGTAGACCC CAGCCTCAAG 720 GCTCTGACCT TCTTCATGTG GGCACAGAGG GTCCTGACAC TCTGGCAGGG CCTGAGCTGG 780 GGCAGGCCTC CCTCAGGGCC AGGGGCGATG GCACCCCGGG GACAGGCAGA CCTCCTTCCT 840 GCCGTCAGCA CCCCCTTCCT TATCACTGTC TGGTCTCCGA GCTTCGGCTG CAGCCTGAGG 900 TGTGTCCTGG GCTCCTCAGA GCCTGAAGCA AGCTTTTGGA AGCCTGCAGT CCTCCCAGCT 960 CCAGTGCAGA AGCCTCTCTC TCCAGCCTTT CCCCAGGCAG GAGTTGGGGT TGGGGGCCTC 1020 TGTCCCTCAT CGCTTACCTT GGAAAGGTGG GAAGCTGGCA ATCTGCACCT TGGGGCCTGG 1080 GCTCCCCCTC TCTGTGCCAG CGGCTTCCCA GCACCTGGGA GGGGCTGCAG CCCCAGCTGG 1140 ACTCCAGCCT GTCCCTCTTA GCACTCTAGC TGCCCACTCC AGGGCAGGGA CTCGAAACCC 1200 CCTCCGTCCT GAGCAGCCAC CTCCAGGGCC CTGTTTGGGA CCACTCTCTC AGTCCCCAGG 1260 TCCTCAGGGC CCCAGAGCGG GAGGGTCTCC TACCTGGAAG TCCCCCTGAG CTCCAGGGCC 1320 CAGCCCTACC TGCCAGTGCT GGTGTCAGGG CACTCAACAC CGAGTGTGGG GGCCACGCCC 1380 CTTGCCATGC CCACGGCCTC CTCCTGTAGC CCCTGCCTGC ACCCACGATG CTGCACGGGC 1440 CCGCCCTGGT GGGGCTCGGC GAGTAATGTG TTTTGTCCCC AGTTAACCAC CATTCTGCGG 1500 CCTGGTTCTG CAAGGAACCA GGGCTGCCCC ACCGCCCGCC GTCTGCCGCC CTAGGCTTCC 1560 TGACTCCATT AGTTCCGACA CTTGTGAAAC TCCGAGAAGT GCTGTGGTCT CAGCAATGCA 1620 CCTGTTTTGT ACATGATTGT GTAATTTAAA GGTATATAAA TACAAATATA TATATATATC 1680 AGTTGTGATT GTATGACTGT GGATAAAATC CAGAACTGTG TCAACCTGAA AAAAAAAA 1738 (2) INFORMATION FOR SEQ ID NO: 94: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2100 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: KIDNNOT09 (B) CLONE: 1418517 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 94 : GGGAAAGCGG CGAGTAAGAT GGAAGATGAG GAGGTCGCTG AGAGCTGGGA AGAGGCGGCA 60 GACAGCGGGG AAATAGACAG ACGGTTGGAA AAAAAACTGA AGATCACACA AAAAGAGAGC 120 AGGAAATCCA AATCTCCTCC CAAAGTGCCC ATTGTGATTC AGGACGATAG CCTTCCCGCG 180 GGGCCCCCTC CACAGATCCG CATCCTCAAG AGGCCCACCA GCAACGGTGT GGTCAGCAGC 240 CCCAACTCCA CCAGCAGGCC CACCCTTCCA GTCAAGTCCC TAGCACAGCG AGAGGCCGAG 300 TACGCCGAGG CCCGGAAGCG GATCCTGGGC AGCGCCAGCC CCGAGGAGGA GCAGGAGAAA 360 CCCATCCTCG ACAGGCCAAC CAGGATCTCC CAACCCGAAG ACAGCAGGCA GCCCAATAAT 420 GTGATCAGAC AGCCTTTGGG TCCTGATGGG TCTCAAGGCT TCAAACAGCG CAGATAAATG 480 CAGGCAAGAA AAGATGCCGC CGTTGCTGCC GTCACCGCCT CCTGGGTCGT CCGCCACGGG 540 TTGCACTGCC GTGGCAGACA GCTGGACTTG AGCAGAGGGA ACGACCTGAC TTACTTGCAC 600 TGTGATCCCC CTTGCTCCGC CCACTGTGAC CTTGAACCCC ATGCACTGTG ACCTCCCCCC 660 TTCTCCCCCT TCCCACTGTG ATTGGCACAT CGACAAGGGC TGTCCCAAGT CAATGGAAAG 720 GGAAAGGGTG GGGGTTAGGG GAAGGTTGGG GGGACCCAGC AAGGACTCAG AGAGTCAGAC 780 AGTGCCACTT GGCCACTTGG GGTAAAGCCA GTGCCAGCAA TAACAGTTTA TCATGCTCAT 840 TAATTTGGGA TTTCAAAACA CAAATGAAAA CTCACACCCA CCCACCCCCA AGTGCATGTC 900 TCCATCACTT AAAAAGTAAG TTCCATTTGA AAATATCCTT TCTTTTTTTT TTCTTCCTAT 960 TTTTGTTTGT TTATACAAAT ATCTGATTTG CAAGAAAAAG TGCATGGGAG GGGTTTTAGT 1020 GGTTTAATGA ATTTTTAATT AAGAAAGGGT AGTTTGGTAG TCTACTTAAA AATGTTTCTG 1080 GGAAATTCAC TAGAAACATT AACCAATAGG ATTTTGGTGA GCTTAGCTTC TGTATTCCTA 1140 CTGCCGCCCA GAAAAGGGGC AGGGCTCTGC AGCCGCCAGG ACAGACGAGC ACCCCATGCC 1200 TATACCTCCC TCCCCGAGCT AAGTCCCAGG GCATCTGGGC CTTGCCTGGA GACTGGGCTA 1260 GCTCTGTAGG CTCGGAGAGC CTGGGGAGGG TGCCAACCCC ACCTCTAGTA TTTTGGGAGA 1320 TAGGGAAAGT GAACCGACTT CCCCTTCCCA TACCCCTCAG GGTGGTTCCC TACCAGCCAG 1380 GCTTACTACT TCTAGAAGAA AGCAGAGTGC CAGGGAGTGA GATTGCATCC CTGGGCTTAG 1440 AAGTGACGGA GAGAAGACTT GTTTAGTATT TTGCCATCAG CACAAGGAAA ACCAGGAGAG 1500 AGTCTGCCTC CAGGACTCTG AGCCTTCTGC CTCGTATGTT CAGAAGGTGG ATAGGTCTTC 1560 CCACTCCAGC ATGGCTTGAA CTCTTAGGGG TCTGCAGTGC TCCATCTCCA TTGGTGGCCC 1620 CAGCTCAGTA ACTATACCTG GTACATTTCC TGTGTGCAAT CAGTACCTTG AAGGCAGAAC 1680 ATTCTGAATA AAGTTGGAAA AAGAACAGCT TTGCTTTGCA AAGATTGATG ACAGACTGGT 1740 TCCTCAGAGG CCTAGGCTAC CCGTCACCCC TTTTTCCAGA GCGAGGGCCT GGAATGAAGG 1800 CAGTTTATCC TCTGTCCCTG GAGCCTGGGG TTTGCTTTGG CTCCTTGAGG TGGAAGAGAC 1860 TAAGAGGGCA GCTGCCCAGA GCAGCTGTGT GTACCTGGCT CCTCTCAGGC TTCCTGATCC 1920 CTTCCATTGC ACTGCGCCTT ATCCCTCAGC CAGCCAGACA GCCTCCCTGC TCCTGACCAG 1980 CAGATACGTT TCGGAGTGGT TGGTGTGGTT TTTGTGATGA GGGCAGCACA TGGTGGCCAA 2040 GGTGGGCAAA GCTGAGTCTC ACAAGGCTCA AATCCCTTCG GTTGGGNTCC CCTTGTGGGG 2100 (2) INFORMATION FOR SEQ ID NO: 95: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2458 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: PANCNOT08 (B) CLONE: 1438165 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 95 : GCGGGCGGAG ATGTAGACCC GGTAGTGTTG TGCCTTGTGG TGACAACTGG CGGCAGCGCG 60 CCGCGGGCCC GAGACTTAGT CTCGGGCCGC CATGGCCAGC GTCCACGAGA GCCTCTACTT 120 CAATCCCATG ATGACCAATG GGGTTGTGCA CGCCAATGTG TTCGGCATCA AGGACTGGGT 180 GACGCCGTAC AAGATCGCGG TGCTGGTGCT GCTGAACGAG ATGAGCCGCA CAGGCGAGGG 240 CGCCGTCAGC CTCATGGAGC GGCGGAGGCT CAACCAGCTG CTCCTGCCCC TGCTGCAGGG 300 CCCAGATATT ACACTGTCAA AACTTTACAA GTTAATTGAA GAGTCTTGTC CACAGCTGGC 360 AAATTCAGTG CAGATCAGAA TCAAACTGAT GGCTGAAGGC GAGTTGAAGG ATATGGAACA 420 GTTTTTTGAT GACCTTTCAG ATTCTTTCTC TGGAACTGAA CCAGAGGTTC ACAAAACAAG 480 TGTAGTAGGT TTGTTTCTGC GTCACATGAT CTTGGCCTAC AGTAAGCTTT CTTTCAGCCA 540 AGTGTTTAAA CTGTACACTG CCCTTCAGCA GTACTTCCAG AATGGTGAGA AAAAGACAGT 600 GGAGGATGCT GATATGGAAC TGACCAGTAG AGATGAGGGT GAAAGAAAAA TGGAAAAAGA 660 AGAACTTGAT GTATCTGTAA GAGAAGAGGA GGTATCTTGC AGTGGGCCTC TGTCCCAAAA 720 ACAAGCAGAA TTTTTTCTTT CTCAACAGGC TTCTTTGCTA AAGAATGATG AGACTAAGGC 780 CCTCACTCCA GCTTCCTTGC AGAAGGAATT AAACAATTTG TTGAAATTTA ATCCTGATTT 840 TGCTGAAGCG CATTATCTCA GCTACTTAAA CAACCTCCGT GTCCAAGATG TTTTCAGTTC 900 AACACACAGT CTCCTCCATT ATTTTGATCG TCTGATTCTT ACCGGAGCCG AAAGCAAAAG 960 TAATGGGGAA GAGGGCTATG GCCGGAGCTT GAGATACGCC GCTCTGAATC TTGCCGCCCT 1020 GCACTGCCGC TTCGGTCACT ATCAACAGGC AGAGCTCGCC CTGCAGGAGG CAATTAGGAT 1080 TGCCCAGGAG TCCAACGATC ACGTGTGTCT CCAGCACTGT TTGAGCTGGC TTTATGTGCT 1140 GGGGCAGAAG AGATCCGATA GCTATGTTCT GCTGGAGCAT TCTGTGAAGA AGGCAGTACA 1200 TTTTGGGTTA CCGAGAGCTT TTGCTGGGAA GACGGCAAAC AAGCTGATGG ATGCCCTAAA 1260 GGACTCCGAC CTCCTGCACT GGAAACACAG CCTGTCAGAG CTCATCGATA TCAGCATCGC 1320 ACAGAAAACG GCCATCTGGA GGCTGTATGG CCGCAGCACC ATGGCACTGC AACAGGCCCA 1380 GATGTTGCTG AGCATGAACA GCCTGGAGGC GGTGAATGCG GGCGTGCAGC AGAACAACAC 1440 AGAGTCCTTT GCTGTCGCAC TCTGCCACCT CGCAGAGCTA CACGCGGAGC AGGGCTGTTT 1500 TGCTGCAGCT TCTGAAGTGT TAAAGCACTT GAAGGAACGA TTTCCGCCTA ATAGTCAGCA 1560 CGCCCAGTTA TGGATGCTAT GTGATCAAAA AATACAGTTT GACAGAGCAA TGAATGATGG 1620 CAAATATCAT TTGGCTGATT CACTTGTTAC AGGAATCACA GCTCTCAATA GCATAGAGGG 1680 TGTTTATAGG AAAGCGGTTG TATTACAAGC TCAGAACCAA ATGTCAGAGG CACATAAGCT 1740 TTTACAAAAA TTGTTGGTTC ATTGTCAGAA ACTGAAGAAC ACAGAAATGG TGATCAGTGT 1800 CCTACTGTCC GTGGCAGAGC TGTACTGGCG ATCTTCCTCC CCTACCATCG CGCTGCCCAT 1860 GCTCCTGCAG GCTCTGGCCC TCTCCAAGGA GTACCGGTTA CAGTACTTGG CCTCTGAAAC 1920 AGTGCTGAAC TTGGCTTTTG CGCAGCTCAT TCTTGGAATC CCAGAACAGG CCTTAAGTCT 1980 TCTCCACATG GCCATCGAGC CCATCTTGGC TGACGGGGCT ATCCTGGACA AAGGTCGTGC 2040 CATGTTCTTA GTGGCCAAGT GCCAGGTGGC TTCAGCAGCT TCCTACGATC AGCCGAAGAA 2100 AGCAGAAGCT CTGGAGGCTG CCATCGAGAA CCTCAATGAA GCCAAGAACT ATTTTGCAAA 2160 GGTTGACTGC AAAGAGCGCA TCAGGGACGT CGTTTACTTC CAGGCCAGAC TCTACCATAC 2220 CCTGGGGAAG ACCCAGGAGA GGAACCGGTG TGCGATGCTC TTCCGGCAGC TGCATCAGGA 2280 GCTGCCCTCT CATGGGGTAC CCTTGATAAA CCATCTCTAG AGAGGACATC CCTGCTGGGC 2340 TGCTGTGCAG AGTATAAGAT TTTGGACTTG TTCATGTCCC CTCTCTCCCT ATAAATGATG 2400 TATTTGTGAC ACCCTATCTT GTCAATAAAC AGCATTCTGA TTAAAAAAAA AAAAAAAA 2458 (2) INFORMATION FOR SEQ ID NO: 96: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2900 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: THYRNOT03 (B) CLONE: 1440381 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 96 : TGCATGGATG GGATACTGGA TGAATCTTTG CTTGAAACCT GTCCAATTCA GTCACCATTA 60 CAAGTTTTTG CAGGAATGGG TGGACTGGCT CTTATTGCTG AAAGACTACC CATGCTATAT 120 CCAGAAGTAA TTCAACAGGT GAGTGCTCCA GTTGTAACAT CTACCACTCA GGAAAAGCCG 180 TATGATAGCG ATCAGTTTGA ATGGGTGACC ATTGAACAGT CAGGGGAGTT AGTTTATGAA 240 GCACCAGAAA CTGTTGCGGC TGAACCTCCA CCTATCAAGT CAGCAGTACA GACCATGTCT 300 CCCATACCTG CCCATTCTTT GGCTGCTTTT GGATTATTTC TTCGTCTTCC GGGCTATGCG 360 GAAGTGCTAC TGAAAGAGAG AAAACATGCC CAGTGCCTTC TTCGATTGGT ATTGGGAGTG 420 ACAGATGATG GAGAAGGAAG TCATATTCTT CAATCTCCAT CAGCCAATGT GCTTCCAACC 480 CTTCCTTTCC ACGTCCTTCG TAGCTTGTTT AGCACTACAC CTTTGACAAC TGATGATGGT 540 GTACTTCTAA GGCGGATGGC ATTGGAAATT GGAGCCTTAC ACCTCATTCT TGTCTGTCTC 600 TCTGCTTTGA GCCACCATTC CCCACGAGTT CCAAACTCTA GCGTGAATCA AACTGAGCCA 660 CAGGTGTCAA GCTCTCATAA CCCTACATCA ACAGAAGAAC AACAGTTATA TTGGGCCAAA 720 GGGACTGGCT TTGGAACAGG CTCTACAGCT TCTGGGTGGG ATGTGGAACA AGCCTTAACT 780 AAGCAAAGGC TGGAAGAGGA ACATGTTACC TGCCTTCTGC AGGTTCTTGC CAGTTACATA 840 AATCCCGTCA GTAGTGCGGT AAATGGAGAA GCTCAGTCAT CTCATGAGAC TAGAGGGCAG 900 AACAGTAATG CCCTTCCTTC TGTACTTCTC GAGCTTCTCA GTCAGTCCTG CCTCATCCCA 960 GCCATGTCAT CTTATCTACG AAATGATTCA GTTCTGGACA TGGCAAGACA TGTGCCACTC 1020 TATCGGGCAC TGCTGGAATT GCTTCGGGCC ATTGCTTCTT GTGCTGCCAT GGTGCCCCTA 1080 TTGTTGCCCC TTTCTACAGA GAACGGTGAA GAGGAAGAAG AACAGTCAGA ATGTCAAACT 1140 TCTGTTGGTA CATTGTTAGC CAAAATGAAG ACCTGTGTTG ATACCTATAC CAACCGTTTA 1200 AGATCTAAAA GGGAAAATGT TAAAACAGGA GTAAAACCAG ATGCGTCTGA TCAAGAACCA 1260 GAAGGACTTA CTCTTTTGGT ACCAGACATC CAAAAGACTG CTGAGATAGT TTATGCAGCC 1320 ACCACCAGTT TGCGGCAAGC AAATCAGGAA AAAAACTGGG TGAATACTCC AAGAAGGCGG 1380 CTAATGAACC CCAAACCTTT GTCAGTATTA AAGTCACTTG AAGAAAAATA TGTGGCTGTT 1440 ATGAAGAAAT TACAGTTTGA TACGTTTGAA ATGGTTTCTG AAGATGAAGA TGGGAAATTG 1500 GGATTTAAAG TAAATTACCA CTACATGTCT CAGGTGAAAA ATGCTAATGA TGCGAACAGT 1560 GCTGCCAGAG CTCGCCGCCT TGCCCAGGAA GCTGTGACGC TTTCAACCTC ACTGCCTCTG 1620 TCTTCATCCT CTAGTGTGTT TGTACGCTGT GATGAGGAGC GACTTGATAT CATGAAGGTT 1680 CTAATAACTG GTCCAGCGGA CACCCCTTAT GCAAATGGCT GCTTTGAGTT TGATGTGTAT 1740 TTTCCTCAAG ATTATCCCAG TTCACCCCCT CTTGTGAATC TAGAGACAAC TGGTGGTCAT 1800 AGCGTGCGAT TCAATCCAAA CCTTTATAAT GATGGCAAGG TTTGTTTAAG CATCTTAAAC 1860 ACGTGGCATG GAAGACCAGA AGAGAAGTGG AATCCTCAGA CCTCAAGCTT TTTGCAAGTG 1920 TTGGTGTCTG TCCAGTCCCT TATATTAGTA GCTGAGCCTT ATTTTAATGA ACCGGGATAT 1980 GAACGGTCTA GAGGCACTCC CAGTGGCACA CAGAGTTCTC GAGAATATGA TGGAAACATT 2040 CGACAAGCAA CAGTTAAGTG GGCAATGCTA GAACAAATCA GAAACCCTTC ACCATGTTTT 2100 AAAGAGGTAA TACACAAACA TTTTTACTTG AAAAGAGTTG AGATAATGGC CCAATGTGAG 2160 GAGTGGATTG CGGATATCCA GCAGTACAGC AGTGATAAGC GGGTAGGCAG GACTATGTCT 2220 CACCATGCAG CAGCTCTCAA GCGTCACACT GCTCAGCTCC GCGAAGAGTT GCTGAAACTT 2280 CCCTGCCCTG AAGGCTTGGA TCCTGACACT GACGATGCCC CAGAGGTGTG CAGAGCCACA 2340 ACAGGTGCTG AGGAGACTCT AATGCATGAT CAGGTTAAAC CCAGCAGCAG CAAAGAACTC 2400 CCCAGTGACT TCCAGTTATG AGCTGCATTG ATGTGGACTT CATAGACACA AAGGCTTCGA 2460 AGCACAAGCC AAATATGTCA ATATTTGTAT GTAAGAAACT AATTATGTAA TAGGTAATGA 2520 AACTGAAACT ATACTATGCC CTTAAGGAGA TCCAGTTTAA TTCAAGGTGA TCTTTTATTT 2580 ACCTGTACAG GAGTGTAAAC TTTTTTGTGC TTTTATTTTT CAATTGTGAG AACCACTGAT 2640 TGGTATGTTC AACAAATTTG TGTATACAAA GAAATGGATA AATCACTGCT ATATAAGGGA 2700 AACTACCTTA GGAAAGAATG TTTACTGAAT GTTTATTTTA TTTTATTTTT TTTTTACTAT 2760 AGAGTGAGGG GTTGTTAACA AAGAATATAT ATTGGTCGTT CTTACAACTA CTATTTAAAG 2820 TCAGCAACTT TTCACTGAAT TTGATAGATT TTATGTTTGG GGGTACGAGC TTGTAAAGCT 2880 CGGGTGCCTN ATGAGTGACC 2900 (2) INFORMATION FOR SEQ ID NO: 97: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1310 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: LUNGNOT14 (B) CLONE: 1510839 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 97 : CCGCTGAGAT GTACGAACTT CCGGTTCTCC GGGCAGCTGC CACTGCTGTA GCTTCTGCCA 60 CCTGCCACGA CCGGGCCTCT CCCTGGCGTT TGGTCACCTC TGCTTCATTC TCCACCGCGC 120 CTATGGTCCC TCTTGGAGCC AGCGTGGCGG GCCTGGCGGC TCCCGGGTGG TGAGAGAGCG 180 GTCCGGGAAC GATGAAGGCC TCGCAGTGCT GCTGCTGTCT CAGCCACCTC TTGGCTTCCG 240 TCCTCCTCCT GCTGTTGCTG CCTGAACTAA GCGGGCCCCT GGCAGTCCTG CTGCAGGCAG 300 CCGAGGCCGC GCCAGGTCTT GGGCCTCCTG ACCCTAGACC ACGGACATTA CCGCCGCTGC 360 CACCGGGCCC TACCCCTGCC CAGCAGCCGG GCCGTGGTCT GGCTGAAGCT GCGGGGCCGC 420 GGGGCTCCGA GGGAGGCAAT GGCAGCAACC CTGTGGCCGG GCTTGAGACG GACGATCACG 480 GAGGGAAGGC CGGGGAAGGC TCGGTGGGTG GCGGCCTTGC TGTGAGCCCC AACCCTGGCG 540 ACAAGCCCAT GACCCAGCGG GCCCTGACCG TGTTGATGGT GGTGAGCGGC GCGGTGCTGG 600 TGTACTTCGT GGTCAGGACG GTCAGGATGA GAAGAAGAAA CCGAAAGACT AGGAGATATG 660 GAGTTTTGGA CACTAACATA GAAAATATGG AATTGACACC TTTAGAACAG GATGATGAGG 720 ATGATGACAA CACGTTGTTT GATGCCAATC ATCCTCGAAG AAGAGAATGT GCCTTTTGAT 780 GAAAGAACTT TATCTTTCTA CAATGAAGAG TGGAATTTCT ATGTTTAAGG AATAAGAAGC 840 CACTATATCA ATGTTGGGGG GGTATTTAAG TTACATATAT TTTAACAACC TTTAATTTGC 900 TGTTGCAATA AATACCGTAT CCTTTTATTA TATCTTTATA TGTATAGAAG TACTCTATTA 960 ATGGGCTCAG AGATGTTGGG GATAAAGTAT ACTGTAATAA TTTATCTGTT TGAAAATTAC 1020 TATAAAACGG TGTTTTCTGA TCGGTTTTTG TTTCCTGCTT ACCATATGAT TGTAAATTGT 1080 TTTATGTATT AATCAGTTAA TGCTAATTAT TTTTGCTGAT GTCATATGTT AAAGAGCTAT 1140 AAATTCCAAC AACCAACTGG TGTGTAAAAA TAATTTAAAA TTTCCTTTAC TGAAAGGTAT 1200 TTCCCATTTT TGTGGGGAAA AGAAGCCAAA TTTATTACTT TGTGTTGGGG TTTTTAAAAT 1260 ATTAAGAAAT GTCTAAGTTA TTGTTTGCAA AACAATAAAT ATGATTTTAG 1310 (2) INFORMATION FOR SEQ ID NO: 98: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2272 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: SPLNNOT04 (B) CLONE: 1534876 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 98 : CCATGCTCCA GGCATACAGA TGTGGTTTCT CGGCTGCACC GGGCCAGGCT GCGGGTGTGC 60 AGGCGTCTGC AAAGTTGTGC CATGTATCAG CACAGGCTTT GAGACGTCTG GACCCTGTCC 120 TTCCTCCCGT GAGGGGTTCT TGTTCTTTCT GACTCAGGTG ACTTTTCAGC CCTTCCAATT 180 CCCCTCTTTT TCTGCCCTCC CCTCCAACTC AGCCAACCCA GGTGTGGGCA GTCAGGGAGG 240 GAGGGAGTGT CCCACCACGT TCTCAGGGCA GCCCTTGACT CCTAAGCCCC TTCCTCCTTC 300 CATTCTGCAT CCCCTCCCCA TCCAACCTAA ATGCCCACAG CTGGGGCTGA GCTGTATTCC 360 TGTGGAGGGA CCTCTGCCGT GCCTCTCTGA GGTCAGGCTG TGCTGTGTGA TGGGCAGGCT 420 TTGCCCCAGC CCACCCCTGG CAAGGTGCAC TTGTTTTCTG GTTTGTACAA GGTGTCCTGG 480 GGGCCCGTCG CTTCCCTGCC AGTGAGGAGT GACTTCTCCC TCTCTTCCAG TCCTGTAGGG 540 GAGACAAAAC CAGATTGGGG GGCCCAAGGG GAGCATGGAA AAGGCCGGCT CCCCTGTCTT 600 TCCTTGGCTG TCAGAGTCAG GGTAACACAC ACCAAGAGTG GAGTGCGGCC AGCAAGTTTG 660 AGACCTGCCC GCCCTCCTCG CAGCTCTGCT CTGTGTCCTC AGGAAGTCAC AGAGTCTACT 720 GAGGCAAGGA GAGGGTGATT CTTTCCCCAA ATCCCTTCTT CCCTGGTTCC CAAACCAAAG 780 ACAGCCTGCA GCCCTTTCTG CATGGGGTGC TCTGTTGACA GGCTTCCCAG ATCCCTGAGT 840 CTCTCTTTCC TTCCTCCTCG ATCTTTAGTT GTCCACGGTC AATTCAGTGC TTCCATTGGG 900 GGACAGTCCC CTCCGGGATG ACCTGATTCA CCTCCAGCCC AGGGAATGGA ATCTAGAGGA 960 ATACGTGGGG TGGGTCTGGA CAAGGAGCGG CAGGAATCAC CACCCATCTC CAGCTGTGGA 1020 GCCCTGTGGA GGGGAAGGGG AAGCTTGGGG TTCAGAGGGA ACTCTTCCAG GAGAGGGGTG 1080 CCCAGCGGAG GTAAAGATGA TAGAGGGTTG TGGGGGGTCT CTAGTTGAAT GTTTTGGCCC 1140 ATGACTTTGG AACATGGCTG GCAGCTTCCA GCAGAAGTCA CGCTCCCCAT CCCCCAGGGG 1200 ACATAGGACC TTTTTCCTGC TTCCTGGTCA CTTTCAAAGA ACTATTTGCG CAATCTGTGG 1260 GTCTGTGGAT TCACGGGGCT TTCTGTGTGG GTGCTGCAGT TGCTTTTGTC TGCAGCAGCA 1320 GGACACATCT TTCCTCTTAC TCAGCCCTTT ATGGCCCATG GGGAACTCCG TGGCTCAGGG 1380 AGAGCTGAAC TCCAGGGGTG TGACCTGGGA CAGGTGGGCC TGAGGTGCCC AGCTCAGGGC 1440 AGCCAGGTGG CTCATGGGCT GTAGTGAGCC AGCTCCCTGG GGGAAAAGGC TGTGGGCCGT 1500 TAGGACCATC CTCCAGGACA GGTGACCTCT ATGAGGTCAC CTACGGCTGT GGCCGTGCAG 1560 GCCTCCTTCC AGCCCAGAGT GGCCCAGTAG AGCAAGGCAG ACAGTGACCT CCACCCCCGC 1620 AGCCCTCTTA AAAGGCCAGT ACTCTTGGGG GTGGGGGGAG GGTTTAGAAA GCATTTGCCC 1680 ATCTGCCTTT CTTTCCCCCA GCCCCCACCC GCTTTGAATG TAGAGACCCG TGGGCACTTT 1740 TCCTTTTGTG GTGGGGGGTG CGGAGGAGGT ACCCCCACCC CTGGCACAGC CGCCTGGAAT 1800 GCAGGACTGT CACTGCTGTT CGGGTGATGA CCTCGTTGCC AAGCTCCTCC TGTCCCCTTG 1860 TTCTGGGGGC AGGCGCTGTG CTTCTGTGAG GTGGTTTAGC TTTTGCTTTC GAAGTGGCCA 1920 GCTGCGGCCA CCAGGTCTCA GCACAAGAGC GCTTCCTTTG CACAGAATGA GCTTCGAGCT 1980 TTGTTCAGAC TAAATGAATG TATCTGGGAG GGGTCGGGGG CACGAGTTGA TTCCAAGCAC 2040 ATGCCTTTGC TGAGTGTGTG TGTGCTGGGA GAGTCAGAGT GGATGTAGAG CGCGGTTTTA 2100 TTTTTGTACT GACATTGGTA AGAGACTGTA TAGCATCTAT TTATTTAGAT GATTTATCTG 2160 GTAAATGAGG CAAAAAAATT ATTAAAAATA CATTAAAGAT GATTTAAAAA AAAGACCAAA 2220 AAACCAAGAA ACCCAAAGCC CAAGAATGCG CGTAGCATCC AAAAAAAAAA GG 2272 (2) INFORMATION FOR SEQ ID NO: 99: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1060 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: SPLNNOT04 (B) CLONE: 1559131 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 99 : GTCAACTTAG CGAGCGCAAC AGGCTGCCGC TGAGGAGCTG GAGCTGGTGG GGACTGGGCC 60 GCAATGGACA AGCTGAAGAA GGTGCTGAGC GGGCAGGACA CGGAGGACCG GAGCGGCCTG 120 TCCGAGGTTG TTGAGGCATC TTCATTAAGC TGGAGTACCA GGATAAAAGG CTTCATTGCG 180 TGTTTTGCTA TAGGAATTCT CTGCTCACTG CTGGGTACTG TTCTGCTGTG GGTGCCCAGG 240 AAGGGACTAC ACCTCTTCGC AGTGTTTTAT ACCTTTGGTA ATATCGCATC AATTGGGAGT 300 ACCATCTTCC TCATGGGACC AGTGAAACAG CTGAAGCGAA TGTTTGAGCC TACTCGTTTG 360 ATTGCAACTA TCATGGTGCT GTTGTGTTTT GCACTTACCC TGTGTTCTGC CTTTTGGTGG 420 CATAACAAGG GACTTGCACT TATCTTCTGC ATTTTGCAGT CTTTGGCATT GACGTGGTAC 480 AGCCTTTCCT TCATACCATT TGCAAGGGAT GCTGTGAAGA AGTGTTTTGC CGTGTGTCTT 540 GCATAATTCA TGGCCAGTTT TATGAAGCTT TGGAAGGCAC TATGGACAGA AGCTGGTGGA 600 CAGTTTTGTA ACTATCTTCG AAACCTCTGT CTTACAGACA TGTGCCTTTT ATCTTGCAGC 660 AATGTGTTGC TTGTGATTCG AACATTTGAG GGTTACTTTT GGAAGCAACA ATACATTCTC 720 GAACCTGAAT GTCAGTAGCA CAGGATGAGA AGTGGGTTCT GTATCTTGTG GAGTGGAATC 780 TTCCTCATGT ACCTGTTTCC TCTCTGGATG TTGTCCCACT GAATTCCCAT GAATACAAAC 840 CTATTCAGCA ACAGCACATA AGCCTTGGGT GCAAGTGATT CCCAGGTGGC AAAAGGCAGC 900 CCCATCAGAG ATCACGGGAG CAACAGTAAG GGACAGAGTT TTGGGGTCCA CTTGTCCCTC 960 AGCATGGAAG CCATCACCGT GGTCCTGCAT AGAGTGAGTC TGCTTCTACT CTGGCATCTG 1020 AGAACAAGTG ACTCTGCTTT AGACAAGCCC CTGGAGAGGG 1060 (2) INFORMATION FOR SEQ ID NO: 100: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 543 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: BLADNOT03 (B) CLONE: 1601473 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 100 : GCTCACAGTA GCCCGGCGGC CAGGGCAATC CGACCACATT TCACTCTCAC CGCTGTAGGA 60 ATCCAGATGC AGGCCAAGTA CAGCAGCACA AGGGACATGC TGGATGATGA TGGGGACACC 120 ACCATGAGCC TGCATTCTCA AGCCTCTGCC ACAACTCGGC ATCCAGAGCC CCGGCGCACA 180 GAGCACAGGG CTCCCTCTTC AACGTGGCGA CCAGTGGCCC TGACCCTGCT GACTTTGTGC 240 TTGGTGCTGC TGATAGGGCT GGCAGCCCTG GGGCTTTTGT GTAAGTCTGC GCTCTGACCT 300 GGGGGAGGAT CCTGGTTCCA AGTTTTTCAG TACTACCAGC TCTCCAATAC TGGTCAAGAC 360 ACCATTTCTC AAATGGAAGA AAGATTAGGA AATACGTCCC AAGAGTTGCA ATCTCTTCAA 420 GTCCAGAATA TAAAGCTTGC AGGAAGTCTG CAGCATGTGG CTGAAAAACT CTGTCGTGAG 480 CTGTATAACA AAGCTGGAGC ACACAGGTGC AGCCCTTGTA CAGAACAATG GAAATGGCAT 540 GGA 543 (2) INFORMATION FOR SEQ ID NO: 101: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2281 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: BRAITUT12 (B) CLONE: 1615809 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 101 : AGCTGGCTCA CCTTCCAGAT TCACCTGCAG GAGCTGCTGC AGTACAAGAG GCAGAATCCA 60 GCTCAGTTCT GCGTTCGAGT CTGCTCTGGC TGTGCTGTGT TGGCTGTGTT GGGACACTAT 120 GTTCCAGGGA TTATGATTTC CTACATTGTC TTGTTGAGTA TCCTGCTGTG GCCCCTGGTG 180 GTTTATCATG AGCTGATCCA GAGGATGTAC ACTCGCCTGG AGCCCCTGCT CATGCAGCTG 240 GACTACAGCA TGAAGGCAGA AGCCAATGCC CTGCATCACA AACACGACAA GAGGAAGCGT 300 CAGGGGAAGA ATGCACCCCC AGGAGGTGAT GAGCCACTGG CAGAGACAGA GAGTGAAAGC 360 GAGGCAGAGC TGGCTGGCTT CTCCCCAGTG GTGGATGTGA AGAAAACAGC ATTGGCCTTG 420 GCCATTACAG ACTCAGAGCT GTCAGATGAG GAGGCTTCTA TCTTGGAGAG TGGTGGCTTC 480 TCCGTATCCC GGGCCACAAC TCCGCAGCTG ACTGATGTCT CCGAGGATTT GGACCAGCAG 540 AGCCTGCCAA GTGAACCAGA GGAGACCCTA AGCCGGGACC TAGGGGAGGG AGAGGAGGGA 600 GAGCTGGCCC CTCCCGAAGA CCTACTAGGC CGTCCTCAAG CTCTGTCAAG GCAAGCCCTG 660 GACTCGGAGG AAGAGGAAGA GGATGTGGCA GCTAAGGAAA CCTTGTTGCG GCTCTCATCC 720 CCCCTCCACT TTGTGAACAC GCACTTCAAT GGGGCAGGGT CCCCCCAAGA TGGAGTGAAA 780 TGCTCCCCTG GAGGACCAGT GGAGACACTG AGCCCCGAGA CAGTGAGTGG TGGCCTCACT 840 GCTCTGCCCG GCACCCTGTC ACCTCCACTT TGCCTTGTTG GAAGTGACCC AGCCCCCTCC 900 CCTTCCATTC TCCCACCTGT TCCCCAGGAC TCACCCCAGC CCCTGCCTGC CCCTGAGGAA 960 GAAGAGGCAC TCACCACTGA GGACTTTGAG TTGCTGGATC AGGGGGAGCT GGAGCAGCTG 1020 AATGCAGAGC TGGGCTTGGA GCCAGAGACA CCGCCAAAAC CCCCTGATGC TCCACCCCTG 1080 GGGCCCGACA TCCATTCTCT GGTACAGTCA GACCAAGAAG CTCAGGCCGT GGCAGAGCCA 1140 TGAGCCAGCC GTTGAGGAAG GAGCTGCAGG CACAGTAGGG CTTCTTGGCT AGGAGTGTTG 1200 CTGTTTCCTC CTTTGCCTAC CACTCTGGGG TGGGGCAGTG TGTGGGGAAG CTGGCTGTCG 1260 GATGGTAGCT ATTCCACCCT CTGCCTGCCT GCCTGCCTGC TGTCCTGGGC ATGGTGCAGT 1320 ACCTGTGCCT AGGATTGGTT TTAAATTTGT AAATAATTTT CCATTTGGGT TAGTGGATGT 1380 GAACAGGGCT AGGGAAGTCC TTCCCACAGC CTGCGCTTGC CTCCCTGCCT CATCTCTATT 1440 CTCATTCCAC TATGCCCCAA GCCCTGGTGG TCTGGCCCTT TCTTTTTCCT CCTATCCTCA 1500 GGGACCTGTG CTGCTCTGCC CTCATGTCCC ACTTGGTTGT TTAGTTGAGG CACTTTATAA 1560 TTTTTCTCTT GTCTTGTGTT CCTTTCTGCT TTATTTCCCT GCTGTGTCCT GTCCTTAGCA 1620 GCTCAACCCC ATCCTTTGCC AGCTCCTCCT ATCCCGTGGG CACTGGCCAA GCTTTAGGGA 1680 GGCTCCTGGT CTGGGAAGTA AAGAGTAAAC CTGGGGCAGT GGGTCAGGCC AGTAGTTACA 1740 CTCTTAGGTC ACTGTAGTCT GTGTAACCTT CACTGCATCC TTGCCCCATT CAGCCCGGCC 1800 TTTCATGATG CAGGAGAGCA GGGATCCCGC AGTACATGGC GCCAGCACTG GAGTTGGTGA 1860 GCATGTGCTC TCTCTTGAGA TTAGGAGCTT CCTTACTGCT CCTCTGGGTG ATCCAAGTGT 1920 AGTGGGACCC CCTACTAGGG TCAGGAAGTG GACACTAACA TCTGTGCAGG TGTTGACTTG 1980 AAAAATAAAG TGTTGATTGG CTAGAACTGC TGCCTCCCTG ACTGTGAGCT GCCTTCCACA 2040 CCCTGCACTG CACTGTGTTC TCTCCTCACC CTTAACCTGC TTCACTCCAG TCTGTTCTGG 2100 CTGTTTATTA CCTTGTTGCA AAACAGGGCC GAAGCAAGGA TTACCTTGAC AACCCTAGCT 2160 TCTCCTTAGC CATCTTCCTT GACAGTGTGA TCTGTTTAGT GAGATTTAGC ATGTGTGAAT 2220 AAAGTATATG CAGGAGGAAA TTGCTTTGTC TTCCCAATCG GTAGAAATTC GAGACCTAGC 2280 C 2281 (2) INFORMATION FOR SEQ ID NO: 102: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 992 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: COLNNOT19 (B) CLONE: 1634813 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 102 : GACAGCTTGG CCTACAGCCC GGCGGGCATC AGCTCCCTTG ACCCAGTGGA TATCGGTGGC 60 CCCGTTATTC GTCCAGGTGC CCAGGGAGGA GGACCCGCCT GCAGCATGAA CCTGTGGCTC 120 CTGGCCTGCC TGGTGGCCGG CTTCCTGGGA GCCTGGGCCC CCGCTGTCCA CGCCCAAGGT 180 GTCTTTGAGG ACTGCTGCCT GGCCTACCAC TACCCCATTG GGTGGGCTGT GCTCCGGCGC 240 GCCTGGACTT ACCGGATCCA GGAGGTGAGC GGGAGCTGCA ATCTGCCTGC TGCGATATTC 300 TACCTCCCCA AGAGACACAG GAAGGTGTGT GGGAACCCCA AAAGCAGGGA GGTGCAGAGA 360 GCCATGAAGC TCCTGGATGC TCGAAATAAG GTTTTTGCAA AGCTCCGCCA CAACACGCAG 420 ACCTTCCAAG CAGGCCCTCA TGCTGTAAAG AAGTTGAGTT CTGGAAACTC CAAGTTATCA 480 TCATCCAAGT TTAGCAATCC CATCAGCAGC AGCAAGAGGA ATGTCTCCCT CCTGATATCA 540 GCTAATTCAG GACTGTGAGC CGGCTCATTT CTGGGCTCCA TCGGCACAGG AGGGGCCGGA 600 TCTTTCTCCG ATAAAACCGT CGCCCTACAG ACCCAGCTGT CCCCACGCCT CTGTCTTTTG 660 GGTCAAGTCT TAATCCCTGC ACCTGAGTTG GTCCTCCCTC TGCACCCCCA CCACCTCCTG 720 CCCGTCTGGC AACTGGAAAG AGGGAGTTGG CCTGATTTTA AGCCTTTTGC CGCTCCGGGG 780 ACCAGCAGCA ATCCTGGGCA GCCAGTGGCT CTTGTAGAGA AGACTTAGGA TACCTCTCTC 840 ACTTTCTGTT TCTTGCCGTC CACCCCGGGC CATGCCAGTG TGTCCCTCTG GGTCCCTCCA 900 AAACTCTGGT CAGTTCAAGG ATGCCCCTCC CAGGCTATGC TTTTCTATAA CTTTTAAATA 960 AACCTTGGGG GTTGATGGAG TCAAAAAAAA AA 992 (2) INFORMATION FOR SEQ ID NO: 103: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1554 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: UTRSNOT06 (B) CLONE: 1638407 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 103 : TCGCCCAGGA GTCATCGGAC GCCAGAATCT GTGTCTCCAG AACGCTATAG CTATGGCACC 60 TCCAGCTCTT CAAAGAGGAC AGAGGGTAGC TGCCGTCGCC GTCGGCAGTC AAGCAGTTCT 120 GCAAATTCTC AGCAGGGTCA GTGGGAGACA GGCTCCCCCC CAACCAAGCG GCAGCGGCGG 180 AGTCGGGGCC GGCCCAGTGG TGGTGCCAGA CGGCGGCGGA GAGGGGCCCC AGCCGCACCC 240 CAGCAGCAGT CAGAGCCCGC CAGACCTTCC TCTGAAGGCA GGTGACACTG TGATGGGGAA 300 ACAGGCTCAG AGAGACATCC GGCTCCGGGT TCGAGCAGAG TACTGCGAGC ATGGGCCAGC 360 CTTGGAGCAG GGCGTGGCAT CCCGGCGGCC CCAGGCGCTG GCGCGGCAGC TGGACGTGTT 420 TGGGCAGGCC ACCGCAGTGC TGCGCTCAAG GGACCTGGGC TCTGTGGTTT GTGACATCAA 480 GTTCTCAGAG CTCTCCTATC TGGACGCCTT CTGGGGCGAC TACCTGAGTG GCGCCCTGCT 540 GCAGGCCCTG CGGGGCGTGT TCCTGACTGA GGCCCTGCGA GAGGCTGTGG GCCGGGAGGC 600 TGTTCGCCTG CTGGTCAGTG TGGATGAGGC TGACTATGAG GCTGGCCGGC GCCGCCTGTT 660 GCTGATGGCG GAGGAAGGGG GGCGGCGCCC GACAGAGGCC TCCTGATCCA GGACTGGCAG 720 GATTGATCCC ACCTCCAAGT CTCCGGGCCA CCTTCTCCTG GGAGGACGAC CATCTCTACC 780 CCTAGAGGAC TGTCACTCTA GCATCTTTGA GGACTGCGAC AGGACCGGGA CAGCAGGCCC 840 CTTGACAGCC CCTCCCACAG GATGTGGGCT CTGAGGCCTA AACCATTTCC AGCTGAGTTT 900 CCTTCCCAGA CTCCTCCTAC CCCCAGGTGT GCCCCCTTAG CCTCCGGAGG CGGGGGCTGG 960 GCCTGTATCT CAGAAGGGAG GGGCACAGCT ACACACTCAC CAAAGGCCCC CCTGCACATT 1020 GTATCTCTGA TCTTGGGCTG TCTGCACTGT CACAGGTGCA CACACTCGCT CATGCTCACA 1080 CTGCCCCTGC TGAGATCTTC CCTGGGCCTC TGCCCTGGCC TGCTTCCCAG CACACACTTC 1140 TTTGGCCTAA GGGCTTCTCT CTCAGGACCT CTAATTTGAC CACAACCAAC CTGGGCTTCA 1200 GCCACATCAG TGGGCACTGG AGCTGGGGTG CACATGGGGC CTGCTCACCT TGCCCACACA 1260 TCTCCAGCCA GCCAGGGCCC TGCCCAGCTT CAATTTACAG ACCTGACTCT CCTCACCTTC 1320 CCCCCTGCTG TCCAGAGCTG AACATAGACT TGCACTTGGA TGTCACCTGG AGTGTCACAT 1380 GGGAGTGTTA TGGCAGCATC ATACCAAGGC CTACTGTTGC ACATGGGGCC AAAACCAGTA 1440 AACAGCCACC TTCTTGGAAA GGGAATGCAA AGGCTTTGGG GGTGATGGAA AAGACCTTTT 1500 ACAAATGATA CCAATTAAAC TGCCCTGGAA AGGGCATAGG TGGGAAAAAA AAAA 1554 (2) INFORMATION FOR SEQ ID NO: 104: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1802 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: PROSTUT08 (B) CLONE: 1653112 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 104 : GTCGCCGGGC TTGCGATGAA CTTCCGGCTG TCAAGCTCCC GGCCGGGCTG ACTCAAGCGG 60 AGGCGCGCGG AACAGTCGCC GAGGCGATTC CCGCCCAGGC TCCTGTAACC GCCAGGCAGC 120 GGCCCCGCCA TGTCCCAGCC CCGGACCCCA GAGCAGGCAC TGGATACACC GGGGGACTGC 180 CCCCCAGGCA GGAGAGACGA GGACGCTGGG GAGGGGATCC AGTGCTCCCA ACGCATGCTC 240 AGCTTCAGTG ACGCCCTGCT GTCCATCATC GCCACCGTCA TGATCCTGCC TGTGACCCAC 300 ACGGAGATCT CCCCAGAACA GCAGTTCGAC AGAAGTGTAC AGAGGCTTCT GGCAACACGG 360 ATTGCCGTCT ACCTGATGAC CTTTCTCATC GTGACAGTGG CCTGGGCAGC ACACACAAGG 420 TTGTTCCAAG TTGTTGGGAA AACAGACGAC ACACTTGCCC TGCTCAACCT GGCCTGCATG 480 ATGACCATCA CCTTCCTGCC TTACACGTTT TCGTTAATGG TGACCTTCCC TGATGTGCCT 540 CTGGGCATCT TCTTGTTCTG TGTGTGTGTG ATCGCCATCG GGGTCGTGCA GGCACTGATT 600 GTGGGGTACG CATTCCACTT CCCGCACCTG CTGAGCCCGC AGATCCAGCG CTCTGCCCAC 660 AGGGCTCTGT ACCGACGACA CGTCCTGGGC ATCGTCCTCC AAGGCCCGGC CCTGTGCTTT 720 GCAGCGGCCA TCTTCTCTCT CTTCTTTGTC CCCTTGTCTT ACCTGCTGAT GGTGACTGTC 780 ATCCTCCTCC CCTATGTCAG CAAGGTCACC GGCTGGTGCA GAGACAGGCT CCTGGGCCAC 840 AGGGAGCCCT CGGCTCACCC AGTGGAAGTC TTCTCGTTTG ACCTCCACGA GCCACTCAGC 900 AAGGAGCGCG TGGAAGCCTT CAGCGACGGA GTCTACGCCA TCGTGGCCAC GCTTCTCATC 960 CTGGACATCT GCGAAGACAA CGTCCCGGAC CCCAAGGATG TGAAGGAGAG GTTCAGCGGC 1020 AGCCTCGTGG CCGCCCTGAG TGCGACCGGG CCGCGCTTCC TGGCGTACTT CGGCTCCTTC 1080 GCCACAGTGG GACTGCTGTG GTTCGCCCAC CACTCACTCT TCCTGCATGT GCGCAAGGCC 1140 ACGCGGGCCA TGGGGCTGCT GAACACGCTC TCGCTGGCCT TCGTGGGTGG CCTCCCACTA 1200 GCCTACCAGC AGACCTCGGC CTTCGCCCGG CAGCCCCGCG ATGAGCTGGA GCGCGTGCGT 1260 GTCAGCTGCA CCATCATCTT CCTGGCCAGC ATCTTCCAGC TGGCCATGTG GACCACGGCG 1320 CTGCTGCACC AGGCGGAGAC GCTGCAGCCC TCGGTGTGGT TTGGCGGCCG GGAGCATGTG 1380 CTCATGTTCG CCAAGCTGGC GCTGTACCCC TGTGCCAGCC TGCTGGCCTT CGCCTCCACC 1440 TGCCTGCTGA GCAGGTTCAG TGTGGGCATC TTCCACCTCA TGCAGATCGC CGTGCCCTGC 1500 GCCTTCCTGT TGCTGCGCCT GCTCGTGGGC CTGGCCCTGG CCACCCTGCG GGTCCTGCGG 1560 GGCCTCGCCC GGCCCGAACA CCCCCCGCCA GCCCCCACGG GCCAGGACGA CCCACAGTCC 1620 CAGCTCCTCC CTGCCCCCTG CTAGCAGCCA CAGAGCCCAC TCCCAGCCGT CCTCACCAGA 1680 GATGGACCAG GGAGGACAGG ATGCTGGGCA GGGGAAGCCA AGTCACGGGC AGGCCGCAGT 1740 GGTTCTTGCG TGGCCTGGTT TTATTTTCAT TGTGAAATAT CATGCTCTTA TTTCAGTCCT 1800 CA 1802 (2) INFORMATION FOR SEQ ID NO: 105: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1395 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: BRSTNOT09 (B) CLONE: 1664634 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 105 : GTACCTCGGC TTATTTCATA AACAGGTACT GAAGGAAGCA GAGGCATGTG GAGGACTTCC 60 CCACCTCGTG CAGCTATTTG GGCCGTGGCA TCTGAAATTT CTTATTTCAG AGTCACCCCT 120 TTGATGACCT TGGCAGTGAA CTGCAGTCAT CTGTTTAGGC CTTTCCATGG CCCACGTCAA 180 TGCCGGTATT TCTGTTTGTT GCACATTTGA TTTCCTTGTT GTTGGCATTT AGAAGGCCCT 240 CGAGCCGCAC TGAGGGACTG AGCCTGGTGT ATATGGCAGC AAGACTGGAT GGTGGCTTTG 300 CAGCAGTCTC CAGAGCATTC CATGAGATCC GGGCTCGAAA TCCAGCATTT CAGCCACAAA 360 CTTTGATGGA CTTTGGCTCA GGTACTGGTT CTGTCACCTG GGCTGCTCAC AGTATTTGGG 420 GCCAGAGCCT ACGTGAATAT ATGTGTGTGG ACAGATCAGC TGCCATGTTG GTTTTGGCAG 480 AAAAACTACT GACAGGTGGT TCAGAATCTG GGGAGCCTTA TATTCCAGGT GTCTTTTTCA 540 GACAGTTTCT ACCTGTATCA CCCAAGGTGC AGTTTGATGT AGTAGTGTCA GCTTTTTCCT 600 TAAGTGACCA GCTACTGACA TTTATACTTT CGTGTAATTC AAGTCTTCTG CATATTTTCC 660 CCTTTTGTGA ACAGGTACTG GTGGAGAATG GAACAAAAGC TGGGCACAGC CTTCTCATGG 720 ATGCCAGGGA TCTGGTCCTT AAGGGAAAAG AGAAGTCACC TTTGGACCCT CGACCTGGTT 780 TTGTCTTTGC CCCGTGTCCC CATGAACTCC CTTGTCCCCA GTTGACCAAC CTGGCCTGTA 840 GCTTCTCACA GGCGTACCAT CCCATCCCCT TCAGCTGGAA CAAGAAACCA AAGGAAGAAA 900 AGTTCTCTAT GGTGATCCTT GCTCGGGGGT CTCCAGAGGA GGCTCATCGC TGGCCCCGTA 960 TCACTCAGCC TGTCCTTAAA CGGCCTCGCC ATGTGCATTG TCACTTGTGC TGTCCAGATG 1020 GGCACATGCA GCATGCTGTG CTCACAGCCC GCCGGCACGG CAGGTATGGG GGGTGTGACC 1080 AAAATCAGTG GGATGTGGCA GGAAGCTGCA GCCCACGCCA GCATCTGTTT CCACAGGGAT 1140 TTGTATCGTT GTGCCCGTGT CAGCTCCTGG GGAGATCTTT TACCTGTGCT TACTCCGTCT 1200 GCGTTTCCTC CATCTACGGC TCAGGATCCC TCTGAGAGTT GATGAGGATG TGTAACAAGT 1260 ATTTTCTTCT ATCGTGCCTG CCAGGGCTGA AGCTGCCTGG TATCCAGGAG GGGAATGCTG 1320 GTATCCCCAT ATGTCTGTGT TTGTTTGAGA TTTTTAATAA TAAATAATAA ATTTTTGAAG 1380 AATGGAAAAA AAAAA 1395 (2) INFORMATION FOR SEQ ID NO: 106: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1635 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: PROSTUT10 (B) CLONE: 1690990 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 106 : CCCTCTTCCT TTTGCGCACG GAAGAACAAA TCACAACAAT CACACACCAG GACTGAATCC 60 ATCAGCAGAT ACTGCCCTGT GGGAAGGGCA GAGGAAAGAG AAGACAGACG GACTGACAGA 120 CACCACAGAG GAACAGGGGA GTTAGCCTGG GACCAATGGA GGAGAAGTAC GAACCCTGGG 180 AAAAAGACGT GTCAGATGAG AAAGTTCCGG AGAGTCCGAT GTCTCATCGC AGGTGTTACA 240 TCATCAGGGT TTGCCATTGG AATACTGAGT GGAGATGGGA AAGAGAAAAG TTAAGGGCTG 300 AAATGGGAGG GGAATGGGAA GAAAAAATGA GAGACAAGAG GGAAATAAGA AAAAACAAAG 360 AGAGCACAAA GACCAGTTTA GGAGAAAGGA CCAATGGGGA CAGTGGCAGA GTGGCGAGGT 420 AGGTGAAGGA CTGAGGCACA GCGTCCTGTT GTGGAGGGAG GAAAGGCAAG CGTTCCGAGG 480 TGGTGAAAAG GAAGGCCTGC TAGGCACGGT GGGGATGAAC GAGGATGCCA TGAGTCACAC 540 AAAAGACAGT GCTGGTGAGG CCCAGCCACA GGAGCCTCAG ATAACTTGGT AAAGGCATGT 600 CTCCCATTTG GGAACTGATG TTCCTAAGAT CCGCACTGAC GCTGCTCAGC CGGTCCATCA 660 CACAGCAAAG GCGTGAGGAA GGGTCACTGC CCAGCTGGAC TCCAGGGTGG TCCACGCATG 720 ACAGTCACAC CGAACCTTCA TGAGGATGTG AACTGTTGGC TCCAATTTAC CATTCCCAGC 780 AATTCCACTC AGATATTTGT ATACTAATGT TCACAGCAGC GTGAACTCCA CAGCAGGTGG 840 AGTAATGTTC CATTGTGTGC ATATGCCACA TTTTGTTTAT CCATTCATCT GTTGATGCAC 900 ATTTCGGTTG TTCCCACCTT TGGGCTATTA TTAATAATGC TGCTGTGAAC ATTCCCAAGA 960 GAAATAGGAA GACGGCTTTG CTAAGAACTA AAAAAGGGAT GGACAACAAG GGCATATACC 1020 CAGGGGCAGT GTTCTATCAT GACAGCTTTA CTGAGAGCAG AGTAGTTCTG CTCAGAATCA 1080 GAACACTTGT TCCCTATAGC CCCCCTGATT GCCCCACAAC CACCACCGCA TACTCCCCTT 1140 TTCCCAACCA TGGGCAGCAG ATTGAGCTAT TAACAGAAGT GTCCTTTCGC TGGATTTCTC 1200 AACCCTTTCC TCATCGTCCA CATAGAGAAA CAGTAACAGA TTGCTACTCA CCCAACACCC 1260 AGGTCAAGTC CAATGCAGGT AGGAATAACA GCAAATCCTT CAATTTCTTG ATTCTGCTCT 1320 TAAAAATCTT AACAGAGGCT TCCAGGTTCT GAAAATATTT TCTGCATAAA CGTGTGACAC 1380 TCCATCACGA AACTCCCTTT GGTTATCTGC TTAAACTTAT CGCAAATGTC TGGAACGCTG 1440 GTGGCTTCCA AAATCAACTC CTGGTGCTGC TTAATTAAGG TCAGGGCCAC CCGGAAGATA 1500 ATCTTCGAGC CTTCGTTAAA CAAACAGTCC CAGATCCGAA GCACTGTCTC CACGGGCAAG 1560 ATGTCCACAA ACAGGCAGAT GAACCAGCGG GACACCAGCA GCGTCCACAG CACACCGAGA 1620 CGCTCCATCA GGGGG 1635 (2) INFORMATION FOR SEQ ID NO: 107: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1485 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: DUODNOT02 (B) CLONE: 1704050 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 107 : TTTTTGGTCC CGNCNAAAGN CCNAAAACCC GGNACCCGGG AAGCCNCCCC AANNCNAAAN 60 TTCCCAGTTN GAANCCCGAA GGNAAAACCC CGGAAAAGNA NNCNGCCCCN AAANTTCNCG 120 GGCNAAAACC CGGCCNTTTT TTCCCCCCCG GGCGGCCGTT TTGGGCCCCN GANTTTCCAT 180 TTAAANTNCC NAGNCTTGGG CAACCTAACC AGGNTTTTCC CCCAANCTGG AAAAAGCCGG 240 GCCAAGTTGA GCCGCACCCG CCCCAGAAGT TCAAGGGCCC CCGGCCTCCT GCGCTCCTGC 300 CGCCGGGACC CTCGACCTCC TCAGAGCAGC CGGCTGCCGC CCCGGGAAGA TGGCGAGGAG 360 GAGCCGCCAC CGCCTCCTCC TGCTGCTGCT GCGCTACCTG GTGGTCGCCC TGGGCTATCA 420 TAAGGCCTAT GGGTTTTCTG CCCCAAAAGA CCAACAAGTA GTCACAGCAG TAGAGTACCA 480 AGAGGCTATT TTAGCCTGCA AAACCCCAAA GAAGACTGTT TCCTCCAGAT TAGAGTGGAA 540 GAAACTGGGT CGGAGTGTCT CCTTTGTCTA CTATCAACAG ACTCTTCAAG GTGATTTTAA 600 AAATCGAGCT GAGATGATAG ATTTCAATAT CCGGATCAAA AATGTGACAA GAAGTGATGC 660 GGGGAAATAT CGTTGTGAAG TTAGTGCCCC ATCTGAGCAA GGCCAAAACC TGGAAGAGGA 720 TACAGTCACT CTGGAAGTAT TAGTGGCTCC AGCAGTTCCA TCATGTGAAG TACCCTCTTC 780 TGCTCTGAGT GGAACTGTGG TAGAGCTACG ATGTCAAGAC AAAGAAGGGA ATCCAGCTCC 840 TGAATACACA TGGTTTAAGG ATGGCATCCG TTTGCTAGAA AATCCCAGAC TTGGCTCCCA 900 AAGCACCAAC AGCTCATACA CAATGAATAC AAAAACTGGA ACTCTGCAAT TTAATACTGT 960 TTCCAAACTG GACACTGGAG AATATTCCTG TGAAGCCCGC AATTCTGTTG GATATCGCAG 1020 GTGTCCTGGG AAACGAATGC AAGTAGATGA TCTCAACATA AGTGGCATCA TAGCAGCCGT 1080 AGTAGTTGTG GCCTTAGTGA TTTCCGTTTG TGGCCTTGGT GTATGCTATG CTCAGAGGAA 1140 AGGCTACTTT TCAAAAGAAA CCTCCTTCCA GAAGAGTAAT TCTTCATCTA AAGCCACGAC 1200 AATGAGTGAA AATGATTTCA AGCACACAAA ATCCTTTATA ATTTAAAGAC TCCACTTTAG 1260 AGATACACCA AAGCCACCGT TGTTACACAA GTTATTAAAC TATTATAAAA CTCTGCTTTG 1320 TCCGACATTT GCAAAGAGGT ACACGAGGAA ATGGAATTGG TATTTCATTT TAATTTTCAT 1380 GACTACTAAC TCACCTGAAC TTGCTATTTT AAACAAATAG TTCTGTCGAC ACCTAAAATA 1440 TAATCTGGCT TCTTGTGTCT GGACTAAGTT AAAAGAATTA AAATA 1485 (2) INFORMATION FOR SEQ ID NO: 108: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 810 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: PROSNOT16 (B) CLONE: 1711840 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 108 : CGAGTGAGCG CGCGGCGGCC CCTGGTCCGC CCGGCCGCGG CCGATCTAGG GGCTGGGGGC 60 TGGAGGCGGG GGTGGGGGTC TGAGCTGCGT CCTGGGCTCG AGGCGTCCCC CGGGGAGTCG 120 CCTCTTAGCG GTGCGTCCGG GCTAGCGGCG AGGGGCCGCC CCAAGTCTTC CCACCGCCGC 180 CACCTTAGCA GCCCGACTTG GGGCCTGGAA AGTGGAGCAC GCGGAGGTGG GAGGGCCCTG 240 CACGCGGCCC CCGGTGGGGA AGGGGACGGG CCAGGGATTC AGACTCGGGC TCTCCCCTCA 300 GGATGCAGCA CCGAGGCTTC CTCCTCCTCA CCCTCCTCGC CCTGCTGGCG CTCACCTCCG 360 CGGTCGCCAA AAAGCAAGAT AAGGTGAAGA AGGGCGGCCC GGGGAGCGAG TGCGCTGAGT 420 GGGCCTGGGG GCCCTGCACC CCCAGCAGCA AAGGATTTGC GGCAGTGGGT TTTCCGCGAG 480 GGCCACCTTG GGGGGGCCCA AGAACCCAAC CGGCAGTCCT GGTTGAAAGG GTTGCCCCTG 540 GAAAGTTGGA AAGAAAGGAG TTTTGGGCAC CCGGACTTTG GAAAGTTGGC CAAATTTTTT 600 GGAAGAAAAC TTGGCGGGTC TGCCGGTCCG TTAAATGGGG GAGGGGACAA AAGAATTGAA 660 AGCCGAAAAA ATGCTTTCTC CGCCGCCAAG AGAGGTCGAA CCCGCGTCTG GCAAGAAGAG 720 AAAAGGGCGC GCCCACACTG TTAACAACAA TATGGCGCCT GAACAGTTGG TGGCACCACA 780 GGGGGAGGGA GACACATACT TGCGCGCGGT 810 (2) INFORMATION FOR SEQ ID NO: 109: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1064 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 109 : TTCCTGGGGC TCCGGGGCGC GGAGAAGCTG CATCCCAGAG GAGCGCGTCC AGGAGCGGAC 60 CCGGGAGTGT TTCAAGAGCC AGTGACAAGG ACCAGGGGCC CAAGTCCCAC CAGCCATGCA 120 GACCTGCCCC CTGGCATTCC CTGGCCACGT TTCCCAGGCC CTTGGGACCC TCCTGTTTTT 180 GGCTGCCTCC TTGAGTGCTC AGAATGAAGG CTGGGACAGC CCCATCTGCA CAGAGGGGGT 240 AGTCTCTGTG TCTTGGGGCG AGAACACCGT CATGTCCTGC AACATCTCCA ACGCCTTCTC 300 CCATGTCAAC ATCAAGCTGC GTGCCCACGG GCAGGAGAGC GCCATCTTCA ATGAGGTGGC 360 TCCAGGCTAC TTCTCCCGGG ACGGCTGGCA GCTCCAGGTT CAGGGAGGCG TGGCACAGCT 420 GGTGATCAAA GGCGCCCGGG ACTCCCATGC TGGGCTGTAC ATGTGGCACC TCGTGGGACA 480 CCAGAGAAAT AACAGACAAG TCACGCTGGA GGTTTCAGGT GCAGAACCCC AGTCCGCCCC 540 CGACACTGGG TTCTGGCCTG TGCCAGCGGT GGTCACTGCT GTCTTCATCC TCTTGGTCGC 600 TCTGGTCATG TTCGCCTGGT ACAGGTGCCG CTGTTCCCAG CAACGCCGGG AGAAGAAGTT 660 CTTCCTCCTA GAACCCCAGA TGAAGGTCGC AGCCCTCAGA GCGGGAGCCC AGCAGGGCCT 720 GAGCAGAGCC TCCGCTGAAC TGTGGACCCC AGACTCCGAG CCCACCCCAA GGCCGCTGGC 780 ACTGGTGTTC AAACCCTCAC CACTTGGAGC CCTGGAGCTG CTGTCCCCCC AACCCTTGTT 840 TCCATATGCC GCAGACCCAT AGCCGCCTGC AAGGAAGAGA GGACACAGGA GTAGCCACCC 900 TGAGTGCCGA CCTTTGGTGG CGGGGGCCTG GGTCTCTCGT CCCCACCCGG AAGGGCACAA 960 GACACCGGGC TTTGCTTGGC AAGGCTTGGG GCCTCTTGTG GTCAACCCAG TTCCCTTGGG 1020 TGCCGTTGCA GAACCCCTTA GCCCCTTCCA ACGTCGACCA GGTT 1064 (2) INFORMATION FOR SEQ ID NO: 110: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1031 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 110 : AGTTCCTGCA GGTGCCGGCG GTGACGCGGG CTTACACCGC AGCCTGTGTC CTCATCCACC 60 GCCGCGGTGC AGCTGGAGCT CCTCAGCCCC TTTCAACTCT ACTTCAACCC GCACCTTGTG 120 TTCCGGAAGT TCCAGGTGAG GCCGCCTCGC GCCGCGCACC TGGGGCCCGA CCCACCCACC 180 CCGCACCTGA CCGCCCGTCC CCCGTAGGTC TGGAGGCTCG TCACCAACTT CCTCTTCTTC 240 GGGCCCCTGG GATTCAGCTT CTTCTTCAAC ATGCTCTTCG TGTATCCTGC GCCTGCGGAC 300 ACGGGCTGGG TGGAGGGCAG GCCGGCCGGG CTGGGAGAGA GGCCGGGACG GGGAAACTGA 360 GGCCCCGCCT GGTGGCACTT CCTATACCGA CGCCGTAGGT TCCGCTACTG CCGCATGCTG 420 GAAGAGGGCT CCTTCCGCGG CCGCACGGCC GACTTCGTCT TCATGTTTCT CTTCGGGGGC 480 GTCCTTATGA CCGTATCCTT CCCGCAGGCT CTGGAACCTC GGGCTAGGGC GCCTCGGCGT 540 CCAGCCTGTG TTGGTCCTGG GGCCAACACA GCCATGCCAG AGAGGGACAC AGTCGCTGTC 600 TCCAGCTTAG CACCGTTCCT GCCTTGGGCG CTCATGGGCT TCTCGCTGCT GCTGGGCAAC 660 TCCATCCTCG TGGACCTGCT GGGGATTGCG GTGGGCCATA TCTACTACTT CCTGGAGGAC 720 GTCTTCCCCA ACCAGCCTGG AGGCAAGAGG CTCCTGCAGA CCCCTGGCTT CCTAAAGCTG 780 CTCCTGGATG CCCCTGCAGA AGACCCCAAT TACCTGCCCC TCCCTGAGGA ACAGCCAGGA 840 CCCCATCTGC CACCCCCGCA GCAGTGACCC CCACCCAGGG CCAGGCCTAA GAGGCTTCTG 900 GCAGCTTCCA TCCTACCCAT GACCCCTACT TGGGGCAGAA AAAACCCATC CTAAAGGCTG 960 GGCCCATGCA AGGGCCCACC TGAATAAACA GAATGAGCTG CAAAAAAAAA AAAAAAGGGC 1020 GGCCGTCGCG A 1031 (2) INFORMATION FOR SEQ ID NO: 111: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2316 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: PROSTUT12 (B) CLONE: 1812375 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 111 : GCTGGATAAG ACACCAGGGG AGTCACTACA TGGTTACCGC ATCTGTATCC AGGCCATCCT 60 GCAAGACAAG CCCAAGATTG CCACGGCAAA CCTAGGCAAG TTCCTGGAAC TGCTGAGGTC 120 CCACCAGAGC CGACCAGCAA AGTGTCTCAC CATCATGTGG GCCCTGGGTC AAGCAGGTTT 180 TGCCAACCTC ACCGAGGGAC TGAAAGTGTG GCTGGGGATC ATGCTGCCTG TGCTGGGCAT 240 CAAGTCTCTG TCTCCCTTTG CCATCACATA CCTGGATCGG CTGCTCCTGA TGCATCCCAA 300 CCTTACCAAG GGCTTCGGCA TGATTGGCCC CAAGGACTTC TTCCCACTTC TGGACTTTGC 360 CTATATGCCG AACAACTCCC TGACACCCAG CCTGCAGGAG CAGCTGTGTC AGCTCTACCC 420 CCGACTGAAA ATGCTGGCAT TTGGAGCAAA GCCGGATTCC ACCCTGCATA CCTACTTCCC 480 TTCTTTCCTG TCCAGAGCCA CCCCTAGCTG TCCCCCTGAG ATGAAGAAAG AGCTCCTGAG 540 CAGCCTGACT GAGTGCCTGA CGGTGGACCC CCTCAGTGCC AGCGTCTGGA GGCAGCTGTA 600 CCCTAAGCAC CTGTCACAGT CCAGCCTTCT GCTGGAGCAC TTGCTCAGCT CCTGGGAGCA 660 GATTCCCAAG AAGGTACAGA AGTCTTTGCA AGAAACCATT CAGTCCCTCA AGCTTACCAA 720 CCAGGAGCTG CTGAGGAAGG GTAGCAGTAA CAACCAGGAT GTCGTCACCT GTGACATGGC 780 CTGCAAGGGC CTGTTGCAGC AGGTTCAGGG TCCTCGGCTG CCCTGGACGC GGCTCCTCCT 840 GTTGCTGCTG GTCTTCGCTG TAGGCTTCCT GTGCCATGAC CTCCGGTCAC ACAGCTCCTT 900 CCAGGCCTCC CTTACTGGCC GGTTGCTTCG ATCATCTGGC TTCTTACCTG CTAGCCAACA 960 AGCGTGTGCC AAGCTCTACT CCTACAGTCT GCAAGGCTAC AGCTGGCTGG GGGAGACACT 1020 GCCGCTCTGG GGCTCCCACC TGCTCACCGT GGTGCGGCCC AGCTTGCAGC TGGCCTGGGC 1080 TCACACCAAT GCCACAGTCA GCTTCCTTTC TGCCCACTGT GCCTCTCACC TTGCGTGGTT 1140 TGGTGACAGT CTCACCAGTC TCTCTCAGAG GCTACAGATC CAGCTCCCCG ATTCCGTGAA 1200 TCAGCTACTC CGCTATCTGA GAGAGCTGCC CCTGCTTTTC CACCAGAATG TGCTGCTGCC 1260 ACTGTGGCAC CTCTTGCTTG AGGCCCTGGC CTGGGCCCAG GAGCACTGCC ATGAGGCATG 1320 CAGAGGTGAG GTGACCTGGG ACTGCATGAA GACACAGCTC AGTGAGGCTG TCCACTGGAC 1380 CTGGCTTTGC CTACAGGACA TTACAGTGGC TTTCTTGGAC TGGGCACTTG CCCTGATATC 1440 CCAGCAGTAG GCCCTGCCTT CCTGGCCACT GATTTCTGCA TGGGTAGACC ATCCAAGACT 1500 GCAGCGGGTA GAAGGTGGCA GTTCTTCATG GGAGTCTTTT TAACTTGGTG CCTGAGTTCT 1560 CTCCTAGGCA AGTGGCCAGT TGCCTCCACC TCAGTTCTTC CATCTTTGGT GGGGACAGGG 1620 CCCAGCAGCA TCTCAGCCTC CTACCCACAA TTCCACTGAA CACTTTTCTG GCCCTACTGC 1680 ACATGGCCCC CAGCCTCCAT CCTTGTGCTG GTAGCCTCTC ACAACTCCGC CCTTGCCCTC 1740 TGCCTTCCAC TTCCTTCCAT CTCATTTCTA AACCCCAAAC AGCTCATCTC TAAAAAGATA 1800 GAACTCCCAG CAGGTGGCTT CTGTGTTCTT CTGACAAATG ATTCCTGCTT CTCCAGACTT 1860 TAGCAGCCTC CTGTTCCCAT TCTTGGTCAC AGCTCTAGCC ACAGCAGAAG GAAAGGGGCT 1920 TCCAGAAGAA TATAGCACCG CATTGGGAAA CAGCAGCCTC ACCTCCACCT GAAGCCTGGG 1980 TGTGGCTGTC AGTGGACATG GGGAGCTGGA TGGAAATGCC TCTCACTTCA AAATGCCCAG 2040 CCTGCCCCAA ATGCCTCTAA GCCCCTCCCT GTCCCCTCCC TTGTAGTCCT ACTTCTTCCA 2100 ACTTTCCATT CCCCATCATG CTGGGGGTCT TGGTCACAAG GCTCAGCTTC TCTCCACTGT 2160 CCATCCCTCC TATCATCTGT AGAGCAGAGC ACAGGCAGTT GTGTGCCTTG GGCCCAGGGA 2220 ACCCTCCATC AACCTGAGAC AGGACTCAGT ATATGGTTCT TGGGTATGCC CTACCAGGTG 2280 GAATAAAGGA CACAGATTTG AAAAAAAAAA AAAAAA 2316 (2) INFORMATION FOR SEQ ID NO: 112: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1169 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: PROSNOT20 (B) CLONE: 1818761 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 112 : AGCAAGGAGC CAGAGGCCAT GCAGTGGCTC AGGGTCCGTG AGTCGCCTGG GGAGGCCACA 60 GGACACAGGG TCACCATGGG GACAGCCGCC CTGGGTCCCG TCTGGGCAGC GCTCCTGCTC 120 TTTCTCCTGA TGTGTGAGAT CCCTATGGTG GAGCTCACCT TTGACAGAGC TGTGGCCAGC 180 GGCTGCCAAC GGTGCTGTGA CTCTGAGGAC CCCCTGGATC CTGCCCATGT ATCCTCAGCC 240 TCTTCCTCCG GCCGCCCCCA CGCCCTGCCT GAGATCAGAC CCTACATTAA TATCACCATC 300 CTGAAGGGTG ACAAAGGGGA CCCAGGCCCA ATGGGCCTGC CAGGGTACAT GGGCAGGGAG 360 GGTCCCCAAG GGGAGCCTGG CCCTCAGGGC AGCAAGGGTG ACAAGGGGGA GATGGGCAGC 420 CCCGGCGCCC CGTGCCAGAA GCGCTTCTTC GCCTTCTCAG TGGGCCGCAA GACGGCCCTG 480 CACAGCGGCG AGGACTTCCA GACGCTGCTC TTCGAAAGGG TCTTTGTGAA CCTTGATGGG 540 TGCTTTGACA TGGCGACCGG CCAGTTTGCT GCTCCCCTGC GTGGCATCTA CTTCTTCAGC 600 CTCAATGTGC ACAGCTGGAA TTACAAGGAG ACGTACGTGC ACATTATGCA TAACCAGAAA 660 GAGGCTGTCA TCCTGTACGC GCAGCCCAGC GAGCGCAGCA TCATGCAGAG CCAGAGTGTG 720 ATGCTGGACC TGGCCTACGG GGACCGCGTC TGGGTGCGGC TCTTCAAGCG CCAGCGCGAG 780 AACGCCATCT ACAGCAACGA CTTCGACACC TACATCACCT TCAGCGGCCA CCTCATCAAG 840 GCCGAGGACG ACTGAGGGCC TCTGGGCCAC CCTCCCGGCT GGAGAGCTCA GGTGCTGGTC 900 CCGTCCCCTG CAGGGCTCAG TTTGCACTGC TGTGAAGCAG GAAGGCCAGG GAGGTCCCCG 960 GGGACCTGGC ATTCTGGGGA GACCCTGCTT CTATCTTGGC TGCCATCATC CCTCCCAGCC 1020 TATTTCTGCT CCTCTCTTCT CTCTTGGACC TATTTTAAGA AGCTTGCTAA CCTAAATATT 1080 CTAGAACTTT CCCAGCCTCG TAGCCCAGCA CTTCTCAAAC TTGGAAATGC ATGCGAATCA 1140 CCCGGGGTTC GTGTTAAATG CAGATTCTG 1169 (2) INFORMATION FOR SEQ ID NO: 113: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1530 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: GBLATUT01 (B) CLONE: 1824469 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 113 : TCACAGACTG CGGAGTGGGT CAGGGGCTGC GAGGGCTGCC CCAAGTCCTA CCGGGTTTGC 60 ACGGGCGCGC CCGGCTCCGC CCGCAAGTGC GCCTTCCTGA CTTACTGCTG GGTGCGCGGG 120 GCTGGGGGTG CGAGTACCAC CCCTGAAGTC TCTTCCTGGG CGACCTCCGG GGCCTCATTC 180 TAGGCCTCCT TAAAGAGAAG GATCTAAATT AGGAAAAGGA AGTGCCCTTA TCCACGACCA 240 AGCTCTTCCA CCTGCGGAGC TCGCTTAGTC TGCACCTCAA CCGTGCGGAA AGTGACTGCC 300 CTGTTTACTG AGGAAAAACT GGGGCTCAGA AAGATACCAT GAGTAGTTTG AAACAGGAAC 360 AAAATCTTCT GAAAGCTCGG AGCAGAAGCC TTTTTGGTCA ACATGGAGGA AAAAAGACGG 420 CGAGCCCGAG TTCAGGGAGC CTGGGCTGCC CCTGTTAAAA GCCAGGCCAT TGCTCAGCCA 480 GCTACCACTG CTAAGAGCCA TCTCCACCAG AAGCCTGGCC AGACCTGGAA GAACAAAGAG 540 CATCATCTCT CTGACAGAGA GTTTGTGTTC AAAGAACCTC AGCAGGTAGT ACGTAGAGCT 600 CCTGAGCCAC GAGTGATTGA CAGAGAGGGT GTGTATGAAA TCAGCCTGTC ACCCACAGGT 660 GTATCTAGGG TCTGTTTGTA TCCTGGCTTT GTTGACGTGA AAGAAGCTGA CTGGATATTG 720 GAACAGCTTT GTCAAGATGT TCCCTGGAAA CAGAGGACCG GCATCAGAGA GGATATAACT 780 TATCAACAAC CAAGACTTAC AGCATGGTAT GGAGAACTTC CTTACACTTA TTCAAGAATC 840 ACTATGGAAC CAAATCCTCA CTGGCACCCT GTGCTGCGCA CACTAAAGAA CCGCATTGAA 900 GAGAACACTG GCCACACCTT CAACTCCTTA CTCTGCAATC TTTATCGCAA TGAGAAGGAC 960 AGCGTGGACT GGCACAGTGA TGATGAACCC TCACTAGGGA GGTGCCCCAT TATTGCTTCA 1020 CTAAGTTTTG GTGCCACACG CACATTTGAG ATGAGAAAGA AGCCACCACC AGAAGAGAAT 1080 GGAGACTACA CATATGTGGA AAGAGTGAAG ATACCCTTGG ATCATGGTAC CTTGTTAATC 1140 ATGGAAGGAG CGACACAAGC TGACTGGCAG CATCGAGTGC CCAAAGAATA CCACTCTAGA 1200 GAACCGAGAG TGAACCTGAC CTTTCGGACA GTCTATCCAG ACCCTCGAGG GGCACCCTGG 1260 TGACGTCAGA GCTTTGAGAG AGAAGCTTCA CTGAAACGGA GCAAACCTTC CACTGAGAAG 1320 CCACTTCAAG AGGCTGGTGC TGCTAGATCT CATGATGTGG CTGTTGGGAA GATGGTGGGG 1380 TTTGTTTGCC AGCTTGGAGT CCTATTAAAT GAAAGCCAGC AACTCATGTT GGTAATAGGT 1440 CTACTGTGGG AACAGTTATC CCTAACCACA GCTCAAAATC GCTATCATCT TTAGGCAAAT 1500 TAAAATCTAT GTGGCAGTGA AAAAAAAAAA 1530 (2) INFORMATION FOR SEQ ID NO: 114: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1336 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: PROSNOT19 (B) CLONE: 1864292 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 114 : AGCTCGTACC CCTCGAGTGA AATTCTGAAA TGAAGATGGA GGAGGCAGTG GGAAAAGTTG 60 AAGAACTCAT TGAGTCCGAA GCCCCACCAA AAGCATCTGA ACAAGAGACA GCCAAGGAGG 120 AAGATGGATC TGTAGAACTG GAATCTCAAG TTCAGAAAGA TGGTGTAGCG GATTCTACAG 180 TTATTTCTTC AATGCCCTGC TTGTTGATGG AACTGAGAAG GGACTCTTCT GAGTCTCAGT 240 TAGCATCCAC AGAGAGTGAC AAGCCTACAA CTGGCCGAGT TTATGAGAGT GACCCCTCTA 300 ATCACTGCAT GCTTTCCCCT TCCTCTAGTG GTCACCTGGC TGATTCAGAT ACGTTGTCTT 360 CCGCAGAAGA GAATGAACCC TCTCAGGCAG AAACGGCGGT AGAAGGAGAC CCTTCAGGAG 420 TGTCTGGTGC CACAGTTGGG CGCAAGTCTA GGCGGTCCCG ATCTGAAAGT GAAACTTCCA 480 CTATGGCTGC CAAGAAAAAC CGGCAATCCA GTGATAAACA GAATGGCCGA GTCGCCAAGG 540 TTAAAGGTCA TCGGAGCCAA AAGCACAAGG AGAGGATCAG GCTACTGAGG CAGAAACGGG 600 AGGCTGCTGC AAGGAAGAAA TATAACCTGC TGCAGGACAG TAGTACCAGT GATAGTGACC 660 TGACTTGTGA CTCAAGCACG AGCTCATCAG ATGATGATGA AGAGGTTTCA GGGAGCAGCA 720 AGACAATCAC TGCAGAGATA CCAGATGGAC CTCCAGTTGT AGCTCATTAT GATATGTCTG 780 ACACCAACTC TGACCCAGAA GTGGTAAATG TGGACAATTT ATTGGCGGCT GCAGTAGTTC 840 AAGAGCACAG TAATTCTGTA GGCGGCCAGG ACACAGGAGC TACCTGGAGG ACCAGCGGGC 900 TTCTAGAGGA GCTGAATGCA GAGGCAGGTC ATTTGGATCC AGGATTCCTA GCAAGTGACA 960 AAACATCTGC TGGCAATGCG CCACTCAATG AAGAAATTAA CATTGCGTCT TCAGATAGTG 1020 AAGTAGAGAT TGTGGGAGTT CAGGAACATG CAAGGTGTGT TCATCCTCGA GGTGGTGTGA 1080 TTCAGAGTGT TTCTTCATGG AAGCATGGCT CGGGCACGCA GTATGTTAGC ACCAGGCAAA 1140 CACAGTCATG GACTGCTGTG ACTCCCCAGC AGACTTGGGC TTCACCAGCA GAAGTTGTTG 1200 ACCTTACCTT GGATGAGGAT AGCAGGCGTA AATACCTACT GTAATACAAT GTCACTGTGT 1260 TTCCTCTGCA CTGTTCCCTT CCACTTCCTC ATCCTCTTTG TGACATGGAA GTTCATTGTC 1320 ATAGGGGTAC GGAGCT 1336 (2) INFORMATION FOR SEQ ID NO: 115: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1742 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: THP1NOT01 (B) CLONE: 1866437 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 115 : GCCCCGCCCC CTCCCCGCCC GCCTTCCCGG TGACCTTCAG GGGCCCGGGT GGCGGGCGCA 60 GGCCCCTGCG GCGGCGGCGG GATGTTCGTG CAGGAGGAGA AGATCTTCGC GGGCAAGGTG 120 CTGCGGCTGC ACATCTGCGC GTCCGACGGC GCCGAGTGGC TGGAGGAGGC CACCGAGGAC 180 ACCTCGGTGG AGAAGCTCAA GGAGCGCTGC CTCAAGCACT GTGCTCATGG GAGCTTAGAA 240 GATCCCAAAA GTATAACCCA TCATAAATTA ATCCACGCTG CCTCAGAGAG GGTGCTGAGT 300 GATGCCAGGA CCATCCTGGA AGAGAACATC CAGGACCAAG ATGTCCTATT ATTGAAAAAA 360 AAGCGTGCTC CATCACCACT TCCCAAGATG GCTGATGTCT CAGCAGAAGA AAAGAAAAAA 420 CAAGACCAGA AAGCTCCAGA TAAAGAGGCC ATACTGCGGG CCACCGCCAA CCTGCCCTCC 480 TACAACATGG ACCGGGCCGC GGTCCAGACC AACATGAGAG ACTTCCAGAC AGAACTCCGG 540 AAGATACTGG TGTCTCTCAT CGAGGTGGCG CAGAAGCTGT TAGCGCTGAA CCCAGATGCG 600 GTGGAATTGT TTAAGAAGGC GAATGCAATG CTGGACGAGG ACGAGGATGA GCGTGTGGAC 660 GAGGCTGCCC TGCGGCAGCT CACGGAGATG GGCTTTCCGG AGAACAGAGC CACCAAGGCC 720 CTTCAGCTGA ACCACATGTC GGTGCCTCAG GCCATGGAGT GGCTAATTGA ACACGCAGAA 780 GACCCGACCA TAGACACGCC TCTTCCTGGC CAAGCTCCCC CAGAGGCCGA GGGGGCCACA 840 GCAGCTGCCT CCGAGGCTGC CGCGGGAGCC AGCGCCACCG ATGAGGAGGC CAGAGATGAG 900 CTGACGGAAA TCTTCAAGAA GATCCGGAGG AAAAGGGAGT TTCGGGCTGA TGCTCGGGCC 960 GTCATTTCCC TGATGGAGAT GGGGTTCGAC GAGAAAGAGG TGATAGATGC CCTCAGAGTG 1020 AACAACAACC AGCAGAATGC CGCGTGCGAG TGGCTGCTGG GGGACCGGAA GCCCTCTCCG 1080 GAGGAGCTGG ACAAGGGCAT CGACCCCGAC AGTCCTCTCT TTCAGGCCAT CCTGGATAAC 1140 CCGGTGGTGC AGCTGGGCCT GACCAACCCG AAAACATTGC TAGCATTTGA AGACATGCTG 1200 GAGAACCCAC TGAACAGCAC CCAGTGGATG AATGATCCAG AAACGGGGCC TGTCATGCTG 1260 CAGATCTCTA GAATCTTCCA GACACTAAAT CGCACGTAGG TGGCGTTGTT CCACTCGGCT 1320 ATCAGGCCAC AGCAGCCCCC TGGTGCGGCC CGAGACCGGG CAGAGTGGAC CTCACCTGGA 1380 AACTCACCTT CAGCGCCTCA GCCCTGGACT GTTAGAGGTG CTGCAGCTGC TCCTGCTCTC 1440 TGATCTTATT GCTTATAAAC TTTGGTGACG GTAGTGTGTA AGGCCGTATT TTTAGCATCT 1500 GACAGGTGTT TACAAAAAAG TGGTTGTCGC ACTGGGAAGT GGAGTGATGG CCTCGTCTCC 1560 AGTGCTCCTC TGGGCTCTTG AGTTGCTGCT TGAATTGCCG TGTAGACATT TGCTTGGAGA 1620 GTCCACTTGT TATTTGACGG AGGTAGGTTT CAACCCAGAG TTAATGTCAA GCATGCTAAT 1680 TTAACTAGTC ACTCACAGAT GACTTTTCTT TAATAAAGTC CCTTTTCCTA TTAAAAAAAA 1740 AA 1742 (2) INFORMATION FOR SEQ ID NO: 116: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1074 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: SKINBIT01 (B) CLONE: 1871375 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 116 : GCGGTGCAGA GGAAGCACAA CCTCTACCGG GACAGCATGG TCATGCACAA CAGCGACCCC 60 AACCTGCACC TGCTGGCCGA GGGCGCCCCC ATCGACTGGG GCGAGGAGTA CAGCAACAGC 120 GGCGGGGGCG GCAGCCCAGC CCCAGCACCC CGGAGTCAGC CACCCTCTCG GAAAAGCGAC 180 GGCGCGCCAA GCAGGTGGTC TCTGTGGTCC AGGATGAGGA GGTGGGGCTG CCCTTTGAGG 240 CTAGCCCTGA GTCACCACCA CCTGCGTCCC CGGACGGTGT CACTGAGATC CGAGGCCTGC 300 TGGCCCAAGG TCTGCGGCCT GAGAGCCCCC CACCAGCCGG CCCCCTGCTC AACGGGGCCC 360 CCGCTGGGGA GAGTCCCCAG CCTAAGGCCG CCCCCGAGGC CTCCTCGCCG CCTGCCTCAC 420 CCCTCCAGCA TCTCCTGCCT GGAAAGGCTG TGGACCTTGG GCCCCCCAAG CCCAGCGACC 480 AGGAGACTGG AGAGCAGGTG TCCAGCCCCA GCAGCCACCC CGCCCTCCAC ACCACCACCG 540 AGGACNANTT TCAAGGGGTG CAAGAATTGA AGNTTCNTAA GGGCCAANTT GGGGGTCCCC 600 TTGACTTGGN TTGGNAANAT TGGGGCAAAA AGGGCCGGTT TTCCCCNTTT CCCGGGANAC 660 CCCAAGGGAA AGGGGNTTCA AAGCTTCTTN GGGGGGGAAA GGGGGAANCC CTTGGGTNTT 720 TTGTTGGCCN TTTGTGANCA NCAGCGAGGA GAGTGCAAAG GTGCAGAGTN AGTTNTAGGN 780 CANTGGGTCC CTGACTGCTG CANATGGTAA GGNCGTTNNC TTGTGGACCC AAGGCAGGNA 840 AAGNTGTGGG GAGGGAAGCT GGTNTGTGCN TTGTGGGTGG AAGCGGGGAN GGCTGTGTTG 900 NANGGCAGGG AGAGGGCNAA NTGAGTTATT TATTGGGGTT CANGTGAAAA GTTTCTTGNN 960 CCCTGTNTTG TGTTNCTGTG GGATTGATTN TAAGATNGNN AGGGGTNGGT TTTTGGGGTT 1020 TTCCTGGTTG GTGGCCAAAN GGGTTGGAAA ATNGNTGGGG GGGGNTTGGA NAAT 1074 (2) INFORMATION FOR SEQ ID NO: 117: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1454 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: LEUKNOT03 (B) CLONE: 1880830 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 117 : CCCGGGGGAG GCCTGACCCC CTCCGCACCA CCGTACGGAG CCGCATTTCC CCCGTTTCCC 60 GAGGGGCATC CAGCCGTGTT GCCTGGGGAG GACCCACCCC CCTATTCACC CTTAACTAGC 120 CCGGACAGTG GGAGTGCCCC TATGATCACC TGCCGAGTCT GCCAATCTCT CATCAACGTG 180 GAAGGCAAGA TGCATCAGCA TGTAGTCAAA TGTGGTGTCT GCAATGAAGC CACCCCAATC 240 AAGAATGCAC CCCCAGGGAA AAAATATGTT CGATGCCCCT GTAACTGTCT CCTTATCTGC 300 AAAGTGACAT CCCAACGGAT TGCATGCCCT CGGCCCTACT GCAAAAGAAT CATCAACCTG 360 GGGCCTGTGC ATCCCGGACC TCTGAGTCCA GAACCCCAAC CCATGGGTGT CAGGGTTATC 420 TGTGGACATT GCAAGAATAC TTTTCTGTGG ACAGAGTTCA CAGACCGCAC TTTGGCACGT 480 TGTCCTCACT GCAGGAAAGT GTCATCTATT GGGCGCAGAT ACCCACGTAA GAGATGTATC 540 TGCTGCTTCT TGCTTGGCTT GCTTTTGGCA GTCACTGCCA CTGGCCTTGC CTTTGGCACA 600 TGGAAGCATG CACGGCGATA TGGAGGCATC TATGCAGCCT GGGCATTTGT CATCCTGTTG 660 GCTGTGCTGT GTTTGGGCCG GGCTCTTTAT TGGGCCTGTA TGAAGGTCAG CCACCCTGTC 720 CAGAACTTCT CCTGAGCCTG ATGACCCACA GACTGTGCCT GGCCCCTCCC TGGTGGGGAC 780 AGTGACACTA CGAAGGGAGC TGGGGTAGTT AAAGGCTCCC GGGGCTTCTA GAAGGAAGCC 840 AAGCAGCTGC CTTCCTTTTC CCTGGGGAGA GGTAGGAAGG AACCAGGCCC TCACTTAGGT 900 TTGGAGGGGC AGATAAGAGC ACTGCTGACC ATCTGCTTTC CTCCAAGGGT TGCTGTGTCT 960 AGGGTGAAGT AGGCAAAACG TTGCCCTTAA AACTGGGCCC TGAAGACGGT TCCAGCCTTG 1020 TCCTTCCTGT GTGCTCCCTG AGAGCCATTC CTGTCCCTTA CACATTCCAG GGCAGGGTGG 1080 GGGTGGGTAG CCCTGGGGGT TCCCCTCCCT CTTGTGCACC ATTAGGACTT TGCTGCTGCT 1140 ATTGCACTTC ACCAGAGGTT GGCTCTGGCC TCAGTACCCT CAGTCTCCTC TCCCCACATT 1200 GTGTCCTGTG GGGGTGGGGT CAGCCGCTGC TCTGTACAGA ACCACAGGAA CTGATGTGTA 1260 TATAACTATT TAATGTGGGA TATGTTCCCC TATTCCTGTA TTTCCCTTAA TTCCTCCTCC 1320 CGACCTTTTT TACCCCCCCA GTTGCAGTAT TTAACTGGGC TGGGTAGGGT TGCTCAGTCT 1380 TTGGGGGAGG TTAGGGACTT ATCCTGTGCT TGTAAATAAA TAAGGTCATG ACTCTAAAAA 1440 AAAAAAAAGG GCGG 1454 (2) INFORMATION FOR SEQ ID NO: 118: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2071 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: OVARNOT07 (B) CLONE: 1905325 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 118 : AGCTTTGAAT TCCTGTATCT GAGAACGGAT CGTTCGAGGT GGTGGAGGGG GTTGGAATTG 60 GGGACCTACG GAAGGCTCAG CTCTTGCCAG GCCAAATTGA GACATGTCTG ACACAAGCGA 120 GAGTGGTGCA GGTCTAACTC GCTTCCAGGC TGAAGCTTCA GAAAAGGACA GTAGCTCGAT 180 GATGCAGACT CTGTTGACAG TGACCCAGAA TGTGGAGGTC CCAGAGACAC CGAAGGCCTC 240 AAAGGCACTG GAGGTCTCAG AGGATGTGAA GGTCTCAAAA GCCTCTGGGG TCTCAAAGGC 300 CACAGAGGTC TCAAAGACCC CAGAGGCTCG GGAGGCACCT GCCACCCAGG CCTCGTCTAC 360 TACTCAGCTG ACTGATACCC AGGTTCTGGC AGCTGAAAAC AAGAGTCTAG CAGCTGACAC 420 CAAGAAACAG AATGCTGACC CGCAGGCTGT GACAATGCCT GCCACTGAGA CCAAAAAGGT 480 CAGCCATGTG GCTGATACAA AGGTCAATAC AAAGGCTCAG GAGACTGAGG CTGCACCCTC 540 TCAGGCCCCA GCAGATGAAC CTGAGCCTGA GAGTGCAGCT GCCCAGTCTC AGGAGAATCA 600 GGATACTCGG CCCAAGGTCA AAGCCAAGAA AGCCCGAAAG GTGAAGCATC TGGATGGGGA 660 AGAGGATGGC AGCAGTGATC AGAGTCAGGC TTCTGGAACC ACAGGTGGCC GAAGGGTCTC 720 AAAGGCTCTA ATGGCCTCAA TGGCCCGCAG GTTTCAAGGG GTCCCATAGC CTTTTGGGCC 780 CGCAGGATTC AAGGACTCGG TTGGCTGCTT GGGCCCGGAG AGCCTTGCTC TCCCTGAGAT 840 CACCTAAAGC CCGTAGGGCA AGGCTCGCCG TAGAGCTGCC AAGCTCCAGT CATCCCAAGA 900 GCCTGAAGCA CCACCACCTC GGGATGTGGC CCTTTTGCAA GGGAGGGCAA ATGATTTGGT 960 GAAGTACCTT TTGGCTAAAG ACCAGACGAA GATTCCCATC AAGCGCTCGG ACATGCTGAA 1020 GGACATCATC AAAGAATACA CTGATGTGTA CCCCGAAATC ATTGAACGAG CAGGCTATTC 1080 CTTGGAGAAG GTATTTGGGA TTCAATTGAA GGAAATTGAT AAGAATGACC ACTTGTACAT 1140 TCTTCTCAGC ACCTTAGAGC CCACTGATGC AGGCATACTG GGAACGACTA AGGACTCACC 1200 CAAGCTGGGT CTGCTCATGG TGCTTCTTAG CATCATCTTC ATGAATGGAA ATCGGTCCAG 1260 TGAGGCTGTC ATCTGGGAGG TGCTGCGCAA GTTGGGGCTG CGCCCTGGGA TACATCATTC 1320 ACTCTTTGGG GACGTGAAGA AGCTCATCAC TGATGAGTTT GTGAAGCAGA AGTACCTGGA 1380 CTATGCCAGA GTCCCCAATA GCAATCCCCC TGAATATGAG TTCTTCTGGG GCCTGCGCTC 1440 TTACTATGAG ACCAGCAAGA TGAAAGTCCT CAAGTTTGCC TGCAAGGTAC AAAAGAAGGA 1500 TCCCAAGGAA TGGGCAGCTC AGTACCGAGA GGCGATGGAA GCAGATTTGA AGGCTGCAGC 1560 TGAGGCTGCA GCTGAAGCCA AGGCTAGGGC CGAGATTAGA GCTCGAATGG GCATTGGGCT 1620 CGGCTCGGAG AATGCTGCCG GGCCCTGCAA CTGGGACGAA GCTGATATCG GACCCTGGGC 1680 CAAAGCCCGG ATCCAGGCGG GAGCAGAAGC TAAAGCCAAA GCCCAAGAGA GTGGCAGTGC 1740 CAGCACTGGT GCCAGTACCA GTACCAATAA CAGTGCCAGT GCCAGTGCCA GCACCAGTGG 1800 TGGCTTCAGT GCTGGTGCCA GCCTGACCGC CACTCTCACA TTTGGGCTCT TCGCTGGCCT 1860 TGGTGGAGCT GGTGCCAGCA CCAGTGGCAG CTCTGGTGCC TGTGGTTTCT CCTACAAGTG 1920 AGATTTTAGA TATTGTTAAT CCTGCCAGTC TTTCTCTTCA AGCCAGGGTG CATCCTCAGA 1980 AACCTACTCA ACACAGCACT CTAGGCAGCC ACTATCAATC AATTGAAGTT GACACTCTGC 2040 ATTAAATCTA TTTGCCATTT CAAAAAAAAA A 2071 (2) INFORMATION FOR SEQ ID NO: 119: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1236 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: BRSTTUT01 (B) CLONE: 1919931 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 119 : ACCTGGGACC CCCAGAACGG CCGCCCCTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT 60 TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTAG AAGGTTGAAA CCAGGCTTAT 120 TTATTTTCAT CTTCTTTCTG CCATCTTTTA ACCAACCTTC TCAGAATAAA ATGTGATTTT 180 TGAGACAGAA TGAAACACAT ATCCAAATTT TAATACAGTA AGAATAGGTA TCCTGAATAA 240 ATGAGAACTC TAGAAAATCA AGGTTTCAAA ATTCTACCCT TCCTGGGAGT TAAAGAAGTT 300 TGGCAGAAAC AGAACAAATT AATCAGCAGA TTCATCACCT GCCAATTTTT TCTGTACAAT 360 TTTCTTGATT CTGGGAGCAT CTGGGTCCAG GCAGATTTTC CTCCCATCCT TCAGTGTGGC 420 TGCTTCTTGT TTCATCCATG GACCCTGCAA GAAATTGCCC CATGTTTCTG TTTGTGCATC 480 ACTGAGAAAG GAAGCATGAA GGTCGCACAG GTCAGGCCAT TCCATTGCCC TCCTGGTGCC 540 GGGTTTGCCC TCCCAATCCT GGGGTTGCTT CAGGGGCTTG TCATTCTCCA TAGTCCCCTC 600 CACATTTCTC AGGTTTCTGC TCAAAAGTCA CCTTTTGGAG GGGTCTCCAC CTGTCACTGT 660 GTTTGTAAGA GCTCCTTCAG TTTCTTTCTA GCTCATCTCA CTCTGGTAAT GTCTTTGATT 720 ACCACCACCA TCTGACCTGG TCTTATGACC TGTTAGCTTT CTTCATCAGA CGTGAGCACC 780 AGGATGGCAG GGGCCTCATC TGTCCTGTTC CTCCTGTGGC CTGGGTCCTA GCACCATGTC 840 TGGTACAGTG TAGATGCTCA AGGGAAGTTT ACTTTGTAAA ACCACTTACC TGGGAGATGT 900 TACTGTTAGT CTAACCTGTA CCATTTTGTA AACCTCCAGC CATTTTGCAG ACTCTGATCA 960 CAGTGAAACG TTCCATGGGA ACTTGGGCCA TGAGAAACAT CCTTCCTAAC CACGTGACTG 1020 CAGAAACATC CTTATCGCGT CCTCCTGGGC AAAGGCCCAA CAGCCTGACT GCAGGGACAT 1080 CCTTGCCATA TCCTGCTGGG CAGCAAGCTC TACCACCCAG ATCCCTCCCT CCCAGTCCCA 1140 TGATTACCCC AGCCTGTGAG TGGCAGTTGG TGCTGGCACT AAGCTGGTTT CCTCCTCCCC 1200 AGGGTTTTGC TGGCAATAAA GATGTTGCTG TTGAAG 1236 (2) INFORMATION FOR SEQ ID NO: 120: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1391 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: BRSTNOT04 (B) CLONE: 1969426 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 120 : GTACTGCCCA CCACCTCCCT GGGCCACCCC TCACTCAGTG CTCCGGCTCT CTCCTCCTCC 60 TCTTCGTCCT CCTCCACTTC ATCTCCTGTT TTGGGCTCCC CCTCTTACCC TGCTTCTTCC 120 CCTGGGGCCT CCCCCCACCA CCGCCGTGTG CCCCTCAGCC CCCTGAGTTT GCTCGCGGGC 180 CCAGCCGACG CCAGAAGGTC CCAACAGCAG CTGCCCAAAC AGTTTTCGCC AACAATGTCA 240 CCCACCTTGT CTTCCATCAC TCAGGGCGTC CCCCTGGATA CCAGTAAACT GTCCACTGAC 300 CAGCGGTTAC CCCCATACCC ATACAGCTCC CCAAGTCTGG TTCTGCCTAC CCAGCCCCAC 360 ACCCCAAAGT CTCTACAGCA GCCAGGGCTG CCCTCTCAGT CTTGTTCAGT GCAGTCCTCA 420 GGTGGGCAGC CCCCAGGCAG GCAGTCTCAT TATGGGACAC CGTACCCACC TGGGCCCAGT 480 GGGCATGGGC AACAGTCTTA CCACCGGCCA ATGAGTGACT TCAACCTGGG GAATCTGGAG 540 CAGTTCAGCA TGGAGAGCCC ATCAGCCAGC CTGGTGCTGG ATCCCCCTGG CTTTTCTGAA 600 GGGCCTGGAT TTTTAGGGGG TGAGGGGCCA ATGGGTGGCC CCCAGGATCC CCACACCTTC 660 AACCACCAGA ACTTGACCCA CTGTTCCCGC CATGGCTCAG GGCCTAACAT CATCCTCACA 720 GGGGACTCCT CTCCAGGTTT CTCTAAGGAG ATTGCAGCAG CCCTGGCCGG AGTGCCTGGC 780 TTTGAGGTGT CAGCAGCTGG ATTGGAGCTA GGGCTTGGGC TAGAAGATGA GCTGCGCATG 840 GAGCCACTGG GCCTGGAAGG GCTAAACATG CTGAGTGACC CCTGTGCCCT GCTGCCTGAT 900 CCTGCTGTGG AGGAGTCATT CCGCAGTGAC CGGCTCCAAT GAGGGCACCT CATCACCATC 960 CCTCTTCTTG GCCCCATCCC CCACCACCAT TCCTTTCCTC CCTTCCCCCT GGCAGGTAGA 1020 GACTCTACTC TCTGTCCCCA GATCCTCTTT CTAGCATGAA TGAAGGATGC CAAGAATGAG 1080 AAAAAGCAAG GGGTTTGTCC AGGTGGCCCC TGAATTCTGC GCAAGGGATG GGCCTGGGGG 1140 AACTCAAGGG AGGGCCTAAA GCACTTGTAA CTTTGAACCG TCTGTCTGGA GGTCAGAGCC 1200 TGTTGGAAAG CAGGGGTAGA GGGGAGCCCT GGAAGCAGGG CTTTTCCGGA TGCCTAGGGG 1260 TGGGCAGTGC CAGCCCCTCC TCACCACTCT TCCCCTTGCA GTGGAGGAGA GAGCCAGAGT 1320 GGATACTATT TTTTATTAAA TATATTATTA TATGTTAATA AAAAAATCAT ATCAAAAAAA 1380 AAAAAAAAAG G 1391 (2) INFORMATION FOR SEQ ID NO: 121: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2183 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: UCMCL5T01 (B) CLONE: 1969948 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 121 : CTCTGTGAAC ATATGATGAG AGAAGCCAAG ATCATGCAGT ATAAGTACCT ACTGTTCAGT 60 CTTCACGCCA TAGTGAAGCT TGGAATCCCT CAGAACACTA TTTTGGTGCA GACTTTGCTG 120 AGGGTGACCC AGGAACGTAT CAATGAGTGT GATGAGATAT GCCTTTCAGT TTTGTCAACT 180 GTTTTAGAGG CAATGGAACC ATGCAAGAAT GTTCATGTTC TACGAACGGG ATTCAGAATA 240 CTAGTTGATC AGCAAGTTTG GAAAATAGAA GATGTCTTCA CATTACAAGT TGTGATGAAG 300 TGTATTGGAA AAGATGCACC GATTGCTCTT AAGAGGAAAC TGGAGATGAA AGCCTTGAGG 360 GGATTAGACA GATTTTCTGT TTTGAATAGC CAACACATGT TTGAAGTACT AGCTGCCATG 420 AATCACCGAT CTCTTATACT CCTGGATGAA TGCAGTAAGG TGGTCCTAGA TAATATCCAT 480 GGGTGTCCTT TAAGAATAAT GATCAACATA TTGCAGTCCT GCAAAGACCT CCAGTACCAT 540 AATTTGGATC TCTTCAAGGG ACTTGCAGAT TATGTGGCTG CAACTTTCGA CATCTGGAAG 600 TTCAGAAAAG TTCTTTTTAT CCTCATTTTA TTTGAAAACC TTGGCTTTCG ACCTGTTGGT 660 TTAATGGACC TGTTTATGAA GAGAATAGTA GAGGATCCTG AATCCCTAAA CATGAAAAAC 720 ATTCTATCTA TTCTTCATAC TTACTCTTCT CTCAATCATG TCTACAAATG CCAGAACAAA 780 GAACAGTTCG TGGAAGTTAT GGCTAGTGCT CTGACTGGTT ATCTTCACAC TATTTCTTCT 840 GAAAACTTAT TGGATGCAGT ATATTCATTT TGCTTGATGA ATTACTTTCC CCTGGCTCCT 900 TTTAATCAGC TTCTGCAAAA AGACATCATC AGTGAGCTGC TGACATCAGA TGACATGAAG 960 AATGCTTACA AGCTGCATAC TTTGGATACT TGTCTAAAAC TTGATGATAC TGTCTATCTG 1020 AGGGACATAG CCTTGTCACT CCCACAGCTG CCGCGGGAGC TGCCATCGTC ACATACAAAT 1080 GCAAAGGTGG CAGAGGTGCT GAGCAGCCTT CTGGGAGGTG AAGGACACTT CTCAAAGGAT 1140 GTGCACTTGC CACACAATTA TCATATTGAT TTTGAAATCA GAATGGACAC TAACAGGAAT 1200 CAAGTGCTAC CACTTTCTGA TGTGGATACA ACTTCTGCTA CAGATATTCA AAGAGTAGCT 1260 GTGCTATGTG TTTCCAGATC TGCTTATTGT TTGGGTTCAA GCCACCCCAG AGGATTCCTT 1320 GCTATGAAAA TGCGGCATTT GAATGCAATG GGTTTTCATG TGATCTTGGT CAATAACTGG 1380 GAGATGGACA AACTAGAGAT GGAAGATGCA GTCACATTTT TGAAGACTAA AATCTATTCA 1440 GTAGAAGCTC TTCCTGTTGC TGCTGTAAAT GTGCAAAGCA CACAATAAAG TGAAAATCAA 1500 CCTTTTCATA TTAGGAGACA TGCATTTGTA AAAATTAATA AAGATGACAA GTCAGTTGTC 1560 AATGGAATTG AGCTATCTGC TAAGACAAAA AATGTTACCT CAGTTCACTA TTAAAATTAA 1620 TTTTAGGAGT GGAAGAAATG TTGTTACTGC CATTTAAAAA TATGCTGAGA AAATTCCAGA 1680 AGGGTTATTT TTCCAACCAC ACCTATTCCC TCTAGTGCCC AGATATTTGA TTTGTGAGCT 1740 GTACGTTTCA CCTTTTCATC TTTGATCTAC TAAAAACTGG TTTCTTAGTT GTGAGGTGTC 1800 ACAGGCAGGT TGATGTGGGT AGTAGTCCTT GTCTTTGGAA TCTGAATATT TATACTCCTG 1860 CTCTAAGCTG TTCTAAGACT TGGGGTTATG CCTTTAAATC ATTTTCAAGC ATTGGCCAAA 1920 TAATAATTGG ACAAAGTTCT AAAGTTGTCA AGTGTGTAAG AATTAGTGAG GTAGCTGTTG 1980 AAAATGAGTG AGGATGGTAT TTGTATTTGT AATAAGCACT GCAGGTAGAG ATATTTCATG 2040 GGTTATAATA AGAGAAACAC AGATGAGATG TAGATGGTAA GGAGTCTTAC TGTTGTTGGG 2100 GTCCTTCCTT TCTCTTTCTT TTTTCCCCCT TACCCCTCCC ACAATTTCAT GAAGTCTTTT 2160 AAATTAAATA TATAGCTTNA ATT 2183 (2) INFORMATION FOR SEQ ID NO: 122: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2066 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: LUNGAST01 (B) CLONE: 1988911 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 122 : AGAACCACTG CAGTGGAGAC TCCATGTGCA AAAGAAAAAA ACCAAATGTG AGGTCATAAA 60 GACTTTCTGC CAGCATGTGG GTGACATTGT TTCTTTGCAG ATTTTGGCTA TGGAAAGGGG 120 AAATGTTCTA AGCAGAGCCC CGTCAAGAGC CCACGGGACA CATTTTGGAG ATGACAGATT 180 TGAAGATCTG GAAGAGGCAA ATCCATTCTC TTTTAGAGAG TTTCTGAAGA CCAAGAACCT 240 CGGCCTCTCG AAAGAGGATC CGGCCAGCAG AATTTATGCA AAGGAAGCCT CGAGGCATTC 300 CCTGGGACTT GACCACAACT CCCCACCCTC CCAAACCGGC GGGTATGGCC TGGAGTATCA 360 GCAGCCATTT TTCGAGGATC CGACAGGGGC TGGTGACCTC CTGGATGAGG AGGAGGATGA 420 GGACACCGGA TGGAGTGGGG CCTACCTGCC GTCCGCCATC GAGCAGACTC ACCCCGAGAG 480 GGTCCCTGCC GGCACGTCGC CCTGCAGCAC ATACCTTTCC TTTTTCTCCA CCCCGTCGGA 540 GCTGGCAGGG CCTGAGTCTC TGCCCTCGTG GGCGTTGAGT GACACTGATT CTCGCGTGTC 600 TCCGGCCTCT CCGGCAGGGA GTCCTAGCGC AGACTTTGCG GTTCATGGAG AGTCTCTGGG 660 AGACAGGCAC CTGCGGACGC TGCAGATAAG TTACGACGCA CTGAAAGATG AAAATTCTAA 720 GCTGAGAAGA AAGCTGAATG AGGTTCAGAG CTTCTCTGAA GCTCAAACAG AAATGGTGAG 780 GACGCTTGAG CGGAAGTTAG AAGCAAAAAT GATCAAGGAG GAAAGCGACT ACCACGACCT 840 GGAGTCGGTG GTTCAGCAGG TGGAGCAGAA CCTGGAGCTG ATGACCAAAC GGGCTGTAAA 900 GGCAGAAAAC CACGTCGTGA AACTAAAACA GGAAATCAGT TTGCTCCAGG CGCAGGTCTC 960 CAACTTCCAG CGAGAGAATG AAGCCCTGCG GTGCGGCCAG GGTGCCAGCC TGACCGTGGT 1020 GAAGCAGAAC GCCGACGTGG CCCTGCAGAA CCTCCGGGTG GTCATGAACA GTGCACAGGC 1080 TTCCATCAAG CAACTGGTTT CCGGAGCTGA GACACTGAAT CTTGTTGCCG AAATCCTTAA 1140 ATCTATAGAC AGAATTTCTG AAGTTAAAGA CGAGGAGGAA GACTCTTGAG GACCCCTGGG 1200 TGTTCTCAGC ATGAAGCTCC GTGTATACCC TGAGGTCACC ACCGCTCGAT CTAAATGTGC 1260 AGTTGTGTCC TTAAATATGC AGTCTTCACC CAGAGTAAAG TGTTGATCGC AAGAGTCCAG 1320 TGTCGTGCCC TCAGCCAGTT CTTGGCCACC ACAATGGGAG CAGCCCTGGC CGAGTTGTCT 1380 CTGTGGTTTC TATGCAGCCC TTCTTGGCGA AATTCCTGCG ATCTTATAGA TTCTAATGAG 1440 CTCTTGGAAG ACATTGTCAT AAAAGCCAGT GATTTTAAGA AAAAGAGTGG TTCTGGAATC 1500 AATGTTTTCC AGTCCCATCC CAGAACATCA GTTGTAAGAT AAGTACAATT GGTTGTCCTT 1560 GATTTCATAA GTAGAACAAA CACTAAATGT GCCTCTGAGA TGGCCACCCC GGGCAGGGAC 1620 CTGTGCCTTC CGCCGATGCT CAGGGCTCCC TCTGGCTCCC GGGTCACTCT TGTGGCCCCA 1680 GTGGGTGGTC CCTGCAGTCA TGGCCTGAGT GCGCAGGGGC CACCGCGTGG CTGCTGCTGT 1740 CCTCCTCCGG GACCCACGGG GACCAAGGTC ACACGTTCCG TGCTGTGAAG CTGTCCAGAT 1800 GTGCCTCTTT GGCTGGGGGT TCTGGTGGAC GTTTCAAGTG GCATTTTGTA CAATGCAGGT 1860 TAGAATTCAG GAATTTCAAG TATGTGCCCG GGTCTGTCAG GTCCCAGTTG CCTTTCTGAC 1920 GGCCCCCCTC AGAGGGACGG CGATGAGCAC TAAATGCTTT TTTGACTATT TTCCTATAGA 1980 TTTTTTTTAA AACTTTTTTT TCCTCCTGTT CCAATTGATA GCTTTCTTAT TTAATAAATT 2040 CTGTAGTTCA CCGCAAAAAA AAAAAA 2066 (2) INFORMATION FOR SEQ ID NO: 123: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1867 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: OVARNOT03 (B) CLONE: 2061561 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 123 : TGGCCAGGCT GGTCTAGAAC TCCTGACTGC AAATGATCAG CCCGCCTCAG CCACCCAAAG 60 TGTTGGGATT ACAGGTGTGA GCCACTGTGC CCAGCGTGAT TTTTTTTTTT TTTAAAGCAA 120 ACTTGTCCTT TGGTTTTGCA GAACAGGCCT GCTCCCTCTC ATCTAGCCCA TCATTTCTTG 180 GGGCCTGAAC CCCAGTGGTC CAAAGTATTG CTTGTGAAAT TTAAAAAATG TGAATATGAT 240 GTGGGGATGG GCCTCTTCTA CATTACCTTG GCCCAGGGGG ATCAGCTGGC TGGGAGGATT 300 AGTGAGCACC TCTGTATTTT GAGGTCTGAG TCTTCTGGAG CTGTGTAGTT AATCTTCGGT 360 TTCTGATAAC CCCTGGGTCC ATCTGGCCAT CAGCCTCAGC AGTGAGCAAA GCAATACCAT 420 ACTCATTTCT ATGTTCCTGT TCCTTCCTCT GCTCCTCCTT TGGAGAAGCA ATAATTCATG 480 GGGGATGATA CAGTAGCACT TTACAAATGG CTCCATGTCA TTCATCCCAG GGGCCATAAT 540 CTCTTGCACC ACCTATTCTT ACTTCCTGTT CAGCTCCTTT ACAGCTTTTA TTTTCAACTG 600 CTTCCCAACT TGGTGGGGCC TCCTTTAAGG ATGAGCCAAT AGTAAGAATG TGGCTGTAAT 660 CAGCAGAGAC CCCTCTGAGG GGTATCTGTT CTGCAGCCCC TAGTGAAATC ATGTGATGTG 720 AGACAGAAAC CTAAACATGG TACTTGATTC TAAACCTGTG CCAGTCTATA GCCTCTGCCT 780 CCCCAAGCAG AGCTCAAGCC AAACGCTTCT GTCCTCTTTC CTTCTGCATT AACCCTTTGC 840 TGATCCTCAG GGGCCACTCC CCCAACACCC CTGTACTTGG GTGAGGGATG TTGGACAGAG 900 CCTGTTTTCA TGTACTGCAG GTGGGGGTGT GCTGACATGT TTGCTCTTGG TTGATGGAGA 960 AGGTACAGAG GCCAGGGAGT GAAAATGGTT GACAGAAGAG GGAAGAGTTA GGTGTCTCAT 1020 AGTCACTCAT AGTGGGGTGG TCAGGGGTAA TGGCATCTCC CCACTTTAGG CTTCTCAAAC 1080 AGACTTTTGA CACCTCTCAA GTTCAGAGCT CTGATGTGGA AAGACAGGAG GTGTGGGGAA 1140 GGAGGGGGAT TTCGTGTGTT TGCATGAGTG TGCGCTTCAG GCCTTGGGAG TTGGCAAGAG 1200 GGAGGGAAGG AAGGAGAGCA AAATCTTCGG AAGGTGTTTC TTGTACCTGA GGGATCCTGC 1260 CCTGAATCTC CATAGTCTCC ACTGTGAACT GAGGAGGGGA GGGGTGTGCT GGGGAATAAA 1320 TCTTGTATGA GAACAATCAA AAATCAAACG AATCCCACCG ACAGACTGCT GCTCCTAGTG 1380 ATCTGGACTC ACCTAGGGGG CATCTGGGCT GGGGTTCCAN GCTTACGTNC GCGTGNATGN 1440 GACGNCANAG CTCTTCGAAA GTGTCCCNAA ANTNCAATTC ATTGGCGGTG GTTTTAAAAG 1500 TTCGGGCCTG GGAAACCCGG GGGNTTACCC ATTTTATCCC NCTTNGANGG CANATTCCCC 1560 TTTTTCCCCA ATTTGGGGAA ATTTNCCAAA NGGGNCCCGT AACGGTTGGC CTTTTCCCAA 1620 AATTTNGGNC GCCCTTAATT GGGGCGATTG TGGGACCCGC GCCCTTTATA GGGGGGGGCT 1680 TTAAAGCGGC GCNGGGGGTT CTTTGGGTGA TTACCGGCGC GGTTGACCCC GGGTAAAATA 1740 TTGACAAGGG CCCTTTAGCG CGCGGTTCCT TGTGGGGTTT TCCTCCCATT TGCTTTTTCC 1800 GCAAAAGTTT TGGCGGGGTT TTCCCCGGAA AAGGTCTTAA AAAGCGGTGT GCCCCTCTTT 1860 GAGGGGG 1867 (2) INFORMATION FOR SEQ ID NO: 124: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1628 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: PANCNOT04 (B) CLONE: 2084489 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 124 : CTCTGGGTCT GTAGCAACCG CCCAGCGTTG AGGCGCGGCT CATGCCCCCA GTATCCCGGT 60 CCAGCTATTC CGAGGACATC GTGGGCTCTC GGAGAAGGCG ACGCAGCTCC TCGGGGAGCC 120 CACCATCCCC GCAGAGCAGA TGTTCCTCTT GGGATGGCTG TTCCCGCTCT CACTCCCGCG 180 GCCGTGAGGG CCTCAGGCCT CCTTGGAGTG AGTTGGACGT GGGCGCTCTT TACCCCTTTA 240 GTCGCTCTGG GTCGCGAGGG CGGCTCCCAA GATTCCGCAA CTACGCCTTC GCGTCCTCCT 300 GGTCGACCTC GTATAGTGGA TATCGCTACC ATCGTCACTG CTATGCAGAA GAACGGCAGT 360 CAGCGGAAGA CTACGAGAAG GAAGAGAGCC ATCGGCAGAG GAGGCTGAAG GAGAGAGAGA 420 GGATTGGGGA ATTGGGAGCG CCTGAAGTGT GGGGGCCGTC TCCAAAGTTC CCTCAGCTAG 480 ATTCTGACGA ACATACCCCA GTTGAGGATG AAGAAGAGGT AACGCATCAG AAAAGCAGCA 540 GTTCAGATTC CAACTCGGAA GAACATAGGA AAAAGAAGAC CAGTCGTTCA AGAAACAAGA 600 AAAAAAGAAA GAATAAGTCG TCTAAAAGAA AGCATAGGAA ATATTCTGAT AGTGACAGTA 660 ACTCAGAGTC TGACACAAAT TCTGACTCTG ATGATGATAA AAAGAGAGTT AAAGCCAAGA 720 AGAAAAAGAA GAAAAAGAAA CACAAAACAA AGAAAAAGAA GAATAAGAAA ACCAAAAAAG 780 AATCCAGTGA CTCAAGCTGT AAAGACTCAG AAGAGGACTT GTCAGAAGCT ACCTGGATGG 840 AGCAGCCAAA TGTGGCAGAT ACTATGGATT TAATAGGGCC AGAAGCACCT ATAATACATA 900 CCTCTCAAGA TGAAAAACCT TTGAAGTATG GCCATGCTTT GCTTCCCGGT GAAGGTGCAG 960 CTATGGCTGA GTATGTAAAA GCTGGAAAGC GAATCCCACG AAGAGGTGAA ATTGGGTTGA 1020 CAAGTGAAGA GATCGGTTCT TTTGAATGCT CAGGTTATGT CATGAGTGGT AGCAGGCATC 1080 GCAGAATGGA GGCTGTACGA CTGCGTAAGG AGAACCAGAT CTACAGTGCT GATGAGAAGA 1140 GAGCTCTTGC ATCCTTTAAC CAAGAAGAGA GACGAAAGAG AGAAAGTAAG ATTTTAGCCA 1200 GTTTCCGAGA GATGGTGCAC AAAAAGACAA AAGAGAAAGA TGACAAGTAA GGACTTACTT 1260 GTTGCACAGC AGGAATTTTA ACAACAAAAA TTTTATGTGA CCAAAAGTGT TAAAAGGCTT 1320 TACAGTGCTA CTGTACTTAC CATATTAGTA AGTCCCTCAG GAAAAAGCTT CTTTTGAGAT 1380 ATCTTTAGCA GCTTATTTTT TGTTATTTTA ACTTTAAAAA GTAATATGTG CACATGGTTT 1440 TAAAAATATT CAACCATTAT AGGAGGAGAG TTAGTAAAAA GTGAATCTTT CACTTTAGCC 1500 CCTGACACCT TTCCCCCAAA AATATATATT TTGGTGTCTT ATATACAGAA TATACATTCT 1560 GTGCATATAC AAGAGTATAT GTTGCAGCAT AAAGATTAAA AGCTATTAAA GTTTTTTTTC 1620 GCTCGTTA 1628 (2) INFORMATION FOR SEQ ID NO: 125: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1200 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: SPLNFET02 (B) CLONE: 2203226 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 125 : GTGGCGGCGG CGAAGGATGC ACCCGGCAGG CTTGGCGGCG GCGGCTGCGG GGACGCCCCG 60 GCTGCCCTCG AAGCGGAGGA TCCCTGTGTC CCAGCCGGGC ATGGCCGACC CCCACCAGCT 120 TTTCGATGAC ACAAGTTCAG CCCAGAGCCG GGGCTATGGG GCCCAGCGGG CACCTGGTGG 180 CCTGAGTTAT CCTGCAGCCT CTCCCACGCC CCATGCAGCC TTCCTGGCTG ACCCGGTGTC 240 CAACATGGCC ATGGCCTATG GGAGCAGCCT GGCCGCGCAG GGCAAGGAGC TGGTGGATAA 300 GAACATCGAC CGCTTCATCC CCATCACCAA GCTCAAGTAT TACTTTGCTG TGGACACCAT 360 GTATGTGGGC AGAAAGCTGG GCCTGCTGTT CTTCCCCTAC CTACACCAGG ACTGGGAAGT 420 GCAGTACCAA CAGGACACCC CGGTGGCCCC CCGCTTTGAC GTCAATGCCC CGGACCTCTA 480 CATTCCAGCA ATGGCTTTCA TCACCTACGT TTTGGTGGCT GGTCTTGCGC TGGGGACCCA 540 GGATAGGTTC TCCCCAGACC TCCTGGGGCT GCAAGCGAGC TCAGCCCTGG CCTGGCTGAC 600 CCTGGAGGTG CTGGCCATCC TGCTCAGCCT CTATCTGGTC ACTGTCAACA CCGACCTCAC 660 CACCATCGAC CTGGTGGCCT TCTTGGGCTA CAAATATGTC GGGATGATTG GCGGGGTCCT 720 CATGGGCCTG CTCTTCGGGA AGATTGGCTA CTACCTGGTG CTGGGCTGGT GCTGCGTGGC 780 CATCTTTGTG TTCATGATCC GGACGCTGCG GCTGAAGATC TTGGCAGACG CAGCAGCTGA 840 GGGGGTCCCG GTGCGTGGGG CCCGGAACCA GCTGCGCATG TACCTGACCA TGGCGGTGGC 900 GGCGGCGCAG CCTATGCTCA TGTACTGGCT CACCTTCCAC CTGGTGCGGT GAGCGCGCCC 960 GCTGAACCTC CCGCTGCTGC TGCTGCTGCT GGGGGCCACT GTGGCCGCCG AACTCATCTC 1020 CTGCCTGCAG GCCCCAAGGT CCACCCTGTC TGGCCACAGG CACCGCCTCC ATCCCATGTC 1080 CCGCCCAGCC CCGCCCCCAA CCCAAGGTGC TGAGAGATCT CCAGCTGCAC AGGCCACCGC 1140 CCCAGGGCGT GGCCGCTGTT ACAGAAACAA TAAACCCTGA TGGGCATGGC AAAAAAAAAA 1200 (2) INFORMATION FOR SEQ ID NO: 126: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1093 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: PROSNOT16 (B) CLONE: 2232884 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 126 : AGAGCCCCAG CCACGCCGGC CCAGGTGGCC TCAGGTGAGG GGGGGCGGAC GCACCTGTGG 60 GGACGGGACG ACGAGTTCAA GCCTCCGTGG GTGCAGTTGG TCGCCAGCGA GGGATGCGGA 120 GACGCCCCTG AACGACCATG GCATCGGCCG ACGAGCTGAC CTTCCATGAA TTCGAGGAGG 180 CCACTAATCT TCTGGCTGAC ACCCCAGATG CAGCCACCAC CAGCAGAAGC GATCAGCTGA 240 CCCCACAAGG GCACGTGGCT GTGGCCGTGG GCTCAGGTGG CAGCTATGGA GCCGAGGATG 300 AGGTGGAGGA GGAGAGTGAC AAGGCCGCGC TCCTGCAGGA GCAGCAGCAG CAGCAGCAGC 360 CGGGATTCTG GACCTTCAGC TACTATCAGA GCTTCTTTGA CGTGGACACC TCACAGGTCC 420 TGGACCGGAT CAAAGGCTCA CTGCTGCCCC GGCCTGGCCA CAACTTTGTG CGGCACCATC 480 TGCGGAATCG GCCGGATCTG TATGGCCCCT TCTGGATCTG TGCCACGTTG GCCTTTGTCC 540 TGGCCGTCAC TGGCAACCTG ACGCTGGTGC TGGCCCAGAG GAGGGACCCC TCCATCCACT 600 ACAGCCCCCA GTTCCACAAG GTGACCGTGG CAGGCATCAG CATCTACTGC TATGCGTGGC 660 TGGTGCCCCT GGCCCTGTGG GGCTTCCTGC GGTGGCGCAA GGGTGTCCAG GAGCGCATGG 720 GGCCCTACAC CTTCCTGGAG ACTGTGTGCA TCTACGGCTA CTCCCTCTTT GTCTTCATCC 780 CCATGGTGGT CCTGTGGCTC ATCCCTGTGC CTTGGCTGCA GTGGCTCTTT GGGGCGCTGG 840 CCCTGGGCCT GTCAGCCGCC GGGCTGGTAT TCACCCTCTG GCCCGTGGTC CGTGAGGACA 900 CCAGGCTGGT GGCCACAGTG CTGCTGTCCG TGGTCGTGCT GCTCCACGCC CTCCTGGCCA 960 TGGGCTGTAA GTTGTACTTC TTCCAGTCGC TGCCTCCGGA GAACGTGGCT CCTCCACCCC 1020 AAATCACATC TCTGCCCTCA AACATCGCGC TGTCCCCTAC CTTGCCGCAG TCCCTGGCCC 1080 CCTCCTAGGA AGG 1093 (2) INFORMATION FOR SEQ ID NO: 127: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1121 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: COLNNOT11 (B) CLONE: 2328134 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 127 : GCGGGGGATG ACGCCACGGA CATGGTGGCC GAGACCGGCG GGGTGGGGGA CGTGTCGCGC 60 GGCCGGGTGG CCTCGGTCGG TACCCTGGGC GCGGACAGCT GCCTCATTAG TATTCGTACC 120 CACGAGGCGG CGCAGCGGGC CCTCGGGGAC AGCGAGCGTC GCGGCTATGG CTTATCACTC 180 GGGCTACGGA GCCCACGGCT CCAAGCACAG GGCCCGGGCA GCCCCGGATC CCCCTCCCCT 240 CTTCGATGAC ACAAGCGGTG GTTATTCCAG CCAGCCCGGG GGATACCCAG CCACAGGAGC 300 AGACGTGGCC TTCAGTGTCA ACCACTTGCT TGGGGACCCA ATGGCCAATG TGGCTATGGC 360 CTATGGCAGC TCCATCGCAT CCCATGGGAA GGACATGGTG CACAAGGAGC TGCACCGTTT 420 TGTGTCTGTG AGCAAACTCA AGTATTTTTT TGCTGTGGAC ACAGCCTACG TGGCCAAGAA 480 GCTAGGGCTG CTGGTCTTCC CCTACACACA CCAGAACTGG GAAGTGCAGT ACAGTCGTGA 540 TGCTCCTCTG CCCCCCCGGC AAGACCTCAA CGCCCCTGAC CTCTATATCC CCACGATGGC 600 CTTCATTACT TACGTGCTCC TGGCTGGGAT GGCACTGGGC ATTCAGAAAA GGTTCTCCCC 660 GGAGGTGCTG GGCCTGTGTG CAAGCACAGC GCTGGTGTGG GTGGTGATGG AGGTGCTGGC 720 CCTGCTCCTG GGCCTCTACC TGGCCACCGT GCGCAGTGAC CTGAGCACCT TTCACCTGCT 780 GGCCTACAGT GGCTACAAAT ACGTGGGAAT GATCCTCAGT GTGCTCACGG GGCTGCTGTT 840 CGGCAGCGAT GGCTACTACG TGGCGCTGGC CTGGACCTCA TCGGCGCTCA TGTACTTCAT 900 TGTGCGCTCT TTGCGGACAG CAGCCCTGGG CCCCGACAGC ATGGGGGGCC CCGTCCCCCG 960 GCAGCGTCTC CAGCTCTACC TGACTCTGGG AGCTGCAGCC TTCCAGCCCC TCATCATATA 1020 CTGGCTGACT TTCCACCTGG TCCGGTGACC CCCTGGCCCC AGATGGCACT GAGTTTTTCA 1080 TTCATTGAAG ATTTGATTTC CTTGAAAAAA AAAAAAAAAG G 1121 (2) INFORMATION FOR SEQ ID NO: 128: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1861 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: ISLTNOT01 (B) CLONE: 2382718 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 128 : CGCGGACTGT GTCTGTTCCC AGGAGTCCTT CGGCGGCTGT TGTGTCAGTG GCCTGATCGC 60 GATGGGGACA AAGGCGCAAG TCGAGAGGAA ACTGTTGTGC CTCTTCATAT TGGCGATCCT 120 GTTGTGCTCC CTGGCATTGG GCAGTGTTAC AGTGCACTCT TCTGAACCTG AAGTCAGAAT 180 TCCTGAGAAT AATCCTGTGA AGTTGTCCTG TGCCTACTCG GGCTTTTCTT CTCCCCGTGT 240 GGAGTGGAAG TTTGACCAAG GAGACACCAC CAGACTCGTT TGCTATAATA ACAAGATCAC 300 AGCTTCCTAT GAGGACCGGG TGACCTTCTT GCCAACTGGT ATCACCTTCA AGTCCGTGAC 360 ACGGGAAGAC ACTGGGACAT ACACTTGTAT GGTCTCTGAG GAAGGCGGCA ACAGCTATGG 420 GGAGGTCAAG GTCAAGCTCA TCGTGCTTGT GCCTCCATCC AAGCCTACAG TTAACATCCC 480 CTCCTCTGCC ACCATTGGGA ACCGGGCAGT GCTGACATGC TCAGAACAAG ATGGTTCCCC 540 ACCTTCTGAA TACACCTGGT TCAAAGATGG GATAGTGATG CCTACGAATC CCAAAAGCAC 600 CCGTGCCTTC AGCAACTCTT CCTATGTCCT GAATCCCACA ACAGGAGAGC TGGTCTTTGA 660 TCCCCTGTCA GCCTCTGATA CTGGAGAATA CAGCTGTGAG GCACGGAATG GGTATGGGAC 720 ACCCATGACT TCAAATGCTG TGCGCATGGA AGCTGTGGAG CGGAATGTGG GGGTCATCGT 780 GGCAGCCGTC CTTGTAACCC TGATTCTCCT GGGAATCTTG GTTTTTGGCA TCTGGTTTGC 840 CTATAGCCGA GGCCACTTTG ACAGAACAAA GAAAGGGACT TCGAGTAAGA AGGTGATTTA 900 CAGCCAGCCT AGTGCCCGAA GTGAAGGAGA ATTCAAACAG ACCTCGTCAT TCCTGGTGTG 960 AGCCTGGTCG GCTCACCGCC TATCATCTGC ATTTGCCTTA CTCAGGTGCT ACCGGACTCT 1020 GGCCCCTGAT GTCTGTAGTT TCACAGGATG CCTTATTTGT CTTCTACACC CCACAGGGCC 1080 CCCTACTTCT TCGGATGTGT TTTTAATAAT GTCAGCTATG TGCCCCATCC TCCTTCATGC 1140 CCTCCCTCCC TTTCCTACCA CTGCTGAGTG GCCTGGAACT TGTTTAAAGT GTTTATTCCC 1200 CATTTCTTTG AGGGATCAGG AAGGAATCCT GGGTATGCCA TTGACTTCCC TTCTAAGTAG 1260 ACAGCAAAAA TGGCGGGGGT CGCAGGAATC TGCACTCAAC TGCCCACCTG GCTGGCAGGG 1320 ATCTTTGAAT AGGTATCTTG AGCTTGGTTC TGGGCTCTTT CCTTGTGTAC TGACGACCAG 1380 GGCCAGCTGT TCTAGAGCGG GAATTAGAGG CTAGAGCGGC TGAAATGGTT GTTTGGTGAT 1440 GACACTGGGG TCCTTCCATC TCTGGGGCCC ACTCTCTTCT GTCTTCCCAT GGGAAGTGCC 1500 ACTGGGATCC CTCTGCCCTG TCCTCCTGAA TACAAGCTGA CTGACATTGA CTGTGTCTGT 1560 GGAAAATGGG AGCTCTTGTT GTGGAGAGCA TAGTAAATTT TCAGAGAACT TGAAGCCAAA 1620 AGGATTTAAA ACCGCTGCTC TAAAGAAAAG AAAACTGGAG GCTGGGCGCA GTGGCTCACG 1680 CCTATAATCC CAGAGGCTGA GGCAGGCGGA TCACCTGAGG TCGGGAGTTC GGGATCAGCC 1740 TGACCAACAT GGAGAAACCC TACTGAGAAT ACAAAGTTAG CCAGGCATGG TGGTGCATGC 1800 CTGTAATCCC AGCTGCTCAG GAGCCTGGCA ACAAGAGCAA AACTCCAGCT CAAAAAAAAA 1860 A 1861 (2) INFORMATION FOR SEQ ID NO: 129: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1975 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: ENDANOT01 (B) CLONE: 2452208 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 129 : GTTTGGAGGA GACTCGGATA TACCTTCTCA GAAGCTGCAC AGGAGGAAAG CAGTGACAAA 60 GAAAGAAGTT GTCATTCTTT GCACGAAACT GGATGGCTTC TACAGGGAGC CAGGCCTCTG 120 ATATAGACGA GATTTTTGGA TTCTTCAACG ATGGCGAACC TCCCACCAAA AAGCCCAGGA 180 AGCTGCTTCC AAGCTTAAAA ACTAAGAAGC CTCGAGAACT TGTGCTAGTG ATTGGAACAG 240 GCATTAGTGC TGCAGTTGCG CCCCAAGTTC CAGCCCTCAA ATCCTGGAAG GGGTTAATTC 300 AGGCCTTACT GGATGCTGCC ATTGATTTTG ATCTTTTAGA AGATGAGGAG AGCAAAAAGT 360 TTCAGAAATG TCTCCATGAA GACAAGAACC TGGTCCATGT TGCCCATGAC CTTATCCAGA 420 AACTCTCTCC TCGTACCAGT AATGTTCGAT CCACATTTTT CAAGGACTGT TTATATGAAG 480 TATTTGATGA CTTGGAGTCA AAGATGGAAG ATTCTGGAAA ACAGCTACTT CAGTCAGTTC 540 TCCACCTGAT GGAAAATGGA GCCCTCGTAT TAACTACAAA TTTTGATAAT CTCTTGGAAC 600 TGTATGCAGC AGATCAGGGG AAACAGCTTG AATCCCTTGA CCTTACTGAT GAGAAAAAGG 660 TCCTCGAGTG GGCTCAGGAG AAGCGTAAGC TGAGCGTGTT GCATATTCAC GGAGTCTACA 720 CCAACCCTAG TGGCATTGTC CTTCATCCGG CTGGATATCA GAACGTGCTC AGGAACACTG 780 AAGTCATGAG AGAAATTCAG AAACTCTACG AAAACAAGTC ATTTCTTTTC CTGGGCTGTG 840 GCTGGACTGT GGATGACACC ACTTTCCAGG CCCTTTTCTT GGAGGCTGTC AAGCATAAAT 900 CTGACCTAGA ACATTTCATG CTGGTTCGGA GAGGAGACGT AGATGAGTTC AAAAAGCTTC 960 GAGAAAACAT GCTGGACAAG GGGATTAAAG TCATCTCCTA TGGAGATGAC TATGCCGATC 1020 TTCCAGAATA TTTCAAGCGA CTGACATGTG AGATCTCCAC AAGGGGTACA TCAGCAGGGA 1080 TGGTGAGAGA AGGTCAGCTA AATGGCTCAT CTGCAGCACA CAGTGAAATA AGAGGCTGTA 1140 GTACATGAGC GAGCTAGAGA AATCACCACC GTTTAGACCA AGCTGTAAGG CCCTACTACA 1200 GACAGTGTTT AACAAGTAAA CTTACAAGAA CCCAACACAA TTCCCAGAAA GTAACAATAG 1260 CCAGAGGTTG AAGGGCGGGG TAGAAGAGGG GGGAATGTTG CAGCGTAATC CTTCATACCA 1320 CCTGGTTCTT GATATTCTGC CGCCTGTTCA AGTTCAAGAA TAAAAGCGAC AGCAGGACCC 1380 AAATGCAGCT CCCAACCCAC TCCCCAGGCT AGACATGCTT GTGTCCACAC AGCACACCAA 1440 TGTGATACTT CCACTGACCG GCTGCAGCTC TGCATGAAGG ACTCGGGGTC TGGATGCCAT 1500 GGAATCACTG TGGCTCTTGT TGCAGTTTTG TACTCTATAC TTGGTTTTTC AATTAAGCTT 1560 AATGGCTTTT TTAAAACATG ACTTGAAGCT CTAGTTTTCT AGATCTTTTA CAGTGTACAG 1620 TATTTTACAT AACTAAGCTG TATTAAAAGC TTGTTCATTT ACTTGCCAGG ACCCTGGCTC 1680 TACTTTTAGA GTCATTGTAA GAAACTCTAA CTTGCATCAA GGTACTAATA AGCTTAATTT 1740 TAATAACCCA AAGTTTAAAG GTTCCGATCT TTCTCCTTGG GGTGGAGTGA TCTCATTCTC 1800 AGGACAACCG TTTACTTACC TGATTCCTCG GAGCATTATC AACTTCTGCT CTGTTGTCCT 1860 GACCATACAT ATGTCCTAGA ACTACAGTTA AGTGTGTTGT GGAATTTTAG TTTTGAATCC 1920 GGAATAAATG AAGTCCCAGG ACTCAAAGAA GAGAGAAAAA AAAAAAGGGG GCCCC 1975 (2) INFORMATION FOR SEQ ID NO: 130: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2160 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: ENDANOT01 (B) CLONE: 2457825 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 130 : TCTACTGTCC CCTGCCCTGT ACCCCCAGGC ATTGATCTGG AGAACATTGT GTACTACAAG 60 GACGACACCC ACTACTTTGT GATGACAGCC AAGAAGCAGT GCCTGCTGCG GCTGGGGGTG 120 CTGCGCCAGG ACTGGCCAGA CACCAATCGG CTGCTGGGCA GTGCCAATGT GGTGCCCGAG 180 GCTCTGCAGC GCTTTACCCG GGCAGCTGCT GACTTTGCCA CCCATGGCAA GCTCGGGAAA 240 CTAGAGTTTG CCCAGGATGC CCATGGGCAG CCTGATGTCT CTGCCTTTGA CTTCACGAGC 300 ATGATGCGGG CAGAGAGTTC TGCTCGTGTG CAAGAGAAGC ATGGCGCCCG CCTGCTGCTG 360 GGACTGGTGG GGGACTGCCT GGTGGAGCCC TTCTGGCCCC TGGGCACTGG AGTGGCACGG 420 GGCTTCCTGG CAGCCTTTGA TGCAGCCTGG ATGGTGAAGC GGTGGGCAGA GGGCGCTGAG 480 TCCCTAGAGG TGTTGGCTGA GCGTGAGAGC CTGTACCAGC TTCTGTCACA GACATCCCCA 540 GAAAACATGC ATCGCAATGT GGCCCAGTAT GGGCTGGACC CAGCCACCCG CTACCCCAAC 600 CTGAACCTCC GGGCAGTGAC CCCCAATCAG GTACGAGACC TGTATGATGT GCTAGCCAAG 660 GAGCCTGTGC AGAGGGACAA CGACAAGACA GATACAGGGA TGCCAGCCAC CGGGTCGGCA 720 GGCACCCAGG AGGAGCTGCT ACGCTGGTGC CAGGAGCAGA CAGCTGGGTA CCCGGGAGTC 780 CACGTCTCCG ATTTGTCTTC CTCCTGGGCT GATGGGCTAG CTCTGTGTGC CCTGGTGTAC 840 CGGCTGCAGC CTGGCCTGCT GGAACCCTCA GAGCTGCAGG GGCTGGGAGC TCTGGAAGCA 900 ACTGCTTGGG CACTAAAGGT GGCAGAGAAT GAGCTGGGCA TCACACCGGT GGTGTCTGCA 960 CAGGCCGTGG TAGCAGGGAG TGACCCACTG GGCCTCATTG CCTACCTCAG CCACTTCCAC 1020 AGTGCCTTCA AGAGCATGGC CCACAGCCCA GGCCCTGTCA GCCAGGCCTC CCCAGGGACC 1080 TCCAGTGCTG TATTATTCCT TAGTAAACTT CAGAGGACCC TGCAGCGATC CCGGGCCAAG 1140 GAAAATGCAG AGGATGCTGG TGGCAAGAAG CTGCGCTTGG AGATGGAGGC CGAGACCCCA 1200 AGTACTGAGG TGCCACCTGA CCCAGAGCCT GGTGTACCCC TGACACCCCC ATCCCAACAC 1260 CAGGAGGCCG GTGCTGGGGA CCTGTGTGCA CTTTGTGGGG AACACCTCTA TGTCCTGGAA 1320 CGCCTCTGTG TCAACGGCCA TTTCTTCCAC CGGAGCTGCT TCCGCTGCCA TACCTGTGAG 1380 GCCACACTGT GGCCAGGTGG CTACGAGCAG CACCCAGGCA GTAGAACGTC TCAGTTCTTC 1440 TTCTCAGCTC TTGTGGCCAT GGAGAAGGAG GAAAAAGAGA GTCCCTTCTC CAGTGAAGAG 1500 GAAGAAGAAG ATGTGCCTTT GGACTCAGAT GTGGAACAGG CCCTGCAGAC CTTTGCCAAG 1560 ACCTCAGGCA CCATGAATAA CTACCCAACA TGGCGTCGGA CTCTGCTGCG CCGTGCGAAG 1620 GAGGAGGAGA TGAAGAGGTT CTGCAAGGCC CAGACCATCC AACGGCGACT AAATGAGATT 1680 GAGGCTGCCT TGAGGGAGCT AGAGGCCGAG GGCGTGAAGC TGGAGCTGGC CTTGAGGCGC 1740 CAGAGCAGTT CCCCAGAACA GCAAAAGAAA CTATGGGTAG GACAGCTGCT ACAGCTCGTT 1800 GACAAGAAAA ACAGCCTGGT GGCTGAGGAG GCCGAGCTCA TGATCACGGT GCAGGAATTG 1860 AATCTGGAGG AGAAACAGTG GCAGCTGGAC CAGGAGCTAC GAGGCTACAT GAACCGGGAA 1920 GAAAACCTAA AGACAGCTGC TGATCGGCAG GCTGAGGACC AGGTCCTGAG GAAGCTGGTG 1980 GATTTGGTCA ACCAGAGAGA TGCCCTCATC CGCTTCCAGG AGGAGCGCAG GCTCAGCGAG 2040 CTGGCCTTGG GGACAGGGGC CCAGGGCTAG ACGAGGGTGG GCCGTCTGCT TTCGTTCCCA 2100 CAAAGAAAGC ACCTCACCCC AGCACAGTGC CACCCCTGTT CATCTGGGCT GCCTGGCAGA 2160 (2) INFORMATION FOR SEQ ID NO: 131: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 546 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: THP1NOT03 (B) CLONE: 2470740 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 131 : GAGGAAGAAG AGGAAGAGGG GGCTCCGATT GGGACCCCTA GGGATCCTGG AGATGGTTGT 60 CCTTCCCCCG ACATCCCTCC TGAACCCCCT CCAACACACC TGAGGCCCTG CCCTGCCAGC 120 CAGCTCCCTG GACTCCTGTC CCATGGCCTC CTGGCCGGCC TCTCCTTTGC AGTGGGGTCC 180 TCCTCTGGCC TCCTGCCCCT CCTGCTGCTG CTGCTGCTTC CATTGCTGGC AGCCCAGGGT 240 GGGGGTGGCC TGCAGGCAGC GCTGCTGGCC CTTGAGGTGG GGCTGGTGGG TCTGGGGGCC 300 TCCTACCTGC TCCTTTGTAC AGCCCTGCAC CTGCCCTCCA GTCTTTTCCT ACTCCTGGCC 360 CAGGGTACCG CACTGGGGGC CGTCCTGGGN CATGAGCTGG CGCCGAAGGC TCATGGGTGT 420 TCCCCTGGGG CTTTGGAACT GCCTGGTTCT TAAGCTTNGG CAAGGCCTAG CTCCAACCTC 480 TGGTGGCTAA TGGCANCCGG GGGGGAANAT GGGTTCNGGA AAAAGGGCCC CCGGGTTTCA 540 CCGGGG 546 (2) INFORMATION FOR SEQ ID NO: 132: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 581 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: SMCANOT01 (B) CLONE: 2479092 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 132 : GCCATGGAGG CCCTGAGGAG GGCCCACGAG GTCGCGCTCC GCCTGCTGCT GTGTAGGCCG 60 TGGGCCTCGC GCGCCGCCGC CCGCCCCAAG CCCAGCGCCT CGGAGGTGCT GACGCGGCAT 120 CTGCTGCAGC GGCGCCTGCC GCACTGGACC TCCTTCTGCG TGCCCTACAG CGCCGTCCGC 180 AACGACCAGT TCGGCCTCTC GCACTTCAAC TGGCCGGTGC AGGGCGCCAA CTACCACGTC 240 CTGCGCACCG GCTGCTTCCC CTTCATCAAG TACCACTGCT CCAAGGCTCC CTGGCAGGAC 300 CTGGCCCGGC AGAACCGCTT CTTCACGGCG CTCAAGGTCG TCAACCTCGG TATTCCAACT 360 TTATTATATG GACTTGGCTC CTGGTTATTT GCCAGAGTCA CAGAGACTGT GCATACCAGT 420 TATGGACCCA TAACAGTTTA TTTTCTCAAT AAAGAAGATG AAGGTGCCAT GTATTGAAAG 480 TGTGCGTCAA AGAACATAAA TATCAGTGGA TTTTCTCTGT GTATATGTGC AGTATTTATT 540 TTTGATCCTT TAAAATAAAA CTTTTGCAAA TAAAAAAAAA A 581 (2) INFORMATION FOR SEQ ID NO: 133: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1259 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: SMCANOT01 (B) CLONE: 2480544 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 133 : GGGCTGGGCC CCGCCGCAGC TCCAGCTGGC CGGCTTGGTC CTGCGGTCCC TTCTCTGGGA 60 GGCCCGACCC CGGCCGCGCC CAGCCCCCAC CATGCCACCC GCGGGGCTCC GCCGGGCCGC 120 GCCGCTCACC GCAATCGCTC TGTTGGTGCT GGGGGCTCCC CTGGTGCTGG CCGGCGAGGA 180 CTGCCTGTGG TACCTGGACC GGAATGGCTC CTGGCATCCG GGGTTTAACT GCGAGTTCTT 240 CACCTTCTGC TGCGGGACCT GCTACCATCG GTACTGCTGC AGGGACCTGA CCTTGCTTAT 300 CACCGAGAGG CAGCAGAAGC ACTGCCTGGC CTTCAGCCCC AAGACCATAG CAGGCATCGC 360 CTCAGCTGTG ATCCTCTTTG TTGCTGTGGT TGCCACCACC ATCTGCTGCT TCCTCTGTTC 420 CTGTTGCTAC CTGTACCGCC GGCGCCAGCA GCTCCAGAGC CCATTTGAAG GCCAGGAGAT 480 TCCAATGACA GGCATCCCAG TGCAGCCAGT ATACCCATAC CCCCAGGACC CCAAAGCTGG 540 CCCTGCACCC CCACAGCCTG GCTTCATGTA CCCACCTAGT GGTCCTGCTC CCCAATATCC 600 ACTCTACCCA GCTGGGCCCC CAGTCTACAA CCCTGCAGCT CCTCCTCCCT ATATGCCACC 660 ACAGCCCTCT TACCCGGGAG CCTGAGGAAC CAGCCATGTC TCTGCTGCCC CTTCAGTGAT 720 GCCAACCTTG GGAGATGCCC TCATCCTGTA CCTGCATCTG GTCCTGGGGG TGGCAGGAGT 780 CCTCCAGCCA CCAGGCCCCA GACCAAGCCA AGCCCTGGGC CCTACTGGGG ACAGAGCCCC 840 AGGGAAGTGG AACAGGAGCT GAACTAGAAC TATGAGGGGT TGGGGGGAGG GCTTGGAATT 900 ATGGGCTATT TTTACTGGGG GCAAGGGAGG GAGATGACAG CCTGGGTCAC AGTGCCTGTT 960 TTCAAATAGT CCCTCTGCTC CCAAGATCCC AGCCAGGAAG GCTGGGGCCC TACTGTTTGT 1020 CCCCTCTGGG CTGGGGTGGG GGGAGGGAGG AGGTTCCGTC AGCAGCTGGC AGTAGCCCTC 1080 CTCTCTGGCT GCCCCACTGG CCACATCTCT GGCCTGCTAG ATTAAAGCTG TAAAGACATA 1140 ACTCATATCA GTCGCATCAT TGGACCCATC CACACCTTCC AGGAACACCG NCTTCAGCTG 1200 GGCCCAGACT GTTGCCCACT CCATATTCCA AAAGTAGGGG AGGGCCAGCA CCAGCATCG 1259 (2) INFORMATION FOR SEQ ID NO: 134: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2033 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: BRAITUT21 (B) CLONE: 2518547 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 134 : CGGCTCGAGG CCGCAGCCCC ATGGACAGTC TTCTGCACCC CCGGGAGCGC CCTGGATCCA 60 CTGCCTCCGA GAGCTCAGCC TCTCTGGGCA GTGAGTGGGA CCTCTCAGAA TCTTCTCTCA 120 GCAACCTGAG TCTTCGCCGT TCCTCAGAGC GCCTCAGTGA CACCCCTGGA TCCTTCCAGT 180 CACCTTCCCT GGAAATTCTG CTGTCCAGCT GCTCCCTGTG CCGTGCCTGT GATTCGCTGG 240 TGTATGATGA GGAAATCATG GCTGGCTGGG CACCTGATGA CTCTAACCTC AACACAACCT 300 GCCCCTTCTG CGCCTGCCCC TTTGTGCCCC TGCTCAGTGT CCAGACCCTT GATTCCCGGC 360 CCAGTGTCCC CAGCCCCAAA TCTGCTGGTG CCAGTGGCAG CAAAGATGCT CCTGTCCCTG 420 GTGGTCCTGG CCCTGTGCTC AGTGACCGAA GGCTCTGCCT TGCTCTGGAT GAGCCCAGCT 480 CTGCAACGGG CACATGGGGG GAGCCTCCCG GCGGGTTGAG AGTGGGGCAT GGGCATACCT 540 GAGCCCCCTG GTGCTGCGTA AGGAGCTGGA GTCGCTGGTA GAGAACGAGG GCAGTGAGGT 600 GCTGGCGTTG CCTGAACTGC CCTCTGCCCA CCCCATCATC TTCTGGAACC TTTTGTGGTA 660 TTTCCAACGG CTACGCCTGC CCAGTATTCT ACCAGGCCTG GTGCTGGCCT CCTGTGATGG 720 GCCTTCGCAC TCCCAGGCCC CATCTCCTTG GCTAACCCCT GATCCAGCCT CTGTTCAGGT 780 ACGGCTGCTG TGGGATGTAC TGACCCCTGA CCCCAATAGC TGCCCACCTC TCTATGTGCT 840 CTGGAGGGTC CACAGCCAGA TCCCCCAGCG GGTGGTATGG CCAGGCCCTG TACCTGCATC 900 CCTTAGTTTG GCACTGTTGG AGTCAGTGCT GCGCCATGTT GGACTCAATG AAGTGCACAA 960 GGCTGTGGGG CTCCTGCTGG AAACTCTAGG GCCCCCACCC ACTGGCCTGC ACCTGCAGAG 1020 GGGAATCTAC CGTGAGATAT TATTCCTGAC AATGGCTGCT CTGGGCAAGG ACCACGTGGA 1080 CATAGTGGCC TTCGATAAGA AGTACAAGTC TGCCTTTAAC AAGCTGGCCA GCAGCATGGG 1140 CAAGGAGGAG CTGAGGCACC GGCGGGCGCA GATGCCCACT CCCAAGGCCA TTGACTGCCG 1200 AAAATGTTTT GGAGCACCTC CAGAATGCTA GAGACCTTAA GCTTCCCTCT CCAGCCTAGG 1260 GTGGGGAAGT GAGGAAGAAG GGATTCTAGA GTTAAACTGC CTCCCTGTTG CCTTCATGGA 1320 GTTGGGAACA GGCTGGGAAG GATGCCCAGT CAAAGGCTCC AAGCGAGGAC AACAGGAAGA 1380 GGGATCCACT GTTACCAAAA GTCCTGATTC CCCCATCACC AACCTACCCA GTTTGTTCGT 1440 GCTGATGTTG GGGGAGATCT GGGGGGAGTT GGTACAGCTC TGTTCTTCCC TTGTCCTATA 1500 CCGGGAACTC CCCTCCAGGG TACCCACAGA TCTGCATTGC CCTGGTCATT TTAGAAGTTT 1560 TTGTTTTAAA AAACAACTGG AAAGATGCAG AGCTACTGAG CCTTTGCCCT GAATGGGAGG 1620 TAGGGATGTC ATTCTCCACC AATAATGGTC CCTCTTCCCT GACGTTGCTG AAGGAGCCCA 1680 AGGCTCTCCA TGCCTTTCTA CCTAAGTGTT TGTATTTTAT TTTAAATTAT TTATTCTGGA 1740 GCCACAGCCC CCTTGCTTAT GAGGTTCTTA TGGAGAGTGA GAAAGGGAAG GGAAATAGGG 1800 CACCATGGTC CGGTGGTTTG TAGTTCCTTC AAAGTCAGGC ACTGGGAGCT AGAGGAGTCT 1860 CAAGCTCCCC TTAGGAAGAA CTGGTGCCCC CTCCAGTCCT AATTTTTCTT GCCTGCCCCG 1920 CCTTGGGGAA TGCCTCACCC ACCCAGGTCC TGACCTGTGC AATAAGGATT GTTCCCTGCG 1980 AAGTTTTGTT GGATGTAAAT ATAGTAAAAG CTGCTTCTGT CTTTTTCAAA AAA 2033 (2) INFORMATION FOR SEQ ID NO: 135: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3007 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: GBLANOT02 (B) CLONE: 2530650 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 135 : GCCCACTGGG CTCTCCCGGC TGCAGTGCCA GGGCGCAGGA CGCGGCCGAT CTCCCGCTCC 60 CGCCACCTCC GCCACCATGC TGCTCCCCCA GCTCTGCTGG CTGCCGCTGC TCGCTGGGCT 120 GCTCCCGCCG GTGCCCGCTC AGAAGTTCTC GGCGCTCACG TTTTTGAGAG TGGATCAAGA 180 TAAAGACAAG GATTGTAGCT TGGACTGTGC GGGTTCGCCC CAGAAACCTC TCTGCGCATC 240 TGACGGAAGG ACCTTCCTTT CCCGTTGTGA ATTTCAACGT GCCAAGTGCA AAGATCCCCA 300 GCTAGAGATT GCATATCGAG GAAACTGCAA AGACGTGTCC AGGTGTGTGG CCGAAAGGAA 360 GTATACCCAG GAGCAAGCCC GGAAGGAGTT TCAGCAAGTG TTCATTCCTG AGTGCAATGA 420 CGACGGCACC TACAGTCAGG TCCAGTGTCA CAGCTACACG GGATACTGCT GGTGCGTCAC 480 GCCCAACGGG AGGCCCATCA GCGGCACTGC CGTGGCCCAC AAGACGCCCC GGTGCCCGGG 540 TTCCGTAAAT GAAAAGTTAC CCCAACGCGA AGGCACAGGA AAAACAGATG ATGCCGCAGC 600 TCCAGCGTTG GAGACTCAGC CTCAAGGAGA TGAAGAAGAT ATTGCATCAC GTTACCCTAC 660 CCTTTGGACT GAACAGGTTA AAAGTCGGCA GAACAAAACC AATAAGAATT CAGTGTCATC 720 CTGTGACCAA GAGCACCAGT CTGCCCTGGA GGAAGCCAAG CAGCCCAAGA ACGACAATGT 780 GGTGATCCCT GAGTGTGCGC ACGGCGGCCT CTACAAGCCA GTGCAGTGCC ACCCCTCCAC 840 GGGGTACTGC TGGTGCGTCC TGGTGGACAC GGGGCGCCCC ATTCCCGGCA CATCCACAAG 900 GTACGAGCAG CCGAAATGTG ACAACACGGG CCAGGGCCCA CCCAGCCAAA GCCCGGGACC 960 TGTACAAGGG CCGCCAGCTA CAAGGTTGTC CGGGTGCCAA AAAGCATGAG TTTCTGACCA 1020 GCGTTCTGGA CGCGCTGTCC ACGGACATGG TCCACGCCGC CTCCGACCCC TCCTCCTCGT 1080 CAGGCAGGCT CTCAGAACCC GACCCCAGCC ATACCCTAGA GGAGCGGGTG GTGCACTGGT 1140 ACTTCAAACT ACTGGATAAA AACTCCAGTG GAGACATCGG CAAAAAGGAA ATCAAACCCT 1200 TCAAGAGGTT CCTTCGCAAA AAATCAAAGC CCAAAAAATG TGTGAAGAAG TTTGTTGAAT 1260 ACTGTGACGT GAATAATGAC AAATCCATCT CCGTACAAGA ACTGATGGGC TGCCTGGGCG 1320 TGGCGAAAGA GGACGGCAAA GCGGACACCA AGAAACGCCA CACCCCCAGA GGTCATGCTG 1380 AAAGTACGTC TAATAGACAG CCAAGGAAAC AAGGATAAAT GGCTCATACC CCGAAGGCAG 1440 TTCCTAGACA CATGGGAAAT TTCCCTCACC AAAGAGCAAT TAAGAAAACA AAAACAGAAA 1500 CACATAGTAT TTGCACTTTG TACTTTAAAT GTAAATTCAC TTTGTAGAAA TGAGCTATTT 1560 AAACAGACTG TTTTAATCTG TGAAAATGGA GAGCTGGCTT CAGAAAATTA ATCACATACA 1620 ATGTATGTGT CCTCTTTTGA CCTTGGAAAT CTGTATGTGG TGGAGAAGTA TTTGAATGCA 1680 TTTAGGCTTA ATTTCTTCGC CTTCCACATG TTAACAGTAG AGCTCTATGC ACTCCGGCTG 1740 CAATCGTATG GCTTTCTCTA ACCCCTGCAG TCACTTCCAG ATGCCTGTGC TTACAGCATT 1800 GTGGAATCAT GTTGGAAGCT CCACATGTCC ATGGAAGTTT GTGATGTACG GCCGACCCTA 1860 CAGGCAGTTA ACATGCATGG GCTGGTTTGT TTCTTGGGAT TTTCTGTTAG TTTGTCTTGT 1920 TTTGCTTTCC AGAGATCTTG CTCATACAAT GAATCACGCA ACCACTAAAG CTATCCAGTT 1980 AAGTGCAGGT AGTTCCCCTG GAGGAAATAA TATTTTCAAA CTGTCGTTGG TGTGATACTT 2040 TGGCTCAAAG GATCTTTGCT TTTCCATTTT AAGCTTCTGT TTTGAGTTTT GCCCTGGGGC 2100 TTGAATGAGT CCCAGAGAGT CGTTCGGATG GTGGGAGGCT GCCTAGGAGG CAGTAAATCC 2160 AGTCACAGTG CCTGGGAGGG GCCCATCCTT CCAAAATGTA AATCCAGTCG CGGTGTGACC 2220 GAGCTGGCTA ACAGGCTTGT CTGCCTGGTT TTCCTCCTAC ACGTGGACAT TATTCTCCTG 2280 ATCCTCCTAC CTGGTCCACC CCAGGGCTAC CGGAAGGTAA AATCTTCACC TGAACCAATT 2340 ATGAGCAGTC TCCTTACTGA AGGTACAGCC GGATACGTGG TGCCCCCGGG GCTGGTGTTG 2400 GCAGCCGGGG GGAGGTGCCT GAGGGTCCCC ACGGTTCCTT TCTGCTTTTC TGAATGCATC 2460 AAGGGTACGA GAACTTGCCA ATGGGAAATT CATCCGAGTG GCACTGGCAG AGAAGGATAG 2520 GAGTGGAATG CCCACACAGT GACCAACAGA ACTGGTCTGC GTGCATAACC AGCTGCCACC 2580 CTCAGGCCTG GGCCCCAGAG CTCAGGGCAC CCAGTGTCTT AAGGAACCAT TTGGAGGACA 2640 GTCTGAGAGC AGGAACTTCA AGCTGTGATT CTATCTCGGC TCAGACTTTT GGTTGGAAAA 2700 AGATCTTCAT GGCCCCAAAT CCCCTGAGAC ATGCCTTGTA GAATGATTTT GTGATGTTGT 2760 GATGCTTGTG GAGCATCGCG TAAGGCTTCT TGCTTATTTA AACTGTGCAA GGTAAAAATC 2820 AAGCCTTTGG AGCCACAGAA CCAGCTCAAG TACATGCCAA TGTTGTTTAA GAAACAGTTA 2880 TGATCCTAAA CTTTTTGGAT AATCTTTTAT ATTTCTGACC TTTGAATTTA ATCATTGTTC 2940 TTAGATTAAA ATAAAATATG CTATTGAAAC TAAAAAAAAA AAAGAGGGGA GAAGAAAAAA 3000 AAAAAGG 3007 (2) INFORMATION FOR SEQ ID NO: 136: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1229 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: THYMNOT04 (B) CLONE: 2652271 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 136 : CTCTCTGCTC CGGTGCAGGC CCGCAGGCGC CCTGGGCTGG GAGCAACGCG ACTGACCGTG 60 GTCGTGGGCG GACGGCGGCT GCAGCGTGGA GGAGCTGGGG TCGCTGTGGG TCGCGAACAG 120 AGCCCGGGAC GTGCGCGCTT GGTGCACGAT CCTGAAGGGG AGCTCCGAGG GGCCCGGGTC 180 TCCAGGGCTG CTGCGGCCAT TCCCGGAGCC CGGCGCGGGG CCCGCGAGAT ACTGGTTTAG 240 GCCGTCCCAG GGCTCCGGGC GCACCCGGTG GCCGCTGCTG CAGCGGAGGG AGCGCGGCGG 300 CGCGGGGGCT CGGAGACAGC GTTTCTCCCG GAAGTCTTCC TCGGGCAGCA GGTGGGAAGT 360 GGGAGCCGGA GCGGCAGCTG GCAGCGTTCT CTCCGCAGGT CGGCACCATG CGCCCTGCAG 420 CCCTGCGCGG GGCCCTGCTG GGCTGCCTCT GCCTGGCGTT GCTTTGCCTG GGCGGTGCGG 480 ACAAGCGCCT GCGTGACAAC CATGAGTGGA AAAAACTAAT TATGGTTCAG CACTGGCCTG 540 AGACAGTATG CGAGAAAATT CAAAACGACT GTAGAGACCC TCCGGATTAC TGGACAATAC 600 ATGGACTATG GCCCGATAAA AGTGAAGGAT GTAATAGATC GTGGCCCTTC AATTTAGAAG 660 AGATTAAGGA TCTTTTGCCA GAAATGAGGG CATACTGGCC TGACGTAATT CACTCGTTTC 720 CCAATCGCAG CCGCTTCTGG AAGCATGAGT GGGAAAAGCA TGGGACCTGC GCCGCCCAGG 780 TGGATGCGCT CAACTCCCAG AAGAAGTACT TTGGCAGAAG CCTGGAACTC TACAGGGAGC 840 TGGACCTCAA CAGTGTGCTT CTAAAATTGG GGATAAAACC ATCCATCAAT TACTACCAAG 900 TTGCAGATTT TAAAGATGCC CTTGCCAGAG TATATGGAGT GATACCCAAA ATCCAGTGCC 960 TTCCACCAAG CCAGGATGAG GAAGTACAGA CAATTGGTCA GATAGAACTG TGCCTCACTA 1020 AGCAAGACCA GCAGCTGCAA AACTGCACCG AGCCGGGGGA GCAGCCGTCC CCCAAGCAGG 1080 AAGTCTGGCT GGCAAATGGG GCCGCCGAGA GCCGGGGTCT GAGAGTCTGT GAAGATGGCC 1140 CAGTCTTCTA TCCCCCACCT AAAAAGACCA AGCATTGATG CCCAAGTTTT GGAAATATTC 1200 TGTTTTAAAA AGCATGAGGT AGGCATGTC 1229 (2) INFORMATION FOR SEQ ID NO: 137: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1972 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: LUNGTUT11 (B) CLONE: 2746976 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 137 : ACAGGGGCTT CCCCTTCGCC GCCGCCGCCG CCGCCGGCCA AGCTCCGCCG CGCCCGCGGC 60 CCGCGGCCGC CATGCAGTTT ATGTTGCTTT TTAGTCGTCA GGGAAAGCTT CGACTGCAAA 120 AATGGTATGT CCCACTATCA GACAAAGAGA AGAGAAAGAT CACAAGAGAA CTTGTTCAGA 180 CCGTTTTAGC ACGGAAACCT AAAATGTGCA GCTTCCTTGA GTGGCGAGAT CTGAAGATTG 240 TTTACAAAAG ATATGCTAGT CTGTATTTTT GCTGTGCTAT TGAGGATCAG GACAATGAAC 300 TAATTACCCT GGAAATAATT CATCGTTATG TGGAATTACT TGACAAGTAT TTCGGCAGTG 360 TCTGTGAACT AGATATCATC TTTAATTTTG AGAAGGCTTA TTTTATTTTG GATGAGTTTC 420 TTTTGGGAGG GGAAGTTCAG GAAACATCCA AGAAAAATGT CCTTAAAGCA ATTGAGCAGG 480 CTGATCTACT GCAGGAGGAT GCGAAAGAAG CTGAAACCCC ACGTAGTGTT CTTGAAGAAA 540 TTGGACTGAC ATAACTCTCC TCCCTTGTTG ATGACTTCTT GTGGCATTTC ACACACTGTA 600 GATGGTCACT CCCTTCATGT CCATGTTAGC TCATGGTGTA AGATGATGTC TTGTCAGTAT 660 TACTGTTTTG CTAAGCCGCT TCATTCATGC CTACACAATT TTTTTTTAAA AGGGAACTTT 720 AGTTAATTAA GTGATAAGGG ACTTAAATAT GAATTAGAAT GGTGCAGAAA GAGATACCTT 780 TTCTGGATAT TTTAAAGTTT AAAGGTCAGT TTCTCTTAAT CTGATTATGT GCACATATGA 840 AAATGGCACA TCATATACAT GTAAAATCAG GCAGTATACA TTTATTAATT ACTGTATTTG 900 ACAAAGGAAA CTCTTAAATT ATAATGTGAA ACCTGGTTTT ATGAAACCAA AGACTAGTGC 960 AGCATTTCAG CATATGTAAA AAAAAAAAAA AAGGGAATTG ACATGTCACA TATCAAATGA 1020 ATGGAAACTT TGTTGAAACT TTAAAAAGCA AATTTACTCC AAAGACTTGT ATTGGAAATT 1080 ACATACCTTT TTTTTTTTTT TTTAAAGGAC TACAGATTAT TTTTAATGAC TAAATTGGAG 1140 TGATACTTCT TACACTAAAA ATTATTTCTT AGGCATTCTG AATCTGGGAT GAGAAACAGG 1200 ATTGTTTCAC AATAGTAAGC ACATAATTTT TAAGGCCAAG GCACATTTGA CTCCTGAGAT 1260 GAATTTTTTG TGGTCATAAT CAAATACTTA GTTGTTTTTG ATGCCCCAAA ATAAAGTGAG 1320 AATGGTAATT TGCCAGGAAT TCTTCATAAC AGTATCTTAC AAAAAACGTG TTGCTCTCTT 1380 CACAGTATTA TGTGTAAAGT CATTGTTTAA AGCACGAATG TTCCCTCTGG GGTACTTGTT 1440 AAAGCTAAAT TTATTTTGCT TCCCTCCACT TAGAAGTGCT GCACACTTTA CAGCAGCTTC 1500 CTTTCTTTCC ATGGCACTGC CTAGTTAACA GAAGTCTTAT AAAAATTTAA AAAGACACAT 1560 TTCTTACAAA AAAGAGTTGA ATGAGGTAAA ATGGCATTAG ATGGCTCTAT ATTTTTTAAA 1620 GCTATGTAAT TGTTCAGCGT CACTTTTCTA AGTACTTATA CATATCTAAA CATGTCTTCA 1680 TGGTTTATAT TTTCACTTAT ATATGCTGGG CTGGATTAAG CTTTGTTGTG ATTGTGACCA 1740 ACATTCAGGC CACGTGAGCA CTGTCTTATC ACATCGCCAA TTAGTTGTAA TAAACGTTCA 1800 ACGTACAAAC ACTGGAGTGT GTTTTTATCT CTTTCCAAAA GTTTGTCAAA CTATGCAGAG 1860 CTGCTGAAGG AAGAATTTCT CATTTTTTTT TCAGTAAAAT GTTGAAAATT CCCCTCCATT 1920 TGAATATGGT GGTTGTTATA AGCACACACA AGATACATGG TGGAAGATCT AG 1972 (2) INFORMATION FOR SEQ ID NO: 138: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1741 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: THP1AZS08 (B) CLONE: 2753496 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 138 : CGGGTTCCGG GCTCCGGGCT CTGGGTGGCG GCGGCTGTGA GCNGCGGCTG ANCCNCCGCG 60 CTGCGCANCG ACGCGGGAAT GAAGCGGGCG CTGGGCAGGC GAAAGGGCGT GTGGTTGCGC 120 CTGAGGAAGA TACTTTTCTG TGTTTTGGGG TTGTACATTG CCATTCCATT TCTCATCAAA 180 CTATGTCCTG GAATACAGGC CAAACTGATT TTCTTGAATT TCGTAAGAGT TCCCTATTTC 240 ATTGATTTGA AAAAACCACA GGATCAAGGT TTGAATCACA CGTGTAACTA CTACCTGCAG 300 CCAGAGGAAG ACGTGACCAT TGGAGTCTGG CACACCGTCC CTGCAGTCTG GTGGAAGAAC 360 GCCCAAGGCA AAGACCAGAT GTGGTATGAG GATGCCTTGG CTTCCAGCCA CCCTATCATT 420 CTGTACCTGC ATGGGAACGC AGGTACCAGA GGAGGCGACC ACCGCGTGGA GCTTTACAAG 480 GTGCTGAGTT CCCTTGGTTA CCATGTGGTC ACCTTTGACT ACAGAGGTTG GGGTGACTCA 540 GTGGGAACGC CATCTGAGCG GGGCATGACC TATGACGCAC TCCACGTTTT TGACTGGATC 600 AAAGCAAGAA GTGGTGACAA CCCCGTGTAC ATCTGGGGCC ACTCTCTGGG CACTGGCGTG 660 GCGACAAATC TGGTGCGGCG CCTCTGTGAG CGAGAGACGC CTCCAGATGC CCTTATATTG 720 GAATCTCCAT TCACTAATAT CCGTGAAGAA GCTAAGAGCC ATCCATTTTC AGTGATATAT 780 CGATACTTCC CTGGGTTTGA CTGGTTCTTC CTTGATCCTA TTACAAGTAG TGGAATTAAA 840 TTTGCAAATG ATGAAAACGT GAAGCACATC TCCTGTCCCC TGCTCATCCT GCACGCTGAG 900 GACGACCCGG TGGTGCCCTT CCAGCTTGGC AGAAAGCTCT ATAGCATCGC CGCACCAGCT 960 CGAAGCTTCC GAGATTTCAA AGTTCAGTTT GTGCCCTTTC ATTCAGACCT TGGCTACAGG 1020 CACAAATACA TTTACAAGAG CCCTGAGCTG CCACGGATAC TGAGGGAATT CCTGGGGAAG 1080 TCGGAGCCTG AGCACCAGCA CTGAGCCTGG CCGTGGGAAG GAAGCATGAA GACCTCTGCC 1140 CTCCTCCCGT TTTCCTCCAG TCAGCAGCCC GGTATCCTGA AGCCCCGGGG GGCCGGCACC 1200 TGCAATGCTC AGGAGCCCAG CTCGCACCTG GAGAGCACCT CAGATCCCAG GTGGGGAGGC 1260 CCCTGCAGGC CTGCAGTGCC CGGAGGCCTG AGCATGGCTG TGTGGAAAGC GTGGGTGGCA 1320 GGCATGTGGC TCTCCTTGCC GCCCCTCAAC CTGAGATCTT GTTGGGAGAC TTAATGGCAG 1380 CAGGCAGCCA TCACTGCCTG GTTGATGCTG CACTGAGCTG GACAGGGGGA GTCCGGGCAG 1440 GGGACTCTTG GGGCTCGGGA CCATGCTGAG CTTTTTGGCA CCACCCACAG AGAACGTGGG 1500 GTCCAGGTTC TTTCTGCACC TTCCCAGCAC ATGCAGAATG ACTCCAGTGG TTCCATCGTC 1560 CCCTCCTGCC CTGTGTACCT GCTTGCCTTT CTCAGCTGCC CCACCTCCCC TGGGCTGGCC 1620 CACTCACCCA CAGTGGAAGT GCCCGGGATC TGCACTTCCT CCCCTTTCAC CTACCTGTAC 1680 ACCTAACCTG GCCTTAGACT GAGCTTTATT TAAGAATAAA ATCGTGGTGG TGAAAAAAAA 1740 A 1741 (2) INFORMATION FOR SEQ ID NO: 139: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2808 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: OVARTUT03 (B) CLONE: 2781553 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 139 : GGCAAGATGG CGGAAGGGGA GGACGTGGGA TGGTGGCGGA GCTGGCTGCA GCAGAGCTAC 60 CAAGCAGTCA AAGAGAAGTC CTCTGAAGCC TTGGAGTTTA TGAAGCGGGA CCTGACGGAG 120 TTTACCCAGG TGGTGCAGCA TGACACGGCC TGTACCATCG CAGCCACGGC CAGCGTGGTC 180 AAGGAGAAGC TGGCTACGGA AGGCTCCTCA GGAGCAACAG AGAAGATGAA GAAAGGGTTA 240 TCTGACTTCC TAGGGGTGAT CTCAGACACC TTTGCCCCTT CGCCAGACAA AACCATCGAC 300 TGCGATGTCA TCACCCTGAT GGGCACACCG TCTGGCACAG CTGAGCCCTA TGATGGCACC 360 AAGGCTCGCC TCTATAGCCT GCAGTCGGAC CCAGCAACCT ACTGTAATGA ACCAGATGGG 420 CCCCCGGAAT TGTTTGACGC CTGGCTTTCC CAGTTCTGCT TGGAGGAGAA GAAGGGGGAG 480 ATCTCAGAGC TCCTTGTAGG CAGCCCCTCC ATCCGGGCCC TCTACACCAA GATGGTTCCA 540 GCAGCTGTTT CCCATTCAGA ATTCTGGCAT CGGTATTTCT ATAAAGTCCA TCAGTTAGAG 600 CAGGAGCAGG CCCGGAGGGA CGCCCTGAAG CAGCGGGCGG AACAGAGCAT CTCTGAAGAG 660 CCCGGCTGGG AGGAGGAGGA AGAGGAGCTC ATGGGCATTT CACCCATATC TCCAAAAGAG 720 GCAAAGGTTC CTGTGGCCAA AATTTCTACA TTCCCTGAAG GAGAACCTGG CCCCCAGAGC 780 CCCTGTGAAG AGAATCTGGT GACTTCAGTT GAGCCCCCAG CAGAGGTGAC TCCATCAGAG 840 AGCAGTGAGA GCATCTCCCT CGTGACACAG ATCGCCAACC CGGCCACTGC ACCTGAGGCA 900 CGAGTGCTAC CCAAGGACCT GTCCCAAAAG CTGCTAGAGG CATCCTTGGA GGAACAGGGC 960 CTGGCTGTGG ATGTGGGTGA GACTGGACCC TCACCCCCTA TTCACTCCAA GCCCCTAACG 1020 CCTGCTGGCC ACACCGGCGG CCCAGAGCCC AGGCCTCCAG CCAGAGTAGA GACTCTGAGG 1080 GAGGAGGCGC CCACAGACTT ACGGGTGTTT GAGCTGAACT CGGATAGTGG GAAGTCTACA 1140 CCCTCCAACA ATGGAAAGAA AGGCTCAAGC ACGGACATCA GTGAGGACTG GGAGAAAGAC 1200 TTTGACTTGG ACATGACTGA AGAGGAGGTG CAGATGGCAC TTTCCAAAGT GGATGCCTCC 1260 GGGGAGCTGG AAGATGTAGA GTGGGAGGAC TGGGAGTGAG GGAGCCAGAG GGAGCAGCTC 1320 CCCCACCCAT GGCATCTCTC GCCTCCCTCG CTCGTCTCAG CCCAGCCCTG GAAGACTGAG 1380 AATGTTCCCC CAAATCTCCT CTGCCAACCA GAGCTCTGGG CACAGATTCT GGTGGCTCCC 1440 TGCTGGCCCT CTTGGGCCTC TGCTCACACC TGGGAAGGGG CTCTCTAAAT CCCGGCCAGA 1500 AACTCTGACT TGTGCCAACA ATAGGATGAC CCAAGGGAGA GGAAACCTAT CCTCCTCACC 1560 AGAAGAGCCT GTGTTTTTCT GCTGAACACC CACTGTTCCT GAGGACTCCT GCTGGGAAGT 1620 CCCAAGGGAT AGTTCTAGCC CTTCTGCCTG TGTAGACAGA AGCTAAACCA CCAGTCTCTC 1680 TCGGAGGAAG CTGAGACAAC ATACTCTGTC CATACATAAG CAGGCAGGGA GGGCCATGCC 1740 ACCTACCCTT GGCTAAACAG GGACAGTGAA CACATTTTGG TTCCTATCCC AGTGGGTAAG 1800 AGGCACTTAT CTCTGGGAAA TTTGCCTCTC TTGGGACTCT CCCCCTCCCA GGCATTTTCC 1860 ATTCCTGGAA AGGCTCCTTT GGGGTTCAGA ATCCAGAGAC CAAACCCTGA CCCACCTCCT 1920 TCCTTTCCTC CAGCCCACGC TGGTCTGTCC CCATGCCTTC CCAGGGCTTC TTCATGTCAG 1980 ATGCACCCAA GTCCTTAGCC CAGCTGTGCC ACCTGCAGGA GTTCGCTCTT GCGTTTCTTC 2040 CCCTCCCCAA GAAGGGAGGG GGCTACTTCA GGCCCTTCTG TGTGTTGCCT GGCAGGATAC 2100 CTTGTCCAAC CAGCTACCCA CCTCAACTCC CCTGTAGTTT AGGACACAAA ACAGCTACCA 2160 GCGGTACAGA GCGGTGATCA AAGCCGAGTA CTTACAACTC TGGTAAGCCT AGCTTCTCCG 2220 CCTCAGCCCT TCTGCTTCTG GAAGGGCTAT CCTGGGGGTG AACTTGAAAC TCTCATCAGG 2280 CTTCTGCAAA AGCTCTTCTT CCTGAAGACA GACCCAGCCT TTGTGCTCTC ACCCTCCACT 2340 CTGGTAAAGC TGCACCTCTG GGGGAATGAG GGGCTGCAGG AATCTCTGGA GAGCCTGGTG 2400 CTTCACGATG CTGCTCTGGT GATTCTTGTA CCTAATCTGG TGTGCTCACC AATGAGTGAA 2460 AGGGATCGTG GGTCAGGGAC ACCGAGAGAG TGAGGTCACT TCCACTTCAA ACCTTCAGTG 2520 AGGGGGTGGG ATGGAGAGAA TGCTGAATCT TTTTTTTGAC GGGATGGGGT TTTTCTCTTT 2580 GTAATTATTT CTTTAGTTTA ATTAACCTTT TGGTTGTTTG TGCAATATTA TATATTTTAA 2640 ATTATAATGC ATCTCCCCAG AGTATTTTGT AGCTGGGAAA AGAAAAAAGG AAAAAAAGAA 2700 AAAAAGATTC TAACAGCTGT TAGTTTTATA ATTAAAAAAG AAAGAAAAAA GAACTTTGTC 2760 CTGAACCTTT TACAGACTTG CCGTTAACAG CATTAAAGTG ATTCACCC 2808 (2) INFORMATION FOR SEQ ID NO: 140: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 717 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: ADRETUT06 (B) CLONE: 2821925 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 140 : CATGCGCCGA CCTTCCTCGG CTGGATTTAC ANGTTNNCCC TTAACACCCG GGATTTAAGG 60 GACCCACACT ACCTTCCCGA AGTTGAAGGC AAGCGGTGAT TGTTTGTAGA CGGCGCTTTG 120 TCATGGGACC TGTGCGGTTG GGAATATTGC TTTTCCTTTT TTTGGCCGTG CACGAGGCTT 180 GGGCTGGGAT GTTGAAGGAG GAGGACGATG ACACAGAACG CTTGCCCAGC AAATGCGAAG 240 TGTGTAAGCT GCTGAGCACA GAGCTACAGG CGGAACTGAG TCGCACCGGT CGATCTCGAG 300 AGGTGCTGGA GCTGGGGCAG GTGCTGGATA CAGGCAAGAG GAAGAGACAC GTGCCTTACA 360 GCGTTTCAGA GACAAGGCTG GAAGAGGCCT TAGAGAATTT ATGTGAGCGG ATCCTGGACT 420 ATAGTGTTCA CGCTGAGCGC AAGGGCTCAC TGAGATATGC CAAGGGTCAG AGTCAGACCA 480 TGGCAACACT GAAAGGCCTA GTGCAGAAGG GGGTGAAGGT GGATCTGGGG ATCCCTCTGG 540 AGCTTTTGGG ATGAGCCCAG CCGTTGAGGT CACATACCTC AAGAAGCAGT GTGAGACCAT 600 GTTNGAGGAG TTTTGAGACA TTGTGGGAGA CTGGTACTTG CACCATCAGG AGCAGCCGCT 660 ACAAGATTTT CTCTGTGAAG GTCATGTGCT GCCAGCTGCT TGAACTGCAT GTCGGGT 717 (2) INFORMATION FOR SEQ ID NO: 141: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2552 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: UTRSTUT05 (B) CLONE: 2879068 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 141 : GGCAGGGGGC GCGCCGGGCC CAGCGCCACG TCACCGCCCA GCAGCCCTCC CGATTGGCGG 60 GCGGGGCGGC TATAAAGGGA GGGCGCAGGC GGCGCCCGGA TCTCTTCCGC CGCCATTTTA 120 AATCCAGCTC CATACAACGC TCCGCCGCCG CTGCTGCCGC GACCCGGACT GCGCGCCAGC 180 ACCCCCCTGC CGACAGCTCC GTCACTATGG AGGATATGAA CGAGTACAGC AATATAGAGG 240 AATTCGCAGA GGGATCCAAG ATCAACGCGA GCAAGAATCA GCAGGATGAC GGTAAAATGT 300 TTATTGGAGG CTTGAGCTGG GATACAAGCA AAAAAGATCT GACAGAGTAC TTGTCTCGAT 360 TTGGGGAAGT TGTAGACTGC ACAATTAAAA CAGATCCAGT CACTGGGAGA TCAAGAGGAT 420 TTGGATTTGT GCTTTTCAAA GATGCTGCTA GTGTTGATAA GGTTTTGGAA CTGAAAGAAC 480 ACAAACTGGA TGGCAAATTG ATAGATCCCA AAAGGGCCAA AGCTTTAAAA GGGAAAGAAC 540 CTCCCAAAAA GGTTTTTGTG GGTGGATTGA GCCCGGATAC TTCTGAAGAA CAAATTAAAG 600 AATATTTTGG AGCCTTTGGA GAGATTGAAA ATATTGAACT TCCCATGGAT ACAAAAACAA 660 ATGAAAGAAG AGGATTTTGT TTTATCACAT ATACTGATGA AGAGCCAGTA AAAAAATTGT 720 TAGAAAGCAG ATACCATCAA ATTGGTTCTG GGAAGTGTGA AATCAAAGTT GCACAACCCA 780 AAGAGGTATA TAGGCAGCAA CAGCAACAAC AAAAAGGTGG AAGAGGTGCT GCAGCTGGTG 840 GACGAGGTGG TACGAGGGGT CGTGGCCGAG GTCAGGGCCA AAACTGGAAC CAAGGATTTA 900 ATAACTATTA TGATCAAGGA TATGGAAATT ACAATAGTGC CTATGGTGGT GATCAAAACT 960 ATAGTGGCTA TGGCGGATAT GATTATACTG GGTATAACTA TGGGAACTAT GGATATGGAC 1020 AGGGATATGC AGACTACAGT GGCCAACAGA GCACTTATGG CAAGGCATCT CGAGGGGGTG 1080 GCAATCACCA AAACAATTAC CAGCCATACT AAAGGAGAAC ATTGGAGAAA ACAGGTGTGT 1140 ATAAGAGTAC AGGAAAACAG TAGAAATGTC TAATTTAATT TAAAGATCAA TAGACAAATG 1200 AAACGTAAAA ACAAAATACT ATGTAGCCTG TTTTTACTAA ATTGTTGATT TTTTAATTGC 1260 TTTATGAGCC TGTTTTGCCT AAAGTGTCTA TAGATCTTTA ACTTTAAAGT CTTATCTCAC 1320 TTTCTTTAGT ATTGCAGAAA AACTTAAGAG TTTTTCTGTT TGCTTTTGTG TACCAGGTGG 1380 TCTAGAGGAA TAATTAAACA TTTTAGAACT ATTAACAGGT AAAGTACTGA AATGGGTACA 1440 ACTTAAGGAA AACAAGAATG TTGTCTTCTA ACTCTGACAT TATACCTTGT TTGTACCCGC 1500 CAGCGGGAAC TTCATTGCAG GCCGTGTGTC ACCCTGACCA CGTCTATCTC TGGGGGTCGC 1560 ACGTTGCGGG CAGAGCGCAA GGCATACACC AGAAAACGCT GTCCTGTGGT ATGGTCTCTT 1620 CCAACTTCAT GTACCAGCGT AAAGATTAAA GTGGAAAACT TCAGACTTTG GCTTCATTTT 1680 TAATCTTTTT GGAGATTAAG TGTCTAAACT TAACTTAAAT GGTTTTTTAC AGGAGTTAAA 1740 GTACATAAAT GCCTTTTTAC AGCTTAATCA TTTTGGTCTT CTGTTTAGTG TTGTATTTCA 1800 ATTGTGGAGC CTCATTTTAA GTGTTCATTC TTTTAAGATT TAATGCTTGC TTTTTCTTTT 1860 TATAGCTAAT AGTGAAATCT ACAAACCAAA ACAAGAACTT TTAAATCTGG GATATAAATT 1920 AAAGATCATA TGCACAGATC AATTTATGTT CTTGTAATAA ACTTATTAGA AATTGGTGTT 1980 TGTGATAGCA TTTTACTTGG GTTACTAGAG ATGCTTCTAG TAGACCTTAA TCTAGCATAG 2040 TTGAACCTCT GAATATGGGA AGGTTGTATT CCCAGATTCT TTCCTGAATA GATTTGAATT 2100 TAATGTCATT TGGGAACTCC AGGGTGAGTT TATTGACTAC CCAAACTGTA TTTTACCAAT 2160 AAATATGCAT ATGATCTTTA ATTATTGAAG AAAATAAAGT GAGGACTTAA AACAATTCAT 2220 GAAAGTGGAC CTTTAAAAGC TTGTCAGAGT TGCACAAATC TAACTGGTAT TTTGTTTTTG 2280 TTTTTAGGAG GAGATGTTAA AGTAACCCAT CTTGCAGGAC GACATTGAAG ATTGGTCTTC 2340 TGTTGATCTA AGATGATTAT TTTGTAAAAG ACTTTCTAGT GTACAAGACA CCATTGTGTC 2400 CAACTGTATA TAGCTGCCAA TTAGTTTTCT TTGTTTTTAC TTTGTCCTTT GCTATCTGTG 2460 TTATGACTCA ATGTGGATTT GTTTATACAC ATTTTATTTG TATCATTTCA TGTTAAACCT 2520 CAAATAAATG CTTCCTTATG TGAAAAAAAA AA 2552 (2) INFORMATION FOR SEQ ID NO: 142: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1046 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: SINJNOT02 (B) CLONE: 2886757 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 142 : TACCAGTGTA AAGCCAGAGC TGAGGTTCTT GATAGTCCAC AATGGGTGAA CCACAGCAAG 60 TGAGTGCACT TCCACCACCT CCAATGCAAT ATATCAAGGA ATATACGGAT GAAAATATTC 120 AAGAAGGCTT AGCTCCCAAG CCTCCCCCTC CAATAAAAGA CAGTTACATG ATGTTTGGCA 180 ATCAGTTCCA ATGTGATGAT CTTATCATCC GCCCTTTGGA AAGTCAGGGC ATCGAACGGC 240 TTCATCCTAT GCAGTTTGAT CACAAGAAAG AACTGAGAAA ACTTAATATG TCTATCCTTA 300 TTAATTTCTT GGACCTTTTA GATATTTTAA TAAGGAGCCC TGGGAGTATA AAACGAGAAG 360 AGAAACTAGA AGATCTTAAG CTGCTTTTTG TACACGTGCA TCATCTTATA AATGAATACC 420 GACCCCACCA AGCAAGAGAG ACCTTGAGAG TCATGATGGA GGTCCAGAAA CGTCAACGGC 480 TTGAAACAGC TGAGAGATTT CAAAAGCACC TGGAACGAGT AATTGAAATG ATTCAGAATT 540 GCTTGGCTTC TTTGCCTGAT GATTTGCCTC ATTCAGAAGC AGGAATGAGA GTAAAAACTG 600 AACCAATGGA TGCTGATGAT AGCAACAATT GTACTGGACA GAATGAACAT CAAAGAGAAA 660 ATTCAGGTCA TAGGAGAGAT CAGATTATAG AGAAAGATGC TGCCTTGTGT GTCCTAATTG 720 ATGAGATGAA TGAAAGACCA TGAAAGATGT TTCTTTTTCT TTTTTTCCTT TTGATAATAG 780 CATCATATAT TAGTTCATTT TCTTTTGGAC AGTCTTAAGA GAAGTTTCAC TAAAAATGTA 840 AACAGCTTTA ATCTTGACTC CAAATTTTTC AATTATGAGA TGTCATAGGC AGTAATTTCG 900 CTGTATAACA AGCATAGACA AATGAGTGTC CCTGCACTAA GAAGAATCAC TTTAAAAAGC 960 AAAGTGTTAG CTGCTGTTGT ATGGGACATT CCTATGTTTT AGAGTTGCAG TAAAACTTTG 1020 ATGATAACCT CAAAAAAAAA TAAAAA 1046 (2) INFORMATION FOR SEQ ID NO: 143: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1864 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: SCORNOT04 (B) CLONE: 2964329 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 143 : GCCCTGGGCT CGCGGCGGTG CCGCGGGGAT GGCGGGAGCC GGAGCTGGAG CCGGAGCTCG 60 CGGCGGAGCG GCGGCGGGGG TCGAGGCTCG AGCTCGCGAT CCACCGCCCG CGCACCGCGC 120 ACATCCTCGC CACCCTCGGC CTGCGGCTCA GCCCTCGGCC CGCAGGATGG ATGGCGGGTC 180 AGGGGGCCTG GGGTCTGGGG ACAACGCCCC GACCACTGAG GCTCTTTTCG TGGCACTGGG 240 CGCGGGCGTG ACGGCGCTCA GCCATCCCCT GCTCTACGTG AAGCTGCTCA TCCAGGTGGG 300 TCATGAGCCG ATGCCCCCCA CCCTTGGGAC CAATGTGCTG GGGAGGAAGG TCCTCTATCT 360 GCCGAGCTTC TTCACCTACG CCAAGTACAT CGTGCAAGTG GATGGTAAGA TAGGGCTGTT 420 CCGAGGCCTG AGTCCCCGGC TGATGTCCAA CGCCCTCTCT ACTGTGACTC GGGGTAGCAT 480 GAAGAAGGTT TTCCCTCCAG ATGAGATTGA GCAGGTTTCC AACAAGGATG ATATGAAGAC 540 TTCCCTGAAG AAAGTTGTGA AGGAGACCTC CTACGAGATG ATGATGCAGT GTGTGTCCCG 600 CATGTTGGCC CACCCCCTGC ATGTCATCTC AATGCGCTGC ATGGTCCAGT TTGTGGGACG 660 GGAGGCCAAG TACAGTGGTG TGCTGAGCTC CATTGGGAAG ATTTTCAAAG AGGAAGGGCT 720 GCTGGGATTC TTCGTTGGAT TAATCCCTCA CCTCCTGGGC GATGTGGTTT TCTTGTGGGG 780 CTGTAACCTG CTGGCCCACT TCATCAATGC CTACCTGGTG GATGACAGCT TCAGCCAGGC 840 CCTGGCCATC CGGAGCTATA CCAAGTTCGT GATGGGGATT GCAGTGAGCA TGCTGACCTA 900 CCCCTTCCTG CTAGTTGGCG ACCTCATGGC TGTGAACAAC TGCGGGCTGC AAGCTGGGCT 960 CCCCCCTTAC TCCCCAGTGT TCAAATCCTG GATTCACTGC TGGAAGTACC TGAGTGTGCA 1020 GGGCCAGCTC TTCCGAGGCT CCAGCCTGCT TTTCCGCCGG GTGTCATCAG GATCGTGCTT 1080 TGCCCTGGAG TAACCTGAAT CATCTAAAAA ACACGGTCTC AACCTGGCCA CCGTGGGTGA 1140 GGCCTGACCA CCTTGGGACA CCTGCGAGAC GACTCCAACC CAACAACAAC CAGATGTGCT 1200 CCAGCCCAGC CGGGCTTCAG TTCCATATTT GCCATGTGTC TGTCCAGATG TGGGGTTGAG 1260 CGGGGGTGGG GCTGCACCCA GTGGATTGGG TCACCCGGCA GACCTAGGGA AGGTGAGGCG 1320 AGGTGGGGAG TTGGCAGAAT CCCCATACCT CGCAGATTTG CTGAGTCTGT CTTGTGCAGA 1380 GGGCCAGAGA ATGGCTTATG GGGGCCCAGG TTGGATGGGG AAAGGCTAAT GGGGTCAGAC 1440 CCCACCCCGT CTACCCCTCC AGTCAGCCCA GCGCCCATCC TGCAGCTCAG CTGGGAGCAT 1500 CATTCTCCTG CTTTGTACAT AGGGTGTGGT CCCCTGGCAC GTGGCCACCA TCATGTCTAG 1560 GCCTATGCTA GGAGGCAAAT GGCCAGGCTC TGCCTGTGTT TTTCTCAACA CTACTTTTCT 1620 GATATGAGGG CAGCACCTGC CTCTGAATGG GAAATCATGC AACTACTCAG AATGTGTCCT 1680 CCTCATCTAA TGCTCATCTG TTTAATGGTG ATGCCTCGCG TACAGGATCT GGTTACCTGT 1740 GCAGTTGTGA ATACCCAGAG GTTGGGCAGA TCAGTGTCTC TAGTCCTACC CAGTTTTAAA 1800 GTTCATGGTA AGATTTGACC TCATCTCCCG CAAATAAATG TATTGGTGAT TTGGAAAAAA 1860 AAAA 1864 (2) INFORMATION FOR SEQ ID NO: 144: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2295 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: SCORNOT04 (B) CLONE: 2965248 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 144 : GTCTGCAGCT CCGGCCGCCA CTTGCGCCTC TCCAGCCTCC GCAGGCCCAA CCGCCGCCAG 60 CACCATGGCC AGCACCATTT CCGCCTACAA GGAGAAGATG AAGGAGCTGT CGGTGCTGTC 120 GCTCATCTGC TCCTGCTTCT ACACACAGCC GCACCCCAAT ACCGTCTACC AGTACGGGGA 180 CATGGAGGTG AAGCAGCTGG ACAAGCGGGC CTCAGGCCAG AGCTTCGAGG TCATCCTCAA 240 GTCCCCTTCT GACCTGTCCC CAGAGAGCCC TATGCTCTCC TCCCCACCCA AGAAGAAGGA 300 CACCTCCCTG GAGGAGCTGC AAAAGCGGCT GGAGGCAGCC GAGGAGCGGA GGAAGACGCA 360 GGAGGCGCAG GTGCTGAAGC AGCTGGCGGA CGGCGCGAGC ACGAGCGCGA GGTGCTGCAC 420 AAGGCGCTGG AGGAGAATAA CAACTTCAGC CGCCAGGCGG AGGAGAAGCT CAACTACAAG 480 ATGGAGCTCA GCAAGGAGAT CCGCGAGGCA CACCTGGCCG CACTGCGCGA GCGGCTGCGC 540 GAGAAGGAGC TGCACGCGGC CGAGGTGCGC AGGAACAAGG AGCAGCGAGA AGAGATGTCG 600 GGCTAAGGGC CCGGGACGGG CGGCGCCCAT CCTGCGACGG AACACGTTCG GGTTTTGGTT 660 TTGTTTCGTT CACCTCTGTC TAGATGCAAC TTTTGTTCCT CCTCCCCCAC CCCAGCCCCC 720 AGCTTCATGC TTCTCTTCCG CACTCAGCCG CCCTGCCCTG TCCTCGTGGT GAGTCGCTGA 780 CCACGGCTTC CCCTGCAGGA GCCGCCGGGC GTGAGACGCG GTCCCTCGGT GCAGACACCA 840 GGCCGGGCGC GGCTGGGTCC CCCGGGGGCC CTGTGAGAGA GGTGGTGGTG ACCGTGGTAA 900 ACCCAGGGCG GTGGCGTGGG ATCGCGGGTC CTTACGCTGG GCTGTCTGGT CAGCACGTGC 960 AGGTCAGGGC AGGTCCTCTG AGCCGGCGCC CCTGGCCAGC AGGCGAGGCT ACAGTACCTG 1020 CTGTCTTTCC AGGGGGAAGG GGCTCCCCAT GAGGGAGGGG CGACGGGGGA GGGGGGTGAT 1080 GGTGCCTGGG AGCCTGCGTG TGCAGCCGGT GCTTGTTGAA CTGGCAGGCG GGTGGGTGGG 1140 GGCTGCAGCT TTCCTTAATG TGGTTGCACA GGGGTCCTCT GAGACCACCT GGCGTGAGGT 1200 GGACACCCTG GGCCTTCCTG GAAGCCTGCA GTTGGGGGCC TGCCCTGAGT CTGCTGGGGA 1260 GTGGGCATTC TCTGCCAGGG ACCCATGAGC AGGCTGCATG GTCTAGAGGT TGTGGGCAGC 1320 ATGGACAGTC CCCCACTCAG AAGTGCAAGA GTTCCAAAGA GCCTCTGGCC CAGGCCCCTC 1380 CGTGGGACAG CCCCGCCGCC CCTCCCCACC AGGGCTTTGC AGATGTCCTT GAAAGACCCA 1440 CCCTAGAGCC CTTTGGAGTG CTGGCCCCTC CTGTGCCCTC TGCCCTGGTG GAAGCGGCAG 1500 CCACAAGTCC TCCTCAGGGA GCCCCAAGGG GGATTTTGTG GGACCGCTGC CCACAGATCC 1560 AGGTGTTGGA AGGGCAGCGG GTAAGGTTCC CAAGCCAGCC CCAACACCCT TCCCACTTGG 1620 CACCCAGAGG GGGCTGTGGG TGGAGGCCTG ACTCCAGGCC TCTCCTGCCC ACACCCTCTG 1680 GGCTGAGTTC CTTCTTTCCC TTGGACGCCC AGTGCTGGCC TTGGAGGACG GTCAGCTGGA 1740 GGATGGCGGT GGGGGAGGCT GTCTTTGTAC CACTGCAGCA TCCCCCACTT CTCCACGGAA 1800 GCCCCATCCC AAAGCTGCTG CCTGGCCCCT TGCTGTAAAG TGTGAAGGGG GCGGCTGAGT 1860 TCTCTTAGGA CCCAGAGCCA GGGCCCTCAA CTTCCATCCT GCGGGAGGCC TTGGCCGGGC 1920 ACTGCCAGTG TCTTCCAGAG CCACACCCAG GGACCACGGG AGGATCCTGA CCCCTGCAGG 1980 GCTCAGGGGT CAGCAGGGAC CCACTGCCCC ATCTCCCTCT CCCCACCAAG ACAGCCCCAG 2040 AAGGAGCAGC CAGCTGGGAT GGGAACCCAA GGCTGTCCAC ATCTGGCTTT TGTGGGACTC 2100 AGAAAGGGAA GCAGAACTGA GGGCTGGGAT ATTCCTCATG GTGGCAGCGC TCATAGCGAA 2160 AGCCTACTGT AATATGCACC CATCTCATCC ACGTAGTAAA GTGAACTTAA AAATTCAATC 2220 AAATGAACAA TTAAATAAAC ACCTGTGTGT TTAAGACAAA ATAAAAATGG AGGAGAACAA 2280 AAAAAAAGGG GCGGT 2295 (2) INFORMATION FOR SEQ ID NO: 145: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 842 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: TLYMNOT06 (B) CLONE: 3000534 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 145 : CGGGGACGGA AGCAGCCCCT GGGCCCGAGG GGCTCGAGGC CGGGCCGGGG CGATGTGGAG 60 CGCGGGCCGC GGCGGGGCTG CCTGGCCGGT GCTGTTGGGG CTGCTGCTGG CGCTGTTAGT 120 GCCGGGCGGT GGTGCCGCCA AGACCGGTGC GGAGCTCGTG ACCTGCGGGT CGGTGCTGAA 180 GCTGCTCAAT ACGCACCACC GCGTGCGGCT GCACTCGCAC GACATCAAAT ACGGATCCGG 240 CAGCGGCCAG CAATCGGTGA CCGGCGTAGA GGCGTCGGAC GACGCCAATA GCTACTGGCG 300 GATCCGCGGC GGCTCGGAGG GCGGGTGCCC GCGCGGGTCC CCGGTGCGCT GCGGGCAGGC 360 GGTGAGGCTC ACGCATGTGC TTACGGGCAA GAACCTGCAC ACGCACCACT TCCCGTCGCC 420 GCTGTCCAAC AACCAGGAGG TGAGTGCCTT TGGGGAAGAC GGCGAGGGCG ACGACCTGGA 480 CCTATGGACA GTGCGCTGCT CTGGACAGCA CTGGGAGCGT GAGGCTGCTG TGCGCTTCCA 540 GCATGTGGGC ACCTCTGTGT TCCTGTCAGT CACGGGTGAG CAGTATGGAA GCCCCATCCG 600 TGGGCAGCAT GAGGTCCACG GCATGCCCAG TGCCAACACG CACAATACGT GGAAGGCCAT 660 GGAAGGCATC TTCATCAAGC CTAGTGTGGA GCCCTCTGCA GGTCACGATG AACTCTGAGT 720 GTGTGGATGG ATGGGTGGAT GGAGGGTGGC AGGTGGGGCG TCTGCAGGGC CACTCTTGGC 780 AGAGACTTTG GGTTTGTAGG GGTCCTCAAG TGCCTTTGTG ATTAAAGAAT GTTGGTCTAA 840 AA 842 (2) INFORMATION FOR SEQ ID NO: 146: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2345 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: HEAANOT01 (B) CLONE: 3046870 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 146 : GTCCCGCCCC GCAGCTGCGC GCAGGCGCTC GACGAGCCGC TCGCATTCTA CGTAACGGAC 60 GGCGGAGGCT ACGTGAAGAG AGGCGCGGCG TGACTGAGCT ACGGTTCTGG CTGCGTCCTA 120 GAGGCATCCG GGGCAGTAAA ACCGCTGCGA TCGCGGAGGC GGCGGCCAGG CCGAGAGGCA 180 GGCCGGGCAG GGGTGTCGGA CGCAGGGCGC TGGGCCGGGT TTCGGCTTCG GCCACAGCTT 240 TTTTTCTCAA GGTGCAATGA AAGCCTTCCA CACTTTCTGT GTTGTCCTTC TGGTGTTTGG 300 GAGTGTCTCT GAAGCCAAGT TTGATGATTT TGAGGATGAG GAGGACATAG TAGAGTATGA 360 TGATAATGAC TTCGCTGAAT TTGAGGATGT CATGGAAGAC TCTGTTACTG AATCTCCTCA 420 ACGGGTCATA ATCACTGAAG ATGATGAAGA TGAGACCACT GTGGAGTTGG AAGGGCAGGA 480 TGAAAACCAA GAAGGAGATT TTGAAGATGC AGATACCCAG GAGGGAGATA CTGAGAGTGA 540 ACCATATGAT GATGAAGAAT TTGAAGGTTA TGAAGACAAA CCAGATACTT CTTCTAGCAA 600 AAATAAAGAC CCAATAACGA TTGTTGATGT TCCTGCACAC CTCCAGAACA GCTGGGAGAG 660 TTATTATCTA GAAATTTTGA TGGTGACTGG TCTGCTTGCT TATATCATGA ATTACATCAT 720 TGGGAAGAAT AAAAACAGTC GCCTTGCACA GGCCTGGTTT AACACTCATA GGGAGCTTTT 780 GGAGAGCAAC TTTACTTTAG TGGGGGATGA TGGAACTAAC AAAGAAGCCA CAAGCACAGG 840 AAAGTTGAAC CAGGAGAATG AGCACATCTA TAACCTGTGG TGTTCTGGTC GAGTGTGCTG 900 TGAGGGCATG CTTATCCAGC TGAGGTTCCT CAAGAGACAA GACTTACTGA ATGTCCTGGC 960 CCGGATGATG AGGCCAGTGA GTGATCAAGT GCAAATAAAA GTAACCATGA ATGATGAAGA 1020 CATGGATACC TACGTATTTG CTGTTGGCAC ACGGAAAGCC TTGGTGCGAC TACAGAAAGA 1080 GATGCAGGAT TTGAGTGAGT TTTGTAGTGA TAAACCTAAG TCTGGAGCAA AGTATGGACT 1140 GCCGGACTCT TTGGCCATCC TGTCAGAGAT GGGAGAAGTC ACAGACGGAA TGATGGATAC 1200 AAAGATGGTT CACTTTCTTA CACACTATGC TGACAAGATT GAATCTGTTC ATTTTTCAGA 1260 CCAGTTCTCT GGTCCAAAAA TTATGCAAGA GGAAGGTCAG CCTTTAAAGC TACCTGACAC 1320 TAAGAGGACA CTGTTGTTTA CATTTAATGT GCCTGGCTCA GGTAACACTT ACCCAAAGGA 1380 TATGGAGGCA CTGCTACCCC TGATGAACAT GGTGATTTAT TCTATTGATA AAGCCAAAAA 1440 GTTCCGACTC AACAGAGAAG GCAAACAAAA AGCAGATAAG AACCGTGCCC GAGTAGAAGA 1500 GAACTTCTTG AAACTGACAC ATGTGCAAAG ACAGGAAGCA GCACAGTCTC GGCGGGAGGA 1560 GAAAAAAAGA GCAGAGAAGG AGCGAATCAT GAATGAGGAA GATCCTGAGA AACAGCGCAG 1620 GCTGGAGGAG GCTGCATTGA GGCGTGAGCA AAAGAAGTTG GAAAAGAAGC AAATGAAAAT 1680 GAAACAAATC AAAGTGAAAG CCATGTAAAG CCATCCCAGA GATTTGAGTT CTGATGCCAC 1740 CTGTAAGCTC TGAATTCACA GGAAACATGA AAAACGCCAG TCCATTTCTC AACCTTAAAT 1800 TTCAGACAGT CTTGGGCAAC TGAGAAATCC TTATTTCATC ATCTACTCTG TTTGGGGTTT 1860 GGGGTTTTAC AGAGATTGAA GATACCTGGA AAGGGCTCTG TTTCAAGAAT TTTTTTTTCC 1920 AGATAATCAA ATTATTTTGA TTATTTTATA AAAGGAATGA TCTATGAAAT CTGTGTAGGT 1980 TTTAAATATT TTAAAAATTA TAATACAAAT CATCAGTGCT TTTAGTACTT CAGTGTTTAA 2040 AGAAATACCA TGAAATTTAT AGGTAGATAA CCAGATTGTT GCTTTTTGTT TAAACCAAGC 2100 AGTTGAAATG GCTATAAAGA CTGACTCTAA ACCAAGATTC TGCAAATAAT GATTGGAATT 2160 GCACAATAAA CATTGCTTGA TGTTTTCTTG TATGTCTACA TTAAACTTGA GAAAAAGTAA 2220 AAATTAGAAC ACTGTATGTA GTAATGAAAT TTCAGGGACC CAGAACATAA TGTAGTATAT 2280 GTTTTTAGGT GGGAGATGCT GATAACAAAA TTAATAGGAA GTCTGTAGGC ATTAGGATAC 2340 TGACA 2345 (2) INFORMATION FOR SEQ ID NO: 147: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2215 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: PONSAZT01 (B) CLONE: 3057669 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 147 : CCCACGCGTC CGCCCACGCG TCCGTTTTCA GTAGGGATTT CCTGTGACCA GACAAGTTCA 60 TCTGAGAGCC AGTTCTCACC ACTGGAATTC TCAGGAATGG ACCATGAGGA CATCAGTGAG 120 TCAGTGGATG CAGCATACAA CCTCCAGGAC AGTTGCCTTA CAGACTGTGA TGTGGAAGAT 180 GGGACTATGG ATGGCAATGA TGAGGGGCAC TCCTTTGAAC TTTGTCCTTC TGAAGCTTCT 240 CCTTATGTAA GGTCAAGGGA GAGAACCTCC TCTTCAATAG TATTTGAAGA TTCTGGCTGT 300 GATAATGCTT CCAGTAAAGA AGAGCCGAAA ACTAATCGAT TGCATATTGG CAACCATTGT 360 GCTAATAAAC TAACTGCTTT CAAGCCCACC AGTAGCAAAT CTTCTTCTGA AGCTACATTG 420 TCTATTTCTC CTCCAAGACC AACCACTTTA AGTTTAGATC TCACTAAAAA CACCACAGAA 480 AAACTCCAGC CCAGTTCACC AAAGGTGTAT CTTTACATTC AAATGCAGCT GTGCAGAAAA 540 GAAAACCTCA AAGACTGGAT GAATGGACGA TGTACCATAG AGGAGAGAGA GAGGAGCGTG 600 TGTCTGCACA TCTTCCTGCA GATCGCAGAG GCAGTGGAGT TTCTTCACAG TAAAGGACTG 660 ATGCACAGGG ACCTCAAGCC ATCCAACATA TTCTTTACAA TGGATGATGT GGTCAAGGTT 720 GGAGACTTTG GGTTAGTGAC TGCAATGGAC CAGGATGAGG AAGAGCAGAC GGTTCTGACC 780 CCAATGCCAG CTTATGCCAG ACACACAGGA CAAGTAGGGA CCAAACTGTA TATGAGCCCA 840 GAGCAGATTC ATGGAAACAG CTATTCTCAT AAAGTGGACA TCTTTTCTTT AGGCCTGATT 900 CTATTTGAAT TGCTGTATCC ATTCAGCACT CAGATGGAGA GAGTCAGGAC CTTAACTGAT 960 GTAAGAAATC TCAAATTTCC ACCATTATTT ACTCAGAAAT ATCCTTGTGA GTACGTGATG 1020 GTTCAAGACA TGCTCTCTCC ATCCCCCATG GAACGACCTG AAGCTATAAA CATCATTGAA 1080 AATGCTGTAT TTGAGGACTT GGACTTTCCA GGAAAAACAG TGCTCAGACA GAGGTCTCGC 1140 TCCTTGAGTT CATCGGGAAC AAAACATTCA AGACAGTCCA ACAACTCCCA TAGCCCTTTG 1200 CCAAGCAATT AGCCTTAAGT TGTGCTAGCA ACCCTAATAG GTGATGCAGA TAATAGCCTA 1260 CTTCTTAGAA TATGCCTGTC CAAAATTGCA GACTTGAAAA GTTTGTTCTT CGCTCAATTT 1320 TTTTGTGGAC TACTTTTTTT ATATCAAATT TAAGCTGGAT TTGGGGGCAT AACCTAATTT 1380 GAGCCAACTC CTGAGTTTTG CTATACTTAA GGAAAGGGCT ATCTTTGTTC TTTGTTAGTC 1440 TCTTGAAACT GGCTGCTGGC CAAGCTTTAT AGCCCTCACC ATTTGCCTAA GGAGGTAGCA 1500 GCAATCCCTA ATATATATAT ATAGTGAGAA CTAAAATGGA TATATTTTTA TAATGCAGAA 1560 GAAGGAAAGT CCCCCTGTGT GGTAACTGTA TTGTTCTAGA AATATGCTTT CTAGAGATAT 1620 GATGATTTTG AAACTGATTT CTAGAAAAAG CTGACTCCAT TTTTGTCCCT GGCGGGTAAA 1680 TTAGGAATCT GCACTATTTT GGAGGACAAG TAGCACAAAC TGTATAACGG TTTATGTCCG 1740 TAGTTTTATA GTCCTATTTG TAGCATTCAA TAGCTTTATT CCTTAGATGG TTCTAGGGTG 1800 GGTTTACAGC TTTTTGTACT TTTACCTCCA ATAAAGGGAA AATGAAGCTT TTTATGTAAA 1860 TTGGTTGAAA GGTCTAGTTT TGGGAGGAAA AAAGCCGTAG TAAGAAATGG ATCATATATA 1920 TTACAACTAA CTTCTTCAAC TATGGACTTT TTAAGCCTAA TGAAATCTTA AGTGTCTTAT 1980 ATGTAATCCT GTAGGTTGGT ACTTCCCCCA AACTGATTAT AGGTAACAGT TTAATCATCT 2040 CACTTGCTAA CATGTTTTTA TTTTTCACTG TAAATATGTT TATGTTTTAT TTATAAAAAT 2100 TCTGAAATCA ATCCATTTGG GTTGGTGGTG TACAGAACAC ACTTAAGTGT GTTAACTTGT 2160 GACTTCTTTC AAGTCTAAAT GATTTAATAA AACTTTTTTT AAATTAAAAA AAAAA 2215 (2) INFORMATION FOR SEQ ID NO: 148: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1395 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: HEAONOT03 (B) CLONE: 3088178 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 148 : GGTTGACATG ATGAACAATC GGTTTCGGAA GGATATGATG AAAAATGCTA GTGAAAGTAA 60 ACTTTCGAAA GACAACCTTA AAAAGAGACT TAAAGAAGAA TTCCAACATG CCATGGGAGG 120 AGTACCTGCC TGGGCAGAGA CTACTAAGCG GAAAACATCT TCAGATGATG AAAGTGAAGA 180 GGATGAAGAT GATTTGTTGC AAAGGACTGG GAATTTCATA TCCACATCAA CTTCTCTTCC 240 AAGAGGCATC TTGAAGATGA AGAACTGCCA GCATGCGAAT GCTGAACGTC CTACTGTTGC 300 TCGGATCTCA TCTGTGCAGT TCCATCCCGG TGCACAGATT GTGATGGTTG CTGGATTAGA 360 TAATGCTGTA TCACTATTTC AGGTTGATGG GAAAACAAAT CCTAAAATTC AGAGCATCTA 420 TTTGGAAAGG TTTCCAATCT TTAAGGCTTG TTTTAGTGCT AATGGGGAAG AAGTTTTAGC 480 CACGAGTACC CACAGCAAGG TTCTTTATGT CTATGACATG CTGGCTGGAA AGTTAATTCC 540 TGTGCATCAA GTGAGAGGTT TGAAAGAGAA GATAGTGAGG AGCTTTGAAG TCTCCCCAGA 600 TGGGTCCTTC TTGCTCATAA ATGGCATTGC TGGATATTTG CATTTGCTAG CAATGAAGAC 660 CAAAGAACTG ATTGGAAGCA TGAAAATTAA TGGAAGGGTT GCAGCATCCA CATTCTCTTC 720 AGATAGTAAG AAAGTATACG CCTCTTCGGG GGATGGAGAA GTTTATGTTT GGGATGTGAA 780 CTCAAGGAAG TGCCTTAACA GATTTGTTGA TGAAGGCAGT TTATATGGAT TAAGCATTGC 840 CACATCTAGG AATGGACAGT ATGTTGCTTG TGGTTCTAAT TGTGGAGTGG TAAATATATA 900 CAATCAAGAT TCTTGTCTCC AAGAAACAAA CCCAAAGCCA ATAAAAGCTA TAATGAACTT 960 GGTTACAGGT GTTACTTCTC TGACCTTCAA TCCTACTACA GAAATCTTGG CAATTGCTTC 1020 AGAAAAAATG AAAGAAGCAG TCAGATTGGT TCATCTTCCT TCCTGTACAG TATTTTCAAA 1080 CTTCCCAGTC ATTAAAAATA AGAATATTTC TCATGTTCAT ACCATGGATT TTTCTCCGAG 1140 AAGTGGATAC TTTGCCTTGG GGAATGAAAA GGGCAAGGCC CTGATGTATA GGTTGCACCA 1200 TTACTCAGAC TTCTAAAGAG ACTATTTGAA GTCCAGTTGA GTCACAAGAG AAGCCTGTCT 1260 TGATATATCA TCTCAGAAAC TTTCCTGAAT ATGTGATAAT ATATGGAAAA TGATTTATAG 1320 ATCCAGCTGT GCTTAAGAGC CAGTAATGTC TTAATAAACA TGTGGCAGCT TTTGTTTGAA 1380 AAAAAAAAAA AAAGG 1395 (2) INFORMATION FOR SEQ ID NO: 149: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2609 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: BRSTNOT19 (B) CLONE: 3094321 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 149 : CCCGCCATGG CACTGTCGCG GGGGCTGCCC CGGGAGCTGG CTGAGGCGGT GGCCGGGGGC 60 CGGGTGCTGG TGGTGGGGGC GGGCGGCATC GGCTGCGAGC TCCTCAAGAA TCTCGTGCTC 120 ACCGGTTTCT CCCACATCGA CCTGATTGAT CTGGATACTA TTGATGTAAG CAACCTCAAC 180 AGACAGTTTT TGTTTCAAAA GAAACATGTT GGAAGATCAA AGGCACAGGT TGCCAAGGAA 240 AGTGTACTGC AGTTTTACCC GAAAGCTAAT ATCGTTGCCT ACCATGACAG CATCATGAAC 300 CCTGACTATA ATGTGGAATT TTTCCGACAG TTTATACTGG TTATGAATGC TTTAGATAAC 360 AGAGCTGCCC GAAACCATGT TAATAGAATG TGCCTGGCAG CTGATGTTCC TCTTATTGAA 420 AGTGGAACAG CTGGGTATCT TGGACAAGTA ACTACTATCA AAAAGGGTGT GACCGAGTGT 480 TATGAGTGTC ATCCTAAGCC GACCCAGAGA ACCTTTCCTG GCTGTACAAT TCGTAACACA 540 CCTTCAGAAC CTATACATTG CATCGTTTGG GCAAAGTACT TGTTCAACCA GTTGTTTGGG 600 GAAGAAGATG CTGATCAAGA AGTATCTCCT GACAGAGCTG ACCCTGAAGC TGCCTGGGAA 660 CCAACGGAAG CCGAAGCCAG AGCTAGAGCA TCTAATGAAG ATGGTGACAT TAAACGTATT 720 TCTACTAAGG AATGGGCTAA ATCAACTGGA TATGATCCAG TTAAACTTTT TACCAAGCTT 780 TTTAAAGATG ACATCAGGTA TCTGTTGACA ATGGACAAAC TATGGCGGAA AAGGAAACCT 840 CCAGTTCCGT TGGACTGGGC TGAAGTACAA AGTCAAGGAG AAGAAACGAA TGCATCAGAT 900 CAACAGAATG AACCCCAGTT AGGCCTGAAA GACCAGCAGG TTCTAGATGT AAAGAGCTAT 960 GCACGTCTTT TTTCAAAGAG CATCGAGACT TTGAGAGTTC ATTTAGCAGA AAAGGGGGAT 1020 GGAGCTGAGC TCATATGGGA TAAGGATGAC CCATCTGCAA TGGATTTTGT CACCTCTGCT 1080 GCAAACCTCA GGATGCATAT TTTCAGTATG AATATGAAGA GTAGATTTGA TATCAAATCA 1140 ATGGCAGGGA ACATTATTCC TGCTATTGCT ACTACTAATG CAGTAATTGC TGGGTTGATA 1200 GTATTGGAAG GATTGAAGAT TTTATCAGGA AAAATAGACC AGTGCAGAAC AATTTTTTTG 1260 AATAAACAAC CAAACCCAAG AAAGAAGCTT CTTGTGCCTT GTGCACTGGA TCCTCCCAAC 1320 CCCAATTGTT ATGTATGTGC CAGCAAGCCA GAGGTGACTG TGCGGCTGAA TGTCCATAAA 1380 GTGACTGTTC TCACCTTACA AGACAAGATA GTGAAAGAAA AATTTGCTAT GGTAGCACCA 1440 GATGTCCAAA TTGAAGATGG GAAAGGAACA ATCCTAATAT CTTCCGAAGA GGGAGAGACG 1500 GAAGCTAATA ATCACAAGAA GTTGTCAGAA TTTGGAATTA GAAATGGCAG CCGGCTTCAA 1560 GCAGATGACT TCCTCCAGGA CTATACTTTA TTGATCAACA TCCTTCATAG TGAAGACCTA 1620 GGAAAGGACG TTGAATTTGA AGTTGTTGGT GATGCCCCGG AAAAAGTGGG GCCCAAACAA 1680 GCTGAAGATG CTGCCAAAAG CATAACCAAT GGCAGTGATG ATGGAGCTCA GCCCTCCACC 1740 TCCACAGCTC AAGAGCAAGA TGACGTTCTC ATAGTTGATT CGGATGAAGA AGATTCTTCA 1800 AATAATGCCG ACGTCAGTGA AGAAGAGAGA AGCCGCAAGA GGAAATTAGA TGAGAAAGAG 1860 AATCTCAGTG CAAAGAGGTC ACGTATAGAA CAGAAGGAAG AGCTTGATGA TGTCATAGCA 1920 TTAGATTGAA CAGAAATGCC TCTAAACAGA ACCCTCTTAC TATTTAGTTT ATCTGGGCAG 1980 AACCAGATTG TTATGTCCTT TGTTCCAAAG GGAAAAAATT GACAGCAGTG ACTTGAAAAT 2040 GATTCTGCTC CCTTTGAAAG CATTCATTTT GCTAGAACTG TTAGACACAT TGCAGTATGC 2100 TGTATTGAAA GTAGGAATAT AGTTTTAAAA ACCCTTTGAA CAAAGTGTGT GCATAACCAG 2160 TCATGAGATA AAACAACACA ATGCATGTTG CCTTTTTAAT GTAAATACCC TTAGGTATCA 2220 TTAATAGTTT CAAAATATTG TGGTTTAGTA AAGTTGATAC CTGGTTATAA ATATTATGCC 2280 TTTATTTTTG GCTAGAAGAA GAATTATTTT TAGCCTAGAT CTAACCATTT TCATACTCTT 2340 AACTGATTGA AACAGATTCA AAGAAGTATC GAGTGCTATG CATTGAAACT TGTTTTTAAA 2400 TGTTAGATGG CACTATGTAT ATTAATGTAA AACAATGTTA ATTTACTCAA GTTTTCAGTT 2460 TGTACCGCCT GGTATGTCTG TGTAAGAAGC CAATTTTTGT GTATTGTTAC AGTTTCAGGT 2520 TATTTATATT CGATGTTTTG TAAAACTCAA ATAACGACTA TACTTATGGA CCAAATAAAT 2580 GGCATCTGCA TTCTTGTTAA AAAAAAAAA 2609 (2) INFORMATION FOR SEQ ID NO: 150: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3633 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: LUNGTUT13 (B) CLONE: 3115936 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 150 : CCTGAGGGAT CCACAGAGGG TGCGGTCCTT GGAGGGAGGA CATGCAGTGC CACGTGCCAT 60 GGACCAGCCA GTGGACCCCA TGGCCAGCAA GGCTGCTCCT GGGGCCAGTG GGGTGGACAG 120 TCCCGCCCAC GCAGGTGACT GAGGTGCCAG TGTGGGAATG AAAATGCGGC CTGTGCTCCT 180 GGGCCCATGC GTCTCACGCT GCCCTTCCTC TCCAGGGAAG CCTGTGTACC TGCTACTTTT 240 TCCCGAACAA TTCATGGTAA AAACACAAAT GGTATATGGA CAAGATACTG AATGTGGAAG 300 AAACCTACTT GACAGTGTTG GTGAAAATAG GGCCAGGATT TCACACCCGT GAATGCTTTT 360 TACTGAAAAG TATTTTGTGT TTTTCTCCCA GTTACAGAAT GTCTGAAGGG GACAGTGTGG 420 GAGAATCCGT CCATGGGAAA CCTTCGGTGG TGTACAGATT TTTCACAAGA CTTGGACAGA 480 TTTATCAGTC CTGGCTAGAC AAGTCCACAC CCTACACGGC TGTGCGATGG GTCGTGACAC 540 TGGGCCTGAG CTTTGTCTAC ATGATTCGAG TTTACCTGCT GCAGGGTTGG TACATTGTGA 600 CCTATGCCTT GGGGATCTAC CATCTAAATC TTTTCATAGC TTTTCTTTCT CCCAAAGTGG 660 ATCCTTCCTT AATGGAAGAC TCAGATGACG GTCCTTCGCT ACCCACCAAA CAGAACGAGG 720 AATTCCGCCC CTTCATTCGA AGGCTCCCAG AGTTTAAATT TTGGCATGCG GCTACCAAGG 780 GCATCCTTGT GGCTATGGTC TGTACTTTCT TCGACGCTTT CAACGTCCCG GTGTTCTGGC 840 CGATTCTGGT GATGTACTTC ATCATGCTCT TCTGTATCAC GATGAAGAGG CAAATCAAGC 900 ACATGATTAA GTACCGGTAC ATCCCGTTCA CACATGGGAA GAGAAGGTAC AGAGGCAAGG 960 AGGATGCCGG CAAGGCCTTC GCCAGCTAGA AGCGGGACTG AGGCTGCCTC ACGTGTTGCA 1020 AGAACAGTTT TGAGCCATTG TTAACAATGC CTTTTTTCTT CACATAAAGT AGTTGATTAC 1080 GAGGGAGTCA AATTTTCTTT TTAAAAAGGA GCTTCAATGA TTTGTAACTG AAATATCAGG 1140 TTCTAGAAGA AACTGGCGCT TAAACCAAAT CGCATGGATT TCTTTTTCAG TGACGTTCAA 1200 GTGTTTCTCA CGGATGGAAT TCTAGTCAGC TGCAGGCGGG AAGCCAGGCG GGTGGAGCCC 1260 ATGGGAGCAA GGGCGAGTGG CCGGTCCCCG CTGTGCCAGG TGGGCAGGCA GGAGCAAGGC 1320 CTGCGAGGGA GGAACGGGCC GCTCCCCGCC AGCCGCCTTC CCCAGCAGCC GCAGGTGGTG 1380 CCAGCCACTC CACAGAGCCC GAGGGATGAT CTAGCCTGAT TCCTGCGTGT CCGAAAGAAC 1440 TTAACGTTTT AAAGGTGATT GTCAAGTAAC TGTGTGGGGT TCTAATGCCA GTTTCCTAAT 1500 TCCATCTCAC TGGAGATGTT TAAAGTTGGC CTCTATCCTA ATGACTCAAA ACTTGGTTCT 1560 TAACTACCAT GATTGCTTTT GAGGGCCCGG AATTATAAAT ATATATTATA TTTTAATTGT 1620 TTGAGATTAT TTTGACACAT TTCTTTGATA CGTAGAGTGT TTTGTTTTTA ATTTAAATCT 1680 GTCCTCATGC AACCCTCCAT GAGGGGCAGC GAAGCTGGCA GGGAGCAGAC TGGCTTTGTA 1740 GGTTCAGCAC TCGGCCCCCC ACTGCGGGAG AGGCGGAACC CACTTGCATG TCAGCGTTTT 1800 TGATTCGAGA AAAGAAATAC TCTCAACGTT TTACCAAGTG ATTTTACCTC CACCTTTACT 1860 AAAGTCTTTA CCTAAAACAT GGCAGTCGCT GGACACAGGA AAGCCCACCT TTTGTTTGGC 1920 CTTTTCGAAA GGTGACCCAT ATTGCACAGC AGAACATCAC AGCTGTGGTC CCAGATGAGA 1980 CACTGACATG CGAGTGAAGG CCTCTCCTCC TGGGCCCCGG GCTGCGCAGG CTCCTCACTC 2040 TGGGCGGTGT TTCCTGTCTC AGAATTGACA CGGTGAATGC TTAGTGTCTG GATTTTCTTG 2100 TGCCAGTGTT TACATATCTG ACATCGAGCT CCTCTAAGAG GCCACGTTCA AGCTTGTGTG 2160 TCCCTGACCC AAGATAGCCA GTGCTGCTCC CAGGTGGTAC TTCTGGTACC GTGTTGAGAC 2220 ACTTGGGATT CTCAGACTGT GGACAGGAGT GTTTGTCATT TTTCATACTG TTTTCTTAAT 2280 AAGCGCTCAG GCCTAAGGTG TGACAGGAAG TCGCACGCGC TTGGCCAGAG CACAGTGAAG 2340 CAAAGGACTG GGTGCTGATG GATGGAGCCA CGGCGGCATC TGCCCACCCG GCCGCAGCCC 2400 CCAGTGCCTC TCCTGGTGGT CCTCCCAGTC TAGAGGGTCA CGGCCCCCCC GCCCTCCTCC 2460 GTCTCTGGCA AGCTGACCTT GACTAACCCA GGAATACAGG GTCATCCTCA TTCCTAAGTA 2520 AGTCAAACAG CAAGACATGG TTTGCGCGGG TCTTTGCCGG AAGCCGGTCC TGCTGGCCAG 2580 GTGTTTTACG TCAGCAGGGA AATGTGGCAC ACGCCCTCGA GGCATTTTAA CACTGTGCTT 2640 CAGGAAATCT CAAGTTCCAT CTTGTGTTAG TAACGTACCC ACATTTTGCT GGAGTTAGTT 2700 TATTAAAGAT GCCTACGGTG AACTCTCTGG CGCAGGTTAA ATGCAGTTTT GAAAACCTGG 2760 AAACATCAAA TGGAGGCGGG AAATAGGCTG GGGCCGAGCT GAGGGGCTGA ACACAGCAGT 2820 GACCGTGGGT CAGCAGGTCG CCTGCCCAGC AGGCCCCCCA GGAGAGGGCT CGGGCGCCCC 2880 TGGCAGCCCC CATACCCCCA GGACCTGGCT CGTGAGTGCG TCTGGGTCAG GAAGAGACCT 2940 CTCTGTGCGT CTCAGGCTGA GATGCAGATT TCTGTTTTCT AAAACTGGAA GCGACCTTGA 3000 CGTGTATTGA AGGTGTGTGT GCCAAATGCT TCCGACGGAG GTGCTGGCCT TGGTTGGTTT 3060 CTCTCTGCCC CGTGTGGTCA TCAAGTCCTG GGGGATGTGC TCTGCCCAGC CGCCCTCGGG 3120 GAGAGCAGCG CCGCCTCCCA TGGGGCCGTG GGGCTGCTGT TCTCACTGCA CTGGCTGAAG 3180 CAACCCGCCA GCCTCCGTGC CCCACCCCAC CCAGCACGCA CTCATTCAGT CCATTGCCTT 3240 AACACAAGCC TGATGGGGCT GTTTTCTCAC AATATAAACG AATAAAGTGT CTTCTGGCCT 3300 ACTTCTGAAT TACTTCTCAA CTGTATGGTT TGGGGAAGGG AGGGAAACCT AAAATCCCGT 3360 CCAAATAAGT GAAATTCCTG AAGAAGTGGC TGAGTCCTAC CAGGTTGGGG TTAGGGAAAT 3420 GTTCTGGGTT CAGGCGCCCC TCCCAGGGCT GAGAAAGCGC AGCCAGGGAC AGCTTTCTGT 3480 TCTCTCCCAG GGTGGCTAGG TTAGTATCTT ACATGACAAA AAACTGAGAG TGTTCTAACT 3540 TCTGTGCAAG CAAGGTTAAT CCTGAGACTA AATCTTGGCG TTCAGACTCC CGTAGAGGTC 3600 ATCTGTGTCC AGGCCCACCC GGGCGCCGGC TCA 3633 (2) INFORMATION FOR SEQ ID NO: 151: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2018 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: LUNGTUT13 (B) CLONE: 3116522 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 151 : TGGCTCGCTG GCCGCTCCTG GAGGCGGCGG CGGGAGCGCA GGGGGCGCGC GGCCCGGGGA 60 CTCGCATTCC CCGGTTCCCC CTCCACCCCA CGCGGCCTGG ACCATGGACG CCAGATGGTG 120 GGCAGTGGTG GTGCTGGCTG CGTTCCCCTC CCTAGGGGCA GGTGGGGAGA CTCCCGAAGC 180 CCCTCCGGAG TCATGGACCC AGCTATGGTT CTTCCGATTT GTGGTGAATG CTGCTGGCTA 240 TGCCAGCTTT ATGGTACCTG GCTACCTCCT GGTGCAGTAC TTCAGGCGGA AGAACTACCT 300 GGAGACCGGT AGGGGCCTCT GCTTTCCCCT GGTGAAAGCT TGTGTGTTTG GCAATGAGCC 360 CAAGGCCTCT GATGAGGTTC CCCTGGCGCC CCGAACAGAG GCGGCAGAGA CCACCCCGAT 420 GTGGCAGGCC CTGAAGCTGC TCTTCTGTGC CACAGGGCTC CAGGTGTCTT ATCTGACTTG 480 GGGTGTGCTG CAGGAAAGAG TGATGACCCG CAGCTATGGG GCCACAGCCA CATCACCGGG 540 TGAGCGCTTT ACGGACTCGC AGTTCCTGGT GCTAATGAAC CGAGTGCTGG CACTGATTGT 600 GGCTGGCCTC TCCTGTGTTC TCTGCAAGCA GCCCCGGCAT GGGGCACCCA TGTACCGGTA 660 CTCCTTTGCC AGCCTGTCCA ATGTGCTTAG CAGCTGGTGC CAATACGAAG CTCTTAAGTT 720 CGTCAGCTTC CCCACCCAGG TGCTGGCCAA GGCCTCTAAG GTGATCCCTG TCATGCTGAT 780 GGGAAAGCTT GTGTCTCGGC GCAGCTACGA ACACTGGGAG TACCTGACAG CCACCCTCAT 840 CTCCATTGGG GTCAGCATGT TTCTGCTATC CAGCGGACCA GAGCCCCGCA GCTCCCCAGC 900 CACCACACTC TCAGGCCTCA TCTTACTGGC AGGTTATATT GCTTTTGACA GCTTCACCTC 960 AAACTGGCAG GATGCCCTGT TTGCCTATAA GATGTCATCG GTGCAGATGA TGTTTGGGGT 1020 CAATTTCTTC TCCTGCCTCT TCACAGTGGG CTCACTGCTA GAACAGGGGG CCCTACTGGA 1080 GGGAACCCGC TTCATGGGGC GACACAGTGA GTTTGCTGCC CATGCCCTGC TACTCTCCAT 1140 CTGCTCCGCA TGTGGCCAGC TCTTCATCTT TTACACCATT GGGCAGTTTG GGGCTGCCGT 1200 CTTCACCATC ATCATGACCC TCCGCCAGGC CTTTGCCATC CTTCTTTCCT GCCTTCTCTA 1260 TGGCCACACT GTCACTGTGG TGGGAGGGCT GGGGGTGGCT GTGGTCTTTG CTGCCCTCCT 1320 GCTCAGAGTC TACGCGCGGG GCCGTCTAAA GCAACGGGGA AAGAAGGCTG TGCCTGTTGA 1380 GTCTCCTGTG CAGAAGGTTT GAGGGTGGAA AGGGCCTGAG GGGTGAAGTG AAATAGGACC 1440 CTCCCACCAT CCCCTTCTGC TGTAACCTCT GAGGGAGCTG GCTGAAAGGG CAAAATGCAG 1500 GTGTTTTCTC AGTATCACAG ACCAGCTCTG CAGCAGGGGA TTGGGGAGCC CAGGAGGCAG 1560 CCTTCCCTTT TGCCTTAAGT CACCCATCTT CCAGTAAGCA GTTTATTCTG AGCCCCGGGG 1620 GTAGACAGTC CTCAGTGAGG GGTTTTGGGG AGTTTGGGGT CAAGAGAGCA TAGGTAGGTT 1680 CCACAGTTAC TCTTCCCACA AGTTCCCTTA AGTCTTGCCC TAGCTGTGCT CTGCCACCTT 1740 CCAGACTCAC TCCCCTCTGC AAATACCTGC ATTTCTTACC CTGGTGAGAA AAGCACAAGC 1800 GGTGTAGGCT CCAATGCTGC TTTCCCAGGA GGGTGAAGAT GGTGCTGTGC TGAGGAAAGG 1860 GGATGCAGAG CCCTGCCCAG CACCACCACC TCCTATGCTC CTGGATCCCT AGGCTCTGTT 1920 CCATGAGCCT GTTGCAGGTT TTGGTACTTT AGAAATGTAA CTTTTTGCTC TTATAATTTT 1980 ATTTTATTAA ATTAAATTAC TGCAGTGGAA AAAAAAAA 2018 (2) INFORMATION FOR SEQ ID NO: 152: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 942 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: LUNGTUT13 (B) CLONE: 3117184 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 152 : CCTCCATCAG CTCGCCGCGC AGCGGCTGTA TTTGCGGCCT GTGCGAGTAG GCGCTTGGGC 60 ACTCAGTCTC CCTGGCGGGC GACGGGCAGA AATCTCGAAC CAGTGGAGCG CACTCGTAAC 120 CTGGATCCCA GAAGGTCGCG AAGGCAGTAC CGTTTCCTCA GCGGCGGACT GCTGCAGTAA 180 GAATGTCTTT TCCACCTCAT TTGAATCGCC CTCCCATGGG AATCCCAGCA CTCCCACCAG 240 GGACCCCACC CCCGCAGTTT CCAGGATTTC CTCCACCTGT ACCTCCAGGG ACCCCAATGA 300 TTCCTGTACC AATGAGCATT ATGGCTCCTG CTCCGACTGT CTTAGTACCC ACTGTGTCTA 360 TGGTTGGAAA GCATTTGGGC GCAAGAAAGG ATCATCCAGG CTTAAAGGCT AAAGAAAATG 420 ATGAAAATTG TGGTCCTACT ACCACTGTTT TTGTTGGCAA CATTTCCGAG AAAGCTTCAG 480 ACATGCTTAT AAGACAACTC TTAGCTAAAT GTGGTTTGGT TTTGAGCTGG AAGAGAGTAC 540 AAGGTGCTTC CGGAAAGCTT CAAGCCTTCG GATTCTGTGA GTACAAGGAG CCAGAATCTA 600 CCCTCCGTGC ACTCAGATTA TTACATGACC TGCAAATTGG AGAGAAAAAG CTACTCGTTA 660 AAGTTGATGC AAAGACAAAG GCACAGCTGG ATGAATGGAA AGCAAAGAAG AAAGCTTCTA 720 ATGGGAATGC AAGGCCAGAA ACTGTCACTA ATGACGATGA AGAAGCCTTG GATGAAGAAA 780 CAAAGAGGAG AGATCAGATG ATTAAAGGGG CTATTGAAGT TTTAATTCGT GAATACTCCA 840 GTGAGCTAAA TGCCCCCTCA CAGGAATCTG ATTCTCACCC CAGGAAGAAG AAGAAGGAAA 900 AGAAGGAGGA CATTTTCGGC AGATTTCAGT GGGCCCACTG AT 942 (2) INFORMATION FOR SEQ ID NO: 153: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2060 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: LNODNOT05 (B) CLONE: 3125156 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 153 : TCCCCCCCTC AGCCTCCCCC CCCCCCACTG GCATATGGTC CTGCCCCTTC TACCAGACCC 60 ATGGGCCCCC AGGCAGCCCC TCTTACCATT CGAGGGCCCT CGTCTGCTGG CCAGTCCACC 120 CCTAGTCCCC ACCTGGTGCC TTCACCTGCC CCATCTCCAG GGCCTGGTCC GGTACCCCCT 180 CGCCCCCCAG CAGCAGAACC ACCCCCTTGC CTGCGCCGAG GCGCCGCAGC TGCAGACCTG 240 CTCTCCTCCA GCCCGGAGAG CCAGCATGGC GGCACTCAGT CTCCTGGGGG TGGGCAGCCC 300 CTGCTGCAGC CCACCAAGGT GGATGCAGCT GAGGGTCGTC GGCCGCAGGC CCTGCGGCTG 360 ATTGAGCGGG ACCCCTATGA GCATCCTGAG AGGCTGCGGC AGTTGCAGCA GGAGCTGGAG 420 GCCTTTCGGG GTCAGCTGGG GGATGTGGGA GCTCTGGACA CTGTCTGGCG AGAGCTGCAA 480 GATGCGCAGG AACATGATGC CCGAGGCCGT TCCATCGCCA TTGCCCGCTG CTACTCACTG 540 AAGAACCGGC ACCAGGATGT CATGCCCTAT GACAGTAACC GTGTGGTGCT GCGCTCAGGC 600 AAGGATGACT ACATCAATGC CAGCTGCGTG GAGGGGCTCT CCCCATACTG CCCCCCGCTA 660 GTGGCAACCC AGGCCCCACT GCCTGGCACA GCTGCTGACT TCTGGCTCAT GGTCCATGAG 720 CAGAAAGTGT CAGTCATTGT CATGCTGGTT TCTGAGGCTG AGATGGAGAA GCAAAAAGTG 780 GCACGCTACT TCCCCACCGA GAGGGGCCAG CCCATGGTGC ACGGTGCCCT GAGCCTGGCA 840 TTGAGCAGCG TCCGCAGCAC CGAAACCCAT GTGGAGCGCG TGCTGAGCCT GCAGTTCCGA 900 GACCAGAGCC TCAAGCGCTC TCTTGTGCAC CTGCACTTCC CCACTTGGCC TGAGTTAGGC 960 CTGCCCGACA GCCCCAGCAA CTTGCTGCGC TTCATCCAGG AGGTGCACGC ACATTACCTG 1020 CATCAGCGGC CGCTGCACAC GCCCATCATT GTGCACTGCA GCTCTGGTGT GGGCCGCACG 1080 GGAGCCTTTG CACTGCTCTA TGCAGCTGTG CAGGAGGTGG AGGCTGGGAA CGGAATCCCT 1140 GAGCTGCCTC AGCTGGTGCG GCGCATGCGG CAGCAGAGAA AGCACATGCT GCAGGAGAAG 1200 CTGCACCTCA GGTTCTGCTA TGAGGCAGTG GTGAGACACG TGGAGCAGGT CCTGCAGCGC 1260 CATGGTGTGC CTCCTCCATG CAAACCCTTG GCCAGTGCAA GCATCAGCCA GAAGAACCAC 1320 CTTCCTCAGG ACTCCCAGGA CCTGGTCCTC GGTGGGGATG TGCCCATCAG CTCCATCCAG 1380 GCCACCATTG CCAAGCTCAG CATTCGGCCT CCTGGGGGGT TGGAGTCCCC GGTTGCCAGC 1440 TTGCCAGGCC CTGCAGAGCC CCCAGGCCTC CCGCCAGCCA GCCTCCCAGA GTCTACCCCA 1500 ATCCCATCTT CCTCCCAAAC CCCCTTTCCT CCCCACTACC TGAGGCTCCC CAGCCTAAGG 1560 AGGAGCCGCC AGTGCCTGAA GCCCCCAGCT CGGGGCCCCC CTCCTCCTCC CTGGAATTGC 1620 TGGCCTCCTT GACCCCAGAG GCCTTCTCCC TGGACAGCTC CCTGCGGGGC AAACAGCGGA 1680 TGAGCAAGCA TAACTTTCTG CAGGCCCATA ACGGGCAAGG GCTGCGGGCC ACCCGGCCCT 1740 CTGACGACCC CCTCAGCCTT CTGGATCCAC TCTGGACACT CAACAAGACC TGAACAGGTT 1800 TTGCCTACCT GGTCCTTACA CTACATCATC ATCATCTCAT GCCCACCTGC CCACACCCAG 1860 CAGAGCTTCT CAGTGGGCAC AGTCTCTTAC TCCCATTTCT GCTGCCTTTG GCCCTGCCTG 1920 GCCCAGCCTG CACCCCTGTG GGGTGGAAAT GTACTGCAGG CTCTGGGTCA GGTTCTGCTC 1980 CTTTATGGGA CCCGACATTT TTCAGCTCTT TGCTATTGAA ATAATAAACC ACCCTGTTCT 2040 GTGAAAAAAA AAAAAAAAAG 2060 (2) INFORMATION FOR SEQ ID NO: 154: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2065 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (A) LIBRARY: LUNGTUT12 (B) CLONE: 3129120 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 154 : CGGGTCCCCG GGTCTGACAG GAGCAGCCTG TGGGCACCGC GGCGGTAGTT GGAGGCGGGA 60 GAGGGTCCGT AGCCGCGCCG CCCTGCCCCG CCATGGGCCT CCTGTCGGAC CCGGTTCGCC 120 GGCGCGCGCT CGCCCGCCTA GTGCTGCGCC TCAACGCGCC GTTGTGCGTG CTGAGCTACG 180 TGGCGGGCAT CGCCTGGTTC TTGGCGCTGG TTTTCCCGCC GCTGACCCAG CGCACTTACA 240 TGTCGGAGAA CGCCATGGGC TCCACCATGG TGGAGGAGCA GTTTGCGGGC GGAGACCGTG 300 CCCGGGCTTT TGCCCGGGAC TTCGCCGCCC ACCGCAAGAA GTCGGGGGCT CTGCCAGTGG 360 CCTGGCTTGA ACGGACGATG CGGTCAGTAG GGCTGGAGGT CTACACGCAG AGTTTCTCCC 420 GGAAACTGCC CTTCCCAGAT GAGACCCACG AGCGCTATAT GGTGTCGGGC ACCAACGTGT 480 ACGGCATCCT GCGGGCCCCG CGTGCTGCCA GCACCGAGTC GCTTGTGCTC ACCGTGCCCT 540 GTGGCTCTGA CTCTACCAAC AGCCAGGCTG TGGGGCTGCT GCTGGCACTG GCTGCCCACT 600 TCCGGGGGCA GATTTATTGG GCCAAAGATA TCGTCTTCCT GGTAACAGAA CATGACCTTC 660 TGGGCACTGA GGCTTGGCTT GAAGCCTACC ACGATGTCAA TGTCACTGGC ATGCAGTCGT 720 CTCCCCTGCA GGGCCGAGCT GGGGCCATTC AGGCAGCCGT GGCCCTGGAG CTGAGCAGTG 780 ATGTGGTCAC CAGCCTCGAT GTGGCCGTGG AGGGGCTTAA CGGGCAGCTG CCCAACCTTG 840 ACCTGCTCAA TCTCTTCCAG ACCTTCTGCC AGAAAGGGGG CCTGTTGTGC ACGCTTCAGG 900 GCAAGCTGCA GCCCGAGGAC TGGACATCAT TGGATGGACC GCTGCAGGGC CTGCAGACAC 960 TGCTGCTCAT GGTTCTGCGG CAGGCCTCCG GCCGCCCCCA CGGCTCCCAT GGCCTCTTCC 1020 TGCGCTACCG TGTGGAGGCC CTAACCCTGC GTGGCATCAA TAGCTTCCGC CAGTACAAGT 1080 ATGACCTGGT GGCAGTGGGC AAGGCTTTGG AGGGCATGTT CCGCAAGCTC AACCACCTCC 1140 TGGAGCGCCT GCACCAGTCC TTCTTCCTCT ACTTGCTCCC CGGCCTCTCC CGCTTCGTCT 1200 CCATCGGCCT CTACATGCCC GCTGTCGGCT TCTTGCTCCT GGTCCTTGGT CTCAAGGCTC 1260 TGGAACTGTG GATGCAGCTG CATGAGGCTG GAATGGGCCT TGAGGAGCCC GGGGGTGCCC 1320 CTGGCCCCAG TGTACCCCTT CCCCCATCAC AGGGTGTGGG GCTGGCCTCG CTCGTGGCAC 1380 CTCTGCTGAT CTCACAGGCC ATGGGACTGG CCCTCTATGT CCTGCCAGTG CTGGGCCAAC 1440 ACGTTGCCAC CCAGCACTTC CCAGTGGCAG AGGCTGAGGC TGTGGTGCTG ACACTGCTGG 1500 CGATTTATGC AGCTGGCCTG GCCCTGCCCC ACAATACCCA CCGGGTGGTA AGCACACAGG 1560 CCCCAGACAG GGGCTGGATG GCACTGAAGC TGGTAGCCCT GATCTACCTA GCACTGCAGC 1620 TGGGCTGCAT CGCCCTCACC AACTTCTCAC TGGGCTTCCT GCTGGCCACC ACCATGGTGC 1680 CCACTGCTGC GCTTGCCAAG CCTCATGGGC CCCGGACCCT CTATGCTGCC CTGCTGGTGC 1740 TGACCAGCCC GGCAGCCACG CTCCTTGGCA GCCTGTTCCT GTGGCGGGAG CTGCAGGAGG 1800 CGCCACTGTC ACTGGCCGAG GGCTGGCAGC TCTTCCTGGC AGCGCTAGCC CAGGGTGTGC 1860 TGGAGCACCA CACCTACGGC GCCCTGCTCT TCCCACTGCT GTCCCTGGGC CTCTACCCCT 1920 GCTGGCTGCT TTTCTGGAAT GTGCTCTTCT GGAAGTGAGA TCTGCCTGTC CGGGCTGGGA 1980 CAGAGACTCC CCAAGGACCC CATTCTGCCT CCTTCTGGGG AAATAAATGA GTGTCTGTTT 2040 CAGCAGCTAT TTGATGCTTG TCACA 2065 

What is claimed is:
 1. An isolated polynucleotide which encodes a polypeptide having an amino acid sequence selected from SEQ ID NOs: 1-77.
 2. A composition comprising the polynucleotide of claim 1 or the complement thereof and a reporter molecule.
 3. An isolated polynucleotide comprising a nucleic acid sequence selected from SEQ ID NOs: 78-154, fragments and complements thereof.
 4. A vector containing the polynucleotide of claim
 1. 5. A host cell containing the vector of claim
 4. 6. A method for using a polynucleotide to produce a polypeptide, the method comprising: a) culturing the host cell of claim 5 under conditions for protein expression; and b) recovering the polypeptide from culture.
 7. A method for using a polynucleotide to detect a nucleic acid encoding a polypeptide having the amino acid sequence of SEQ ID NOs: 1-77 in a sample, the method comprising the steps of: a) hybridizing the polynucleotide of claim 1 or the complement thereof to at least one nucleic acid in the sample, thereby forming a hybridization complex; and b) detecting the hybridization complex, wherein the presence of the hybridization complex indicates the expression of the nucleic acid in the sample.
 8. The method of claim 7 wherein the nucleic acids of the sample are amplified prior to hybridization.
 9. The method of claim 7 wherein the polynucleotide is operably-linked a substrate.
 10. A method of using a polynucleotide to screen a plurality of molecules to identify a molecule which specifically binds the polynucleotide, the method comprising: a) combining the polynucleotide of claim 1 with the plurality of molecules under conditions to allow specific binding; and b) detecting specific binding, thereby identifying a molecule which specifically binds the polynucleotide.
 11. The method of claim 10 wherein the molecule is selected from DNA molecules, RNA molecules, peptide nucleic acids, artificial chromosome constructions, peptides, and proteins.
 12. A purified polypeptide comprising an amino acid sequence selected from SEQ ID NOs: 1-77 and fragments thereof.
 13. A method for using a polypeptide to screen a plurality of molecules to identify a molecule which specifically binds the polypeptide, the method comprising: a) combining the polypeptide of claim 12 with the molecules under conditions to allow specific binding; and b) detecting specific binding, thereby identifying a molecule which specifically binds the polypeptide.
 14. The method of claim 13 wherein the molecules are selected from agonists, antagonists, antibodies, DNA molecules, RNA molecules, peptide nucleic acids, immunoglobulins, inhibitors, drug compounds, peptides, and pharmaceutical agents.
 15. A method of using a polypeptide to purify a molecule which specifically binds the polypeptide from a sample, the method comprising: a) combining the polypeptide of claim 12 with a sample under conditions to allow specific binding; b) recovering the bound polypeptide; and c) separating the molecule from the polypeptide, thereby obtaining the purified molecule.
 16. A composition comprising the polypeptide of claim 12 and a pharmaceutical carrier.
 17. A method for using a polypeptide to produce an antibody, the method comprising: a) immunizing an animal with the polypeptide of claim 12 under conditions to elicit an antibody response; and b) isolating antibodies which bind specifically to the polypeptide.
 18. A method for using a polypeptide to identify an antibody which specifically binds the polypeptide, the method comprising: a) combining the polypeptide of claim 12 with a plurality of antibodies under conditions allow specific binding, b) recovering the bound polypeptide, and c) separating the antibody from the polypeptide, thereby obtaining antibody which specifically binds the polypeptide.
 19. The method of claim 18, wherein the antibodies are selected from polyclonal antibodies, monoclonal antibodies, chimeric antibodies, single chain antibodies; Fab fragments, Fv fragments, and F(ab′)₂ fragments.
 20. An antibody which specifically binds the polypeptide of claim
 12. 